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UNIVERSITY OF SOUTHAMPTON 
ABSTRACT: 
FACULTY OF BIOMEDICAL SCIENCE 
SCHOOL OF MEDICINE 
Doctor of Medicine 
Mechanisms of multidrug resistance in bladder cancer:  The role of 
nuclear membrane  
By Jonathan Mark Featherstone 
Multidrug resistance (MDR) describes the phenomenon whereby cancer cells 
exposed to a single cytotoxic drug develop cross resistance to numerous other 
structurally unrelated chemotherapeutics.  The development of MDR is a major 
cause of cancer chemotherapy treatment failure in all types of cancer.         
  Numerous mechanisms of MDR have been elucidated which include ATP-
binding cassette (ABC) transporter proteins, cytoplasmic vaults, alterations in 
topoisomerase II and increased expression of glutathione-S-transferases, all of 
which result in reduced chemotherapeutic efficacy.   
  Superficial bladder cancer is commonly treated with adjuvant intravesical 
chemotherapy using mitomycin C or epirubicin (an anthracycline), following 
surgical resection.  However, despite this treatment, the recurrence rates of 
these tumours can approach 60%.  This high recurrence rate represents the 
development of MDR in many cases.   
  Previous work using anthracycline fluorescence has shown that MDR cells 
have reduced levels of anthracycline uptake and also demonstrate a 
characteristic nuclear sparing of drug uptake.   This nuclear sparing 
phenomenon in MDR cells transcends tissue type and suggests that the 
nuclear membrane may also play a role in MDR.   
  The work described herein discusses the current role of chemotherapy in the 
treatment of superficial bladder cancer, mechanisms of MDR and the role of the 
nuclear membrane in MDR.  Following this our investigation of the role of the 
nuclear membrane is described, using a number of novel techniques including 
cell fusion and microinjection.  In addition, we investigated MDR modulation by 
verapamil, with analysis of changes in cellular, cytoplasmic and nuclear drug 
uptake mediated by this known MDR reversing agent. 
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MVAC   methotrexate,  vinblastine, adriamycin and cisplatin  
MVP    major vault protein 
MXR    mitoxantrone resistance protein 
NBD    nucleotide binding domain 
NE   nuclear  envelope 
NPC    nuclear pore complex 
PARP   poly(ADP-ribose)  polymerase 
PBS   phosphate  buffered  saline 
PBSI    PBS containing protease and phosphatase inhibitors   
P-gp   P-glycoprotein 
PI   propidium  iodide 
PLC    prelysosomal sorting compartment 
PMSF   phenylmethylsulphonyl fluoride 
RanGAP  RanGTPase activating protein 
RanGEF  Ran guanine nucleotide exchange factor   20
Rb   retinoblastoma  gene 
ROI    region of interest 
RNA   ribonucleic  acid 
rpm   revolutions  per  minute 
RT-PCR  reverse transcriptase-polymerase chain reaction 
SSC   side  scatter 
TCC    transitional cell carcinoma  
TEMED  N,N,N’N’ – tetramethylethylenediamine 
TEP1    telomerase associated protein 
TMD   transmembrane  domain 
TNM    tumour nodes metastases (classification) 
TOPO II  topoisomerase II 
TUR    transurethral resection  
TURBT  transurethral resection of bladder tumour 
VEGF    vascular endothelial growth factor 
VER   verapamil 
VPARP  vault-poly (ADP-ribose) polymerase 
WGA    wheat germ agglutinin 
WHO    World Health Organisation 
5-ALA   5-aminolevulinic acid 
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Chapter 1.  Introduction and literature review  
1.1:  Bladder Cancer: 
The majority of bladder cancers (90 – 95%) are transitional cell carcinomas 
(TCC) with the remainder being either squamous cell, adeno- or small cell 
carcinomas.  The incidence of transitional cell carcinoma of the bladder had 
until recently been rising annually, in both the western world and developing 
countries.  This increase mirrored the increasing prevalence of cigarette 
smoking in western societies and the spread of smoking to developing 
countries, throughout the last century.   
However, since the introduction of the new World Health Organisation (WHO) 
grading system in 2004, some low-grade, non-invasive tumours are no longer 
classified as cancers, so do not appear in cancer registry statistics with a 
resultant fall in the reported incidence of bladder cancer.       
Incidence 
In England, bladder cancer is the fourth most common cancer in males, 
accounting for 4.9% of all malignant neoplasms, while in females it is ranked 
tenth accounting for only 2% of all cancers [1] (excluding non-melanomatous 
skin cancers).  
In 2004, 8,137 new cases were diagnosed in England, affecting 5,800 males 
and 2,337 females.  These figures give age standardised incidence rates of 
18.8 per 100,000 of the male population and 5.5 per 100,000 of the female 
population [1]. 
In 2004, bladder cancer was the eighth most common cancer death 
accounting for 4,301 deaths in England and Wales, 2,840 in males and 1,461 
in females.  These figures give age standardised mortality rates of 8.4 per 
100,000 males and 2.8 per 100,000 females [2].  
The incidence of bladder cancer increased through the mid-1970s peaking in 
the late 1980s.  There has also been a gradual decline in the male to female 
ratio of age standardised incidence rates from 4.1 : 1 in 1971 to 3.4 : 1 in 
1997 (Figure 1).  This narrowing of the sex ratio has been widely attributed to 
increased rates of cigarette smoking amongst women and was predicted to 
narrow further [3].  However, the latest figures from 2004 show that the sex 
ratio has remained steady at 3.4 : 1 [1].   
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Figure 1:    Age-standardised incidence of bladder cancer, England and 
      Wales, 1971 – 1997 (Reproduced with kind permission of  
      National Statistics [4]). 
 
Despite this increasing incidence, mortality from bladder cancer has fallen in 
males since the early 1970s from just under 13 deaths per 100,000 to 8.4 per 
100,000 in 2004.  However, the female mortality rate has remained fairly static 
at around 3 per 100,000 females since 1950 (Figure 2).   
 
 
 
 
 
 
 
 
 
 
Figure 2:   Age-standardised bladder cancer mortality by sex, England 
      and Wales, 1950 – 1999 (Reproduced with kind permission 
      of National Statistics [4]). 
 
Regional bladder cancer statistics for the South West region supplied by 
South West Public Health Observatory (SWPHO), show that in 2005 bladder 
cancer was the seventh commonest cancer accounting for 708 new cancer   23
registrations in men and 267 in women.  In the same year it was the tenth 
most common cause of cancer death accounting for 285 deaths in men and 
153 deaths in women.   
These figures for bladder cancer in the South West in 2005, give regional age 
standardised incidence rates of 20.0 and 5.6 per 100,000 for men and women 
respectively.  These are similar to the national age standardised incidence 
rates for the same year (Table 1).   
Age standardised mortality incidences for bladder cancer in the South West  
in 2004 were 7.7 and 2.8 per 100 000 population for men and women 
respectively.  These figures are again similar to the national age standardised 
mortality rates for the same year (Table 1). 
 
 Age  standardised 
Incidence 
/100,000 population 
Age standardised 
Mortality 
/100,000 population 
 
England and Wales 2004 
Male 
Female 
England 
 
18.8 
5.5  
England and Wales 
 
8.4 
2.8 
 
South West 2004 
Male 
Female 
 
 
20.0 
5.6 
 
 
7.7 
2.8 
 
Table 1:    Comparison of National and Regional Age standardised  
      incidence and mortality of bladder cancer from 2004. 
 
From the age of forty the incidence of bladder cancer rises steadily up to the 
age of 60, where the rate of increase becomes steeper peaking in the over 85 
age group in both sexes (Figure 3).  Mortality incidences show a similar 
pattern peaking in the over 85 age group (Figure 4).  
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Figure 3:    Age specific incidence of bladder cancer, England and  
      Wales, 2004 (Produced from data published by National  
      Statistics [1]).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4:   Age specific bladder cancer mortality, England and Wales, 
      2004 (Produced from data published by National Statistics 
      [2]).   
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Aetiology 
Bladder cancer aetiology is multifactorial, with both environmental and genetic 
factors playing a role in carcinogenesis.     
Environmental Factors 
A number of occupational and non-occupational environmental factors are 
associated with the development of bladder cancer (Table 2).  The most 
important factors will be dealt with in this section. 
Occupational Non-occupational 
2-Naphthylamine 
4-Aminobiphenyl 
Benzidine 
4,4’Methylenebis(2-chloroaniline) 
4-Chloro-o-toluidine 
o-toluidine 
Methylene dianiline 
Benzidine-derived azodyes 
Cigarette smoking 
Phenacetin-containing analgesics / 
Analgesic abuse nephropathy 
Cyclophosphamide 
Chlornaphazine 
Thiotepa* 
Melphalan* 
Radiotherapy 
Balkan Nephropathy 
Arsenic 
Bladder calculi 
Recurrent UTI 
Schistosomiasis  
Long-term catheterisation 
 
Table 2:    Aetiological factors in bladder cancer  
      (*Associated with radiotherapy)   
 
Occupational / Industrial factors 
Historically, occupational or industrial exposure has contributed to bladder 
cancer causation, accounting for 18 – 35% of cases in men and 1 – 6% of 
cases in women [5].  Aniline dye workers were reported to be at increased risk 
of developing bladder cancer in 1895 [6].  However, the carcinogenic 
compound responsible, 2-naphthylamine, was only identified in 1938 [7].  In 
1954, links were demonstrated between exposure to aromatic amines and 
bladder cancer in a large number of British industrial workers, not only in the 
dye industry but also the rubber, textile and chemical industries [8,9].  
Exposure to other aromatic amines, such as benzidine and 4-amino-biphenyl   26
was subsequently shown to be the cause of these industry related bladder 
cancers.   
Bladder cancers caused by industrial exposure are now declining due to 
increased awareness of the carcinogens responsible and the introduction of 
appropriate protective measures to reduce worker exposure to these 
occupational carcinogens.   
Non-occupational factors 
Cigarette smoking is the single most important cause of bladder cancer in 
industrialised developed countries, accounting for 25 – 60% of all cases of 
bladder cancer [10].  The increase in cigarette smoking throughout the 
twentieth century appears to be responsible for the rising incidence of bladder 
cancer in Western countries [3,11].  The precise mechanism by which 
cigarette smoking causes bladder cancer remains unresolved, although it is 
most likely related to one or more of the numerous chemicals present in 
cigarette smoke.  There is considerable evidence that aromatic amines, 
especially 4-aminobiphenyl and o-toluidine, are associated with cigarette 
smoking and bladder cancer [12,13].  Other aromatic amines, including 
pyrolysis products, are possible contributors.  Acrolein is the simplest of the 
α,β-unsaturated aldehydes, compounds that are ubiquitous in the 
environment.  A single cigarette contains approximately 100µg of acrolein.  
These aldehydes are toxic, mutagenic and possibly carcinogenic.  Acrolein 
has been shown to initiate bladder carcinogenesis in rats [14].  The risk of 
bladder cancer is 2 – 4 times greater among male cigarette smokers than 
among non-smokers [15,16].  A linear relationship between duration of 
smoking and bladder cancer risk has been demonstrated, with odds ratios 
ranging from 1.96 after 20 years to 5.57 after 60 years [17].  A dose 
relationship between the number of cigarettes smoked per day and bladder 
cancer has also been observed, up to a threshold limit of 15 – 20 cigarettes 
per day, odds ratio 4.5.  Quitting smoking results in an immediate reduction in 
bladder cancer risk of up to 30% after 1 – 4 years and over 60% at 25 years, 
however even after 25 years the reduction in risk does not reach the level of 
non-smokers [17].     27
Analgesic abuse nephropathy is associated with an increased risk of 
developing urinary tract tumours, particularly in the renal pelvis but also in the 
ureter and bladder.  Phenacetin-containing analgesics cause papillary 
necrosis and chronic interstitial nephritis leading to nephropathy.  The relative 
bladder cancer risk of analgesia abuse nephropathy varies from 2.3 to 12.2 in 
different series [18-20]. 
Cyclophosphamide induced bladder cancer was first described in 1971 [21].  
Cyclophosphamide is used to treat neoplastic and non-neoplastic diseases in 
approximately 500,000 patients worldwide annually.  In a study of 6,171         
2-year survivors treated for non-Hodgkin’s lymphoma with chemotherapy 
regimens containing cyclophosphamide, 48 patients developed urinary tract 
cancers.  There was a 4.5-fold increase in bladder cancer risk in these 
patients.  A dose-response relationship was also demonstrated with the 
relative risk in patients who had received less that 20g being 2.4 compared to 
14.5 in patients who had received over 50g.  The mean latency period for 
bladder cancer development after cyclophosphamide treatment was 8.5 
years, with a range of 3 – 21 years [22]. 
Conditions leading to chronic irritation of the urothelium may also induce 
carcinomas, although these tend to be of squamous cell type rather than 
transitional cell carcinomas, so will not be discussed here.  Conditions that 
can precipitate malignant transformation of the urothelium include chronic 
infection, long-standing bladder calculi, long-term catheterisation and 
schistosomiasis infection. 
Bladder cancer:  Genetics 
The exact sequence of events that leads to malignant transformation of the 
normal urothelium is unknown.  Activation of oncogenes or inactivation or 
deletion of tumour suppressor genes is likely to play a role in this 
transformation process.  Our understanding of the genetics of TCC has 
advanced significantly over the past few years with numerous oncogenes, 
tumour suppressor genes and chromosome abnormalities having been linked 
with bladder cancer genesis. 
The majority of bladder cancers (over 70%) present as low-grade non-
invasive papillary tumours that have not invaded the epithelial basement 
membrane (Ta).  The rest are either muscle-invasive tumours (>T2) or non-  28
muscle-invasive tumours that have invaded the basement membrane (T1), 
which have a high risk of progression to muscle invasion.   
Molecular analysis has demonstrated striking differences between these 
groups.  This has led to the current two-pathway model for tumour 
development, with a postulated third pathway leading to the development of 
T1 tumours (Figure 5).  
The first pathway which leads to genomically stable low-grade (Ta) disease 
occurs through mutations in the oncogene, fibroblast growth factor (FGF) 
receptor 3 (FGFR3).  The second pathway which leads to muscle invasive 
bladder cancer is thought to arise via flat dyplasia which undergoes malignant 
transformation to carcinoma in situ (CIS) and the progresses to muscle 
invasive disease, as a result of mutations in the tumour suppressor gene p53.   
Oncogenes  
Several oncogenes have been implicated in TCC development and 
progression.  Oncogenes contribute to the malignant phenotype in a dominant 
manner, either by being overexpressed or mutated to produce an oncoprotein 
[23].  Overexpression of the normal product is the most common mechanism, 
achieved either by gene amplification or chromosome translocation placing 
the gene downstream of a powerful promoter region [24]. 
Activating mutations of FGFR3 are the most common genetic alterations 
identified in bladder cancer to date.  The gene for FGFR3 is found on 
chromosome 4p16.  FGFR3 mutations have been found in up to 80% of low-
grade Ta tumours, but are only seen in 0 – 34% of T2 – T4 tumours.   
Activation of FGFR3 is thought to induce signalling via the mitogen-activated 
protein (MAP) kinase pathway.  Some studies suggest that mutation of 
FGFR3 confers an increased risk of recurrence, but no studies have 
demonstrated any increase in the risk of progression [25].  
The oncogene c-erb-B2 (chromosome 17q21) encodes a transmembrane 
receptor-like protein with homology to the epidermal growth factor receptor 
(EGFR).  Overexpression of c-erb-B2 has tyrosine kinase activity similar to 
that of EGFR and the ability to stimulate cellular growth.  C-erb-B2 is 
overexpressed in some TCCs by gene amplification and where present 
overexpression is associated with higher stage and grade tumours [26-30].  
Overexpression has also been associated with poor clinical outcome [27] and    29
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 5:   Model for pathogenesis of bladder cancer based on known 
     histopathological  and  molecular data [25]. 
in multivariate analysis, c-erb-B2 gene amplification and overexpression of its 
oncoprotein have a predictive value for death from bladder cancer [29]. 
Epidermal growth factor receptor status has also been shown in multivariate 
analysis to be an independent predictor of survival and stage progression 
[31].  In addition, EGFR status was found to be 80% sensitive and 93% 
specific in predicting stage progression in T1, grade 3 TCC [31].  
The proto-oncogene CCND1 (Chromosome 11q13) is also amplified and 
overexpressed in a subset of TCCs [32-34].  The product of CCND1 is cyclin 
D1, a gene involved in cell cycle progression via the retinoblastoma (Rb) 
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pathway.  Overexpression of cyclin D1 has been associated with early tumour 
recurrence but not survival in TCC [35]. 
The c-myc oncogene (chromosome 8 long arm) codes for protein, p62
c-myc.  
This protein is associated with the nucleus and may be actively involved with 
DNA synthesis [36].  The overexpression of p62
c-myc in bladder cancer was 
been linked to superficial disease [36].  It also appears to be overexpressed in 
some high-grade TCCs [37], but does not appear to predict any difference in 
survival or progression in these tumours [38]. 
Expression of a mutant protein product or oncoprotein is a less common 
mechanism of activation and is exemplified in TCC by the RAS gene family 
member H-ras.  H-ras codes for a protein anchored to the cytoplasmic side of 
the cell membrane that is involved in signal transduction and may be involved 
with bladder cancer genesis.  H-ras mutations have been found in up to 36% 
of bladder tumours [39,40]. 
Several studies have also identified common over-representation of certain 
chromosome arms and regions of high-level DNA amplification in TCC [41-
44].  These changes have been shown mainly in T1 tumours and are much 
rarer in Ta tumours [42].  These alterations include over-representation of 1q, 
8q, 3q, 5p, 6p and 10p and amplification at 1q22–24, 3p24–25, 6p22, 8p12, 
8q21–22, 10p12–14, 11q13, 12q15–21, 13q31–33, Xp11–12 and Xq21–22.           
Tumour suppressor genes  
Deletion or inactivation of specific tumour suppressor genes or other specific 
genetic regions have been linked to cancer development.  Multiple tumour 
suppressor genes have been implicated in the development of TCC. 
The retinoblastoma (Rb) gene (Chromosome 13q14) encodes a nuclear 
phosphoprotein (pRb) that functions as a cell cycle regulator.  Loss of 
heterozygosity at the Rb locus correlates strongly with the absence of Rb 
protein expression.  Rb genetic mutations have been demonstrated in 
approximately 30% of TCCs [45].  Failure to detect pRb 
immunohistochemically is associated with increased tumour grade and stage 
(especially muscle invasion) and decreased survival [45-47].  
Hyperphosphorylation of pRb which can be identified immunohistochemically 
as intense nuclear staining, is linked to TCC progression and carries with it a 
similarly ominous prognosis as absence of Rb staining [48,49].    31
Evidence of allelic loss of chromosome 17p in high grade compared to low 
grade TCCs, was the first suggestion that p53 may play a role in bladder 
carcinogenesis [50].  The p53 gene (chromosome 17p13) encodes a 53kDa 
transcription factor which plays a vital role in DNA repair and apoptosis.  The 
half-life of mutated p53 is significantly longer than that of wild-type p53, which 
allows its detection by immunohistochemistry.  Nuclear overexpression of p53 
has been shown in up to 62% of muscle-invasive TCCs and is associated with 
increased stage and grade [51-53].  In superficially invasive disease (T1), p53 
overexpression is less common, but where present is associated with a higher 
rate of disease progression and a poorer outcome.  Mutated p53 status is also 
an independent predictor of decreased survival.  In muscle-invasive disease, 
it has been associated with a doubling in the risk of death from bladder cancer 
[54]. Altered p53 is frequently seen in carcinoma in situ, which again 
reinforces the argument that p53 plays a role in bladder cancer genesis and 
progression in high-grade TCCs [54].   
Studies of KAI1 (Chromosome 11p11.2), a metastasis suppressor gene, have 
shown a dramatic reduction in expression of this gene is common in both 
invasive and metastatic bladder cancer, suggesting that the loss of KAI1 is an 
important and unfavourable step in tumour progression [55].   
A loss of KAI1 has also been associated with increased invasive behaviour in 
bladder cancer cell lines [56].   
Deletions on chromosome 9 occur in greater than 60% of bladder cancers 
across all stages and grades and are likely to represent an initiating event  
[57].  Cytogenetic and molecular evidence has shown that it is often the only 
chromosomal aberration in early disease.  Deletions of chromosome 9 alone 
are often associated with recurrence, but rarely associated with progression.  
The p21 region of chromosome 9 (9p21) has been found to be mutated in a 
variety of malignancies suggesting the presence of a common tumour 
suppressor gene.  This complex genomic region encodes three distinct 
proteins, p16, p14ARF and p15, all of which are negative cell cycle regulators.  
In TCC, it is common for all three of these 9p21 genes to be deleted [58,59].  
The potential prognostic implications of inactivation of one or all of these 
genes has not yet been studied in detail.    32
There are also 2 regions on 9q (9q11 – 13 and 9q33 – 34) that are also 
selectively deleted in a significant proportion of bladder cancers.  The specific 
locations and functional proteins from these two putative tumour suppressor 
genes remain to be identified.  Their deletion is more commonly associated 
with low-grade cancers [23].  
The pattern of allelic loss at chromosome 9p21 (p16 gene locus) and 17p13 
(p53 gene locus) in primary bladder cancer has been shown to be maintained 
during cancer progression to metastasis with an identical pattern of allelic loss 
in primary cancer being conserved in paired metastatic carcinoma, suggesting 
that allelic loss of these chromosome regions occurs prior to the metastatic 
sequence [60].    
Another tumour suppressor gene PTEN (chromosome 10q23) which is 
inactivated by loss of heterozygosity or mutation has been identified in some 
cases of TCC [61,62]. 
Several other chromosome arms show non-random deletions in bladder 
cancer including 3p, 4p, 4q, 8p, 11p, 11q, 14q and 18q [24].  
The GSTM1 gene is another form of tumour suppressor gene, which codes 
for the Glutathione-S-Transferase M1 enzyme which is effective at detoxifying 
some carcinogenic compounds and protecting against cancer development 
[63].  Approximately half of the Caucasian population are homozygous 
deleted for this allele and fail to express the protein [64].  Several studies 
have demonstrated that in subjects lacking GSTM1 activity there is a 
significantly increased risk of developing bladder cancer [65,66].  These 
studies also estimate that as many as 17 – 25% of bladder cancers may be 
attributable to the GSTM1 deficiency. 
Molecular biology of cancer progression 
Bladder cancer cells need to acquire certain properties to enable them to 
grow rapidly, invade and metastasise.  These properties include uninhibited 
growth and cellular mobility, mediated partially by epidermal growth factor 
(EGF) and EGFRs, expression or loss of expression of specific cell adhesion 
molecules and increased production of angiogenic factors.   
EGF and EGFRs 
Abnormal expression or function of growth factor receptors can enhance 
malignant cell proliferation.  EGF is a potent mitogen excreted in high   33
concentrations in human urine [67].  In patients with TCC, EGF is excreted in 
urine at much lower concentrations [68].  These lower urinary concentrations 
of EGF are thought to be due to increased ligand binding to EGFR receptors.  
EGFRs are normally found only in the basal layer of the urothelium, however 
in TCC these receptors become abnormally expressed throughout the entire 
urothelium, including those cells directly exposed to urine.  EGFR expression 
as detected by immunohistochemistry has been shown to correlate with 
increased grade and stage and with a poor prognosis in bladder cancer [69].  
High levels of EGFR expression have also been shown in cystoscopically 
normal urothelium in patients with TCCs elsewhere in the bladder [70].  This 
observation supports the existence of a urothelial field defect [71] and 
suggests that abnormal EGFR expression may be an early event in bladder 
carcinogenesis.  Ligand stimulation of EGFRs also induces cellular motility, 
suggesting these receptors may also play a role in transepithelial motility and 
tumour invasion, as well as proliferation.   
Extracellular Matrix and Cell Adhesion Molecules 
Extracellular matrix and cell adhesion molecules have been extensively 
studied because they form natural barriers to tumour metastases.   
Urothelial cells are bound to each other and to the underlying basal lamina by 
cell adhesion molecules and extracellular matrix, in order to allow some 
cellular disaggregation and local movement these connections must be 
altered in some way.  In addition, many of these molecules are involved with 
cell-cell communication, regulation of the expression and function of 
membrane bound growth factor receptors, manipulation of the activity of cell 
cycle regulatory molecules and other processes involved in urothelial 
carcinogenesis (e.g. angiogenesis). 
E-Cadherin 
The cadherins are a family of transmembrane glycoproteins involved in 
calcium-dependent cell-cell adhesion.  Reduced expression of E-cadherin (an 
epithelial subclass) has been linked to increased tumour recurrence and 
invasiveness [38] and a reduction in overall survival of bladder cancer patients 
[72].  Advanced tumour stage and grade have also been associated with loss 
of cadherin-associated molecules (alpha, beta and gamma catenins) and the 
presence of multiple abnormalities in the E-cadherin-catenin complex [73].    34
Possible mechanisms accounting for decreased function of E-cadherin in 
bladder cancer cells include suppression or mutation of the E-cadherin gene, 
allelic loss of 16q, decreased E-cadherin protein expression and increased 
protease-mediated degradation.  However, the mechanisms by which  
E-cadherin expression is decreased remain unknown. 
Integrins 
The integrins comprise a family of transmembrane heterodimeric proteins, 
functioning as receptors for each other and for extracellular matrix 
components, such as laminin, fibronectin and collagen.  Alpha-6 beta-4 
integrin associates with collagen VII on the basement membrane of the 
urothelium, forming a hemidesmosomal achoring complex, which prevents 
cell migration.  In bladder cancer cells this association of apha-6 beta-4 
integrin with collagen VII is lost, possibly explaining the problem with urothelial 
barrier function that occurs in malignancy [74].  This disruption of the structure 
and function of integrins may also enhance the ability of intraluminal urinary 
constituents with angiogenic, locomotive, mitogenic or mutagenic properties to 
gain unusual access to the interstices of the bladder wall. 
Angiogenesis 
Neovascularisation or angiogenesis are prerequisites to tumour growth and 
metastasis [75].  Angiogenesis inducers (e.g. vascular endothelial growth 
factor (VEGF) or substances that activate angiogenesis inducers (e.g. basic 
fibroblast growth factor (b-FGF)) are produced by the tumour cells or released 
from extracellular matrix or tumour associated stromal cells, or they may be 
products of inflammatory cells that infiltrate tumours [76].  
Immunohistochemical methods looking at increased microvascular density 
(angiogenesis) have shown an association with tumour progression and 
decreased overall survival in bladder cancer patients [77,78].  In addition, 
increased urinary excretion of b-FGF, angiogenic factors such as autocrine 
motility factor (AMF) [79], and hyaluronic acid and its degradation products 
[80] have been found in patients with bladder cancer and could potentially 
provide a means of tumour detection and monitoring in the future. 
Potent inhibitors of angiogenesis also appear to be expressed in abnormally 
low levels in bladder cancers compared with normal urothelium.  Decreased 
expression of Thrombospondin-1, an extracellular matrix glycoprotein, has   35
been correlated with higher recurrence rates and decreased survival in 
bladder cancer patients, when compared with patients whose bladders have 
higher levels of expression [81].     
Presentation  
The majority of patients (75 – 90%) with bladder cancer will present with 
haematuria, which can be either macroscopic or microscopic.  The degree of 
haematuria does not correlate with the extent of disease.   
Bladder cancer may also present with recurrent urinary tract infections, sterile 
pyuria, pelvic pain or irritative voiding symptoms, such as frequency and 
urgency of voiding.  Occasionally patients may present with anaemia, uraemia 
or symptoms related to metastatic disease, such as bone pain or weight loss.  
Screening for asymptomatic haematuria is not recommended because its 
positive predictive value to too low (0.5%) to warrant mass screening [82,83].  
However, routine screening for microscopic haematuria may be indicated for 
populations exposed to bladder carcinogens, including heavy smokers and 
workers in high risk occupations.    
Physical examination is usually normal except in locally advanced disease, 
when a mass may be palpable.   
Bladder cancers are usually diagnosed during investigation of patients with 
haematuria.  Haematuria should always be investigated with either an 
intravenous urogram (IVU) or an ultrasound and plain X-ray of the kidneys, 
ureters and bladder combined with cystoscopy.  Bladder cancers are usually 
diagnosed definitively at cystoscopy with either a rigid or a flexible 
cystoscope.   However, bladder cancer may also be diagnosed as a filling 
defect in the bladder on an IVU or a mass lesion in the bladder on ultrasound.  
Computed tomography (CT) may also detect incidental bladder cancer when 
patients are being investigated for other conditions.  These radiological 
investigations can miss smaller bladder lesions and areas of carcinoma in 
situ, so cystoscopy is mandatory in patients with haematuria.   
Urine cytology may reveal the presence of malignant cells in the urine 
suggesting a urothelial tumour.  Cytology is particularly useful when a high-
grade malignancy or Carcinoma in situ (Cis) is present [84,85].  However, 
negative urinary cytology does not exclude the presence of a low-grade 
bladder tumour.   36
Newer urinary markers of bladder cancer may gain a role in bladder cancer 
screening and disease monitoring in the future.  There are several tests 
already commercially available including bladder tumour antigen, NMP22 
(Nuclear Matrix Protein), fibrin-degradation products, Quanticyt and 
Immunocyt.  Most have better sensitivity for detecting bladder cancer, but 
lower specificity with false positive tests leading to unnecessary imaging and 
bladder biopsies.   
New aids to the diagnosis of flat areas of TCC or Cis are currently being 
developed, as these lesions can often be missed using conventional white 
light cystoscopy.  These techniques were pioneered using 5-Aminolevulinic 
Acid (5-ALA), a molecule that is metabolised via the Haem biosynthesis 
pathway into protoporphyrin IX.  Protoporphyrin IX is a fluorescent molecule 
that is synthesised preferentially by tumour cells, accumulating about ten 
times the level of normal urothelium.  Combination with blue light fluorescence 
cystoscopy allows areas of TCC or carcinoma in situ (Cis) to be clearly 
visualised as red fluorescent lesions.  A newer molecule, Hexyl 5-
aminolevulinate (HAL) is now available for clinical use, with the advantage 
that it doubles the fluorescence with only half the instillation time of 5-ALA and 
also uses a lower drug concentration.  
Staging investigations 
Once the patient is anaesthetised bimanual examination is performed to 
assess whether there is a palpable mass and if so, whether or not it is fixed to 
the pelvic wall.  Another bimanual examination may be performed at the end 
of the resection to determine whether there is still a mass palpable, 
suggesting extravesical tumour.  Transurethral resection (TUR) of the bladder 
tumour is then performed taking care to preserve the architectural detail and 
relationship of the tumour to the various layers of the bladder wall to allow 
accurate pathological staging.   
Biopsy specimens of the tumour and suspected area should be taken to map 
the extent of the disease.  Both cold cup biopsies to preserve the histological 
architecture and TUR biopsies to determine the extent of the disease should 
be performed [86].  Random biopsies of normal mucosa are indicated in the 
presence of positive cytology, even in the absence of tumour, or in any non-
papillary tumour.  Random biopsies in patients with solitary papillary lesions   37
are contra-indicated because of the absence of additional information [87] and 
because of the risk of tumour implantation [88].  Prostatic urethral biopsies by 
TUR are indicated if there is suspicion of Tis in view of the high frequency of 
prostatic urethral involvement [89]. 
Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) are used 
to evaluate the extent of invasive bladder tumours and also to look for pelvic 
and abdominal lymph node metastasis.  CT cannot detect microscopic lymph 
node disease and can therefore only provide information on lymph node 
enlargement and possible liver metastases [90]. 
Bone scanning is only recommended in patients who have a raised alkaline 
phosphatase or are suffering from bone pain [91].  
Pathological staging and grading of bladder cancer 
Bladder cancer is staged using the TNM staging system, first introduced by 
the Union International Contre le Cancer (UICC) in 1992.  The TNM 
classification is updated periodically based on new prognostic information 
creating more sub-stages that more accurately predict survival.  The latest 
version introduced in 2002 is shown below [92] (Figure 6 / Table 3).  This 
update divided the T2 stage into T2a (inner half) and T2b (outer half). 
The T (Tumour) stage relates to the degree of local invasion of the primary 
tumour, the N (Node) stage indicates the extent of nodal involvement and the 
M (Metastasis) denotes whether any metastases are present.   
Initial TNM staging is based on a combination of clinical examination and 
radiological imaging.  Tumours that are resected endoscopically or excised at 
open operation are submitted to histological staging, the tumour stages then 
receive the prefix pT.  Muscle invasive tumours treated with radiotherapy or 
chemotherapy do not therefore receive a definitive pathological T stage, which 
has implications when comparing different treatment modalities in bladder 
cancer.  
Approximately 75 – 80% of patients present with disease confined to the 
mucosa (stage Ta – Tis) or submucosa (T1), so-called non-muscle invasive 
(superficial) cancers.  The other 15 – 20% have muscle invasion or nodal 
disease (T2 – 4, N+) at presentation [93].  
The grouping of tumours confined to the mucosa and submucosa (Ta, Tis and 
T1) together as the so-called “non-muscle invasive” or “superficial” bladder   38
cancers remains controversial as the potential for recurrence and/or 
progression in each of these tumour types is vastly different.   
Molecular biology techniques and clinical experience have demonstrated the 
highly malignant and invasive potential of Tis and T1 lesions [94,95]. 
For Ta disease the chance tumour recurrence and progression to invasive 
disease is 2 – 4% compared to 30% for T1 lesions.   
Tis, also known as carcinoma in situ (Cis) should not be regarded as 
superficial disease as it carries a high risk of developing aggressive invasive 
disease over time [96].  Between 40 and 83% of patients with Tis treated by 
endoscopic resection alone will progress to muscle invasive disease [97].   
Tis is therefore widely regarded as a separate entity to Ta and T1 disease and 
consequently treated more aggressively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6:    TNM Staging of Bladder cancer (Figure reproduced with kind 
      permission of Cancer Research UK).   39
 
 
T (Primary tumour) 
 TX  Primary tumour cannot be assessed 
  T0  No evidence of primary tumour 
  Ta  Non-invasive papillary carcinoma 
  Tis  Carcinoma in situ (“flat tumour”) 
  T1a  Tumour invades subepithelial connective tissue 
  T2  Tumour invades muscle 
T2a   Tumour invades superficial muscle (inner half) 
T2b  Tumour invades deep muscle (outer half) 
  T3  Tumour invades preivesical tissue  
  T3a  microscopically 
  T3b  macroscopically (extravesical mass) 
  T4  Tumour invades any of the following: prostate, uterus, vagina, 
    pelvic wall, abdominal wall 
T4a  Tumour invades prostate, uterus or vagina 
  T4b  Tumour invades pelvic wall or abdominal wall 
N (Lymph nodes) 
 NX  Regional lymph nodes cannot be assessed 
 N0  No regional lymph node metastasis 
  N1  Metastasis in a single lymph node 2cm or less in greatest dimension 
  N2  Metastasis in a single lymph node more than 2cm but not more than 
    5cm in greatest dimension, or multiple lymph nodes, none more than 
    5cm in greatest dimension 
  N3  Metastasis in a lymph node more than 5cm in greatest dimension 
M (Distant metastasis) 
 MX  Distant metastasis cannot be assessed 
 M0  No distant metastasis 
  M1 Distant  metastasis 
 
 
Table 3:    Bladder cancer staging:  2002 TNM classification    
      approved by the Union International Contre   le Cancer (UICC)  
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Bladder cancers of any pathological stage are also subjected to histological 
grading.  In 1998, a new classification of non-invasive urothelial tumours was 
proposed by the World Health Organization (WHO) and the International 
Society of Urological Pathology (ISUP) (1998 WHO/ISUP classification) and 
published by the WHO in 2004 [98,99] (Table 4).   
 
 
2004 WHO grading 
Urothelial papilloma 
Papillary urothelial neoplasm of low malignant potential (PUNLMP) 
Low-grade papillary urothelial carcinoma 
High-grade papillary urothelial carcinoma 
 
 
  Table 4:    2004 WHO Histological grading  
 
This grading system differentiates between papillary urothelial neoplasms of 
low malignant potential (PUNLMP) and low-grade and high-grade urothelial 
carcinomas. PUNLMP are defined as lesions without cytological features of 
malignancy but having normal urothelial cells in a papillary configuration.  
They have a negligible risk of progression, but are not completely benign and 
still have a tendancy to recur.  Tumour grade also has profound effects of 
recurrence rates [100-103]. 
Treatment 
Following primary resection and staging investigations, the patients’ cancer 
can be classified as either non-muscle invasive (Ta – T1), carcinoma in situ 
(Cis) or invasive (T2 – T4, N+).  The treatment and follow-up of these three 
groups is vastly different and is outlined below. 
Treatment of Ta – T1 lesions  
The treatment of Ta – T1 lesions should take into account the risk of disease 
recurrence and progression, side effects and cost effectiveness.  Non-muscle 
invasive cancers have a tendency to recur even after adequate treatment 
[95,104].  The risk of progression to invasive cancer is low in the majority of 
these cancers, but increases to 50% in high-grade T1 G3 tumours [94,95].    41
Following disease staging at initial TUR and with radiological investigations, 
the risk of disease recurrence and progression can be calculated from the 
clinical and pathological findings.  Several prognostic factors have been 
identified that may predict tumour behaviour [105-108].  For disease 
recurrence they are: 
1. Number  of  tumours present at diagnosis 
2.  Recurrence rate in the previous period; a recurrence at 3 months 
3.  Size of the tumour: the larger the tumour the higher the risk of recurrence 
4.  Histological grade of the tumour: Poorly differentiated or undifferentiated 
tumours showing higher recurrence rates 
For progression to invasive disease, the histological grade and T-category are 
the most important.  Tumours of the bladder neck have a worse prognosis 
than elsewhere [109]. 
Based on prognostic factors, superficial bladder cancers can be divided into 
the following risk groups: 
    Low-risk:  single, Ta, G1, < 3cm diameter 
    High-risk:  T1, G3, multifocal or highly recurrent, Cis 
      Intermediate:  All other tumours, Ta – T1, G1 – G2, multifocal,  
     >3cm  diameter 
Following transurethral resection of non-muscle invasive bladder tumours, a 
single chemotherapeutic instillation with epirubicin or mitomycin C within 6 
hours is able to reduce the recurrence rate by 50%.  This treatment is 
therefore advocated in all cases of superficial bladder cancer, except where 
bladder perforation is suspected [110,111].   
Low-risk tumours (Single, Ta – T1, G1 smaller than 3cm diameter and 
papillary tumours) need no further treatment as their risk of progression is 
very low with this management (<0.2% / year). 
Tumours of intermediate- or high-risk of recurrence (recurrent multiple, Ta – 
T1, G1 – G2) should receive a further 4 – 8 week course of intravesical 
chemotherapy instillations followed by monthly maintenance instillations up to 
6 months post-TUR [112].   
Recurrent disease should be treated in the same way.  In cases of highly 
recurrent tumours or multiple recurrence, Bacille Calmette Guerin (BCG) 
therapy should be instituted as this has been shown to be effective [113,114].   42
BCG instillations 
The mechanism of BCG activity is not yet understood, although most 
evidence points towards some immunotherapeutic mode of action.  BCG 
immunotherapy is more effective in high-risk non-muscle invasive bladder 
cancer and has been shown to prevent disease progression [115,116].  Six-
weekly induction instillations are required to elicit an immunological response 
followed by three booster cycles to obtain a good immunological reaction.  In 
papillary, Ta – T1, G1 – G2 tumours, the dose can be reduced to 25% whilst 
maintaining the same effectiveness as the full dose and reducing side effects 
[117-119]. 
BCG maintenance therapy up to 3 years given at 3 – 6 monthly intervals has 
been reported to lead to lower disease recurrence rates [116].  Whilst this 
heavy schedule is not suitable for all patients, it is suitable for patients with 
highly recurrent and high risk non-muscle invasive bladder tumours.  
Chemotherapy may still be effective after failure of BCG therapy and vice 
versa.      
Treatment of Tis 
The current standard treatment of Tis consists of intravesical BCG instillations 
given over a 6-week period.  Complete remission is obtained in up to 70% of 
cases.  If cytology and biopsies remain positive a further cycle of treatment 
may induce an additional 15% complete remission.  Maintenance therapy with 
booster cycles at 3, 6, 12, 18, 24, 30 and 36 months are indicated in order to 
prevent recurrence of this highly malignant disease.  If a second cycle of 
treatment does not achieve a cure or if there is early disease recurrence, 
cystectomy with urethrectomy is indicated.  Bladder preservation is achieved 
in 70% of cases. 
Treatment of T1 G3 bladder tumours 
T1 G3 tumours represent 10% of all non-muscle invasive tumours and 
progress to invasive disease in up to 50% of cases [94,95].   Because of this 
high progression rate some experts tend to carry out early cystectomy with 
excellent long-term survival rates.  However, several studies have 
demonstrated that 50% of patients with T1 G3 tumours can conserve their 
bladder with intravesical chemotherapy or BCG instillations [113-116,120].  
Factors that may influence a decision towards cystectomy include solid   43
appearance of the tumour (as opposed to papillary), high recurrence rate, 
multiplicity of tumours and the presence of concomitant Tis.     
Follow-up of non-muscle invasive bladder cancer after TUR 
Cystoscopy is the gold standard of follow-up, with flexible cystoscopy being 
well tolerated and more convenient for patients. 
Incomplete resection, tumour cell implantation at traumatised sites in the 
bladder and rapid growth of epithelial malignancy all contribute to higher 
recurrence rates of non-muscle invasive bladder cancer after TUR at 3 
months.  Early cystoscopy is therefore advised in all cases of superficial 
bladder cancer.  In higher risk lesions (T1, G2 and G3), another resection at 
the site of the TUR should be performed within 3 months.  In this group of 
tumours, repeat TUR will yield positive biopsies in up to 35% at 4 – 6 weeks 
after the initial resection [121].  Early repeat TUR can be justified on these 
grounds alone, but the effect of early re-TUR on the outcome of these 
tumours compared to cystoscopy and re-TUR at 3-months has not been 
established. 
The frequency of follow-up cystoscopies should be tailored to the prognostic 
factors of the tumour [122].  In non-muscle invasive bladder cancer the 
recurrence rate is highest in the first 2 years of follow-up, with the number of 
positive cystoscopies becoming less frequent thereafter.  In low-risk tumours 
(single, primary, Ta G1, < 3cm diameter) with no recurrence at 3 months, a 
follow-up cystoscopy can be delayed until 9 months later followed by yearly 
cystoscopies for up to 5 years because of the very low recurrence rate [123].   
In over 95% of cases the histological findings of recurrent tumours are the 
same as those of the primary tumour.  In patients with high-risk tumours, 
cystoscopy is performed every 3 months during the first 2 years.  The 
frequency of cystoscopy is then reduced to every 4 months in the third year, 
every 6 months until the fifth year and thereafter on a yearly basis.  The 
schedule of follow-up in the intermediate group lies between that of the low- 
and high-risk groups.  After any disease recurrence, the cystoscopy schedule 
is restarted from the beginning.   
Kaplan-Meier curves of bladder cancer recurrence rates demonstrate a 
continuous downward trend with time without plateau formation.  Recurrences 
continue to occur during follow-up for up to 10 – 12 years [123-125].  Patients   44
with regular recurrence will continue to have recurrences until cystectomy or 
death.  Patients with recurrences during the first 4 years after TUR continue to 
have lifelong recurrences [124].   
From the available data, follow-up may be stopped after 5 years in single Ta 
G1 tumours with absence of recurrence.  In all other cases, yearly follow-up is 
advised for up to 10 years, with lifelong follow-up for the high-risk group [125].    
Treatment of Muscle-Invasive Bladder cancer (T2+) 
Radical Cystectomy 
Radical cystectomy is widely regarded as the gold standard treatment for 
muscle invasive bladder cancer.  Muscle-invasive disease (T2 – T4a, N0-NX, 
MO) is the primary indication for radical cystectomy.  Other indications include 
high-risk superficial tumours (T1 G3 and BCG-resistant Tis) and extensive 
papillary disease that cannot be controlled with conservative measures.  
Contraindications for cystectomy are major co-morbidity and patients not 
willing to accept the surgical risks.  Patients who are keen to preserve their 
bladder may also opt for primary radiotherapy and/or chemotherapy, reserving 
cystectomy for salvage treatment if necessary.   
The overall staging error between clinical and pathological staging can be as 
high as 44% [126] and appears to be highest for T2 tumours [127].  The 
frequency of regional lymph node metastases varies with T stage, from less 
than 10% in T1 to almost 33% in T3 – T4 disease. 
The operative mortality from radical cystectomy is between 1.2 and 3.7% 
[128,129].  Early surgical morbidity is around 30% but is usually transient 
[130,131].  The risk of impotence is high and age dependant [132].  Late 
morbidity usually relates to urinary diversion. 
Survival rates 
The 5-year survival rate lies within the range of 40 – 60% and has not 
significantly improved in recent times.  The use of pre-operative radio- or 
chemotherapy has not improved these outcomes.  A recent study reported 5-
year stage specific survival rates for radical cystectomy alone of 75% of stage 
pT1, 63% for stage pT2, 31% for stage pT3 and 21% for stage pT4 disease 
[133].  Approximately 10% of cystectomy specimens are without tumour 
(stage pT0) due to radical TUR.  It is uncertain whether or not this confers any 
survival advantage [134,135].  Tumour stage and nodal involvement are the   45
only independent predictors of long-term survival [136].  P53 overexpression 
and mutation are not superior to staging as prognostic markers [137,138]. 
Radiotherapy 
Definitive radiotherapy with curative intent and the aim of bladder preservation 
is performed in T1 – T4, N0, M0 TCC of the bladder.  There are no adequate, 
modern, randomised trials comparing radiotherapy and cystectomy.  When 
selection bias in radiotherapy series is taken into account, radiotherapy 
produces comparable survival values to cystectomy.  A large multinational 
randomised investigation into the role of neoadjuvant chemotherapy in the 
management of muscle-invasive bladder cancer showed selection bias for 
radiotherapy as opposed to cystectomy, with patients undergoing 
radiotherapy having a generally poorer performance status [129].  The 
decision for or against radiotherapy is therefore based on prognostic factors, 
patient co-morbidities and desire to preserve their bladder.   
Factors that give a more favourable outcome with external beam radiotherapy 
are low T-stage disease (T2), solitary tumour, lack of upper urinary tract 
dilatation and complete TUR of all visible tumour [139]. 
Other factors that may improve outcome are normal haemoglobin level, low 
tumour volume (<5cm diameter) and lack of concomitant Cis [140-143].   
External beam radiotherapy is delivered in 30 – 40 fractions in doses up to 
68Gy [140,141].    
Local recurrence or recurrence elsewhere in the bladder will occur in more 
that 30% of patients undergoing bladder preserving treatment.   
Modern radiotherapy techniques involve the use of CT-planned radiotherapy, 
which allows more accurate delivery of treatment and reduces the incidence 
and severity of side effects.  Radiotherapy complications include enteritis, 
proctitis and cystitis, which are usually self-limiting.  Late toxic effects 
including radiation cystitis (5%), proctitis (5%) and bowel obstruction (3%) are 
less common in more recent series [141,142,144].  Erectile dysfunction 
occurs in more than two-thirds of male patients [145].    
The 5-year survival rate after definitive external beam radiotherapy is reported 
as 60 – 80%, 26 – 59% and 20 – 38% for T1, T2 and T3 tumours respectively.  
Patients with T4 tumours rarely survive for 5 years without tumour progression 
[140,141,144,146,147].  A recently published series reported a 10-year   46
disease specific survival of 42%, with an over 80% bladder preservation rate 
in the survivors [148].  With modern techniques with increased accuracy of 
treatment, via CT-guided radiotherapy, local disease control is much improved 
with approximately 70% of patients having no signs of disease in their 
bladders at first cystoscopy [148,149].  Local recurrence or the development 
of a second bladder tumour occurs in approximately 50% of patients [141].  
These patients will require salvage cystectomy, with a favourable long-term 
outcome being achieved in up to 40% [144].  The morbidity of salvage 
cystectomy after radical radiotherapy is higher when compared to unirradiated 
patients.  Despite this salvage cystectomy with bladder reconstruction is still 
possible [150], so patients should not be denied bladder-conserving treatment 
due to concerns about bladder reconstruction in the irradiated pelvis.    
Contraindications to radiotherapy for bladder cancer include inflammatory 
bowel disease, extensive previous pelvic surgery, previous radiotherapy or 
severe irritative bladder symptoms.  Relative contraindications to radiotherapy 
are concomitant carcinoma in situ, a large primary tumour or ureteric 
obstruction.  The elderly tolerate pelvic irradiation as well as younger patients 
so age alone is not a contraindication to radiotherapy [151] or even 
synchronous chemoradiotherapy [152].   
Hypoxia has been shown to be clinically important in TCC of the bladder.  
Several trials have assessed the effects of modifying tumour hypoxia either 
with hyperbaric oxygen or hypoxic cell sensitizers, with promising results.  A 
recently published phase II study [153] of bladder cancer patients treated with 
nicotinamide and carbogen (95% O2 with 5% CO2) in combination with 
radiotherapy showed significant improvements in local control, disease-free 
survival and overall survival, when compared to historical controls.  The 
ARCON study (funded by Cancer Research UK), a multicentre, randomised, 
controlled trial comparing conventional radiotherapy with radiotherapy given in 
combination with nicotinamide and carbogen is currently recruiting in the UK.    
There is increasing evidence that combination of cisplatin chemotherapy with 
radiotherapy improves local control rates up to 80% in T2 – T3 tumours 
[144,154-156], but it is unclear whether this regimen has led to improved 5 
year survival rates.  Randomised trials comparing radiotherapy with 
chemoradiotherapy are lacking.   47
Pre-operative radiotherapy has been shown to down-stage muscle-invasive 
bladder cancers.  A meta-analysis of the results of randomised controlled 
trials of pre-operative radiotherapy in muscle-invasive bladder cancer 
concluded that the available clinical trial data does not support the routine use 
of pre-operative radiotherapy, but that additional well-designed trials are 
needed [157].    
Follow-up after external beam radiotherapy 
Life-long follow-up is required using cystoscopy, exfoliative urine cytology and 
other investigations to detect disease dissemination, as in patients who 
undergo cystectomy.  Recurrent Tis and Ta TCC can be treated with 
intravesical immunotherapy (Tis) or TUR and adjuvant intravesical therapy.  
Patients with muscle invasive tumours should undergo radical cystectomy 
wherever possible.  
Systemic chemotherapy  
Up to 50% of patients who have undergone radical cystectomy for muscle 
invasive bladder carcinoma may develop metastases, usually occurring within 
2 years of surgical resection [158].  Systemic, cisplatin-based chemotherapy 
regimens produce response rates in 40 – 70% of bladder tumours and are 
now being used in locally invasive disease in combination with cystectomy or 
radiotherapy, as either neo-adjuvant or adjuvant therapy.  Most trials of 
chemotherapy in bladder cancer have used a combination of Methotrexate, 
Vinblastine, Adriamycin (Doxorubicin) and Cisplatin (M-VAC) which is only 
suitable for patients with good performance status and good renal function, as 
it carries a 3% risk of death due to toxicity.  Recent studies have reported the 
use of Gemcitabine and Cisplatin in advanced bladder cancer which has 
shown equal efficacy with much less toxicity [159].   
Neo-adjuvant chemotherapy 
Non-randomised studies have clearly established the feasibility and safety of 
giving neo-adjuvant chemotherapy.  Overall response rates of 60 – 70% with 
complete responses in around 30% of cases have been reported [158].  Neo-
adjuvant chemotherapy can “downstage” tumours to the extent that 
inoperable cases may become operable [129,160].  Several studies of 
neoadjuvant chemotherapy have shown that the cystectomy specimen is pT0 
in a higher proportion of patients who have had initial neoadjuvant   48
chemotherapy combined with a TUR (20 – 40 %) compared to TUR alone (7 – 
17%) [154].   
The Medical Research Council (MRC) Meta-analysis group obtained original 
patient data from 10 prospective randomised trials of neo-adjuvant 
chemotherapy, with >2600 patients eligible for analysis [139].  This analysis 
revealed conflicting results from several of the studies, some showing benefit 
and others not.  The largest single study, a multinational trial co-ordinated 
jointly by the MRC and EORTC [129], recruited almost 1000 patients and was 
powered to detect a 10% survival improvement at 3 years.  Initial analysis of 
the data, at median follow-up of 4 years, failed to show a clinically worthwhile 
benefit for patients who underwent three cycles of chemotherapy (cisplatin, 
methotrexate, vinblastine) before definitive treatment with cystectomy +/- pre-
operative radiotherapy or radiotherapy alone.  The respective 3-year survival 
was 50% and 55.5%.  A more recent analysis, now with a median follow-up of 
7 years, is of interest, as there were several late events [161].  The difference 
in absolute survival at 5 and 7 years remained 6% (44% vs 50% (p=0.075) 
and 37% vs 43% (p=0.048)) but the additional events added statistical power, 
meaning this difference has now reached statistical significance [161].  Patient 
data from the original South West Oncology Group neoadjuvant study showed 
a 14% survival benefit at 5 years, but this did not reach statistical significance 
(p=0.06) [162]. 
Response to chemotherapy is also an important predictor of survival in 
bladder cancer patients.  The 5-year survival rate is 75% in patients who had 
down-staging of the primary tumour to pT0 or superficial disease compared to 
only 20% in patients who had residual muscle-infiltrating disease (>pT2) 
[163,164]. 
Neo-adjuvant chemotherapy and bladder preservation 
Selected patients with invasive bladder tumours after neo-adjuvant 
chemotherapy may preserve their bladders [165].  Long-term disease free 
survivors, 55 – 70% at 33 – 60 months, have been reported among patients 
with muscle-invasive cancers that have been treated by neo-adjuvant 
platinum based chemotherapy regimens alone, where their planned radical 
procedure was not carried out [157].     49
Bladder preservation may be possible in approximately 40% of patients using 
a combination of chemotherapy and radiotherapy [156,166-170], with 5-year 
survival rates between 42% and 63%.  Several groups have selected patients 
suitable for bladder preservation based on the response of the primary tumour 
to chemotherapy, with or without radiotherapy after TUR.  If their tumour is 
responsive this treatment is followed up with a course of radiotherapy with 
curative intent.  Prognostic factors for local disease curability were small 
tumour size, absence of hydronephrosis, papillary histology, visible complete 
TUR and complete response to induction chemotherapy.  These combination 
regimens have however not been confirmed by randomised trials.    
Bladder preservation in selected patients with muscle-invasive bladder cancer 
treated with either extensive TUR or partial cystectomy alone, have been 
reported in several published series.  Survival rates in some of these series 
are equivalent to those in conventional cystectomy series [157]. 
Other series have reported results of treatment with systemic chemotherapy, 
either platinum-containing regimens or high-dose methotrexate, combined 
with conservative surgery, either extensive TUR or partial cystectomy.  
Survival rates for these selected patients are similar to those reported after 
cystectomy, many surviving with intact and functioning native bladder.   
Randomised controlled trials comparing survival and quality of life after radical 
surgery and bladder reconstruction with a modern bladder conserving 
approach combining extensive TUR, systemic chemotherapy and 
radiotherapy are needed.  
A randomised, multicentre UK trial of Selective bladder Preservation Against 
Radical Excision (cystectomy) in muscle invasive T2 / T3 transitional cell 
carcinoma of the bladder (SPARE trial) aims to recruit 1015 patients by 2014.  
Recruitment began in July 2007 and to date 24 patients have been enroled in 
this study (personal communication - Rebecca Lewis, SPARE trial 
coordinator).  Following 3 cycles of neo-adjuvant chemotherapy patients will 
undergo cystoscopy.  Responders will be randomised to have either radical 
cystectomy or radical radiotherapy, with a fourth cycle of chemotherapy being 
given before definitive local treatment.  Non-responders will undergo 
immediate radical cystectomy.     50
Adjuvant chemotherapy 
Adjuvant chemotherapy is given to patients who have undergone potentially 
curative, definitive local treatment and who are apparently disease-free, but 
are at high risk of recurrence or metastasis.  A few trials have attempted to 
assess the impact of adjuvant chemotherapy on survival of patients with 
bladder cancer [171-175].  However, these published series have been 
criticised because the trials were stopped early, they included too few 
patients, or inappropriate statistical analysis was used.  Large multicentre 
trials are needed to clarify the role of adjuvant chemotherapy.  A major 
international collaborative study is underway, coordinated by the European 
Organisation for the Research and Treatment of Cancer (EORTC) 
Genitourinary group, designed to establish the value of immediate post-
operative chemotherapy versus chemotherapy deferred until relapse (EORTC 
30994).  Eligible patients must have had a radical cystectomy and bilateral 
lymphadenectomy for a TCC, pT3 or pT4 and/or node-positive (pN1 – 3), be 
free of any evidence of residual disease and be fit for treatment with cisplatin-
based chemotherapy regimen.  Patients will be randomised to receive either 
four cycles of chemotherapy given immediately after cystectomy, or deferred 
until relapse.  The primary endpoint of the trial is survival.  Recruitment of 
1344 patients is required to detect a 7% improvement in absolute survival at 5 
years, from 35% to 42% in the immediate chemotherapy arm [139].    
Palliative treatment of bladder cancer 
All treatment modalities are used in the palliative treatment of patients with 
metastatic or locally advanced bladder cancer.   
Radiotherapy provides effective palliation of local, cancer-related symptoms in 
bladder cancer.  Regimens in which fewer relatively larger fractions are given 
are more convenient and less distressing for patients.  A large prospective 
randomised trial of palliative radiotherapy in bladder cancer [176], showed 
68% of patients had symptomatic improvement with palliative radiotherapy.  
Haematuria is well palliated by radiotherapy in 50-90% of patients [176].  
Dysuria and frequency are only improved by radiotherapy in approximately 
20% of patients.      51
Prevention  
As with all diseases prevention is better than cure.  Bladder cancer has 
several known factors that lead to carcinogenesis.  Reduction in population 
smoking figures would dramatically cut the numbers of patients presenting 
with bladder cancer.  Reduction of worker exposure to industrial carcinogens 
would also lead to a reduction in bladder cancer incidence.  It has been 
calculated that there are 820 preventable cases and 630 preventable deaths 
from bladder cancer each year as a results of socio-economic deprivation [4].  
Additionally several dietary factors have been postulated to have a protective 
role against bladder cancer including green tea and Indole-3-carbinole (found 
in brassicas – cabbage, brussel sprouts, broccoli) [177].    
Prognosis 
Bladder cancer is one of the few cancers in which men have a substantial 
survival advantage over women.  Comparison of both 1 and 5-year survival 
rates demonstrates a clear survival advantage.  One- and five-year survival 
figures for patients diagnosed with bladder cancer in England and Wales and 
Wessex are shown in Table 5.  In patients diagnosed between 1991 and 1999 
figures for 1-year survival were 81 – 83% for men and 72 – 75% for women 
and 5-year survival figures were 64 - 70% for men and 56 - 65% for women.  
Survival in bladder cancer also appears to have a deprivation gradient with 
most affluent groups have around 6% better survival at both 1 and 5 years 
after diagnosis than more deprived groups.     
England 
and Wales 
1991-95 
1-year survival 
(%)      
1991-95 
5-year survival 
(%) 
1996-99 
1-year survival 
(%) 
1996-99 
5-year survival 
(%) 
Male  81.7 64.2 81.2 64.4 
Female  73.1 59.0 72.9 56.0 
South 
West  
1992-94 
1-year survival 
(%) 
1992-94 
5-year survival 
(%) 
1994-96 
1-year survival 
(%) 
1994-96 
5-year survival 
(%) 
Male  82 70 83.7  68.8 
Female  72 64 75.0  64.5 
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  The prognosis of individual patients with bladder cancer obviously depends 
largely on the stage and grade of their disease.   
For superficial disease, the European Organisation for Research and 
Treatment of Cancer (EORTC) have developed tables that can predict the 
chances of disease recurrence and progression, based on variables including 
T category, grade, primary or recurrent tumour, number and size of tumours 
and the presence of concomitant Cis [103].  On the EORTC website 
(www.eortc.be), there is a calculator which utilises the EORTC Risk Tables for 
Stage Ta T1 Bladder Cancer, to predict the probability of recurrence and 
progression for the individual patient over the next 5 years.   
Similar nomograms have been developed for predicting the 5-year risk of 
recurrence following radical cystectomy [178].  This nomogram predicts the 
probability of remaining disease free 5 years after cystectomy, based on 
variables including sex, age, number of days from diagnosis to cystectomy, 
pathological stage, tumour grade, histological type, and pathological node 
status.  The Memorial Sloan-Kettering Cancer Centre (MSKCC) website 
(www.mskcc.org) provides an easy to use calculator based on this 
nomogram.    
As highlighted earlier, cancers which express several oncogenes or tumour 
suppressor genes have been associated with a poorer prognosis.  Several 
studies have investigated whether any of these markers could predict 
response to treatment.  Altered p53 has been the most studied in this area.   
In terms of surgery, p53 status could not predict which patients would suffer 
recurrence or die following cystectomy and thus could not identify patients in 
whom cystectomy would be beneficial [179]. 
In studies of chemotherapy treatment, altered p53 expression was shown to 
be an independent prognostic marker for survival and an indicator of 
treatment failure in patients with invasive bladder cancer treated with 
neoadjuvant MVAC (methotrexate, vinblastine, adriamycin (doxorubicin) and 
cisplatin) [180].  However, some have reported opposing findings suggesting 
that only those with abnormal p53 expression associated with local and 
regionally extensive TCC benefit from cisplatin-based chemotherapy [181]. 
There are however several problems with using p53 as a prognostic utility in 
the clinical setting which would need to be resolved before it could be used   53
widely as a prognostic indicator and guide to treatment.  Currently, there is no 
consensus as to how many tumour cells must exhibit nuclear overexpression 
of p53 before it can predict the response of that tumour to treatment.  There 
are also several technical factors that need to be resolved and standardised 
including antibodies used to detect p53, means of tissue preservation (frozen 
or formalin fixed) and methods of optimising antigen detection and 
quantification.      54
1.2:  Chemotherapy in bladder cancer 
Chemotherapy has been used widely in bladder cancer, both as intravesical 
and systemic chemotherapy.  Intravesical chemotherapy following 
transurethral resection has a clearly proven role in the prevention of 
superficial TCC recurrence and is now part of standard care.  Systemic 
chemotherapy is starting to find a role in the neoadjuvant setting following 
recent meta-analyses confirming a survival benefit.  However, adjuvant 
systemic chemotherapy is still awaiting trial data to support its use.   
Intravesical chemotherapy 
Various anticancer agents have been instilled directly into the bladder in order 
to reduce recurrence rates in superficial bladder cancers, so-called 
intravesical chemotherapy.  These agents include cytotoxic drugs and 
immunotherapeutic agents including BCG alone or in combination with 
various interferons.   
We will deal only with cytotoxic drugs in this section, as it is these drugs that 
are susceptible to the multidrug resistance phenomenon which is the main 
focus of this research.  
The rationale for intravesical chemotherapy 
Eighty percent of bladder cancers are superficial, meaning that their major risk 
is of recurrence rather than disease progression.  It is for this reason that 
ways of providing local control were sought and hence intravesical 
chemotherapy came into being.   
The rationale for intravesical chemotherapy was based on the easy 
accessibility of the bladder via catheterisation allowing administration of local 
therapy and the ability to give relatively high doses with minimal systemic 
absorption and side effects.   Practically, local side effects of cystitis have 
limited the doses that can be given. 
Intravesical chemotherapy can either be adjunctive, prophylactic or 
therapeutic.  Adjunctive chemotherapy is when a single instillation is given 
immediately post-TURBT in order to kill tumour cells that are liberated as a 
result of tumour morcellation.  The aim is to prevent tumour cell implantation 
and recurrence by that mechanism.  Prophylactic use is where intravesical 
chemotherapy is given as a course of repeated instillations after complete 
tumour resection.  This aims to prevent new recurrences forming from a   55
genetically unstable urothelial field change, as is found in a significant 
proportion of bladder cancer patients.  Therapeutic use means repeated 
instillations to treat residual unresected disease, either carcinoma in situ (Cis) 
or extensive papillary tumour.   
Intravesical chemotherapy regimens should be tailored to the patient’s 
disease.  Giving a single dose of intravesical chemotherapy post-operatively 
is now part of routine clinical practice, with further courses being dictated by 
clinical and histological features that predict a higher chance of recurrence.    
In terms of the choice of drug to use, there is no single best agent for 
intravesical chemotherapy.  The features that would be desirable in a “gold-
standard” drug would be prevention of recurrence and disease progression in 
100% of cases, requiring only a single instillation to do so.  The cost of the 
drug should be reasonable and there should be no local or systemic toxicity.  
The optimal course of intravesical chemotherapy is not known. 
Chemotherapeutic agents need to be in direct contact with the urothelium to 
be effective.  Most chemotherapeutic agents are cell cycle dependent 
meaning that they only affect dividing cells, meaning that repeated instillations 
are necessary to produce a response with tumour cell killing.  The 
concentration of the drug and the dwell time in the bladder are also important 
determinants of tumour cell kill with chemotherapy but studies looking at these 
variables are lacking.   
A brief history of intravesical chemotherapy… 
The first use of intravesical chemotherapy in bladder cancer was reported by 
Jones and Swinney in 1961 [182].  They gave 16 patients with superficial 
tumours four doses of intravesical thiotepa, an alkylating agent.  Eight patients 
showed a significant response with their tumours almost completely 
disappearing at 6 and 12 week cystoscopies.  Two patients developed 
haematological problems following treatment, one a mild leucopenia and one 
severe thrombocytopenia requiring treatment.  It was later discovered that 
these haematological side effects were due to transvesical absorption of 
thiotepa.  Molecules smaller than about 200MW can be absorbed 
transvesically and thiotepa’s molecular weight is only 189.     
The first clinical trial of adjuvant intravesical chemotherapy using thiotepa was 
published in 1978 [183].  This study recruited 22 patients with recurrent TCC.    56
In group 1, patients were treated with 30mg of thiotepa twice daily for 3 days 
post-operatively.  Their recurrence free interval increased to 33 months 
compared to 9.5 months before treatment.  In group 2, patients were given 
additional intravesical thiotepa treatments indefinitely, their recurrence free 
interval increased to 41 months.  Two patients developed leukopenia from 
systemic absorption. 
The Medical Research Council (MRC) carried out a multicentre randomised 
clinical trial of either one or five installations of intravesical thiotepa (30mg) 
post-TURBT in the treatment of newly diagnosed superficial bladder cancer 
[184].  After transurethral resection, four hundred and seventeen patients 
were randomised to receive either: no thiotepa; one instillation of thiotepa at 
the time of resection or one instillation at the time of resection and then at 3-
monthly intervals for one year (five instillations in total).  The median follow-up 
for this study was 8 years and 9 months.  This study failed to demonstrate any 
difference between the three groups with respect to time to first recurrence, 
recurrence rates or the failure-free interval rate.  They concluded that thiotepa 
should not be used for patients with newly diagnosed superficial bladder 
cancer.     
A later EORTC randomised trial, compared adjuvant intravesical thiotepa, 
doxorubicin and cisplatin in 356 patients with recurrent superficial TCC [185].  
After transurethral resection of all visible tumour, patients were given their 
allocated intravesical chemotherapy weekly for 4 weeks and then monthly for 
11 months.  At a mean follow-up of 41 months, there were no significant 
differences between the treatments in terms of recurrence rate or disease free 
interval.    
Ethoglucid 1% (Epodyl), another alkylating agent was investigated in the 
1970’s in view of its lower risk of systemic absorption due to its higher 
molecular weight of about 250.   
One study reported the treatment of 44 patients with multifocal, superficial 
TCC with intravesical Epodyl [186].  Irritative cystitis occurred in 16 per cent of 
patients and they were withdrawn from the study.  In those patients who were 
able to tolerate the treatment without side effects, complete or partial 
responses were observed in 66% (19 of 29).     57
Ethoglucid failed to gain widespread use, due to its main side effect of severe 
chemical cystitis which occurred in a significant proportion of patients.    
Doxorubicin, an anthracycline antitumour antibiotic, was discovered 1969 
[187] and was soon demonstrated to have potent antitumour activity [188].  
This was the next drug to be evaluated as an intravesical agent.   
A study from the EORTC compared the treatment of superficial TCC with 
transurethral resection alone or transurethral resection followed by 
intravesical chemotherapy with either doxorubicin or ethoglucid for 1 year 
[189].  443 patients were randomised.  The time to first recurrence was 
significantly longer for both intravesical chemotherapy groups.  The 
recurrence rates per year were also significantly lower for both treatment arms 
compared to the resection only group (30% versus 68%).  There were no 
differences in progression rates or death from bladder cancer between the 
groups.  
The two most commonly used intravesical agents currently are epirubicin and 
Mitomycin C.   
Epirubicin, a semi-synthetic epimer of doxorubicin, was first introduced into 
clinical use in the 1970s [190].  It was first evaluated as intravesical treatment 
for superficial bladder cancer in the 1980s [191], where a complete or partial 
response rate was demonstrated in 55% of patients.   
Mitomcyin C was discovered in the 1960s [192] and its first intravesical use 
was in 1980 [193].  In this initial study, sixty-three patients with superficial 
TCC were given intravesical mitomycin C 20-60mg once a week for 8 weeks.  
The overall response rate was 67%, with a 45% complete remission rate.  
There were no systemic side effects and local side effects occurred 
infrequently.  
Mitomycin was later subjected to a head-to-head trial with thiotepa by the 
National Bladder Cancer Group [194].  They reported the results of a 
prospective randomized clinical trial comparing Thiotepa and Mitomycin C in 
the treatment of residual superficial TCC of the bladder.  Eight weekly 
instillations were given followed by cystoscopy 4 weeks after the treatment 
was stopped. Mitomycin C had a higher complete response rate than 
Thiotepa, 39 versus 26 percent.  When partial responses were included the   58
overall response rate increased to 63 percent for mitomycin C and 53 percent 
for thiotepa.   
Mitomycin C is the most commonly used intravesical cytotoxic agent in the UK 
currently.   
Intravesical chemotherapy: Randomised controlled trials and meta-
analyses  
Although earlier randomised controlled trials had demonstrated a clear benefit 
from intravesical chemotherapy following TURBT, it was only in the 1990s 
following the publication of a large EORTC trial using epirubicin and an MRC 
study using mitomycin C, that intravesical chemotherapy came to be used 
routinely following TURBT.     
EORTC trial of intravesical epirubicin: 
In 1993 the results of a prospective EORTC trial comparing transurethral 
resection followed by a single intravesical instillation of epirubicin or water for 
solitary Ta / T1 papillary bladder carcinoma were reported [111].   
This randomised multicentre trial included 431 eligible patients with solitary, 
primary or recurrent, Ta-T1, G1-3 bladder tumours.  Patients with carcinoma 
in situ were excluded.  The patients underwent standard transurethral 
resection of their tumours and were then randomised to receive a single dose 
of either epirubicin 80mg in 50ml of physiological solution or 50ml of sterile 
water, given within 6 hrs of resection for a period of 60 minutes.  All patients 
were followed up with cystoscopic surveillance, 3 monthly for the first year, 4 
monthly for the second year and 6 monthly thereafter.  They were evaluated 
by several criteria of disease recurrence, including disease free interval (the 
interval between initial TURBT and date of first tumour positive bladder 
biopsy), recurrence rate per year (the total number of positive cystoscopic 
studies divided by total years of follow-up from initial TURBT to the time of the 
last cystoscopic examination) and the tumour rate per year (the total number 
of tumours observed during all positive cystoscopic studies divided by the 
total years of follow-up from initial TURBT to the time of the last cystoscopic 
examination).   
The disease-free interval was significantly longer in the epirubicin group 
(p=0.02).  The recurrence rates per year in the epirubicin group and water 
group respectively were 0.17 and 0.32, which was a highly statistically   59
significant difference (p <0.0001).   The tumour rates per year were 0.31 and 
0.56 in the epirubicin and water groups respectively, again showing a 
statistically significant difference in favour of the epirubicin group (p = 0.01).  
Similar reductions in recurrence rates were noted in favour of the epirubicin 
group, in all subgroups examined as defined by T stage and grade.   
This study therefore concluded that a single intravesical instillation of 
epirubicin 80mg post-TURBT reduced the recurrence rate by nearly 50% 
compared to water at a mean follow-up of 2 years in single Ta-T1, G1-3 
transitional cell carcinomas of the bladder.  
MRC trial of intravesical Mitomycin C: 
In 1996, the results of an MRC randomised controlled trial looking at the effect 
of Mitomycin C on recurrence rates in newly diagnosed superficial bladder 
cancer were reported [110].  This study included 452 eligible patients with 
newly diagnosed Ta / T1, solitary or multifocal superficial TCC.  Patients with 
carcinoma in situ were excluded.  Following transurethral resection of their 
tumour(s) they were randomised into 3 groups: a control group who had no 
further treatment, Mitomycin C Group 1 who had a single instillation of 
Mitomycin C 40mg immediately after TURBT (MMC Group 1) and     
Mitomycin C Group 2 who had an instillation of Mitomycin C 40mg 
immediately after TURBT and 4 further instillations at 3-month intervals over 
the next 12 months (total 5 instillations) (MMC Group 2).  The initial 
instillations were all given within 24 hrs of TURBT (median time from TURBT 
to instillation was 1 hour) for 60 minutes duration. The patients then 
underwent cystoscopic surveillance 3 monthly for year 1, 6 monthly for year 2 
and annually thereafter.  The median follow-up was 7 years at the time of 
analysis.  The principal end points they used to assess the efficacy of 
Mitomycin C were the recurrence-free interval (interval to first recurrence from 
randomisation) and the recurrence rate during the initial 2 years (the number 
of positive cystoscopies divided by the total follow-up interval for 2 years).  
Secondary end points were progression to invasive disease, progression to 
metastases and death from bladder cancer.  These 3 secondary end points 
were combined to define the progression free interval for each of the 3 
groups.  Overall survival was also documented for each group.     60
Pairwise comparison of recurrence-free intervals showed hazard ratios for 
MMC Group 1 versus controls of 0.66 and for MMC Group 2 versus controls 
of 0.50 representing a decrease in subsequent risk of recurrence by an 
estimated 34% in MMC Group 1 and 50% in MMC Group 2.    
Pairwise comparison of annual recurrence rates in the first 2 years for the 
control group (recurrence rate 0.82), MMC Group 1 (recurrence rate 0.42) and 
MMC Group 2 (recurrence rate 0.31) are shown in the table 6 below. 
 
 
Comparison 
 
MMC Group 1  
versus 
Control 
 
 
MMC Group 2 
versus 
Control 
 
MMC Group 2  
versus 
MMC Group 1 
 
Ratio of 
recurrences* 
 
95% 
Confidence 
Interval 
 
P value 
 
 
0.52 
 
 
 
0.34 – 073 
 
 
0.001 
 
0.38 
 
 
 
0.26 – 0.53 
 
 
<0.001 
 
0.73 
 
 
 
0.48 – 1.11 
 
 
0.14 
 
  Table 6:    Data from MRC trial of intravesical mitomycin C in superficial 
      bladder cancer: Pairwise comparison of annual recurrence 
      rates in first 2 years 
       *Ratio of 1 indicates equivalence of groups being compared. Ratio <1  
      indicates annual recurrence rate in first 2 years was in favour of first  
      group listed in the comparison 
Both of the Mitomycin C groups had significantly lower annual recurrence  
rates than controls, with an estimated decrease in recurrence rates per year 
of 48% MMC group 1 and 62% in MMC group 2.   
Although the results for 5 instillations (MMC group 2) were better than for a 
single post-operative instillation (MMC group 1) across the board,  the 
difference between these two groups failed to reach statistical significance.  
This study also failed to demonstrate any significant difference in progression 
free interval or overall survival between the 3 groups, possibly because so few 
patients developed progressive disease or died.    
The MRC study group therefore concluded that intravesical mitomycin C,   61
either using single or multiple instillations, reduces the number of subsequent 
recurrences and increased the recurrence-free interval, but failed to 
demonstrate any benefit in terms of disease progression.   
Meta-analyses of intravesical chemotherapy trials: 
Several meta-analyses of the results of intravesical chemotherapy following 
transurethral resection have also been published.  These have all come out in 
favour of intravesical chemotherapy but have sought to answer specific 
questions about its applicability in terms of timing and length of use and 
specific patient groups.   
One meta-analysis looked at the question of early versus delayed instillations 
and short-term versus long-term treatment.  It used results from 2 EORTC 
studies looking at intravesical Mitomycin C and Doxorubicin [112].   
Early intravesical treatment, defined as instillation within 24 hours of TURBT, 
was found to be superior to delayed treatment, defined as instillation 7 – 15 
days post-TURBT (p = 0.01).   
Looking at the role of maintenance therapy, there appeared to be no benefit 
except in the delayed treatment group.  The results were equivalent in the 
early instillation with maintenance, early instillation without maintenance and 
the delayed instillation with maintenance groups, all of which were 
significantly superior to the delayed instillation without maintenance group.   
Another meta-analysis looked simply at adjuvant treatment versus no 
adjuvant treatment for superficial bladder cancer, with specific emphasis on its 
effect on disease-free interval and disease progression [104].  
They used the results from 4 EORTC studies and 2 MRC trials and showed 
that adjuvant treatment was significantly better than no adjuvant treatment in 
terms of disease-free interval (p<0.01).  However they failed to demonstrate a 
clear advantage of adjuvant treatment with respect to progression to invasive 
disease, time to metastases, duration of survival or progression-free 
survival.  The trials included in this meta-analysis were heterogeneous in 
terms of the drug used, mode of administration, dose, duration of instillations, 
interval between instillations and duration of treatment, so no other 
conclusions were drawn.    62
A further meta-analysis looked more specifically at intravesical chemotherapy 
for primary superficial bladder cancer and the effect of the duration of 
treatment on recurrence rates [195].  
It examined the results of 3703 patients from 11 randomized trials.   
Overall intravesical chemotherapy was found to reduce the 1 year recurrence 
rate by an average of 44%.  They then examined the results by duration of 
treatment.  Short-term protocols, where patients has a single instillation or 
multiple instillations for less than 2 months following TURBT, showed a 
reduction in 1 and 2 year tumour recurrence rates of 30% and 32% 
respectively.  One-year protocols where patients received regular intravesical 
instillations for 1 year post-TURBT, demonstrated a reduction in 1 and 2 year 
tumour recurrence rates of 35% and 31% respectively.  Two-year protocols 
where patients received intravesical instillations for 2 years following TURBT, 
showed a reduction in 1 and 2 year tumour recurrence rates of 80% and 73% 
respectively.  This discrepancy between the results of 1 and 2 year protocols 
was curious.  In the 2 year protocols instillations were often more frequent, 
with one study giving instillations every 2 weeks for the first year and then 
monthly for the second year, whereas some of the 1 year protocols only gave  
patients instillations every 3 months.  This suggested that a dose response 
may account for the differences in the results of the 1 and 2 year protocols.  
Another meta-analysis focused on the impact of intravesical chemotherapy on 
recurrence rates in recurrent superficial TCC [196].   
Meta-analysis of results for 1609 patients from 8 randomised trials 
demonstrated a reduction in 1-year tumour recurrence rates of an average of 
38% in those having adjuvant intravesical chemotherapy.  Odds ratios for 2 
and 3 year recurrence were 0.46 (95% CI 0.33-0.63; p=0.006) and 0.35 (95% 
CI 0.23-0.54; p<0.001) respectively, favouring TURBT with adjuvant 
chemotherapy over TURBT alone.          
An additional meta-analysis examined the effect of a single immediate post-
operative instillation of chemotherapy in reducing the risk of recurrence in 
patients with solitary or multifocal superficial bladder cancer [Sylvester RJ et 
al. 2004].  They reviewed the results of 1476 patients from 7 randomised 
trials.  Chemotherapy reduced the risk of recurrence by 39% overall 
(p<0.0001), with a significant effect being seen for both single and multifocal   63
tumour patients.  However, the overall recurrence rate for those with multiple 
tumours was 65.2% compared to 35.8% for single tumours, suggesting that a 
single instillation is insufficient treatment for those with multifocal disease.   
Optimising intravesical chemotherapy: The variables 
Timing of instillations: 
Most of the trials reporting benefits from intravesical chemotherapy following 
TURBT have given a single dose within 6 hours of surgery.  It is therefore 
recommended that where possible chemotherapy should be given within this 
time frame to achieve its maximum benefit.   
Dosing of drugs: 
Very few trials have been performed looking at optimising drug doses for 
intravesical chemotherapy.  Logically one would assume that higher drug 
doses would be more effective, but this has to be balanced against side 
effects of chemical cystitis that may impact of the patients ability to retain the 
drugs for enough time to be effective.   
Improving the pharmacokinetics of intravesical agents: 
Several factors may affect the efficacy of intravesical chemotherapy including, 
drug dilution with residual urine or excessive urinary output during the 
exposure period, instability of chemotherapeutic drugs at low urinary pH, 
inadequate duration of exposure and limited penetration of the drug into the 
bladder wall.  These factors can be optimised to improve the efficacy of the 
intravesical therapy. 
Preventing drug dilution: 
Elimination of residual urine from the bladder is desirable prior to instillation of 
the chemotherapy.  Ensuring that the bladder has been adequately drained by 
repositioning the catheter or changing the position of the patient will help to 
avoid excessive residual volumes of urine. 
Fasting patients for 6 – 8 hours prior to each instillation reduces urine output 
and hence dilution of the drug by up to 20% [197,198].  Administration of oral 
desmopressin 0.2mg 1 hour before each instillation is also effective, 
increasing mean intravesical drug concentration by up to 38% [198].   
Alkalinisation of the urine: 
Oral doses of 1.3g of sodium bicarbonate given the night before, morning of, 
and 30 minutes before intravesical chemotherapy with mitomycin C have   64
been shown to improve drug stability, cellular uptake and penetration into the 
deep muscle layers.  An optimum pH of > 7 is achieved using this regimen. 
In vitro studies have also shown that alkalinisation improves the cellular 
uptake and cytotoxicity of epirubicin in bladder cancer cell lines [199].  Urinary 
alkalinisation may therefore be desirable for all types of chemotherapy, 
especially as urine is generally acidic.   
Duration of each instillation: 
The majority of the large trials of intravesical chemotherapy used instillation 
times of 1 hour.  Prolonged exposure of the urothelium and exfoliated cells to 
intravesical chemotherapeutics seems likely to improve their cytotoxic action.                     
Patients should be encouraged to retain the instillate as long as possible.   
Optimising intravesical chemotherapy: Trial data  
Whilst many studies have now demonstrated an improvement in terms of 
recurrence rates and disease free interval, they have been different in terms 
of the drugs used, doses and concentrations used, duration of instillations, 
timing of instillations, number of instillations and the period over which they 
are given.  There are also issues about dilution of drug concentrations by 
urine production and the effects of urinary pH on drug stability.  The effects of 
some of these variables have been addressed by some recent studies.    
One study investigated the effect of drug concentration for intravesical 
epirubicin on recurrence of superficial bladder cancer [200].  Six hundred and 
fourteen patients with primary or recurrent, single or multifocal, Ta/T1, G1-2 
bladder cancers were randomised to receive intravesical epirubicin at doses 
(concentrations) of 20mg/40ml (0.5mg/ml), 30mg/40ml (0.75mg/ml) or 
40mg/40ml (1mg/ml).                                                                                  
Group A (N=205) received 17 instillations of 20mg/40ml over 12 months (total 
dose 340mg), Group B (N=204) received 12 instillations of 30mg/40ml over 7 
months (total dose 360mg) and Group C (N=205) received 9 instillations of 
40mg/40ml over 4 months (total dose 360mg).  The best results were 
achieved with the highest dose (and concentration) administered over the 
shortest period of time.  The 1-year recurrence free rates were 0.671, 0.730 
and 0.739 for groups A, B and C respectively and the 2-year recurrence free 
rates were 0.487, 0.551 and 0.601 for groups A, B and C, respectively.    65
Another recent randomised phase III study looked to increase the efficacy of 
Mitomycin C with pharmacokinetic modification to increase the drug 
concentration and alkalinise the urine to aid drug stability [197].  Patients with 
TCC who were at high risk of recurrence were randomised to receive weekly 
instillations for 6 weeks in either the standard-treatment arm where they 
received Mitomycin C 20mg in 20mls of normal saline without 
pharmacokinetic manipulations or urine alkalinisation, or the  
optimised-treatment arm where they received mitomycin 40mg with 
pharmacokinetic manipulations to increase drug concentration by decreasing 
urine volume and urine alkalinisation to stabilise the drug.  The modifications 
made to the administration of the chemotherapy in this group included 
increased drug dose (40mg versus 20mg), reduced dose volume (from normal 
40ml to 20ml), minimising residual urine before instillation by adequate 
catheter drainage, voluntary dehydration for 8 hours before the chemotherapy 
was given and alkalinisation of the urine by administration of sodium 
bicarbonate 1.3g orally the night before, the morning of and 30 minutes before 
treatment.  The instillations were retained in the bladder for 2 hours.   
The results showed an increase in the median time to recurrence from 11.8 
months in the standardised group to 29.1 months in the optimised group (p = 
0.005).  The recurrence free fraction at 5 years was 24.6% in the standard- 
treatment group compared to 41% in the optimised-treatment group.    
It stands to reason that maintaining higher concentrations of cytotoxic drugs in 
the bladder for a longer period of time will lead to improved efficacy.   
Increasing bladder wall drug penetration 
Electromotive drug administration (EMDA), a technique based on 
iontophoresis and electro-osmotic phenomena, increases drug transport 
through biological membranes by 4 – 7 times and significantly enhances the 
efficacy of intravesical agents in comparison with passive administration 
[201,202].   
Local microwave induced hyperthermia induced by an endovesical microwave 
applicator also enhances the effectiveness of intravesical drugs [201,203].  
Electromotive administration of intravesical therapy: 
Recently study data have been published for a new technique called 
electromotive drug administration (EMDA).  This technique applies an electric   66
current across the urothelial surface which accelerates drug delivery into and 
across biological membranes, improving drug delivery to the urothelium.   
A randomised study of electromotive Mitomycin C versus passive transport 
Mitomycin C for high risk superficial bladder cancer has recently been 
reported [202].  Patients with high risk superficial bladder cancer (108 patients 
with multifocal Cis, including 98 with T1 tumours) were randomised into 3 
equal groups of 36 patients.  Each of these groups received either 
electromotive Mitomycin C 40mg with a 20mA pulsed electric current applied 
for 30 minutes or for passive Mitomycin C 40mg for 60 minutes or intravesical 
BCG 81mg for 120 minutes.  Treatments were given weekly for 6 weeks 
initially.  Non-responders were given a further 6 weekly treatments and the 
responders were given monthly treatments for 10 months.   
Treatment response was assessed by cystoscopy, biopsy and urine cytology. 
The primary end points were complete response rates at 3 and 6 months, as 
defined by negative biopsies and cytology.  
Complete response rates at 3 months were 53%, 28% and 56% and at 6 
months were 58%, 31% and 64% for electromotive Mitomycin C, passive 
Mitomycin C and BCG respectively, with the difference between Mitomycin 
groups being significant in favour of the electromotive group at 3 months (p = 
0.036) and 6 months (p = 0.012).  The median time to recurrence was also 
significantly longer in the electromotive MMC group, 35 months, compared to 
the passive MMC group, 19.5 months (p = 0.013).  With BCG showing a 
median time to recurrence of 26 months.    
EMDA increases bladder uptake of Mitomycin C, resulting in improved 
response rates in high risk superficial bladder cancer. 
Combination intravesical chemotherapy: 
Unlike systemic chemotherapy regimes, combination chemotherapy has not 
found widespread use in intravesical chemotherapy.   
Some small trials have been performed using known MDR reversing agents in 
combination with chemotherapy in an attempt to improve efficacy. 
Verapamil has been shown to reverse multidrug resistance in bladder cancer 
cell lines in vitro [199].  Its effects as part of a combination intravesical 
chemotherapy regime have been subject to several small scale studies, some   67
of which have yielded promising results, suggesting that larger scale studies 
may be warranted.      
One randomised study looked at the effect of combining verapamil with 
epirubicin given intravesically following resection of recurrent superficial 
bladder carcinoma [204].  Intravesical instillations were performed 4 hours 
before surgery and then at weekly intervals for 1 month and then once a 
month until 2 years from initial resection.  In the epirubicin and verapamil 
group only 37% developed recurrent tumours compared to 50% in the 
epirubicin group.  The difference in recurrence rates between the two 
treatment arms did not reach statistical significance, but only 75 patients were 
included in this trial.    
Verapamil has also been combined with doxorubicin for prophylactic 
intravesical instillation [205].  Following  transurethral resection patients were 
randomised to receive Doxorubicin 30mg plus Verapamil 15mg or Doxorubicin 
30mg alone for 19 instillations over 1 year.  The overall 3-year non-recurrence 
rate was significantly higher in the doxorubicin and verapamil group than 
doxorubicin alone, being 78.4% and 64.5% respectively (p = 0.0303).  There 
was no difference in the incidence or severity of side effects between the two 
groups. 
Combined intravesical chemotherapy and immunotherapy regimes have 
gained some interest recently following the publication of a recent study 
combining BCG and Mitomycin C therapy.  This compared sequential 
intravesical BCG and electromotive Mitomycin C versus BCG alone for 
high-risk superficial bladder cancer [206].  
Two hundred and twelve patients with T1 bladder cancers were randomised 
into 2 groups.   One group received 81mg of BCG intravesically for 120 
minutes once a week for 6 weeks.  Complete responders were then placed on 
maintenance therapy consisting of 81mg of BCG once a month for 10 months.  
The other group received 81mg of BCG intravesically for 120 minutes once a 
week for 2 weeks, followed by 40mg of mitomycin C with electromotive 
delivery with a 20mA electric current for 30 minutes once a week for 3 weeks.  
Complete responders went on to have further electromotive mitomycin C once 
a month for 2 months followed by 81mg of BCG once a month for 3 months.     68
The primary endpoint for this study was disease free survival with secondary 
endpoints being time to progression, overall survival and disease-specific 
survival. 
The electromotive mitomycin C / BCG group had significantly longer disease-
free interval (69 versus 21 months, p = 0.0012), a lower recurrence rate 
(41.9% versus 57.9%, p = 0.0012), a lower progression rate (9.3% versus 
21.9%, p = 0.004), a reduced overall mortality (21.5% versus 32.4%, p = 
0.045) and a reduction in disease-specific mortality (5.6% versus 16.2%, p = 
0.01).   
So intravesical sequential BCG and electromotive MMC leads to higher 
disease free interval, lower recurrence and progression and improved 
overall survival and disease-specific survival compared to BCG alone in 
high-risk superficial bladder cancer, suggesting a potential role in the future 
management of superficial bladder cancer.   
The future 
Newer agents are awaiting trial data to support their use in superficial bladder 
cancer.   
Pirarubicin (tetrahydropyranyl-doxorubicin (THP)) is the only new agent that 
has proven effective in reducing recurrence rates after TURBT [207].  Other 
agents have been tested in phase I and II trials with promising results but 
phase 3 and 4 results are lacking. 
Gemcitabine is a deoxycytidine analogue used systemically in the treatment 
of locally advanced or metastatic bladder cancer.  Phase 1 studies have 
demonstrated its safety for intravesical administration [208] and phase 2 
studies have shown its cytotoxic potential [209].  
Meglumine γ-linolenic acid (MeGLA) is an essential fatty acid with cytotoxic 
activity which has shown to be effective both in vitro and in vivo.  An initial 
phase 1 study looking at a single dose of intravesical MeGLA for recurrent 
superficial bladder cancer, showed a reduction in the size of marker lesions in 
43% of patients [210].  Combination of MeGLA and epirubicin in vitro has 
demonstrated a synergistic increase in cytotoxicity in human bladder cancer 
cell lines.  It would seem logical therefore to subject this combination 
intravesical therapy to evaluation in randomised controlled clinical trials to see   69
if there are further benefits above and beyond standard chemotherapy 
regimens.      
Suramin is an antitrypanosomal agent with antitumoural properties, that 
blocks epidermal growth factor (EGF) from accessing its receptor (EGFR).  
Phase 1 studies have shown its safety when administered intravesically, with 
negligible local toxicity and low systemic absorption [211,212].  Phase II trials 
are warranted to assess the efficacy of Suramin in the treatment of superficial 
bladder cancer.    
Photosensitising agents have also been trialled in bladder cancer.  These 
agents are selectively taken up by tumour cells when administered 
intravesically.  When an intravesical light source is applied, the agent exerts 
its cytotoxic effect.  This therapeutic option would therefore seem particularly 
attractive in patient where a “field change” has occurred within the urothelium 
such as multifocal TCC and Cis, allowing malignant cells throughout the entire 
urothelium to be treated selectively.   
Photofrin was the first photosensitizing drug used in the treatment of 
superficial bladder cancer, but had significant local and systemic side effects 
[213].  Photodynamic therapy (PDT) with intravesical instillations of 5-
aminolevulenic acid (5-ALA) has been used in superficial bladder tumours that 
could not be controlled by TURBT, in primary CIS and in BCG resistant 
tumours with good results and limited morbidity [214,215].  Porfimer sodium is 
another photosensitising agent that has been shown to be effective in BCG 
resistant CIS [216].  Hypericin [217] and more recently PAD-S31 [218] have 
been highly effective in destroying bladder tumours in animal models.  Despite 
all the research that has gone into PDT as yet there are no randomised 
controlled trials to prove its efficacy over and above conventional treatments.   
Chemosensitivity tests 
It is possible that in vitro chemosensitivity assays could be performed to 
determine the sensitivity of a tumour to several drugs prior to instillation [219].  
The drug regimen could then be tailored to the individual patient with the aim 
of improving response rate and reducing recurrences.  To date there are no 
studies that have addressed the possibility of such a chemosensitivity assay 
in superficial bladder tumours.  
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Systemic Chemotherapy 
Systemic therapy is reserved for muscle-invasive or metastatic bladder 
cancers and may be used in neoadjuvant or adjuvant settings.  The role of 
systemic chemotherapy and available trial data has already been discussed in 
chapter 1.  
The rationales for neoadjuvant and adjuvant systemic therapy are different.   
In neoadjuvant therapy the idea is to treat micrometastatic disease and 
downstage the primary tumour prior to surgery.  It also has the advantages of 
being able to assess the chemotherapeutic response of the primary tumour 
and the benefit of an improved performance status in the patients pre-
operatively meaning they are less likely to have complications.  The 
disadvantages of neoadjuvant chemotherapy are that there is a delay in the 
definitive local treatment and that treatment is decided based on clinical 
staging meaning that some patients may receive unnecessary chemotherapy.   
Adjuvant chemotherapy is used to try and deal with residual disease and 
micrometastatic disease.  The advantages of this approach to systemic 
therapy are that patients are treated on the basis of pathological staging (low-
risk patients can be spared toxicity) and that immediate local treatment is not 
delayed in operable patients.  Adjuvant chemotherapy is the strategy of 
choice in other chemo-sensitive cancers e.g. breast, colon.  The problems 
with adjuvant therapy are that there is a lack of evidence for this approach 
with the trials conducted so far being small and of poor quality.  One meta-
analysis of adjuvant chemotherapy has been conducted suggesting a 3-year 
survival benefit of 9%, but its power is limited.  The EORTC are running a 
study (EORTC 30994) of immediate versus deferred chemotherapy following 
cystectomy which may be the last chance to answer the question of whether 
immediate adjuvant chemotherapy confers a survival advantage in muscle-
invasive bladder cancer.     71
1.3:  Multidrug resistance in cancer 
Different cancers vary in their response to cytotoxic drugs, with some being 
sensitive to treatment whilst others are resistant.  Understanding the 
mechanisms of resistance may lead to the development of markers of 
resistance which can predict treatment outcomes and may also identify future 
therapeutic targets.   
The term “multidrug resistance” (MDR) describes a phenomenon whereby 
cancer cells exposed to a single cytotoxic drug develop cross resistance to a 
number of other structurally unrelated cytotoxic compounds.   
It was first described in 1970, when it was noted that Chinese hamster ovarian 
cancer cells exposed to actinomycin D developed cross-resistance to many 
other cytotoxic drugs, including the anthracyclines (daunomycin and 
doxorubicin), etoposide, colchicine and the vinca alkaloids (vincristine, 
vinblastine and vindesine) [220]. 
Cells exhibiting MDR were found to have much lower intracellular drug 
concentrations and this accumulation deficit was shown to be mediated by a 
170 Kilodalton (KDa) transmembrane glycoprotein [221].  This glycoprotein 
was later named permeation-glycoprotein or P-glycoprotein (P-gp).    
Subsequent studies suggested that the reduced intracellular levels of drug 
were as a result of increased drug efflux by an energy dependent process 
[222].   P-gp was found to be acting as an ATP-coupled drug efflux pump, 
removing cytotoxic compounds from MDR cells, thereby reducing their 
cytotoxic potential.   
Since these early days many more mechanisms of multidrug resistance have 
been elucidated.  It is accepted that tumours exhibiting MDR may have more 
than one of these mechanisms involved in their MDR status.   
Some tumours exhibit intrinsic or natural resistance, meaning they do not 
respond to standard chemotherapy from the outset.  Many other tumours 
appear responsive to chemotherapy initially and later develop resistance.  
This acquired resistance is likely to be due to either selection or induction of 
resistance, or both.  Selection implies that tumours contain clones of cells that 
possess intrinsic MDR which are selected out by chemotherapy.  Induction of 
resistance implies that chemotherapeutic exposure has stimulated   72
upregulation of the cellular MDR mechanisms of the tumour cells, rendering 
them resistant.   
Clinically both of these scenarios would manifest as patients who respond 
well to chemotherapy initially, but then developing recurrent disease arising 
from these residual selected or induced MDR clone cells, that are insensitive 
to further courses of chemotherapy.  This phenomenon is seen by oncologists 
relatively commonly, supporting these theories.  
Selection and induction MDR theories are also supported by in vitro studies 
where MDR cell lines have been derived from sensitive parental cell lines 
either by low-dose chronic exposure to chemotherapy (induced MDR) or by 
high-dose pulsed chemotherapy (selected MDR).      
Mechanisms of MDR: 
P-glycoprotein (P-gp)  
P-glycoproteins are members of the superfamily of ATP-binding cassette 
(ABC) transporter proteins.  They are expressed in normal human tissues 
including gastrointestinal mucosal cells, biliary canalicular cells, adrenocortical 
cells, capillary endothelial cells (in brain and testis), renal tubular cells and 
placental trophoblastic cells.  Here they are thought to act as a detoxification 
or cytoprotective mechanism by actively pumping toxins out of the cells.   
P-glycoprotein otherwise known as P-gp or P170 is an energy dependant 
transmembrane glycoprotein efflux pump that is able to transport a variety of 
compounds that are structurally dissimilar.  Most P-gp substrates are plant-
derived or chemically-synthesised cytotoxic drugs or antibiotics, but are not 
limited to these substances.    
Overexpression of P-gp is responsible for “classical” or “typical” MDR and 
occurs following amplification of the normal human gene, MDR-1.   
Gene coding and product.   
Two separate genes code for P-gp in humans, MDR-1 [223] and MDR-3 
[224].  In humans MDR-1 codes for P-gp 1 and MDR-3 codes for P-gp 2 (in 
rodents three MDR genes have been identified hence this discrepancy in 
human nomenclature).   
Both MDR-1 and MDR-3 genes are found on chromosome 7q21.1 [225].  
There is a high degree of homology between the MDR-1 gene which is 4669   73
base pairs in length and the MDR-3 gene which is around 3900 base pairs 
long [226].    
However, only MDR-1 expression resulting in functioning P-gp 1, has been 
associated with resistance to cytotoxic drugs.  Cells with intrinsic MDR-1 
expression or cells transfected with MDR-1 have been shown to develop the 
MDR phenotype [227], with levels of drug resistance increasing even with 
very low levels of MDR-1 expression [228].    
The MDR-1 gene is regulated by two promoters, with the down stream 
promoter being more important in normal tissues and the upstream promoter 
in some MDR cell lines [229].    
Structure  
P-gp is a membrane glycoprotein with a molecular weight of 170KDa (hence 
P170).  Each P-gp molecule is about 1280 amino acids long, consisting of two 
halves with very similar sequences, suggesting that it arose from the fusion of 
two closely related genes.  It is composed of 12 hydrophobic transmembrane 
domains (TMDs) and 2 hydrophilic nucleotide-binding domains (NBD).  Each 
half of the protein includes a short highly hydrophilic N-terminal segment. One 
NBD connects two TMDs with a hydrophilic NBD loop.  Each NBD has an 
ATP-binding site where ATP is hydrolysed, liberating the energy necessary for 
the active transport process of this pump (Figure 7).   
Cellular distribution and function  
P-gp is predominantly distributed on the plasma membrane, but has also 
been located on other intracellular organelles such the luminal side of the 
golgi stack apparatus [230-232], lysosomes [233] and the nuclear membrane 
in MDR breast cancer cells [234]. 
The effects of P-gp on cellular accumulation of cytotoxic drugs have been 
mainly studied in relation to it role on the plasma membrane, where is acts as  
a drug efflux pump.  The precise molecular mechanism whereby P-gp can 
transport such a wide variety of structurally diverse drugs have only been 
hypothesised and several models have been proposed.   
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  Figure 7:    A membrane topology model of P-glycoprotein.     
      (Reproduced with kind permission of BioMed Central Ltd)   
 
The TMDs form channels for substrate drugs, determine the characteristics of 
the substrates to be transported and efflux substrate drugs.  The NBDs are 
located in the interior of the cytoplasm and participate in ATP binding and 
hydrolysis [235].  P-gp undergoes conformational changes following binding of 
nucleotide to the NBDs [236-239].  This conformational change induced by 
nucleotide binding, involves a major reorganisation of the TMDs throughout 
the entire depth of the membrane.  In the absence of nucleotide, the two 
TMDs form a single barrel 5 – 6 nm in diameter and about 5nm deep with a 
central pore that is open to the extracellular surface, spanning much of the 
depth of the membrane.  Nucleotide binding induces reorganisation of the 
TMDs into three compact domains that are each 2 – 3nm in diameter and 5 – 
6nm deep.  This opens the central pore along its length, allowing access of 
hydrophobic drugs (transport substrates) directly from the lipid bilayer to the 
central pore of the transporter [238].  
Inactivation of one of the two NBDs inhibits drug transport and ATP hydrolysis 
at the other NBD, indicating that the two NBDs function cooperatively and can 
not hydrolyse ATP independently [240].   
Structural changes to the NBDs are also thought to occur as a result of drug 
binding to the TMD, resulting in a change in the distance between NBDs 
which affects their ATPase activity (Figure 8).     75
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 8:    Model of NBD conformational change by drug binding to  
      TMD (Reproduced with kind permission of BioMed Central 
     Ltd).   
      
Many suggest that P-gp acts as a transmembranous pore, binding drugs in 
the cytoplasm and expelling them into the extracellular space [241].  Others 
have suggested that P-gp binds substrates within the plasma membrane and 
pumps them out of the cell [242].  It has also been postulated that P-gp acts 
as a “flippase”, flipping substrates from the intramembrane space to the outer 
leaflet promoting diffusion back into the extracellular matrix [243].    
Certainly the function of P-gp involves an energy dependent process as it 
requires ATP to be effective, with studies showing that the effects of P-gp on 
drug efflux can be neutralised by reducing the temperature of cells or adding 
metabolic inhibitors such a sodium azide.   
The discovery of P-gp at other cellular sites including Golgi apparatus and 
lysosomes suggests another pathway for drug expulsion may exist.  It is 
possible that migrating membranous P-gp found on the prelysosomal sorting 
compartment (PLC] may actively pump drug into vesicles or the PLC [244].  
Here the drug would remain trapped until released into the extracellular 
compartment by exocytosis.  
Chemotherapeutic substrates transported by Pgp are shown in Table 7.   76
Drug 
Anthracyclines 
Daunorubicin 
Doxorubicin 
Epirubicin 
Vinca alkaloids 
Vincristine 
Vinblastine 
Podophyllotoxins 
Etoposide 
Teniposide 
Taxenes 
Paclitaxel 
Docetaxel 
Mitomycin C 
Mitoxantrone 
Methotrexate (Only in carrier deficient cells) 
Actinomycin D 
Colchicine 
 
Table 7:    Cytotoxic substrates of P-glycoprotein  
 
Multidrug resistance-associated protein (MRP)  
It became apparent with time that P-gp was not the only mechanism involved 
in MDR, as many resistant cell lines did not exhibit P-gp overexpression.   
Multidrug resistance-associated protein (MRP) was discovered in 1992 [245], 
when a human small cell lung cancer cell line was found to be resistant to 
doxorubicin and vincristine, but did not express P-gp.  Overexpression of 
MRP has been found in many, but not all non-P-gp expressing MDR cell lines.  
Normal tissues have also been shown to express MRP, including lung, 
spleen, thyroid, testis, bladder, adrenal and gall bladder [246], but the levels 
of MRP expression in tumour cells are much higher.  Its distribution in these 
tissues may suggest a protective role against toxic compounds [247].   
MRP overexpression has been demonstrated in the non-P-gp expressing 
MDR bladder cancer cell line, T24 [248].  MRP has also been identified in 
leukaemic cells [249] and in bladder tumours with no previous exposure to 
cytotoxic agents [250].   
Whether MRP expression has any prognostic significance remains to be 
established.     77
Since the discovery of the first MRP (MRP1), numerous other MRPs have 
been identified and this “MRP family” now extends to nine members [251].  
Their distribution in normal tissues is shown in table 8.   
Gene coding and products: 
The MRP1 gene is located on the short arm of chromosome 16 at band 13.1.  
The product of this gene, like P-gp, belongs to the ABC superfamily of 
transport molecules.  The product of MRP1 is a 1531 amino acid phospho-
glycoprotein with a molecular weight of 190KDa.  It has more phosphorylated 
residues than P-gp and a cycle of dephosphorylation and rephosporylation 
occurs which may be important in its biological activity.  Transfection of the 
MRP1 gene has been shown to confer the MDR phenotype [252].   
The other MRP family gene loci have also been established (Table 8). 
 
Name  Gene locus  Tissue distribution 
 
MRP1 16p13.1   
 
Lung, spleen, thyroid, testis, bladder, 
adrenal, gall bladder, brain 
MRP2 
 
10q24 
 
Liver, gut, kidney, placenta 
 
MRP3  17q21.3  Liver, gut, adrenal cortex, placenta, 
pancreas, gut 
MRP4  13q32  Prostate, lung, muscle, pancreas, testis, 
ovary, bladder, gallbladder 
MRP5 3q27  Ureter,  urethra,  placenta, heart, brain  
 
MRP6 16p13.1  Liver,  kidney 
 
MRP7 6p12-21  Pancreas, liver, placenta, lung, kidney, brain, 
ovary, lymph node, spleen, heart, 
leukocytes, colon, skin, testis, stomach 
MRP8 16q12.1  Breast,  testis 
 
MRP9 Unknown Breast,  testis 
 
 
Table 8:    Gene loci and tissue distribution of MRP molecules  
 
A schematic representation of the primary protein structures of the products of 
the MRP1 – 9 genes are shown in Figure 9.   
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Figure 9:    Schematic representation of the protein domains of MRP  
      proteins 1 – 9.  Stripes, membrane spanning domains;  
      open, cytoplasmic loops located between MSD0 and  
      MSD1, NBF1 and MSD2 and at the C terminus; black,  
      nucleotide binding folds. (Reproduced with kind permission of 
      Nature Publishing Group) 
 
Structure 
MRP1 is composed of a large “core” segment similar to P-glycoprotein, but in 
addition has an N-terminal region composed of a third membrane spanning 
domain (MSD0) made up of five transmembrane domains (TMD), an 
intracellular loop (L0) and an extracellular N-terminus (Figure 10).  The core 
region is similar to P-gp in that it has two nucleotide binding domains (NBDs), 
two membrane spanning domains (MSDs) consisting of six transmembrane 
spanning helices and a linker segment (L1) located between NBD1 and  
MSD2.   Not all of the MRPs possess MSD0 domains.  MRP4, MRP5, MRP8 
and MRP9 lack the third membrane spanning domain (MSD0), but possess 
the L0 domains.  MRP2, MRP3, MRP6, MRP7 resemble MRP1 with a TMD0 
domain (Figure 10).  
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Figure 10:    Topological model of MRP1 (similar to MRP2, MRP3, MRP6 
      and MRP7) and MRP4 (similar to MRP5, MRP8 and MRP9).  
      NBF: nucleotide binding fold; MSD: membrane spanning  
      domain (Reproduced with kind permission of Nature  
     Publishing  Group) 
 
Cellular distibution and function 
Unlike P-gp, MRP1 is mainly localised to the endoplasmic reticulum, but some 
monoclonal antibody studies have also demonstrated MRP on the plasma 
membrane [253].   
Cells exhibiting MRP over-expression display resistance to a range of drugs 
similar to those excreted by P-gp, but may not have drug accumulation 
deficits as with P-gp mediated resistance.  These drugs are generally either 
cationic or neutral and lipophilic.  MRP expressing cells have reduced 
intracellular drug concentrations [254].  In addition to acting as a direct efflux 
pump, there is evidence that MRP packages drug within intracytoplasmic 
vesicles where the drugs are unable to act [255].  In non-P-gp MDR cells 
known to express MRP, drug has been shown to accumulate in a perinuclear 
localisation within the Golgi and lysosomes.  This may represent a resistance   80
transport mechanism, where drug is transported away from the nucleus via 
the pre-lysosymal sorting compartment (PLC) to the outside of the cell [255].  
MRP1 is one of the elusive glutathione-S-conjugate (GS-X) pumps, a 
transporter able to recognise and transport drugs conjugated to glutathione 
out of the cell [256] and also acts as a membrane bound ATP efflux pump 
ejecting hydrophobic drugs from the cell [257].   
MRP1 appears to contribute to the inherent sensitivity of cancers in which it is 
expressed.  However, there is no consensus with respect to its role in 
acquired resistance or its prognostic significance [251]. 
All of the characterised members of the MRP family are lipophilic anion 
pumps with the potential to confer resistance to anticancer drugs.   
Chemotherapeutic substrates transported by the MRP family of ABC 
transporters are shown in Table 9.  
 
Name   Cytotoxic substrate 
 
MRP1 Anthracyclines, cochicine, etoposide, heavy metals (arsenite, 
arsenate, antimonials), vincristine, vinblastine, paclitaxel 
MRP2 Cisplatin, CPT-11, doxorubicin, etoposide, methotrexate, SN-
38,vincristine, vinblastine 
MRP3  
 
Cisplatin, doxorubicin, etoposide, methotrexate, teniopside, 
vincristine 
MRP4  
 
Methotrexate, nucleotide analogs, PMEA 
 
MRP5  
 
Doxorubicin, methotrexate, nucleotide analogs, topotecan 
MRP6  
 
Doxorubicin, etoposide, teniposide 
 
MRP7 Doxorubicin, vincristine, vinblastine, docetaxel, paclitaxel 
 
MRP8  
 
5'-Fluorouracil, 5'-fluoro-2'-deoxyuridine, 5'-fluoro-5'- 
deoxyuridine, PMEA 
MRP9 Unknown 
 
 
Table 9:    Substrates of the multidrug resistance-associated protein  
      (MRP) family of transporters 
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Breast Cancer Related Protein 
Breast cancer resistance protein (BCRP) also known as mitoxantrone-
resistance protein (MXR), was first described in a multi-drug resistant human 
breast cancer cell line which did not express Pgp or MRP [258].   
Overexpression of BCRP is associated with high levels of resistance to a 
variety of anticancer agents, including mitoxantrone, anthracyclines, and the 
camptothecins, by enhancing drug efflux.   
In normal tissues BCRP is thought to play an important role in drug disposition 
as it is prominently expressed in organs important for absorption (small 
intestine), distribution (placenta, blood-brain barrier), and elimination (liver and 
small intestine) of drugs.   
BCRP overexpression has been detected in a variety of mitoxantrone-
resistant cell lines, including those derived from human breast cancer (MCF-
7), colon carcinoma (S1), gastric carcinoma (EPG85–257), and fibrosarcoma 
(EPF86–079).   The expression of BCRP and/or mRNA has been detected in 
numerous types of human cancers, including haematological malignancies 
and solid tumours.  BCRP expression was analysed in 150 untreated human 
solid tumours comprising 21 tumour types using a monoclonal antibody BXP-
21.  Moderate or strong expression of BCRP was seen in ~ 60% of the tumour 
samples examined [259].  BCRP expression was observed in all tumour types 
but was more frequently expressed in gastric carcinoma, hepatocellular 
carcinoma, endometrial carcinoma, colonic carcinoma, small cell lung 
carcinoma and malignant melanoma [259].  These results implicate BCRP as 
a mechanism of MDR in certain solid tumours.   
BCRP expression in tumour samples from 42 patients with colorectal 
carcinoma, showed that BCRP mRNA expression in hepatic metastases after 
irinotecan-based chemotherapy were higher than those in irinotecan-naïve 
metastases.  This suggests that upregulation of BCRP may be involved in the 
development of resistance to irinotecan in patients with colonic carcinoma 
[260].  
Gene coding and product 
Multidrug resistant human breast cancer cell lines expressing BCRP were 
found to overexpress a 2.4kb mRNA species by Northern blot analysis.  This 
PCR product was radiolabelled and used as a probe to isolate a full length   82
cDNA from a lambda phage library derived from the same cell line [258].  The 
full length cDNA coded for a novel 655 amino-acid polypeptide with properties 
of a half-transporter, characteristic for members of the ABCG subfamily.  The 
BRCP gene has subsequently been localised to locus 22 on chromosome 4, 
downstream from a TATA-less promoter [261].   
Structure 
BCRP is a 72 KDa half-transporter, consisting of a single nucleotide binding 
domain (NBD) and ABC signature motif within a relatively hydrophilic amino-
terminal domain, and a relatively hydrophobic carboxyl-terminal domain 
containing a membrane spanning domain (MSD) with six putative 
transmembrane domains and four potential N-glycosylation sites (Figure 11) 
[258].  The BCRP sequences are similar to one-half of the Pgp or MRP1 
molecule, except that in BCRP the nucleotide binding domain precedes the 
transmembrane domain (Figure 12).  Current experimental evidence suggests 
BCRP may function as a homodimer or homotetramer.   
 
 
 
 
 
 
 
 
  
 
  
Figure 11:   A membrane topology model of BCRP 
 
 
 
 
 
 
Figure 12:   Comparison of ABC transporter molecular configuration.  
      TMD = Transmembrane domain; NBD = Nucleotide binding 
     domain   
Pgp / MRP1: NH2 – TMDs – NBD1 – TMDs – NBD2 – COOH 
BCRP:   NH2 – NBD – TMDs – COOH     83
Cellular distribution and function 
BCRP has been localised to plasma membrane of drug-resistance cells 
overexpressing this transporter [262,263].  Recent evidence suggests that 
BCRP functions as a homodimer bridged by disulfide bonds.  The fact that 
BCRP transfection directly confers MDR status suggests that BCRP is able to 
function by homodimerisation [258].  Co-transfection of BCRP with a mutant 
form of BCRP with an L554P alteration in the fifth transmembrane domain 
was found to partially inhibit BCRP function, again suggesting BCRP functions 
as a homodimer.  Western blot protein analysis coupled with polyclonal 
antibodies directed against peptide epitopes of BCRP, after denaturation or 
treatment with cross-linking agents demonstrated a molecular mass shift from 
a 72KDa band to a 180KDa band, again suggesting the functional 
configuration of BCRP is through homodimerisation.   
BCRP is a 72KDa member of the ABC superfamily of transporters which 
confers resistance to mitoxantrone, doxorubicin and daunorubicin, reduces 
daunorubicin accumulation and retention, and enhances efflux of rhodamine 
123 in an ATP dependent fashion [258].  Most of the drug-selected cell lines 
exhibiting BCRP overexpression display strong resistance to mitoxantrone, 
suggesting that mitoxantrone is a high affinity substrate for BCRP [264]. 
Transport of anthracyclines is variable and appears to depend on the amino 
acid at position 482 in the BCRP molecule.  If this amino acid is Threonine or 
Glycine then resistance to anthracyclines if conferred, but if it is an Arginine 
then anthracycline resistance is not conferred.    
Chemotherapeutic substrates transported by BCRP are shown in Table 10. 
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Drug 
Anthracyclines* 
Daunorubicin 
Doxorubicin 
Epirubicin 
Anthracenes 
Mitoxantrone 
Bisantrene 
Aza-athrapyrazole (BBR 3390) 
Camptothecin Derivatives 
Topotecan 
SN-38 
9-amino-captothecin 
Irinotecan 
Diflomotecan 
Polyglutamates* 
Methotrexate 
Methotrexate-Glu2 
Methotrexate-Glu3  
 
Table 10:   Substrates of breast cancer resistance protein (BCRP) 
      (*Transport of these substrates depends on the BCRP amino 
      acid at position 482) 
 
Lung resistance-related Protein (LRP) and vaults: 
Lung resistance protein (LRP) was first described in 1993 in a non-small cell 
lung cancer non-P-gp MDR cell line [265].  LRP is widely expressed in normal 
tissues such as bronchial cells, intestinal epithelium, renal tubular cells, 
keratinocytes, adrenal gland and macrophages.  All of these cells have an 
excretory or secretory function and are chronically exposed to xenobiotics and 
potentially toxic agents, suggesting that in normal cells LRP expression may 
play a protective role against toxic compounds.  
LRP is overexpressed in several non-Pgp MDR cells lines of different 
histogenetic origin [265].  In a panel of 61 human cancer cell lines LRP and 
MRP were expressed in 78% and 87%, compared to just 24% for P-gp [266].  
Of 174 clinical tumour specimens from 27 different tumour types, LRP was 
expressed in 63% [267].  LRP expression was found to be the greatest 
individual marker of in vitro resistance to a variety of MDR related drugs.  
LRP has also been identified as the human major vault protein [268-270].     85
Gene coding and product 
The LRP gene is found on the short arm of chromosome 16, the same 
chromosome as the gene for MRP, which is located just next door.  It codes 
for a 110KDa unglycosylated protein which is 896 amino acids long.  Analysis 
of the LRP protein sequence has revealed that it is the human major vault 
protein (MVP) which forms the major component of vaults [268-270].  Most 
MDR cell lines expressing LRP also express MRP [253,266].  However most 
P-gp MDR cell lines are LRP negative [265]. 
Vaults 
Vaults are barrel-like cytoplasmic ribonucleoprotein organelles which are 
probably associated with vesicles.   
They are ovoid structures with dimensions of approximately 35 x 65nm and 
resemble a barrel with lobular walls and two centres of mass (Figure 13) 
[268,269].  This barrel structure can be split apart in vitro, and each half opens 
into a flower-like structure with eight petals surrounding a central ring [269].  
Electron micrographs of vault particles at a resolution of 31 – 32 Å, have 
shown that the barrel structure is thin walled, solid structure which is 
hollow and has two protruding caps and an invaginated waist (Figure 
13) [271].    
 
 
 
 
 
 
 
 
 
Figure 13:    A: Three-dimensional reconstruction of rat vault structure  
      from cryoelectron microscopy image at approximately 31 Å 
      resolution B: Electron microscopy of negatively stained 
      rat vaults  (Reproduced with kind permission of  
      Cambridge University Press)   
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Vaults have a mass of 13MDa and are the largest known ribonucleoprotein 
complexes.  They are composed of multiple copies of three proteins, 240, 193 
and 104KDa in size and small untranslated RNA molecules of 88 – 141 bases 
(Table 11).   
 
 
Component 
 
Name 
 
Size 
 
Copies per vault 
 
 
Proteins 
Major Vault  
(Barrel protein) 
Minor Vault  
(Cap proteins) 
 
 
MVP (LRP) 
 
p240 (TEP1) 
p193 (VPARP)
 
 
~ 104KDa 
 
~ 240KDa 
~ 193KDa 
 
 
96 
 
2 
8 
 
 
RNAs 
Vault RNA 
 
 
hvg1 
hvg2 
hvg3 
hvg4 
 
 
98 bases 
88 bases 
88 bases 
101 bases 
 
 
Unknown 
Unknown 
Unknown 
Unknown 
 
  
Table 11:   Mammalian vault components 
 
The 104KDa subunit (LRP) is termed the major vault protein, as it contributes 
more than 70% of the vaults mass.  Two high molecular weight minor vault 
proteins have also been identified [272,273].  The p240 protein is identical to 
the telomerase-associated protein (TEP1) [273].  TEP1 is also present in the 
telomerase complex, another ribonucleoprotein complex, which helps to 
maintain the length of chromosomal telomeres in dividing cells [274].   
The other high molecular weight minor vault protein, p193, is a poly (ADP-
ribose) polymerase (PARP), called vault-PARP (VPARP) [272].  This protein 
ADP-ribosylates itself and the MVP in purified rat vaults.  Proteins with PARP 
activity may play a role in differentiation, proliferation, tumour transformation 
and repair of damaged DNA [275-278].   
Four species of vault RNA (vRNA) have been identified (hvg 1 – 4).  The  
vRNA contributes less than 5% of the vault mass and exhibits species-specific 
length variation ranging from 88 – 141 bases.  The vRNAs are not structural 
components of the vaults, but are likely to function in RNA-RNA recognition in   87
association with other cellular RNAs or proteins with the vault to facilitate 
localisation and / or transport.  
Cellular distribution and function:  
Vaults are present in high numbers, 10,000 – 100,000 copies per cell  
[279].  Most vaults appear to be located in the cell cytoplasm, as 
demonstrated by immunohistochemical staining with a monoclonal antibody to 
LRP (LRP-56) which demonstrated a coarsely granular, cytoplasmic 
distribution suggesting an association with cytoplasmic vesicles or lysosomal 
structures [265].  Vaults have also been shown to specifically associate with 
the nuclear membrane in tissue sections and with NPC’s of isolated nuclei 
[280].  In mammalian cells, generally not more than 5% of the total vault 
fraction is found associated with the nucleus.   
The cellular function of vaults has not been elucidated.  Several studies have 
implicated vaults in nucleocytoplasmic trafficking and transport [281-284].  
The hollow vault structure is consistent with a role in either 
compartmentalisation of macromolecular assemblies or in subcellular 
transport.  The partial co-localisation of vaults with cytoskeletal elements has 
led to the hypothesis that vaults can be transported along cytoskeletal 
elements, in particular microtubules.  Cytoskeletal-mediated transport would 
certainly allow vaults to shuttle cargo directionally to specific subcellular 
locations.  
It has been postulated that vaults may control the bidirectional transport of a 
variety of substrates between the nucleus and cytoplasm [280].  Vault induced 
drug resistance may therefore be conferred through vesicular sequestration or 
nucleocytoplasmic transport of drugs [285].   
There is some direct evidence that vaults play a role in nuclear efflux of 
anthracyclines from the nuclei of resistant cells [286-288].  A colorectal cancer 
cell line was treated with sodium butyrate which induced overexpression of 
MVP making the cells significantly less sensitive to doxorubicin, etoposide 
(VP-16), vincristine, paclitaxel and gramicidin D.  Doxorubicin was shown to 
be effluxed from the nuclei of resistance cells more rapidly and was inhibited 
by anti-(MVP) antibodies and PAK-104P, a pyridine analogue specific inhibitor 
of vault-mediated drug efflux [287].    88
The minor vault proteins, TEP1 and VPARP, mass also play a role in 
protection of the genome contributing to drug resistance.   
The proposed mechanisms of vault mediated MDR are shown in Figure 14.  
 
Atypical MDR: Topoisomerase II mediated drug resistance 
In the 1980s, a new form of non-P-gp related MDR was described in a 
leukaemia cell line that was found to have alterations in Topoisomerase II 
(TOPO II), a DNA repair enzyme [289].  Cell lines which exhibit drug 
resistance due to altered TOPO II are called at-MDR (altered TOPO II activity 
or atypical MDR).  This type of MDR results in no alteration of drug 
accumulation, but is characterised by cross-resistance to anthracyclines and 
epipodophyllotoxins, but not vinca alkaloids.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14:    Hypothetical mechanisms of vault mediated multidrug  
      resistance. Vaults may mediate multidrug resistance by  
      transporting drugs away from their intracellular targets e.g. 
      the nucleus (1) or by transporting them to efflux pumps (2) or 
     exocytotic  vesicles  (3).  Based on the characteristic of the  
      minor vault proteins, vaults or vault components are possibly 
      involved in DNA damage control (4).  (Figure reproduced with 
      kind permission of Lippincott Williams & Wilkins, Inc.) 
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Other at-MDR cell lines have also demonstrated this alteration in drug-
induced DNA cleavable complex formation associated with reduced levels 
and activity of TOPO II.   
Alterations in TOPO II drug activity are divided into two groups:  
(1) Quantitative changes: e.g. decreased levels of TOPO II protein by 
downregulation of transcription, increased degradation or deletion of one 
allele; or (2) Qualitative changes: e.g. mutations resulting in altered drug-
DNA-protein interaction or ATP binding, alterations in the ratio of isoenzymes, 
or altered enzymatic function by post-translational modification [289,290].  
Most at-MDR cell lines have been selected by epipodophyllotoxin exposure, 
but at-MDR is also common in anthracycline selected cell lines.  Most of these 
cell lines exhibit more than one mechanism of MDR. Thus, nuclear extracts 
from anthracycline-resistant PGP-positive murine P388 and Ehrlich ascites 
tumour cell lines demonstrated reduced amounts of TOPO II. [291,292].  
Decreased levels of TOPO II have also been demonstrated in a DOX-
resistant CHO cell line, despite unchanged DNA and mRNA content, 
suggesting that post-transcriptional events might lead to decreased enzyme 
levels [291]. 
Modulators of classical P-gp mediated MDR, such as verapamil, are unable to 
modify at-MDR.  Other strategies may be effective in at-MDR, the most 
obvious being the use of non-TOPO II substrates.  Some anthracycline 
analogs demonstrate equal cytotoxicity in at-MDR and drug-sensitive cells. 
The efficacy of TOPO II inhibitors is dependent on the proliferation status of 
the cells. Hence manipulation of cellular proliferation could alter sensitivity to 
TOPO II inhibitors.   
There is a lack of data correlating at-MDR status to clinical cancer 
chemoresistance and outcomes of therapy.   
Glutethione-S-Transferases (GST) 
Glutathione-S-Transferases (GSTs) are a family of phase II detoxification 
enzymes that catalyse the conjugation of glutathione (GSH) to a wide variety 
of endogenous and exogenous electrophilic compounds, rendering them 
inactive.  GSTs are divided into two super-family members: the membrane-
bound microsomal and cytosolic family members.  Microsomal GSTs are 
involved in endogenous metabolism of leukotrienes and prostaglandins.    90
Human cytosolic GSTs are divided into 6 classes: α, μ, ω, π, θ, ζ.  The π and 
μ classes of GSTs play a regulatory role in the mitogen-activated protein 
(MAP) kinase pathway that participates in cellular survival and death signals.    
GSTs have been implicated as a mechanism of multidrug resistance.  It is 
possible that they do this through two pathways, either by direct detoxification 
or as an inhibitor of the MAP kinase pathway.  They also possess intrinsic 
peroxidase activity leading to elimination of free-radicals induced by certain 
cytotoxic drugs [293]. 
A 45-fold increase in GST levels was initially described in a MDR subline of 
the MCF-7 (breast cancer cell line) [294], suggesting a role in MDR.  High 
levels of GSTs have since been reported in many different tumour types [294].   
A list of anticancer agents that have been shown to be subject to GST 
mediated multidrug resistance are shown in table 12.   
 
 
Substrates of GST: 
 
Chlorambucil 
Melphalan 
Nitrogen Mustard 
Phosphoramide mustard 
Acrolein 
Carmustine 
Hydroxyalkenals 
Ethacrynic acid 
Steroids 
 
 
Not characterised as GST substrates: 
 
Antimetabolites* 
Antimicrotubule drugs* 
Topoisomerase I & II inhibitors* 
Bleomycin 
Hepsulfam 
Mitomycin C* 
Doxorubicin* 
Cisplatin* 
Carboplatin 
 
 
Table 12:   Anticancer agents associated with resistance secondary  
      to increased GST expression  
      * Require MAP kinase activation for cytotoxicity 
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Some of these are direct substrates of GSTs that are inactivated by catalytic 
conjugation to glutathione through thioether bond formation.  Many others are 
metabolised to electrophilic species that are detoxified through glutathione 
metabolism or alternatively exert their apoptotic effects through the MAP 
kinase pathway, which is inhibited by elevated levels of GST.    
In addition glutathione conjugates are effluxed by a 38KDa membrane protein, 
which has been implicated in efflux of cytotoxic drugs including daunomycin 
and daunorubicin [295].  Glutathione is also required specifically by MRP for 
the export of drugs from cells, suggesting a role in cytotoxic drug efflux [296].   
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Reversal of multidrug resistance  
Multidrug resistance is one of the most important reasons for 
chemotherapeutic failure.  There has been an extensive research effort in this 
area over the last 30 years or so, to find ways of reversing or inactivating the 
causes of multidrug resistance.    
P-gp is widely recognised as the main mechanism of multidrug resistance.  
Much research has been done focusing on molecules that can inactivate this 
drug efflux pump, rendering MDR cells sensitive to chemotherapy.  Research 
into the inactivation of the other MDR-related ABC transporter pumps, MRP 
and BCRP, has also been performed.    
Many drugs have now been identified that can reverse MDR, making cells 
sensitive to chemotherapy again, so-called chemosensitisers.  Some of these 
drugs are effective against one transporter, whilst others exert their effects at 
more than one site (Table 13).   
Verapamil (a calcium channel antagonist) was the first reported 
chemosensitiser, restoring sensitivity to alkaloids and doxorubicin in MDR 
cells [297-299].   
The mechanisms of MDR inactivation by each drug are different.  Verapamil 
and Cyclosporin A inhibit resistance by functioning as competitive substrates  
of P-gp, which is thought to be through competition for the drug binding sites 
on P-gp.   
The majority of these MDR reversing agents are unrelated, but share some 
structural similarities such a hydrophobicity and phenyl rings [300] and often 
have side chains containing a tertiary amine [301].  
The first generation chemosensitizers were hampered by high levels of 
toxicity at resistance-inhibiting doses coupled with lower MDR reversing 
capabilities.  Second generation chemosensitizers that have been developed 
specifically for their chemosensitizing effects have much lower toxicity, are 
more potent and have fewer drug interactions.    
Most of the chemosensitizers act by binding with the TMD regions of the 
transporter molecules.  Some newer chemosensitizers, e.g. steroid and 
flavanoid, inhibit the transporter molecules by binding to the NBD regions.  
The binding site of steroid on the NBD is near but not directly on the ATP 
binding site [302].  The flavanoids appear to bind to both the steroid binding   93
site and the ATP binding site [303].  It is believed that flavanoid 
chemosensitizers have a significant advantage with respect to their 
therapeutic index.   
 
Name Year  Chemosensitizer 
 
Pgp  2004  Benzyl-, phenethyl-, and alpha-naphthyl isothiocyanates*, diallyl sulfide, PK11195, small 
scFv recombinant, Pgp antibody fragment 
 2003  Amooranin, etrandrine, fangchinoline, ginsenoside Rg(3), KR30031, 
methylenedioxyethylamphetamine, protopanaxatriol ginsenosides, saquinavir, siRNA of mdr1 
gene, tRA 98006  
 2002  3,5-dibenzoyl-1,4-dihydropyridines, PKC412, pyronaridine, sinensetin 
 2001  Agosterol  A, haloperidol and dihydrohaloperidol, SB203580, tropane alkaloid esters, SNF4435C 
and D, tea polyphenol, trans-N,N'-bis(3,4-dimethoxybenzyl)-N-solanesyl-1,2-diaminocyclo hexane 
(N-5228)  
 2000  Astemizole, atorvastatin, 7-O-benzoylpyripyropene A, 5-O-benzoylated taxinine k, 
clarithromycin and YM17K (3,4'-dideoxy mycaminosyl tylonolide hydrochloride), cyclopamine and 
tomatidine, 3,5-diacetyl-1,4-dihydropyridines, 7, 8-dihydroxy-3-benzazepine, doxorubicin-
gallium-transferrin conjugate, macrolide antibiotics (josamycin, tamolarizine), nelfinavir, 
norverapamil, ontogen (ONT-093, formerly OC-144-093), R101933, taxuspine C, 2'-
desacetoxyaustrospicatine and 2-desacetoxytaxinine, V-104 
 1999  D-alpha-tocopheryl polyethylene glycol 1000 succinate, anti-MDR1 ribozymes, AR-2, carvedilol, 
erythromycin,  ketoconazole, kopsiflorine, nomegestrol, PAK-200S, pluronic block copolymer, 
reversin, ritonarvir, rosemary extract, TTD, XR9576(2) 
 1998  Ardeemins, AV200, 5-O-benzoylated taxuspine C, bromocriptine, dipyridamole, droloxifene, 
imidazothiazole derivatives (N276-12, N276-14, N276-17), oxalyl bis(N-phenyl)hydroxamic 
acid, tetrandine and fangchinoline, tiamulin, XR9051 
 1997  Biricodar  (VX-710;  Incel), cyproheptadine  
 1996  CL 329,753, indole-3-carbinol, itraconazole, LY335979, medroxyprogesterone, mefloquine, 
mifepristone (RU-486), reserpine  
 1995  Azelastine and flezelastine, B9209-005, dexniguldipine (B8509-035), dexverapamil, epidermal 
growth factor (EGF), insulin-like growth factor I (IGF-I), quercetin  
 1994  MS-209, pentoxifylline, Ro11-2933 (DMDP), RU486  
 1993  Dilantin, GF120918, meperidine, pentazocine, and methadone, Pgp monoclonal antibodies and 
antisense oligonucleotide, tamoxifen and toremifene  
 1992  Staurosporine and NA-382  
 1991  Biperidil, SDZ PSC 833 
 1990  Cremophor EL  
 1989  Cefoperazone, cetriaxone, phenothiazine, YM534  
 1987  Diltiazem, cyclosporine A  
 1986  Amiodarone  
 1984  Quinidine   
 1981  Verapamil  
MRP  2004  benzyl-, phenethyl-, and alpha-naphthyl isothiocyanates  
 2003  tRA  98006   
 2001  Agosterol  A   
  2000  5-O-benzoylated taxinine k, 4-deacetoxyagosterol A, doxorubicin-gallium-transferrin 
conjugate, V-104, pluronic block copolymer, quinoline-based drugs (chloroquine, quinine, 
quinidine, and primaquine), 
 1999  dipyridamole, erythromycin and ofloxacin, mifepristone (RU-486), MS-209, rifampicin  
 1998  Biricodar  (VX-710;  Incel), imidazothiazole derivatives (N276-12, N276-14, N276-17), NSAIDs 
(indomethacin, sulindac, tolmetin, acemetacin, zomepirac and mefenamic acid), ONO-1078, 
quercetin 
 1997  Indomethacin, probenecid 
 1996  Acrolein and chloroacetaldehyde, d,l-buthionine-(S,R)-sulfoximine, itraconazol, PAK-104P  
 1995  Difloxacin, MK571 
BCRP 2004  Chrysin and biochanin A, genistein and naligenin, Imatinib mesylate (Gleevec, STI571) 
 2003  Estrone, diethylstilbestrol and TAG-139, tRA 98006  
 2002  Ko143 
 1999  GF120918   
 1998  fumitremorgin C 
  
Table 13:    Chemosensitizers inhibiting P-gp, MRP and BCRP. *Boldface 
      compounds indicate chemosensitizers inhibiting more than 
     two  transporters  [304]   94
1.4:  Bladder cancer and multidrug resistance  
As with most MDR research, much of our understanding about the 
mechanisms of MDR involved in bladder cancer is derived from work using 
cancer cell lines rather than clinical tumour specimens.  Cancer cell lines offer 
the advantages of being readily available, more easily cultured and of single 
cell type, allowing experiments to be repeated to ensure that results are 
reliable.  They are useful to study certain facets of cancer cell biology and 
drug resistance, but may not provide a true representation of the multiclonal 
cancers they aim to model.   
Clinical tumour samples by comparison are less user friendly, being difficult to 
obtain, of variable quality, requiring lengthy processing, having variability in 
cell populations and also finite viability.  However, they do provide an accurate 
reflection of the tumour biology of “in vivo” cancers.  Recent advances in 
molecular biological techniques have aided the study of MDR mechanisms in 
clinical tumour material.         
Studies of MDR mechanisms in bladder cancer cell lines 
In 1979, an in vitro assay allowing assessment of the sensitivities of several 
bladder cancer cell lines (MGH-U1, MGH-U2 and RT4) to cytotoxic drugs was 
described [305].   
In 1985, another group reported testing a urothelial cancer cell line, RT-112, 
against a panel of twelve cytotoxic agents.  The RT-112 cells were particularly 
susceptible to methotrexate, mitoxantrone, doxorubicin, mitomycin C and 
cisplatin, leading this group to suggest that such cytotoxicity assays could 
form the basis of a clinical tumour sensitivity assay [306].     
Using the wild-type T24 bladder cancer cell line, another group demonstrated 
that the cytotoxic effects of doxorubicin and thiotepa were improved when 
combined with verapamil, despite verapamil having no independent 
cytotoxicity.  This was the first reported use of verapamil as a chemosensitizer 
in bladder cancer cells, although it was suggested that verapamil exerted its 
effects through the “intracellular calcium environment”, with no mention of 
MDR or P-glycoprotein mediated effects [307]. 
In 1988, McGovern et al established a doxorubicin resistant human bladder 
cancer cell line, MGH-U1R, by growing MGH-U1 (a subculture of T24) wild-
type cells in increasing concentrations of the doxorubicin [308].  This group   95
also showed that reversal of doxorubicin resistance could be achieved by 
exposure to verapamil [309]. 
In 1990, Floyd et al confirmed the multidrug-resistant nature of the MGH-U1R 
cell line.  Compared to MGH-U1, it was found to be 40 times more resistant to 
doxorubicin, 188 times more resistant to vinblastine and 13 times more 
resistant to etoposide, whilst remaining sensitive to bleomycin.  They also 
reported that the observed multidrug resistance of MGH-U1R cells was due to 
overexpression of the MDR-1 gene [310].  In 1994, the MGH-U1R cell line 
was also shown to be resistant to epirubicin [311].    
Several other doxorubicin resistant bladder cell lines have subsequently been 
established.  Cell line KK47/ADM was established in 1992 [312] exhibiting 
cross-resistance to epirubicin, vinca alkaloids and etoposide, but not to 
cisplatin, carboplatin or mitomycin C.  Cell line RT112/D21 was established in 
1995 [313] and demonstrated cross-resistance to epirubicin and vinblastine.  
Sensitivity to methotrexate and mitomycin C were unchanged.  Cell line BIU-
87/ADMR was established in 1997 [314] and showed cross-resistance to 
epirubicin, daunorubicin, vincristine and etoposide, but not to cisplatin and 
mitomycin C.  All of these cells lines demonstrated reversal of MDR following 
exposure to verapamil.  Two of these cell lines were tested for P-gp 
expression with 70 – 75% of cells staining positive with monoclonal antibodies 
directed against P-gp [312,314].   
In 1995, Hasegawa et al examined the expression of MDR-1, MRP and 
topoisomerase II in three doxorubicin resistant and one vincristine resistant 
bladder cancer cell lines which they had established.  They demonstrated a 
concomitant induction of increased levels of MRP mRNA, decreased levels of 
topoisomerase II mRNA and decreased drug accumulation with variable 
MDR-1 expression within these MDR cell lines, suggesting that MDR is a 
multifactorial process [248].  
Also in 1995, Naito et al, reported a doxourubicin resistant cell line without 
overexpression of MDR-1, which demonstrated decreased cellular levels of 
DNA Topo II, suggesting that at-MDR may also play a role in bladder cancer 
MDR [315].   
Kim et al, reported further non-P-gp expressing MDR cell lines which 
appeared to achieve resistance status by a combination of overexpression of   96
MRP, reduced topo II activity, increased glutathione levels and glutathione-S-
transferase activity [316]. 
Studies of MDR mechanisms in bladder cancer clinical tumour 
specimens 
In 1993 Thomas et al published an immunohistochemical study of the 
expression of glutathione-S-transferase π in normal urothelium, 23 superficial 
bladder tumours and 26 invasive tumours (these invasive tumours had all 
received platinum-based chemotherapy).  Cytoplasmic GSTπ staining was 
demonstrated in all specimens.  Nuclear staining was seen in one superficial 
tumour and in 13/26 invasive tumours (p=0.003), although there was no 
association between nuclear staining and response to systemic chemotherapy 
in those patients with invasive disease.  A possible association between 
GSTπ expression and disease progression was proposed [317]. 
In 1994, Park et al evaluated the expression of Pgp in 29 cystectomy 
specimens (from patients with no previous chemotherapeutic drug exposure) 
and bladder biopsies taken from 9 patients before treatment with intravesical 
doxorubicin and again at the time of recurrence.  Pgp was expressed in 75% 
of the cystectomy specimens.  There was no correlation between the level of 
P-gp expression and tumour pathological grade, stage or morphology.   
Of the small series of superficial tumours examined (n = 9), five developed 
recurrences following intravesical doxorubicin and four remained recurrence 
free during follow up (15 – 60 months).  Of the recurrent group, four had 
tumours that expressed P-gp before exposure to intravesical chemotherapy, 
whilst all five recurrences were P-gp positive.  Of those with no recurrence, 
three tumours were P-gp positive before exposure to chemotherapy.  The 
presence of P-gp overexpression in tumour cells before exposure to 
chemotherapy did not predict tumour sensitivity or recurrence in this series. 
They concluded that a significant proportion of bladder cancers exhibit P-gp 
overexpression without prior exposure to chemotherapeutic agents, and that 
the incidence of intrinsic MDR (as opposed to acquired) in bladder tumours 
was likely to be high [318]. 
In the same year, Petrylak et al, looked at P-gp expression in pre- and post-
chemotherapy, primary and metastatic tumour tissue samples from patients   97
with TCCs treated with M-VAC (methotrexate, vinblastine, adriamycin and 
cisplatin).  Untreated primary lesions were positive for P-gp in 13% compared 
to 38% post chemotherapy.  None of the untreated metastases were positive, 
but 55% of the post-therapy specimens showed various degrees of P-gp 
positivity (p=0.002).  The group with the highest percentage of cells staining 
positive for Pgp were those who had received 6 or more cycles of 
chemotherapy.  They concluded that exposure to combination chemotherapy 
increased the proportion of cells exhibiting Pgp positivity [319].   
In 1996, Pu et al, examined the expression of the MDR-1 gene in 14 bladder 
cancer cell lines (10 sensitive and 4 MDR) and in tumour/normal urothelium 
pairs from 88 patients, using reverse transcriptase-polymerase chain reaction 
(RT-PCR) and Southern blotting.  They also assessed functional P-gp activity 
using a flow cytometric rhodamine-123 retention and efflux technique, an 
established P-gp model.  They then examined the relationship between MDR-
1 expression and response to systemic (n = 28) or intravesical (n = 60) 
chemotherapy.  None of the 60 patients in the intravesical group, and only 5 in 
the systemic group had received prior intravesical chemotherapy. 
Of the ten wild-type cell lines only two were MDR-1 positive, and only one 
exhibited functioning P-gp.  In contrast, all four MDR lines had positive MDR-1 
status and the two MDR lines that were produced by doxorubicin exposure 
also had functioning P-gp. 
Of the 88 normal mucosa/tumour pairs, all 88 mucosal samples and 62 (75%) 
of the tumour samples expressed the MDR-1 gene.  There appeared to be no 
correlation between MDR-1 positivity and subsequent response to 
chemotherapy (either systemic or intravesical) [320].  
Expression of the MRP gene has been implicated in non-P-glycoprotein 
mediated MDR.  In 1996, Clifford et al examined MRP and MDR-1 mRNA 
expression, using a sensitive RT-PCR-based technique, in a series of 
previously untreated TCCs (n = 24) and normal bladder samples (n = 5).  
MRP mRNA was detected in all samples analysed, but demonstrated up to 
190-fold variation between tumour samples. Their results showed that MRP 
mRNA levels were significantly reduced in a higher proportion of high-grade 
(G3) bladder tumours (55%, 6/11) when compared to low- and moderate-
grade (G1/2) bladder tumours (8%, 1/13) (P=0.018), suggesting that MRP   98
mRNA levels may be reduced as a result of tumour progression to advanced, 
poorly differentiated disease.  There was no relationship between MRP mRNA 
levels and recurrence or progression risk, and no association with 
chemotherapy response.  There was no correlation between MRP and MDR1 
mRNA expression, suggesting that these two genes do not share common 
regulation or expression mechanisms [250].    
Also in 1996, Kim et al examined the expression of the MDR-1, MRP, GSTπ 
and topo II genes in 44 patients with urothelial cancers, 14 of whom had 
received prior chemotherapy.  Using a RT-PCR assay they examined 52 
tumours samples and three normal urothelial samples and demonstrated that 
the mean expressions of MRP and GSTπ were higher than those for MDR-1 
and topo II, and that the level of MRP expression correlated significantly with 
that of MDR-1 and GSTπ.  They were unable to demonstrate any significant 
influence of chemotherapy on the induction of expression of MDR-1 or MRP, 
but established that the expression of GSTπ was significantly higher in those 
who did not receive chemotherapy.  They concluded that the intrinsic and 
acquired resistance exhibited by urothelial cancers resulted from a 
multifactorial mechanism, and suggested that MRP and GSTπ expression 
activation occurred during tumorigenesis [321]. 
In 1996, Gan et al, looked at biological factors affecting doxorubicin sensitivity 
using primary cultures from seven superficial (Ta and T1) and nine invasive 
(T2 – T4) human bladder tumours.  Firstly, they determined the sensitivities of 
each of these tumours, with IC50 values for the superficial tumours ranging 
from 0.14 to 5.2 micrometer and for the invasive tumours ranging from 1.4 to 
>100 micrometer.   The difference in doxorubicin sensitivity between 
superficial and invasive tumours was more than 700-fold.   Using previously 
acquired concentration-depth profiles (pharmacokinetic data predicting 
doxorubicin penetrance into normal bladder tissue) they compared predicted 
tissue concentrations with the IC50 and IC90 values of the tumour specimens.  
They predicted that the IC50 would be reached in all Ta tumours, 67 – 100% 
of T1 tumours, but only one out of nine invasive tumours.  The IC90 was 
achieved in all Ta tumours, but none of the other tumours.    99
They then examined the relationship of chemosensitivity with pathological 
tumour variables and with expression of p-glycoprotein (P-gp) and p53 
protein. The invasive, high-grade, highly proliferative, p53- and P-gp-positive 
tumours were more resistant than the superficial, lower-grade, p53- and P-gp-
negative tumours.  None of the tumours expressed bcl-2.  
They concluded that the variability in response rates of superficial bladder 
cancer to intravesical doxorubicin therapy were due to a 35-fold variability in 
tumour sensitivity and, to a lesser extent, a 4-fold variability in tissue 
pharmacokinetics.  The invasive tumours were less responsive to intravesical 
doxorubicin due to inadequate tissue concentrations in the deeper muscle 
layers and reduced sensitivity of more aggressive tumours.  The most 
significant predictors of doxorubicin sensitivity appeared to be p53 expression 
and high stage, with P-gp expression being the least important factor in this 
study [322].   
In 1997, Nakagawa et al, examined the prognostic significance of multi-drug 
resistance associated protein and P-glycoprotein in patients with bladder 
cancer.  The expression of MRP and P-gp were investigated 
immunohistochemically using monoclonal antibodies, before and after 
chemotherapy. The correlation between expression of these MDR proteins 
and clinical outcome (tumour recurrence rate, cystectomy rate and 5-year 
survival rate) were assessed in 33 patients.  MRP was expressed in 1 of 28 
patients (4%) and P-gp was expressed in 22 of 33 (67%) of patients before 
chemotherapy.  MRP expression was induced by chemotherapy in 6 of 28 
patients (21%) compared to P-gp induction in 4 patients (14%).  MRP 
induction appeared to be dose dependent, being more frequent in patient 
receiving high dose (more than 300mg) than low dose (less than 300mg) 
anthracyclines (p < 0.01).  Co-expression of MRP and Pgp occurred in 5 of 28 
patients (18%) post-chemotherapy.  They concluded that MRP and P-gp 
expression can be induced by chemotherapy for bladder tumours, but that the 
presence of P-gp expression pre-chemotherapy did not predict their clinical 
outcome.   
In 2001, Chen Z et al studied the expression MRP, P-gp, P53 and Bcl-2 
proteins in 40 specimens of bladder transitional cell carcinoma.  The overall 
expression rates for MRP, P-gp, P53 and Bcl-2 were 52.5%, 57.5%, 47.5%   100
and 62.5% respectively.  When analysed by grade the positive rate of MRP, 
Pgp, P53 and Bcl-2 were 46.3%, 38.5%, 38.5%, 23.1% for grade I tumours,  
52.9%, 39.8%, 47.1%, 76.4% for grade II tumours and 60.0%, 80.0%, 60.0%, 
90.0% for grade III of tumours, respectively.  In 24 primary tumour specimens 
the expression rates for MRP, P-gp, P53 and Bcl-2 were 37.5%, 41.7%, 
33.3%, 45.8% compared to 75.0%, 81.3%, 68.8%, and 87.5% in 16 recurrent 
cases following chemotherapy.  They concluded that the rates of MRP, P-gp, 
P53 and Bcl-2 expression increased with higher tumour grade and were also 
significantly increased in recurrent cases following chemotherapeutic 
exposure (p < 0.05), suggesting that these proteins play a role in 
chemotherapy failure [323].  
In 2002, Tada Y et al, examined the relationship between MDR1, MRP1, 
MRP2 and MRP3 expression and clinical outcome and response to 
doxorubicin chemotherapy in 47 clinical bladder cancer samples.  MDR 
protein expression was assessed using a combination of quantitative RT-PCR 
analysis and immunohistochemical staining using monoclonal antibodies to 
MDR1, MRP1, MRP2 and MRP3.  The chemosensitivity of bladder tumour 
samples to doxorubicin was determined using the in vitro succinate 
dehydrogenase inhibition test.  They confirmed a significant correlation of 
MDR1, MRP1 and MRP3 mRNA levels with resistance to doxorubicin and 
demonstrated that expression of MDR1, MRP1, MRP2 and MRP3 in recurrent 
and residual tumours following chemotherapeutic treatment was higher than 
that in untreated primary tumours.  Levels of MDR1 expression in residual 
tumours were particularly high, being 5.7 times higher than in untreated 
primary tumours [324].  
In 2003, Diestra et al,  investigated the predictive value of expression of MDR 
related proteins P-gp, MRP1, breast cancer resistance protein (BCRP) and 
lung resistance related protein/major vault protein (LRP/MVP) in the response 
to neoadjuvant chemotherapy, bladder preservation and prognosis in locally 
advanced bladder cancer.  Immunohistochemical methods were used to 
determine the expression of MDR proteins in tumours from 83 patients with 
locally advanced bladder cancer treated with neoadjuvant chemotherapy 
using a bladder sparing approach.  P-gp, MRP1, BCRP and LRP/MVP 
showed high level expression in 53%, 59%, 28% and 70% of cases,   101
respectively.  P-gp expression correlated with shorter progression-free 
survival (p = 0.04) but not with overall survival. Surprisingly MRP1 expression 
correlated with an improved response rate (p = 0.005) and an increased 
chance of bladder preservation following neoadjuvant chemotherapy (p = 
0.001).  BCRP had no impact on prognosis. High LRP/MVP expression was 
associated with a significantly worse response to neoadjuvant chemotherapy 
and a decreased probability of bladder preservation (p = 0.035).  They 
concluded that MRP1 and LRP/MVP could potentially be of use in 
combination with other clinicopathological prognostic factors for selecting 
patients with locally advanced bladder cancer to be candidates for bladder 
preservation after neoadjuvant chemotherapy.  Although larger prospective 
studies are warranted to confirm these results [325].  
In 2004, Zhu et al, looked at the expression of lung resistance-related protein 
(LRP) in a group of 66 patients with newly diagnosed primary bladder cancer, 
without prior exposure to either radiotherapy or chemotherapy.  Reverse 
transcriptase-polymerase chain reaction analysis was used to measure LRP, 
MDR1 and MRP1 mRNA expression.  Expression of LRP, p53 and p63 
proteins were also examined using immunohistochemistry.  LRP 
demonstrated the highest levels of expression in primary bladder cancer 
being expressed by 63.6% of tumours.  LRP mRNA levels were significantly 
higher in normal bladder tissue than in bladder cancer tissue (P <0.01) and in 
superficial cancers than in invasive cancers (P = 0.013).  LRP mRNA 
expression did not correlate with either MDR1 or MRP1 expression, but was 
closely related to the LRP levels (P = 0.001). LRP was expressed more 
frequently in low-grade (P <0.01) and low-stage (P <0.05) cancers, but bore 
no relation to the expression of tumour suppressor proteins, p53 or p63. The 
higher levels of expression in lower grade and stage-related bladder cancer, 
suggest that LRP may be an indicator of intrinsic MDR in early bladder 
cancer.  Cytotoxic drugs that are not susceptible to LRP resistance may be 
more effective in early bladder cancers [326].   102
1.5:  Anthracyclines in multidrug resistance 
Anthracycline Antibiotics 
Anthracyclines antibiotics are cytotoxic drugs that are used to treat a wide 
variety of malignancies, both haematological and visceral.                    
Daunorubicin, the first drug discovered in this class, was isolated from a strain 
of the soil fungus Streptomyces peucetius.  It’s activity on experimental 
tumours was first described in 1959 [327], indicating the anti-tumour potential 
of the anthracyclines.  Daunorubicin demonstrated activity against various 
tumours including Ehrlich carcinoma, sarcoma 180, Yoshida hepatoma and a 
variety of human haematological tumours.  Doxorubicin (formerly known as 
adriamycin) was the next anthracycline to be discovered being derived from a 
mutant strain of Streptomyces peucetius.  Doxorubicin was a more potent 
cytotoxic agent than daunorubicin, but was hampered by its dose limiting 
cardiotoxicity.  Since then numerous anthracycline derivatives have been 
synthesised in an attempt to increase their antitumour activity and eliminate 
their unwanted side effects, the most limiting being their cumulative 
cardiotoxicity.  Most of the newer anthracyclines are produced by a 
combination of microbial synthesis and biochemical modification.  They 
include epirubicin, idarubicin and pirarubicin. 
The anthracyclines are characterised by a tetracycline group attached by a 
glycoside bond to one or several sugar groups (Figure 15). 
Epirubicin (4’-Epi-doxorubicin; molecular weight 580) is a stereoisomer of 
doxorubicin, differing from its parent molecule, doxorubicin, by a different 
configuration of the hydroxyl group (-OH) on the C4 position of the amine 
sugar.  This minor alteration has not affected its antitumour activity, but has 
reduced its cardiotoxicity [328]. 
Idarubicin (molecular weight 497) differs from daunorubicin by the absence of 
a methoxy group at the carbon-4 position.  This alteration results in increased 
lipophilicity which increases the rate of intracellular uptake and enhances its 
cytotoxicity.   
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Figure 15:   Biochemical structures of the anthracyclines: Doxorubicin, 
      epirubicin and idarubicin 
 
Anthracycline Autofluorescence 
Anthracyclines possess the property of autofluorescence, which allows their 
study by a variety of fluorescence based techniques, including confocal 
microscopy and flow cytometry.  These techniques have aided the study of 
intracellular accumulation and distribution of the anthracyclines in sensitive 
and MDR cancer cell line models.   
This autofluorescence is attributed to the aromatic ring structure of 
doxorubicin, epirubicin and idarubicin (Figure 16).  It is this four ring tetracene 
group which has a diffuse cloud layer of “Pi” electrons floating above and 
below it.  These “Pi” electrons are easily excited into higher energy states by 
laser light of certain wavelengths.  When these electrons fall back to their 
original unexcited energy state they liberate energy as photons of light, 
otherwise known as autofluorescence. 
   R 1   R2   R3   R4 
Doxorubicin   OCH3   H   OH   OH 
Epirubicin   OCH3   H   OH   OH 
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Doxorubicin, epirubicin and idarubicin have almost identical excitation and 
emission spectra as shown in Figure 16.  Their peak excitation is achieved 
using a laser with a wavelength of 490nm (range 400 – 560nm).  This yields a 
peak emission of 590 – 600nm wavelength (range 510 – 700nm). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16:   Excitation and emission spectra of the anthracyclines:  
     Doxorubicin,  epirubicin, daunorubicin and idarubicin. 
 
Anthracyclines: Mechanisms of action   
Major research efforts have been directed towards elucidating the mechanism 
of action and clinical pharmacology of known anthracycline compounds. 
At present there are four major groups of action that have been postulated. 
1. DNA intercalation 
There is high affinity binding of the anthracyclines to cellular DNA through 
intercalation, with consequent blockade of the replication and transcription of 
the DNA [329-331].  This intercalation of anthracycline and DNA has several 
consequences; local relaxation with the DNA helix unwinding by 15 degrees 
and disruption of the ability of nucleic acid to act as a template for 
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polymerases leading to inhibition of DNA synthesis and repair, and 
fragmentation of DNA.   
2. Membrane binding 
Anthracyclines are able to bind onto membranes altering their fluidity, ion 
transport and interfering with membrane based signalling systems [332].  It 
has been suggested that the primary cytotoxic effect of the anthracyclines on 
non-dividing cells, may arise from their tendency to disrupt the electrolyte 
balance of the cell, by increasing the sodium permeability and altering the 
calcium handling of the cells [333].  
3. Free radical formation 
Many of the anthracyclines can be reduced through cytochrome P450 
mediated reductive processes to generate semiquinone free radicals.  These 
free radicals can further reduce molecular oxygen to the superoxide ion, 
which causes damage to DNA, cell membranes and mitochondria through 
perioxidation of membrane lipids [334,335].  This action may also be 
responsible for cardiac toxicity through oxygen radical-mediated damage to 
the membranes, as heart muscle cells lack the enzyme catalase which 
inactivates oxygen free radicals [332]. 
4. Topoisomerases 
Another important cytotoxic action of the anthracyclines takes place in the 
nucleus of the cell and appears to be mediated, at least partly, through an 
effect on topoisomerase II (a DNA gyrase), the activity of which is markedly 
increased in proliferating cells.  The topoisomerases catalyse the 
interconversion of topoisomers in DNA.  The significance of these enzymes 
lies in the fact that during replication of the DNA helix in mammalian cells, 
reversible swivelling needs to take place around the replication fork in order to 
prevent daughter DNA molecules becoming inextricably entangled during 
mitotic segregation.  This swivelling is produced by a three step process: 
1.  Cleavage of one (topoisomerase I) or both strands (topoisomerase II) of 
DNA, 
2.  Passage of a segment of DNA through this break, and 
3.  Resealing of the break (topoisomerase II). 
Cleavage of DNA by topoisomerase II is stimulated by, but not dependent 
upon, ATP.  The anthracyclines are thought to act on topoisomerase II   106
stimulating formation of cleavable complexes with topoisomerase in vitro and 
inducing protein-linked DNA breaks in vitro and in vivo.  The mechanism of 
DNA breakage induced by the anthracyclines is most likely due to the drug 
stabilisation of a cleavable complex formed between topoisomerase II and 
DNA, resulting in both double- and single-strand DNA breaks [336-339]. 
Anthracyclines: Mechanisms of resistance 
Most information regarding mechanisms of resistance to anthracyclines is 
derived from in vitro models, where cells can be exposed to doses of drugs 
that cannot be achieved clinically.  There are multiple mechanisms of 
resistance to anthracyclines and resistance is often multifactorial.  The main 
mechanisms of action are outline below: 
1. Classical P-glycoprotein mediated MDR   
Anthracyclines are susceptible to classic P-gp mediated multidrug resistance.   
Active drug efflux by P-gp leads to reduced intracellular accumulation and 
efficacy of anthracyclines.    
2. Non-Pgp mediated MDR 
Anthracyclines are also subject to efflux by other plasma membrane pumps 
including MRP and BCRP.   
3. Changes in the intracellular distribution of the drug 
In both classic and non-P-gp mediated MDR, the subcellular localisation of 
anthracyclines has been shown to alter from mainly nuclear in wild-type cells 
to mainly cytoplasmic, with more free drug present in acidic vesicles or bound 
to the membranes of vesicles in MDR cells [340,341].  This 
compartmentalisation of the anthracyclines away from their nuclear target is 
an additional mechanism of resistance in both P-gp and non-P-gp mediated 
MDR. 
4. Glutathione-S-transferases (GSTs) and detoxification mechanisms   
These enzymes conjugate glutathione to chemically reactive groups and have 
been found to be overexpressed in several doxorubicin resistant cell lines.  
Direct evidence of GST activity in anthracycline resistance is missing.  
However, elevated levels of GSTs may indirectly lead to anthracycline 
resistance by inhibition of the MAP kinase apoptotic pathway.    107
5. Alterations in TOPO II (at-MDR)   
Low levels of expression or alterations in TOPO II may contribute to 
anthracycline resistance, as one of their modes of action is via interaction with 
TOPO II in dividing cells.  
6. Increased DNA repair  
In several cell lines, increased levels of DNA repair have been associated with 
resistance to doxorubicin [342].   
Anthracyclines in the study of MDR 
The anthracyclines are substrates for several of the ABC transporters 
including P-gp, MRP1 and BCRP and are also susceptible to other 
mechanisms of MDR.  They also possess the property of autofluorescence 
which allows their study by a variety of fluorescence based techniques 
including confocal microscopy and flow cytometry.  For these reasons the 
anthracyclines have been used extensively in the study of MDR mechanisms 
in cell line models.  These studies have principally looked at drug uptake and 
localisation within cells, as well as some dynamic variables such as efflux.     
Initial studies were able to demonstrate reductions in anthracycline uptake in 
MDR cells.  Cellular localisation of drug could also be studied.  MDR cells 
have altered cellular distribution of anthracyclines with predominantly 
cytoplasmic drug localisation, where it appears to be sequestered within 
vesicles.  This gives the so-called nuclear sparing appearance which is 
characteristic of MDR drug uptake.   
Flow cytometric experiments: 
In 1979, Krishan et al, described how intracellular levels of anthracyclines 
could be detected and quantified using laser flow cytometry.  Krishan used 
two methods, an indirect method based on the interference of the 
anthracyclines with nuclear DNA binding of propidium iodide and therefore 
reducing fluorescence levels and a direct method where intracellular 
anthracycline fluorescence was excited and detected [343].  
In 1980, Krishan et al, demonstrated how laser flow cytometry could be used 
to examine the pharmacokinetics of intracellular anthracycline uptake.  They 
were able to examine dose responses and rates of drug uptake for several 
anthracyclines including adriamycin (doxorubicin) and daunomycin 
(daunorubicin).  Drug fluorescence was also detectable in tumour and spleen   108
samples from animals that were injected with adriamycin (4 mg/kg) and 
sacrificed 3 hours later [344]. 
In 1982, the same group demonstrated how flow cytometry could be used to 
rapidly compare and quantitate cellular Adriamycin (ADR) fluorescence in 
ADR-sensitive P388 leukemia (P388/S) and ADR-resistant P388 leukemia 
(p388/R) cells.  Drug levels in resistant cells were two to fourfold lower that 
levels in sensitive cells exposed to the same concentration of adriamycin (1 – 
10 µg/ml) [345] 
Confocal microscopy experiments 
In 1991, Gervasoni et al, first described the use of Laser-assisted Confocal 
Microscopy to look at the subcellular distribution of anthracyclines in cancer 
cell lines.  They examined the difference in cellular localisation of 
daunorubicin in four well defined MDR cell lines (HL-60/AR, P388/ADR, KBV-
1 and MCF-7/ADR) and their drug sensitive counterparts (HL-60/S, P388/S, 
KB3-1 and MCF-7/S).   Both resistant and sensitive cells showed rapid 
distribution of drug from the plasma membrane to the perinuclear region 
within 2 minutes. From 2 – 10 minutes, in the drug sensitive HL-60/S, P388/S, 
and MCF-7/S cells drug was redistributed throughout the cytoplasm and into 
the nucleus in a diffuse pattern.  In contrast, drug-resistant HL-60/AR, 
P388/ADR, and MCF-7/ADR cells redistributed drug away from the nucleus 
into cytoplasmic vesicles, seen as a "punctate" cytoplasmic pattern of drug 
fluorescence.  The redistribution of daunorubicin away from the nucleus in 
MDR cells was inhibited by glucose deprivation and by lowering the 
temperature of the medium below 18
oC, suggesting that this was an energy 
dependent phenomenon.  The differences in distribution between sensitive 
and resistant cells did not appear to be related to the levels of intracellular 
Daunorubicin or as a result of cell death. Drug-sensitive KB3-1 and -resistant 
KBV-1 cells demonstrated an intermediate intracellular distribution of 
Daunorubicin with both "punctate" and nuclear/cytoplasmic uptake, 
sometimes in the same cell.  The nuclear sparing of Daunorubicin uptake in 
resistant cells was felt to represent another mechanism of drug resistance 
independent of P-glycoprotein overexpression, presumably by protecting 
cellular DNA against drug toxicity [244].   109
In 1993, Coley et al, used laser scanning confocal microscopy to study the 
intracellular distribution of anthracyclines in two pairs of parental and 
multidrug resistant (MDR) cell lines.  They used mouse mammary tumour 
cells lines EMT6/P (parental) and EMT6/AR1.0 (resistant)) and a human large 
cell lung cancer line COR-L23/P (parental) and the COR-L23/R (resistant).                         
Sensitive cell lines demonstrated predominantly nuclear and cytoplasmic drug 
fluorescence.  Whilst in the resistant cell lines intracellular fluorescence levels 
were much lower, with comparatively more loss of nuclear fluorescence than 
cytoplasmic fluorescence.  The COR-L23/R cell line additionally showed an 
area of intense perinuclear staining consistent with drug localised in the Golgi 
apparatus.  The addition of verapamil during anthracycline exposure led to 
increased levels of fluorescence in the MDR lines, particularly in the nucleus.  
Verapamil exerted minimal effects in parental lines.   
They summarised that confocal microscopy is a useful tool for examining the 
subcellular distribution of anthracyclines in parent and MDR cell lines, which 
may provide useful insights into the mechanisms of MDR and suggest 
strategies to circumvent MDR [340]. 
Anthracyclines in the study of MDR in bladder cancer 
Anthracyclines have also been used to investigate mechanisms of MDR in 
bladder cancer.  Here their use is particularly pertinent as doxorubicin and 
epirubicin are agents that are in regular use as intravesical cytotoxic agents.    
In 1996, Duffy et al, published two papers comparing epirubicin uptake and 
distribution in a sensitive (MGH-U1) and a MDR (MGH-U1R) bladder cancer 
cell line, using flow cytometry in one and confocal microscopy in the other.   
The flow cytometric analysis looked at the detection of intracellular levels of 
epirubicin using autofluorescence in both sensitive and resistant bladder 
cancer cell lines in vitro [346].  This study also examined the effects of 
verapamil, a known MDR reversing agent on epirubicin accumulation within 
these cells.  They found a reliable, highly significant and consistent difference 
in intracellular epirubicin uptake between the resistant and sensitive bladder 
tumour cells. The resistant cell lines demonstrated significantly lower levels of 
epirubicin fluorescence.  Over the range of epirubicin concentrations between 
1 to 40µg/ml there was a consistent eightfold difference in epirubicin uptake   110
between sensitive and resistant cell lines.  They demonstrated that verapamil 
increased the levels of epirubicin uptake in MDR cell lines to almost the same 
levels as in sensitive cell lines.  It was suggested that such an assay of 
epirubicin uptake could be applied to clinical tumour specimens allowing 
targeted treatment of sensitive tumours.  They also suggested that verapamil 
in combination with epirubicin may improve the efficacy of treatment in 
patients whose tumors exhibit MDR.   
The confocal microscopy paper looked at the intracellular distribution of 
epirubicin in sensitive and resistant bladder cancer cell lines, in particular 
looking at the effects of temperature, viability and verapamil [347].  They 
demonstrated a striking and consistent difference in the intracellular 
distribution of the drug between resistant and sensitive cells.  Sensitive cells 
demonstrated greater overall levels of epirubicin fluorescence, predominantly 
accumulating in the nucleus.  In contrast epirubicin fluorescence in resistant 
cells was cytoplasmic with a granular appearance, with characteristic sparing 
of uptake from the nucleus.  When incubated at 0
oC, both cell lines showed 
an absence of nuclear uptake, resembling the nuclear sparing pattern of 
resistant cells at 37
oC.  Dead cells developed brightly fluorescent nuclei of 
sensitive phenotype very rapidly, highlighting the need to assess cell viability 
before making any claims about reversal of the nuclear uptake pattern by 
pharmacological means.  Addition of the MDR-reversing agent verapamil 
changed resistant cells to the sensitive phenotype, which were subsequently 
proven viable by Trypan blue exclusion.  They concluded that sensitive and 
resistant cells could be differentiated reliably by confocal microscopy and 
pointed to another mechanism of resistance to epirubicin, namely the nuclear 
exclusion of drug.  The technique described in this study could be applied to 
clinical tumours specimens to detect tumours containing resistant cells that 
could potentially benefit from MDR-reversing agents such as verapamil as 
part of a combination chemotherapy regime.   
Another study from the same research group used confocal microscopy to 
examine cellular uptake and localisation of epirubicin and mitozantrone (a 
cytotoxic drug from the anthraquinone group also demonstrating 
autofluorescence) in combination with gammalinolenic acid (an essential fatty 
acid) or verapamil in sensitive (MGH-U1) and resistant (MGH-U1R) cell lines.    111
Mitozantrone exhibited similar differences in terms of cellular drug localisation 
with sensitive cells having a predominantly nuclear uptake and resistant cells 
sparing drug from the nucleus.  At a mitozantrone dose of 20μg/ml, the ratio 
of sensitive to resistant nuclear uptake was 10:1, which with the addition of 
GLA decreased to 6:1.  For epirubicin similar patterns of drug localisation to 
those described by Duffy et al, were reported, with reversal of the MDR cells 
to a nuclear uptake pattern with the addition of verapamil [348].  
The demonstration of nuclear exclusion of another class of cytotoxic drug, 
suggests that this “nuclear sparing phenomenon” may be a common 
mechanism of resistance to many different cytotoxic agents with nuclear 
modes of action.  
In another study from the same group, primary cells cultured from bladder 
cancer explants also demonstrated heterogeneity in their nuclear uptake of 
epirubicin, with many demonstrating the MDR phenotype [349].   
Multidrug resistance in bladder cancer: Does the nuclear membrane 
play a role? 
Like MDR, nuclear sparing has been demonstrated in MDR cell lines from 
numerous organs, appearing to transcend tissue type.  It has also been 
shown in viable clinical tumour material.  It seems likely therefore that this 
mechanism is an important reason for chemotherapeutic failure in tumours 
exhibiting MDR, as many cytotoxic drugs have their main mode of action 
within the nucleus.     
Nuclear sparing has also been demonstrated using other fluorescent 
chemotherapeutics such as the anthraquinones, which include Mitozantrone 
[348,350,351].   Difficulties in visualising the cellular distribution of non-
fluorescent chemotherapeutic agents makes it impossible to prove that in 
MDR cells, nuclear sparing limits the efficacy of all MDR-affected anticancer 
agents and not just those possessing autofluorescence.   
Previous investigators have questioned whether the nuclear sparing 
phenomenon is merely a reflection of low levels of drug accumulation in MDR 
cells, due to drug efflux by P-glycoprotein, or whether the nuclear membrane 
is also playing a role [234,244,340,347,352]    112
Previous work looking at the role of the nuclear membrane in adriamycin 
uptake in isolated sensitive and MDR nuclei, from a lymphoblastic tumour cell 
line [352], showed that in isolated nuclei, nuclear transport of adriamycin 
(doxorubicin) was reduced in MDR cells compared to sensitive cells.  
Blockade of active nuclear transport by Wheat Germ Agglutinin (WGA; 
Triticum vulgaris lectin) reduced sensitive nuclear uptake of adriamycin to 
approximately the level of MDR nuclear uptake, but had no effect on 
adriamycin accumulation in MDR nuclei.  These results suggested that there 
are two mechanisms of drug uptake at play in sensitive cells, namely passive 
diffusion and active transport.  
The role of the nuclear membrane in this nuclear sparing phenomenon in 
MDR cancer cells has not been clearly established, but clearly warrants 
further investigation.   
Nuclear sparing of anthacycline uptake in bladder cell lines: The enigma 
of idarubicin 
Idarubicin is somewhat of an enigma in terms of its uptake and subcellular 
distribution in MDR cancer cell lines.  Idarubicin demonstrates high levels of 
intracellular drug fluorescence, but unlike the other anthracyclines there is 
clear nuclear sparing pattern of subcellular localisation in both sensitive and 
MDR cell lines [350,353].  Most cells demonstrate high levels of cytoplasmic 
drug fluorescence with an area of intense peri-nuclear staining, probably 
representing drug within the Golgi apparatus.  The addition of verapamil 
results in no change in the cellular distribution of idarubicin, but does result in 
increased cytotoxicity presumably as a result of increased intracellular drug 
levels [353].  This suggests that substantial nuclear drug fluorescence may 
not be required for all anthracyclines to exert their cytotoxic effects.   
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1.6:  The nuclear membrane and nuclear pore complexes 
Molecular trafficking of ions, small molecules and macromolecules, between 
nucleus and cytoplasm occurs via nuclear pore complexes (NPCs).   These 
large (~125 MDa) supramolecular assemblies are an integral part of the 
double-membraned nuclear envelope.  The nuclear membrane of a 
proliferating human cell has approximately 3000–5000 NPCs.  NPCs allow 
passage of molecules by two mechanisms:  passive diffusion and facilitated 
translocation.   
In eukaryotic cells the spatial separation of transcription and translation is a  
powerful mechanism for controlling gene expression, but requires selective 
transport between the nuclear and cytoplasmic compartments to maintain the 
distinctive composition of each.  Consequently, it is vital that both proteins and 
RNA are transported across the nuclear membrane in a regulated manner.   
NPCs have been implicated in carcinogenesis and have also been suggested 
as a possible mechanism of nuclear MDR [352].  
The nuclear membrane:                                                                                   
In eukaryotic cells during interphase, the nucleus is separated from the 
cytoplasm by the nuclear envelope (NE), consisting of a double membrane 
enclosing a lumen or “perinuclear space”.  The outer membrane faces the 
cytoplasm and is in continuity with the endoplasmic reticulum (ER), so that the 
perinuclear space communicates with the lumen of the ER.  This outer 
cytoplasmic leaf is often studded with ribosomes forming the rough ER.  The 
inner nuclear membrane faces the nucleoplasm and its inner surface is lined 
by the nuclear lamina, a polymer of intermediate filament-like proteins, the 
nuclear lamins.  The nuclear lamina provides a general framework for NE 
structure and provides an anchoring site for interphase chromatin. At irregular 
intervals the inner and outer nuclear membranes are fused to form the “pore 
membrane”, sites at which the NPCs traverse the nuclear envelope.                                    
Nuclear pore complexes (NPCs) 
NPCs are sites of bidirectional exchange of material between the nucleus and 
the cytoplasm.  They allow passive diffusion of ions and small molecules, but 
molecules above 9nm in diameter do not freely cross the NPC.  
Macromolecules greater than ~ 40Kda are transported actively across the 
nuclear envelope through NPCs using soluble transport factors or carrier   114
molecules that cycle between the cytoplasm and nucleus [354-357]. These 
larger molecules are selectively imported by a signal-requiring and ATP-
dependent mechanism.  Macromolecular assemblies such as 
ribonucleoprotein (RNP) particles containing mRNA also undergo selective 
nuclear export.                                                                                        
Nuclear pore complexes: Structure                                                         
Nuclear membrane pores in vertebrates are huge macromolecular protein 
structures approximately 1200 Å in diameter with a depth of about 700 Å, 
where they cross the nuclear envelope [358,359].  NPCs are constructed from 
multiple copies of about 30 different proteins, collectively known as 
nucleoporins [360-362].  NPCs in vertebrates have a tripartite architecture 
with a molecular weight of around 125MDa [363].  The central framework for 
the NPC is a ~ 55 MDa ring-like assembly built of eight multidomain spokes 
each consisting of two roughly identical halves [358,363]. 
This central framework is sandwiched between a ~ 32 MDa cytoplasmic ring 
and a ~ 21 MDa nucleoplasmic ring.  The cytoplasmic ring radiates eight 
short, kinky fibrils, whereas the nuclear ring anchors a basket-like structure (or 
fishtrap), assembled from eight thin 50nm long filaments joined distally by a 
30–50nm diameter ring [364].  The central framework of the NPC has a 
central channel, about 40 nm [365] in diameter, through which molecules 
diffuse or are transported.  This central channel of the NPC is often plugged 
with a distinct particle of variable appearance, called the central plug or 
transporter [366].   
A schematic diagram of the nuclear pore substructures is shown in Figure 17.  
Nuclear pore complex: Function                                                             
Nuclear pores form aqueous channels through which all nuclear – cytoplasmic 
transport of molecules proceeds, either by passive diffusion or facilitated 
transport.  
Passive diffusion through NPCs                                                                   
The passive diffusion channel of the NPC has functional diameter of 
approximately 9nm [367].  Passive diffusion is relatively fast for small 
molecules < 20–30KDa, but becomes very inefficient as the size of the 
molecule approaches the 9nm limit, which translates to a molecular weight of 
around 40KDa.      115
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17:   Schematic diagram of nuclear pore complex substructures 
      (Figure reproduced with kind permission of Cell Press) 
 
Facilitated transport through NPCs                                                                                    
In contrast, facilitated transport permits the translocation of much larger 
objects, often against a gradient of chemical activity [354].  Particles with 
molecular weights of several megadaltons can be transported by this process, 
such as ribosomal subunits (1.4 and 2.8 MDa) or Balbiani ring particles 
(>10MDa).  Facilitated transport is an energy dependent process which 
requires specific interactions between the translocating molecule and the 
NPC, making the process very selective.   
There are several nuclear transport pathways, each transporting a specific 
range of macromolecules into or out of the nucleus.  Most pathways use a 
homologous family of carrier molecules collectively called β-karyopherins, with 
import carriers called importins and export carriers called exportins.   
Many proteins are imported to the nucleus using importin-β, often using 
importin-α as an adaptor.  Other proteins are transported by other importins, 
such as transportin.  Nuclear export of proteins is mediated in many cases by 
the export carrier CRM1.  Various exportins facilitate nuclear export of RNA, 
for example pre-micro-RNA is exported by exportin-5 and t-RNA is exported 
by exportin-t, both of which are importin-β analogues.  In contrast, mRNA is 
exported by the NXF1:NXT1 heterodimer which is unrelated to karyopherins.     116
Nuclear protein import occurs by different pathways many of which share 
common features based on a concerted series of protein:protein interactions 
allowing cargo recognition in the cytoplasm, translocation through NPCs and 
release into the nucleus.  In each pathway, cargo proteins are targetted for 
nuclear import by short sequences of amino acids know as nuclear 
localisation sequences (NLS).  Each of the different import pathways requires 
a specific NLS.   
The classic nuclear protein import pathway is the best characterised nuclear 
transport cycle, transporting a wide range of cargo proteins using importin-β 
as a carrier.  This pathway has been studied in substantial detail and all of its 
components have been identified.  
The classic nuclear protein import cycle 
The classic nuclear protein import cycle is driven by a series of protein:protein 
interactions and generates transport rates of ~ 100 – 1,000 cargoes per 
minute per NPC [365].   
The nuclear protein import cycle can be conveniently divided into four steps: 
assembly of the cargo:carrier import complex in the cytoplasm; translocation 
through NPCs; import-complex disassembly in the nucleus; and importin 
recycling (Figure 18a).  
In the cytoplasm, proteins containing a classic NLS are imported by importin-
β, which binds them through the adaptor protein importin-α, forming an import 
complex, importin-α:β heterodimer, which facilitates movement through NPCs.  
In the nucleus, RanGTP binds to importin-β, which dissociates importin-β from 
importin-α. The NLS carrying cargo protein is then released by importin-α.  
Importin-β complexed with RanGTP is recycled to the cytoplasm, whereas 
importin-α is exported complexed with its nuclear export factor, β-karyopherin 
CAS and RanGTP.  Finally, in the cytoplasm RanGAP (Ran GTPase 
activating protein) stimulates GTP hydrolysis by Ran GTPase, generating 
RanGDP, which then dissociates from the importins, releasing them for 
another import cycle. 
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  Figure 18a:  Overview of classic nuclear protein import cycle.   
  Figure 18b:   RanGTP/GDP cycle associated with nuclear protein import. 
      (Reproduced with kind permission of Nature Publishing  
     Group) 
  
Interactions between cargoes and carriers are coordinated by the nucleotide 
state of Ran, which cycles between GTP- and GDP-bound states  
(Figure 18b). The state of the Ran nucleotide is controlled by its guanine 
nucleotide-exchange factor (RanGEF), which catalyses recharging of 
RanGDP with GTP, and RanGAP, which stimulates GTP hydrolysis.  RanGEF 
is nuclear and RanGAP is cytoplasmic, and so nuclear Ran is in the GTP-
bound state, whereas cytoplasmic Ran is GDP bound. RanGTP is exported 
from the nucleus bound to β-karyopherin carriers and, after RanGAP-
mediated GTP hydrolysis, cytoplasmic RanGDP is transported to the nucleus 
by its specific carrier, nuclear transport factor-2 (NTF2) [368,369], for 
recharging with GTP. The conformation of key structural loops in Ran (the 
switch I and II loops) changes markedly with nucleotide state. This structural 
change determines the way in which importin-β family transport factors 
interact with cargoes, and so ultimately, the Ran GTPase provides the energy 
for nuclear transport.   118
Nuclear pore complexes and cancer 
The targeting of a tumour suppressor, transcription factor or oncoprotein to its 
intracellular site of action is regulated at multiple points.  Such regulatory 
steps include upstream cell-signalling events, protein modification and the 
ability of nuclear transport proteins to recognise and bind nuclear transport 
signals.  Transport signals can be masked by the binding of another protein or 
folding of an inhibitory domain, making the signal inaccessible to nuclear 
transport receptors.  Any of these processes can be altered, resulting in 
subcellular mislocalisation, which could result in uncontrolled cell growth.   
Cell cycle regulatory proteins 
Cyclin B1 is a cell cycle regulator that requires nuclear localization to be 
biologically active [370].  During the S and G2 phases of the cell cycle, cyclin 
B1 accumulates in the cytoplasm following which at the beginning of mitosis, it 
rapidly relocates to the nucleus.  This relocalisation is the result of regulated 
nuclear export [371,372], suggesting that deregulation of this process can 
alter the mitotic process and could lead to cancer.  Several other mitotic 
inducers have been identified and shown to rely on nuclear transport to exert 
their effects, such as Cdc 25, cyclin D1 and p27
kip1 [373,374].  Cyclin D1 is 
overexpressed in many different tumours and decreased expression of p27
kip1 
correlates with a poorer prognosis in breast and colon cancer. 
Inactivation of p53 
P53 is a well described tumour suppressor gene and over half of all human 
cancers contain mutations in p53 that result in its inactivation [375].  
Interestingly, p53 inactivation can also occur from mutation-independent 
mechanisms, such as sequestration of p53 in the cytoplasm [375,376].  The 
function of p53 depends on nuclear localisation, so its nuclear-cytoplasmic 
transport is tightly regulated.  Increased nuclear levels of p53 are required 
during times of cell stress, such as DNA damage, where p53 activates 
transcription of its target genes.  The regulation of p53 by nuclear transport 
has only recently been studied and characterised [377,378].  P53 contains 3 
nuclear localisation signals (NLS) [379] and one nuclear export signal (NES).  
Functional cytoplasmic p53 has been discovered in many different types of 
human cancers.  The mechanism by which p53 is sequestered in the 
cytoplasm of tumour cells is unknown. It may be a result of increased export,   119
due to expression of a hyperactive form of MDM2.  Nuclear exclusion could 
also result from binding to a cytoplasmic anchor protein, such as the 
glucocorticoid receptor or the parkin-like ubiquitin ligase (PARC)                  
Cellular Apoptosis                                                                                       
Apoptosis, or programmed cell death, is necessary to maintain homeostasis in 
normal tissues.  Failure of apoptosis is now recognised as an important factor 
in carcinogenesis.  Apoptotic signals are transmitted through a common 
pathway that involves the death-driving ICE-family proteases and anti-cell 
death protein Bcl-2 in the cytoplasm.  These signals must be transported from 
the cytoplasm to the nucleus.  Blockade of active nuclear pore transport with 
WGA prevented Fas-induced apoptotic nuclear changes, such as chromatin 
condensation, nuclear fragmentation and the formation of apoptotic bodies 
[380].  Caspases, the major execution system in apoptosis, also alter 
nucleocytoplasmic transport by degradation of nucleoporins [381].                                       
Alterations in nucleoporins                                                                        
Several cancer-associated fusion proteins have been identified that involve 
nucleoporins.  Many of these involve NUP98 fusions, most of which appear to 
be associated with haematogenous cancers, such as myeloid and lymphoid 
malignancies [382].  Another fusion involving the nucleoporin CAN or NUP214 
and the nuclear binding protein DEK has also been associated with acute 
myeloid leukaemia [383].  These fusion proteins retain the FXFG repeat 
region that is characteristic of several nucleoporins and helps to regulate the 
nuclear-cytoplasmic transport of proteins and RNAs as well as functioning as 
docking sites for importins.  These FXFG repeat regions are also required for 
cell transformation and transactivation and act as transcriptional activators.     
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1.7:  Summary of study hypotheses, aims and objectives: 
The main object of this study was to investigate and further define the role of 
the nuclear membrane in the nuclear sparing of anthracycline uptake 
associated with the multidrug resistance phenomenon.  
Hypothesis 1: 
The nuclear membrane is responsible for nuclear sparing of epirubicin uptake 
in MDR bladder cancer cells.  
Aims and Objectives: 
1.  To establish sensitive and MDR nuclear epirubicin uptake phenotypes in 
bladder cancer cell lines using confocal microscopy.  
2.  To establish the nuclear epirubicin uptake characteristics of cell fusion 
products arising from fusion of sensitive and MDR cells.  
3.  To establish the chromosomal epirubicin staining patterns of sensitive and 
MDR bladder cancer cells during metaphase arrest.  
4.  To determine the nuclear epirubicin uptake characteristics of sensitive and 
MDR bladder cancer cell lines following cytoplasmic microinjection of 
epirubicin.   
Hypothesis 2: 
An active efflux mechanism is responsible for nuclear sparing of epirubicin in 
MDR bladder cancer cells.  
Aims and Objectives: 
1.  To determine the effects of incubation temperature and cell death on 
nuclear uptake of anthracyclines in sensitive and MDR bladder cancer 
cells using confocal microscopy.  
2.  To assess anthracycline uptake in nuclear isolates exposed to epirubicin 
pre- and post-nuclear fractionation using confocal microscopy. 
3.  To determine the size of molecules that can diffuse through nuclear pores 
of live cells using various sized FITC-labelled dextrans. 
4.  To demonstrate peri-nuclear localisation of Wheat Germ Agglutinin and 
establish whether WGA nuclear pore blockade affects nuclear uptake of 
FITC-dextrans or epirubicin. 
5.  To determine the effect of temperature on nuclear uptake characteristics of 
sensitive and MDR bladder cancer cells following cytoplasmic 
microinjection of epirubicin.   121
6.  To establish whether P-glycoprotein is expressed on the nuclear 
membrane of MDR bladder cancer cells using a monoclonal FITC-labelled 
anti-Pgp antibody with confocal microscopy and flow cytometric analysis.  
7.  To determine the effect of verapamil on cytoplasmic and nuclear epirubicin 
uptake in sensitive and MDR cells using time series confocal microscopy 
and flow cytometric studies.  
 
In addition we sought to clarify some other questions that have been raised by 
previous researchers from our group.  
Hypothesis 3: 
The nuclear membrane is not responsible for nuclear exclusion of idarubicin in 
sensitive and MDR bladder cancer cells. 
Aims and Objectives: 
1.  To establish sensitive and MDR nuclear idarubicin uptake phenotypes in 
bladder cancer cell lines using confocal microscopy. 
2.  To assess idarubicin uptake in nuclear isolates exposed pre- and post-
nuclear fractionation using confocal microscopy. 
3.  To establish the chromosomal idarubicin staining patterns of sensitive and 
MDR bladder cancer cells during metaphase arrest.  
Hypothesis 4: 
Mitomycin C fluorescence can be detected using direct or indirect 
fluorescence methods, allowing us to study its cellular uptake and localisation. 
Aims and Objectives: 
1.  To assess whether Mitomycin C fluorescence could be detected in 
sensitive and MDR cells using confocal microscopy (including time series 
uptake studies) and flow cytometric analysis. 
2.  To assess cellular Mitomycin C uptake in sensitive and MDR cells 
indirectly by exclusion of acridine orange DNA staining, using confocal 
microscopy and flow cytometric analysis.  
Hypothesis 5: 
GFP fluorescence can be used as a viability stain in cell lines.  
Aims and Objectives: 
1.  To assess loss of GFP fluorescence as a marker of cell death following cell 
killing using confocal microscopy and time series confocal studies.    122
Hypothesis 6: 
Changes in the localisation of epirubicin in MDR bladder cancer cells following 
cell death are due to leakiness of the cell and nuclear membranes.  
Aims and Objectives: 
1.  To determine the effects of cell death on nuclear uptake of anthracyclines 
in sensitive and MDR bladder cancer cells using confocal microscopy.  
2.  To establish the cellular and nuclear uptake pattern of a 77KDa FITC-
labelled dextran in dead cells using confocal microscopy.   
 
Overall design of experiments to address our main hypotheses: 
Rationale for experiments to address hypothesis 1: 
“The nuclear membrane is responsible for nuclear sparing of epirubicin uptake 
in MDR bladder cancer cells.” 
1. Nuclear epirubicin uptake characteristics of sensitive and MDR cells to be 
confirmed with incubation studies. 
2. Cell fusion experiments:  Attempting to fuse sensitive and resistant cells 
followed by examination of the nuclear epirubicin uptake characteristics of 
these “mixed” cell fusion products.  Demonstration of phenotypically different 
nuclei in the same cell environment would provide strong evidence that the 
nuclear membrane is responsible for the nuclear sparing phenomenon in 
MDR cells. 
3. Metaphase arrest experiments: During metaphase the nuclear membrane 
is absent.  Chromosomal epirubicin staining in MDR cells arrested in 
metaphase would implicate the nuclear membrane in the nuclear sparing 
phenomenon.  
4. Microinjection studies:  Direct microinjection of MDR cells with epirubicin 
overcomes the cell membrane P-gp pump which is a major mechanism of 
drug resistance.  If cells continue to demonstrate nuclear sparing following 
direct injection of drug into the cytoplasm, this would implicate the nuclear 
membrane in this phenomenon. 
Rationale for experiments to address hypothesis 2: 
“An active efflux mechanism is responsible for nuclear sparing of epirubicin in 
MDR bladder cancer cells.”   123
1.  Active cell processes are abolished by cell cooling and by cell death.  
Studying the effects of these factors on nuclear epirubicin uptake in 
sensitive and MDR bladder cancer cells gives insight into the effects of the 
energy dependent processes involved in MDR.  
2.  The assessment of epirubicin uptake in nuclear isolates exposed to 
epirubicin pre- and post-nuclear fractionation gives insight into nuclear 
drug uptake when active cellular processes are at play when compared to 
“non-viable” extracted nuclei.  
3.  Nuclear pore sizing using various sized FITC-dextrans in conjunction with 
scrape-loading and microinjection techniques allows assessment of the 
size of molecules that are able to freely diffuse across the nuclear 
membrane, which should gain entry to the nucleus.  
4.  Wheat Germ Agglutinin is known to block nuclear pores by reducing their 
functional diameter and abolishing active transport processes.  Following 
WGA nuclear pore blockade, we assessed whether diffusion of a 19.5KDa 
FITC-dextran across the nuclear membrane was affected and also 
assessed whether there were any changes in the nuclear uptake of 
epirubicin using confocal microscopy and flow cytometric analysis of 
cellular and nuclear uptake.   
5.  Direct microinjection of cells that were cooled on ice, allowed us to 
determine whether any energy dependent processes are involved in the 
nuclear exclusion of epirubicin from MDR nuclei.  
6.  The MDR cell lines used in this study were known to express P-
glycoprotein.  We performed experiments using a FITC-labelled anti-Pgp 
antibody to determine whether P-gp is expressed on the nuclear 
membrane of these MDR cell lines, which might account for the nuclear 
exclusion of epirubicin.   
7.  Verapamil is known to increase nuclear uptake of epirubicin in MDR cells.  
We assessed the effects of verapamil on the uptake of epirubicin in the 
cytoplasmic and nuclear cell compartments to determine whether its action 
was likely to be at the cell membrane or the nuclear membrane.  We also 
assessed the affects of incubation time on MDR reversal by verapamil 
using flow cytometric time series.  
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Chapter 2:  Materials and Methods 
2.1:  General Procedures 
The following section describes general procedures undertaken throughout 
the research period.  Any modification to these procedures is described in 
more detail in the relevant section. 
Cytotoxic drug storage 
Both epirubicin (Pharmacia, UK) supplied in solution (2mg/ml) and idarubicin 
(Pharmacia, UK) supplied as dry powder were diluted with sterile water to 
1mg/ml stock concentrations.  Stock solutions were divided into 1ml aliquots 
and stored at -20
oC to maintain drug stability.  They were reconstituted in 
fresh culture medium supplemented with 1:100 HEPES buffering solution 
(Sigma, UK) at the time of use.  
Mitomycin C was diluted with sterile water to a 1mg/ml stock solution and 
diluted further in culture medium and used immediately.  Any remaining stock 
solution was discarded, as mitomycin C is highly unstable once solubilised.  
Fluorescein Diacetate (FDA) 
A stock solution of fluorescein diacetate (FDA) (Sigma, UK) 500µg/ml in 
acetone was prepared.  This was stored at -20
oC to prevent drug deterioration 
and diluted at the time of use to a concentration of 500ng/ml in phosphate 
buffered saline (PBS). 
Acridine Orange (AO) 
Acridine Orange (AO) (Sigma, UK) stock solution was prepared by dissolving 
15mg AO in 1ml of 95% ethanol followed by further dilution in 49mls of 
distilled water.  The stock solution was divided into 1ml aliquots and stored at 
-20
oC.  At the time of use the stock solution was diluted 1:100 with PBS to 
make a final concentration of 3µg/ml.  This working concentration was stored 
at 4
oC and used for up to one month, after which it was discarded. 
Ethidium Bromide (EB) 
Ethidium Bromide (EB) (Sigma, UK) stock solution was prepared by dissolving 
50mg EB in 1ml 95% ethanol followed by further dilution in 49mls of distilled 
water.  The stock solution was divided into 1ml aliquots and stored at -20
oC.  
At the time of use the stock solution was diluted 1:100 in PBS to make a final 
concentration of 10µg/ml.  Working concentrations were stored at 4
oC and 
used for up to one month, after which it was disposed of.   125
Cell lines  
The derivation and sourcing of cell lines used in this research are shown 
below.    
1.  Sensitive bladder transitional cancer cell lines: 
MGH-U1 (Human, female, superficial TCC cell line (T1 G3), donated by 
Professor John Masters, UCL) [384]. 
RT112 (Human, female, TCC cell line (G2), purchased from Deutsche 
Sammlung von Mikroorganismen und Zellkulturen (DSMZ); catalogue 
Number: ACC 418). 
MGH-U1-GFP (Green fluorescent protein (GFP) expressing subline of MGH-
U1, produced in house by transfection with GFP [385]. 
2.  Multidrug resistant (MDR) bladder transitional cancer cell lines  
MGH-U1R (MDR subline of MGH-U1, produced by continuous low-dose 
exposure to Doxorubicin [308], donated by Professor John Masters, UCL).  
MGHU-MMC (MDR subline of MGH-U1, produced in house by continuous 
low-dose exposure to mitomycin C [386].   
MGH-U1R-GFP (GFP expressing subline of MGH-U1R, produced in house by 
transfection with GFP [385].  
Cell culture 
Cell lines were cultured in 25 – 75cm
2 culture flasks.  All cell lines were 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma, UK) 
supplemented with 10% foetal calf serum (FCS) and 2mM L-glutamine, and 
100µg/ml of both penicillin / streptomycin solution (Both: Sigma, UK).  
Cultures were maintained in a humidified incubator with 5% CO2 at 37
oC. 
Cells were passaged when 85% confluent.  For passage, culture medium was 
tipped off and cells were washed twice with PBS.  For 25 cm
2 flasks, ten 
drops of EDTA (Sigma, UK) and 3-4 drops of 1% trypsin-EDTA (Sigma, UK) 
were added to release cells.  Release was hastened by incubation at 37
oC for 
3-4 minutes.  Ten millilitres of supplemented culture medium was added to 
neutralise trypsin activity.  Cells were then aliquotted into new flasks 
containing 6.5mls of fresh culture medium.  The number of flasks and the 
thickness of the passage was adjusted according to experimental 
requirements.  Generally cells were passaged twice a week, for which 0.4 – 
0.6mls of cell suspension were seeded into each new flask.    126
For confocal microscopy experiments adherent cells were sub-cultured in 
40mm diameter culture grade polystyrene Petri dishes, before assay 
application (Nunc, UK for normal experiments and Orange Scientific, UK for 
microinjection experiments (shallower sides)).  
Cell suspensions for flow cytometry experiments were achieved using the 
same technique as for cell passage, applied after cell exposure to the various 
drug regimes.  Cells were then centrifuged in a Heraeus Labofuge
® 400 at 
438g (1500rpm) for 3 minutes, supernatant was poured off and the cells were 
resuspended in fresh culture medium, transferred to flow cytometry test tubes 
and placed on ice.      127
2.2:  A guide to fluorescent probes 
Various fluorescent probes or fluophores were used throughout this research.  
Anthracyclines: 
Epirubicin and idarubicin belong to the anthracycline antibiotic group of 
chemotherapeutic agents.  They possess the property of autofluorescence 
which allows us to study their cellular uptake and distribution using a variety of 
fluorescence based techniques.  These two drugs have similar excitation and 
emission spectra (see chapter 1.4), being excited maximally by laser light of 
480nm wavelength resulting in maximal emission at a wavelength of 595nm 
(red).  
Fluorescein Isothiocyanate (FITC) 
FITC is a fluorescent molecule that can be attached to many different 
molecules to allow their study.  During our research we used several FITC 
labelled molecules including dextrans, wheat germ agglutinin (WGA) and an 
antibody directed at P-gp.  FITC is excited maximally by light of 495nm 
wavelength and has maximal emission at a wavelength of 520nm.   
Fluorescein Diacetate (FDA): 
FDA is a fluorescein probe and a viability stain.  In viable cells, FDA 
undergoes hydrolysis by intracellular esterases in an ATP dependent reaction 
to form fluorescein, which fluoresces green.  Fluorescein is excited maximally 
by laser light of 501nm wavelength, with maximal emission detected at a 
wavelength of 525nm.    
Acridine Orange (AO): 
AO is amongst other things, a marker of cell viability, staining the nuclei of 
viable cells green by complexing with DNA [387].  It has similar excitation 
characteristics to FITC, but its emissions are detected over a wider range of 
wavelengths extending into the orange-red spectrum.  Maximal excitation is 
achieved by a laser of 502nm wavelength with maximal emission at a 
wavelength of 525nm.   
Ethidium Bromide (EB): 
EB is a DNA stain which can be used as quantitative DNA stain for analysis of 
cell cycle populations and also acts indirectly as a viability stain, where it 
stains the nuclei of dead cells orange [388].  EB fluorescence is excited   128
maximally by laser light of 520nm wavelength, with maximal emission 
detected at a wavelength of 604nm.    
Propidium Iodide (PI): 
PI is a DNA stain which again can be used for analysis of cell cycle 
populations and is also an indirect viability stain, staining the nuclei of dead 
cells red.  Cell membrane integrity stops PI from staining viable and apoptotic 
cells.  PI is excited maximally with laser light of 533nm wavelength, with 
maximal emission detected as a wavelength of 620nm.    129
2.3:  Principles of confocal microscopy 
Confocal microscopy differs from conventional light microscopy and 
fluorescence microscopy, in that it allows the collection of light exclusively 
from a single plane within the subject being studied.  
A point light source produces a small, well-defined light spot in the focal 
plane.  Emitted fluorescent light from the focal plane is collected by the 
objective lens and sent back through a beam splitter (Dichroic mirror), which 
directs it into a photomultiplier tube detector.  A pinhole sitting parallel to the 
focal plane only allows light through to the detector from that particular plane, 
with light that is reflected or emitted from any other planes being kept from the 
detector (Figure 19).   
 
 
 
 
 
 
 
 
 
  
  
 
  
 
Figure 19:    Schematic picture of confocal microscope showing how  
      fluorescence is detected only from the plane that is focused 
      through the confocal pinhole (Figure reproduced with the kind 
      permission of Carl Zeiss)  
 
Confocal microscopy is therefore able to produce optical sections of the 
specimen being studied that are always in focus.  The thickness of the optical 
image slice is affected by the numerical aperture of the objective lens, the 
detector pinhole diameter and the excitation wavelength of the light used, with   130
thicker slices resulting in a less focused image akin to that produced by 
conventional fluorescence microscopy.  
The laser scanning microscope scans the sample sequentially point by point 
and line by line and assembles the pixel information to form a single image. 
This allows optical slices of the specimen to be imaged with high contrast and 
high resolution in x, y and z axes.  A pixel based image is displayed on a high 
resolution computer screen for the purposes of fluorescence intensity analysis 
and photographic image capture.  
By moving the focal plane, single images or optical slices can be taken 
through the specimen, called a z-stack.  These images can be digitally 
processed afterwards to create three dimensional images of the specimen. 
Origin of fluorescence  
Fluorescent molecules are called fluorochromes or fluophores.  When these 
molecules are excited by laser light of a wavelength (Lex), certain electrons 
are excited to higher energy levels.  During a very short dwell time these 
electrons lose some of their energy dropping back to their original level whilst 
emitting light of a longer wavelength (Lem).  The emitted light always has a 
longer wavelength that the excitatory light wavelength (Lem > Lex), the 
difference between these wavelengths is known as the Stokes shift.  In 
multiphoton excitation, the energies of several photons with n times the 
excitation wavelength add together to raise the electrons to the higher energy 
level (Figure 20).   
 
 
 
 
 
 
 
  
 
 
Figure 20:    The origin of fluorescence (Figure reproduced with the  
      kind permission of Carl Zeiss) 
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Fluorescence Spectra 
A fluorescent molecule can be irradiated with different wavelengths within its 
excitation spectrum and, accordingly, will emit light with a characteristic 
emission spectrum.  Its amplitude is determined by the intensity of radiation 
and the excitation efficiency, which is a function of the excitation wavelength 
(Figure 21).  
       
      
 
 
 
 
 
 
 
 
 
Figure 21:   Fluorescence spectra (Figure reproduced with the kind  
      permission of Carl Zeiss) 
 
Zeiss LSM 510 Confocal Microscope 
The Zeiss LSM 510 confocal microscope was used for visualisation of cells 
and nuclei in all confocal experiments  
This microscope allows direct visualisation of cellular or nuclear fluorescence 
via a mercury vapour lamp fluorescence microscope, allowing detection of 
blue, green and red fluorescence.  Once cells or nuclei exhibiting 
fluorescence have been identified they can then be viewed by confocal 
microscopy.  Confocal microscopy allows direct imaging of the uptake and 
distribution of the various fluophores within the studied cells and nuclei with 
images being captured in digital format.   
Lens Selection 
The microscope has a selection of lenses, of which the x20 dry and x40 water 
immersion lens were most frequently used during image capture for our 
experiments.  The x20 dry lens was used for experiments in which cells or 
nuclei were coverslipped, with the x40 water immersion lens being used for   132
visualisation of live cells.  Using the immersion lens, cells can be visualised in 
various media from PBS to culture medium.   
Time Series Function 
The Zeiss LSM 510 confocal microscope also has a time series function 
which used in combination with the water immersion lens and culture medium 
containing HEPES buffering solution and our drug(s) of choice, allowed time 
series of drug uptake to be performed.  This allows the study drug uptake and 
localisation in real time.    
Image Optimisation 
Confocal images were enhanced by optimising a number of factors that 
contribute to better images.  Firstly the image was brought into sharp focus by 
focusing the specimen whilst in scanning mode.  Whilst still in scanning mode 
the differential interference contrast (DIC) image was also focused to give a 
sharp image of the cells ultrastructural characteristics.  The fluorescence gain 
and background were then finely tuned whilst in scanning mode to reduce all 
background interference and optimise the fluorescence gain to allow better 
definition of the fluophore localisation.  Increasing the scanning time means 
that more time is spent scanning each pixel of the image, resulting in more 
detailed images.  The image was then sharpened further by increasing the 
number of averages to either 8 or 16, meaning that each pixel was scanned  
8 – 16 times and the average pixel count was included in the final image.   
The Zeiss LSM 510 also features digital zoom function allowing you to 
magnify a certain area of the cell or nucleus for a more detailed look.  At the 
higher range of the digital zoom the image begins to pixelate slightly.   
Laser Excitation Wavelegths 
The Zeiss LSM confocal microscope features 3 different lasers, one Argon 
laser and two Helium-Neon (HeNe) lasers, each exciting different 
wavelengths.  The Argon Laser is able to excite at 458, 488, 505 and 514nm.  
The HeNe1 laser excites at 543nm and the HeNe2 laser excites at 633nm.  
The laser used obviously depends on the excitation wavelength of the 
fluophore being used, although many fluophores can be excited by lasers of 
different wavelengths depending on their excitation spectra.    
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Emission Detection  
Fluorescence emitted at the focal plane and at planes above and below is 
directed via an XY scanner onto a main dichroic beam splitter, which 
separates the emissions from the excitation light.  The fluorescences are 
separated from each other by a series of dichroic beam splitters and directed 
to individual photomultipliers.    
Up to four simultaneous image acquisition channels, usable for reflection or 
fluorescence, and an additional transmitted-light channel can be used for the 
investigation of specimens stained with multiple fluophores.  
The emission filters can be changed for each of these four acquisitions 
channels.  A variety of filters can be used to optimise fluorescence detection 
for the fluophore being used.  Long pass (LP) filters will allow detection of all 
fluorescence above a certain wavelength (e.g. LP 560nm, means all 
fluorescence with a wavelength longer than 560nm will be collected) whilst 
band pass (BP) filters detect fluorescence between two wavelength values 
(e.g. BP 505 – 530nm, means fluorescence between 505nm and 530nm will 
be filtered exclusively).      
Where samples stained with multiple fluophores are examined, identical 
optical sections are obtained for each confocal channel. This allows 
comparison of the cellular distribution of each fluophore within the same 
optical slice.   
The microscope's transmitted-light channel is also equipped with a 
photomultiplier, allowing multiple fluorescence images to be superimposed on 
a brightfield, differential interference or phase image. 
The laser excitation and emission wavelengths and filter settings for the 
various fluophores used in our experiments are listed below (Table 14).   
Multitrack Mode 
The multitrack scanning mode was used where more than one fluophore was 
being used.  This mode excites one fluophore at a time by scanning the 
specimen with one excitation laser at a time.  This reduces cross interference 
in the fluorescent signals of the fluophores resulting in clearer definition of the 
cellular localisation of the individual fluophores.  
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Fluophore 
 
Excitation 
Wavelength 
(nm) 
 
Emission 
Wavelength 
(nm) 
 
Detection Filter Set used 
Epirubicin  488 or 543  > 560  Rhodamine /Texas Red  
 
LP 560 
Idarubicin  488 or 543  > 560  Rhodamine / Texas Red  
 
LP 560 
Fluorescein-
Isothiocyanate 
(FITC) 
488 >  505  FITC 
 
LP 505 or BP 505 – 530  
Fluorescein 
Diacetate (FDA) 
488  > 505  FITC  
 
LP 505 or BP 505 – 530  
Acridine  
Orange (AO) 
488  > 505  FITC / Rhodamine / Texas Red  
 
LP 505 or BP 505 – 530  
Ethidium 
Bromide (EB) 
488 or 543  > 560  Rhodamine / Texas Red 
 
LP 560 
Propidium  
Iodide (PI) 
488 or 543  > 560  Rhodamine / Texas Red 
 
LP 560 
 
Table 14:    Confocal microscopy:  Fluophore laser excitation    
      wavelengths, fluorescence emission wavelengths and  
      detection filter sets 
 
Data analysis 
Confocal microscopy was predominantly used to visualise the cellular or 
nuclear localisation of various fluophores within the specimens being studied.  
However, the Zeiss LSM 510 also allows semi-quantitative analysis of drug 
and fluophore uptake via its region of interest mode (ROI).  This allows you to 
draw around a region of interest and the analysis software will then generate 
data on the area size and the fluorescence average per unit of area, for the 
area of interest.   
It is important when capturing images of different samples that you wish to 
compare that you ensure that all image capture settings are the same 
including the laser wavelength used, laser power settings, fluorescence gain, 
scanning time, averages and zoom settings.  Any difference in these settings 
will produce inaccurate results, meaning that direct comparisons between 
samples cannot be made.  Within each sample, variation in the levels of 
fluorescence between optical slices can be marked.  Comparisons between 
samples may also be biased by this interslice variation.  Bleaching of   135
fluorescence levels can also occur with prolonged scan times, which may 
introduce further inter-sample variation.  This is why confocal microscopy can 
only be regarded as semi-quantitative.   
The ROI mode can also be used for time series data analysis allowing us to 
plot a graph of drug uptake in certain areas of the cell over time.  Time series 
utilise cells as their own control comparing drug fluorescence with their 
baseline fluorescence without drug, which obviously gives a more accurate 
picture of the rate of drug uptake within certain cellular compartments.  During 
time series experiments the samples are scanned many times which may 
result in some bleaching of the samples.  This may account for some 
fluctuations in the fluorescence levels detected.  Also, during time series cells 
do move around slightly so accurate placement of the ROI allowing for this 
movement is necessary.  Some hyper-mobile cells are thus excluded from this 
type of analysis.  This movement artefact may also account for some of the 
fluctuations in fluorescence levels throughout the time series.  The ROI time 
series data once generated can be exported into an Excel database allowing 
more detailed analysis.     136
2.4:  Principles of flow cytometry 
Flow cytometry is a technique which permits rapid analysis of particles (cells, 
nuclei, chromosomes etc) in suspension.  These particles are forced to flow in 
single file within a fluid sheath by a suitable hydrodynamic system.  They are 
delivered to a fixed point where they intersect a beam of monochromatic laser 
light, when several optical parameters can be measured. 
Measurement of Physical Characteristics of Cells 
The light scattered by the particle in the forward direction (2-19
o)(Forward 
scatter (FSC)) travels to the forward angle scatter detector and gives direct 
information about the size of the particle, increased scatter indicating 
increased size.  Light that is scattered sideways (Side scatter (SSC)) due to 
collision with particular contents is detected at 90
o to the laser and provides a 
measure of the granularity, increased scatter indicating increased granularity.   
These two parameters can give us an idea of the morphology of the particles 
we are looking at.  Using these parameters and adjusting the forward and side 
scatter detectors we are able spread our particle population on scatter plots 
(Figure 22).   
Gating of live cell populations 
For experiment purposes it is important to only examine drug uptake or 
fluorescence within a population of viable individual cells, as clumps of cell 
with more fluorescence or debris particles with less fluorescence would skew 
our results.   
Using FDA fluorescence as a marker of viability, we were able to determine 
the FSC – SSC dot plot characteristics of our viable individual cell population 
for each cell type.  We could then gate out the viable individual cell population 
for each cell type for subsequent fluorescence data collection and analysis.  In 
addition we set the FSC threshold at 200 to exclude any smaller particles of 
debris from fluorescence detection (Figure 22). 
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Figure 22:    A scatter plot showing cells plotted according to their side  
      scatter (SSC) and forward scatter (FSC) characteristics.  Live 
      cells have been gated in region1 (R1) (Red) 
 
Measurement of Fluorescent Events 
Three other photomultiplier detectors are also present within the system.  
These are used to detect fluorescent emissions.  Each detector works within a 
specified range; FL-1 (530nm +/- 15), FL-2 (585nm +/- 15) and FL-3 
(>650nm).  Different wavelengths of emitted light from particles that are 
carrying more than one type of fluorescent molecule (acting as a marker or 
probe) can be detected simultaneously (Figure 23). 
FL-1 detects light in the green part of the visual spectrum (515 – 545nm),  
FL-2 detects light in the orange – near red part of the visual spectrum (570 – 
600nm) and FL-3 detect light in the far red part of the spectrum (>650nm).    
Fluorescent signals and scattered light signals pass through lenses and are 
focused onto photomultiplier detectors.  The photomultipliers convert the 
signals into electric signals which vary according to the amount of 
fluorescence or scatter detected.  
The measurements that take place are performed on each separate particle 
within the suspension and are not just an average value for the whole 
population.   138
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 23:  Measurement of simultaneous fluorescent events  
 
Flow cytometry allows large numbers of particles to be assessed very rapidly, 
with typical sample sizes being between 10,000 and 20,000 cells. 
The applications of flow cytometry are numerous.  A wide range of fluorescent 
probes are available for direct estimation of cellular parameters such as 
nucleic acid content, enzyme activity, calcium flux, membrane potential and 
pH.  Conjugation of fluorescent dyes to ligands and to mono- and polyclonal 
antibodies has enabled the density and distribution of cell surface and 
cytoplasmic determinants and receptors to be studied and functional 
subpopulations of cells to be identified. 
Flow cytometry has many advantages over older techniques since it is 
capable of analysing enormous numbers of cells very quickly;  it is also able 
to monitor drug retention in individual cells allowing it to demonstrate the 
concept of heterogeneity, meaning, some cells may take up and concentrate 
more of the drug than other cells within the same tumour.  One problem of 
flow cytometry is that some anthracyclines quench their fluorescence on 
binding to DNA or other target molecules, so-called drug quenching. 
ANTHRACYCLINE 
FLUORESCEIN 
DIACETATE 
CELL 
ARGON LASER 
488nm 
FL-3  
FL-2  
FL-1  
DETECTORS   139
The laser excitation and emission wavelengths and filter settings for the 
various fluophores used in our flow cytometry experiments are listed below 
(Table 15).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 15:  Flow cytometry: Fluophore laser excitation wavelengths,  
      fluorescence emission wavelengths and detection filter sets  
 
Explanation of Data Display and Analysis 
The electrical pulses generated by all of the photomultiplier detectors are then 
amplified, measured, computerised and displayed.  The display data is a 
record of the photon signal emitted translated as a voltage signal. 
The result of analogue to digital conversion is a steam of numbers which can 
be printed or held in computer memory or on mass storage devices. 
The most common and useful forms of data display are the frequency 
histogram and the dual parameter dot plot.   
The frequency histogram is a direct graphical representation of the number of 
events occurring for each channel or number of events plotted against 
fluorescence intensity (on a logarithmic scale) (Figure 24).   
 
Fluophore 
 
Excitation 
Wavelength (nm) 
 
Emission Detector 
(Wavelength (nm)) 
 
 
Epirubicin 
 
488  
 
FL-2 (585 +/- 15) 
 
 
Idarubicin 
 
488  
 
FL-2 (585 +/- 15) 
 
 
Fluorescein-
Isothiocyanate (FITC) 
 
 
488 
 
FL-1 (530 +/- 15) 
Fluorescein Diacetate  
(FDA) 
488  FL-1 (530 +/- 15) 
 
Acridine Orange (AO) 
 
 
488 
 
FL-1 (530 +/- 15) 
 
Ethidium Bromide (EB) 
 
 
488  
 
FL-2 (585 +/- 15) 
 
Propidium Iodide (PI) 
 
 
88  
 
FL-2 (585 +/- 15)   140
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24:    A frequency histogram, plotting number of events against  
      FL-2 fluorescence intensity (logarithmic scale) 
 
The dot plot is a two-dimensional extension of the frequency histogram.  In 
this case, the channels of one detector are correlated against another, for 
example, side scatter against forward scatter.  This produces a plot where 
each cell is represented at the coordinates appropriate to the measured 
values (Figure 22).   
Gating can be undertaken on any of these plots to examine sub-populations 
of interest in more detail.   
Statistics are also generated for each sample run including mean, geomean 
and median fluorescence, standard deviations, peak fluorescence and peak 
channel of fluorescence.  As such large numbers of particles are analysed 
any difference between samples treated in the same way is likely to be 
significant. 
The flow cytometer we used for our experiments was a Becton Dickinson 
FACScaliber flow cytometer.  
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2.5:  Principles of microinjection 
Microinjection allows direct injection of substances, whether they be drugs, 
fluophores or labelled-antibodies, either into the cell cytoplasm or nucleus.   
Many of these substances have difficulties in overcoming the plasma 
membrane barrier due to their size or their lipophobicity or because their 
molecular charges exclude them.  Multidrug resistant cancer cells also 
exclude many cytotoxic drugs because they express a plasma membrane 
glycoprotein efflux pump, P-glycoprotein, that actively effluxes these drugs.  
Microinjection provides a novel technique for studying the intracellular 
localisation of many of the above mentioned molecules, as direct 
microinjection into cell cytoplasm overcomes the plasma membrane barrier in 
all instances.   
Equipment for Microinjection 
Microinjection was performed using an Eppendorf InjectMan® NI 2 
micromanipulator combined with an Eppendorf Femtojet microinjector.  The 
micromanipulator is mounted on a Zeiss Axiovert 200 microscope.  Pre-drawn 
capillaries with a tip diameter of 0.5µm were used for microinjection 
(Femtotip
®/Femtotip
®II, Eppendorf).  The Femtojet system allows the pressure 
of injection (150KPa), time of injection (0.5 sec) and background pressure 
(50KPa - to counteract capillarity) to be set, in order to control the amount 
injected.  There are variations in how well the capillaries breach the cell 
membrane, hence the amount of drug injected cannot be accurately quantified 
and can vary significantly between cells.   
The injection buffer used was 48mM K2HPO4, 4.5mM KH2PO4, 14mM 
NaH2PO4, pH 7.2 (Eppendorf - personal communication).  All injection fluids 
were mixed in eppendorf tubes and then centrifuged at 16000g (13000rpm) 
for 3 minutes in a Heraeus Biofuge pico centrifuge, before transfer into 
capillaries, to ensure that any particles were separated from the injection 
liquid.  Injection fluid was pipetted into capillaries using Eppendorf 
Microloaders, taking care not to stir up any precipitate.    
Technique for microinjection of cells  
Cells were cultured in 40mm low-sided Petri dishes (Orange scientific, UK) for  
2 – 3 days to allow cells to become fully adherent.  Cell culture media was 
changed prior to microinjection to HEPES buffered culture medium (1:25   142
HEPES buffer solution) (Sigma, UK), to keep cells adequately buffered whilst 
out of the incubator.  Cells were microinjected at ambient temperature (18 – 
20
oC).  Cells were placed on the microscope mounting stage and viewed 
using the x40 objective lens.  The focus was then altered to bring the loaded 
microinjection capillary into view.  The capillary was then lowered under direct 
visualisation until the cells were also in focus.  The capillary was then lowered 
onto a cell until an indentation in the plasma membrane could be clearly seen.  
This indentation of the plasma membrane was usually accompanied by a 
slight swelling of the cell, associated with membrane breach and some 
leakage of the capillary into the cell, as a result of the back pressure against 
capillary action.  The depth of injection was then fixed at this depth.  The 
capillary could then be moved around the Petri using a joystick to control the 
mechanically driven capillary holder.  The capillary was moved until it lay over 
individual cells and then the microinjection button (Joystick mounted) was 
depressed to deliver a single, semi-automatic intracytoplasmic injection under 
direct visualisation.   The cell can be seen to swell during injection.  This 
process was repeated until a sufficient number of cells had been injected.  
The cells were then placed into an incubator to recover before visualisation 
under a confocal microscope.         143
2.6:  Principles of Cytotoxicity Assay 
The differences in cellular and nuclear uptake of cytotoxic drugs are 
meaningless without evidence linking these to differences in cellular 
cytotoxicity.  It is therefore important to study not only drug uptake and 
localisation within cells, but also to measure drug cytotoxicity directly by 
means of cytotoxicity assay.  Cytotoxicity assays also allow in vitro testing of 
potential MDR reversing agents.   
The MTT (3-(4,5-dimethylthlazol-2-yl)-2,5-diphenyltetrazolium) assay is a 
widely used cytotoxicity assay [389].  It is a colorimetric dye assay based on 
the ability of viable cells to reduce MTT to a purple formazan dye. 
Cells are exposed to various drugs or drug combinations in 96-well plates.  
Following a period of cell recovery and when control wells have reached 90 
percent confluence, MTT is added to each well and the plates are cultured for 
a further 3 – 4 hours.  Viable cells will then metabolise MTT into purple 
formazan dye crystals.  These crystals are dissolved by the addition of 
dimethyl sulphoxide (DMSO), forming a purple liquid.  The optical density of 
this purple liquid can then be analysed on a photometric well-plate reader, 
which correlates directly with the residual viable biomass of each well.      
Data can be transferred from the well-plate reader to a spreadsheet allowing 
the mean percentage viable cellular biomass to be calculated for each drug 
dilution compared to control wells.  Cytotoxicity curves can then be plotted to 
include 95% confidence intervals.   The IC50 value which is the concentration 
of the drug required to inhibit cell growth by 50%, can then be calculated from 
the cytotoxicity curve.  
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2.7:  Specific experiments 
2.71: Confocal  Experiments 
Anthracycline incubation studies: Establishing cell phenotypes 
Epirubicin and Idarubicin uptake at 37
oC: 
Cells were cultured in 40mm Petri dishes until 75 – 100% confluent.  Cells 
were then exposed to either epirubicin or idarubicin at a concentration of 
10µg/ml in HEPES buffered medium (1:100 HEPES) for 2 hours at 37
oC.  
Culture medium was then pipetted off and replaced with PBS.  Fluorescein 
diacetate (FDA), a viability stain, was added to the PBS to a final 
concentration of 500ng/ml.  Cells were then viewed on the con-focal 
microscope to assess the drug uptake and accumulation characteristics of 
viable cells. 
Epirubicin and Idarubicin uptake at 0 – 4
oC: 
Cells were cultured in 40mm Petri dishes until 75-100% confluent.  Cells were 
then exposed to either epirubicin or idarubicin at a concentration of 10µg/ml in 
HEPES buffered medium (1:100 HEPES) for 60 minutes and placed on ice in 
a fridge (0 – 4
oC).  Culture medium was then pipetted off and replaced with 
ice-cold PBS.  FDA, a viability stain, was added to the PBS to a final 
concentration of 500ng/ml.  Cells were then viewed on the con-focal 
microscope to assess the drug uptake and accumulation characteristics of 
viable cells. 
Epirubicin and Idarubicin uptake in dead cells at 37
oC: 
Cells were cultured in 40mm Petri dishes until 75-100% confluent.  Cells were 
then killed by microwaving them in a 650W oven for 10 seconds on 100% 
power.  Cells were then exposed to either epirubicin or idarubicin at a 
concentration of 10µg/ml in HEPES buffered medium (1:100 HEPES) for 60 
minutes at 37
oC.  Culture medium was then pipetted off and replaced with 
PBS.  Cells were then viewed on the con-focal microscope to assess the drug 
uptake and accumulation characteristics of non-viable cells.  Viability stains 
were then added, either FDA to a concentration of 500ng/ml or ethidium 
bromide (EB) to a final concentration of 10µg/ml.  Cell death was confirmed 
by lack of FDA fluorescence or the presence of EB nuclear staining.      145
Anthracycline incubation studies: Uptake in isolated nuclei 
Epirubicin and Idarubicin uptake at 37
oC: 
Nuclear epirubicin and idarubicin uptake was assessed in nuclei harvested 
from whole cells that had been pre-exposed to these drugs and prepared 
nuclei that were exposed to drug immediately following extraction from cells.  
For pre-exposed cell nuclei, cells were cultured to confluence and then 
incubated with epirubicin 10µg/ml or idarubicin 20µg/ml for 2 hours at 37
oC.   
Nuclear preparations were then prepared according to an established protocol 
[390] (Appendix 1).  Nuclei were re-suspended in PBS containing protease- 
and phosphatase-inhibitors (PBSI), dropped onto microscope slides and 
cover-slipped.  They were then visualised on the confocal microscope. 
For experiments looking at direct nuclear exposure to drug, nuclear 
preparations were performed according to a standardised protocol (Appendix 
1).  Nuclei were then exposed to either epirubicin 10µg/ml or idarubicin 
20µg/ml in cultured medium for 10 minutes at 37
oC.  Nuclei were centrifuged 
at 800g for 5 minutes and the drug was then pipetted off and replaced with 
PBSI.  Nuclei were resuspended, dropped onto microscope slides and cover-
slipped.  Con-focal microscopy was then used to assess drug uptake in these 
nuclei.   
Mitomycin C fluorescence 
Several attempts were made to see if we could elicit fluorescence from 
Mitomycin C.  Mitomycin C is a similar molecule to the anthracyclines, with a 
three ring structure, suggesting that it might fluoresce.   
MGH-U1 and MGH-U1R cells were cultured in 40mm Petri dishes until 75-
100% confluent and then used for the following experiments.   
Direct fluorescence experiments: 
Dose response: 
Cells were then either exposed to mitomycin C at various concentrations from 
100, 250 and 1000µg/ml in HEPES buffered medium (1:100 HEPES) for 60 
minutes at 37
oC.  Culture medium was then pipetted off and replaced with 
PBS.  Cells were then viewed on the con-focal microscope in an attempt to 
assess the drug uptake and accumulation characteristics of viable cells 
compared to unexposed control cells.  Laser excitation was performed using   146
458, 488, 505, 514, 543, 633nm wavelengths with appropriate filter and 
detector settings. 
Time series:  
For time series experiments culture medium was replaced with HEPES 
buffered medium (1:100 HEPES).  Cells were then viewed on the confocal 
microscope and baseline fluorescence was assessed.  As soon as the time 
series had been started mitomycin C was added to a concentration of 
250mcg/ml.  Time series was performed looking at FITC fluorescence in 
response to excitation at 488nm.  The gain setting was fixed at 900.  
Indirect fluorescence experiments: 
Cells were then either exposed to mitomycin C at concentrations of 250 and 
1000µg/ml in HEPES buffered medium (1:100 HEPES) for 60 minutes at 
37
oC.  Culture medium was then pipetted off and replaced with PBS.  Acridine 
orange was then added to a final concentration of 3µg/ml.   Mitomycin C is 
said to bind to the same DNA sites as acridine orange, meaning that any 
reduction in nuclear uptake of AO can be assessed by con-focal microscopy 
as an indirect measure of nuclear mitomycin uptake, by comparing unexposed 
cells with mitomycin C exposed cells.  The FITC confocal filter settings were 
used to detect nuclear uptake of AO.  Analysis was then undertaken by 
measuring nuclear fluorescence using a region of interest function for all 
evaluable nuclei within each sample to prevent any selection bias.                                      
Wheat  Germ Agglutinin (WGA) nuclear pore binding studies 
FITC-WGA cellular localisation studies: 
The cytotoxicity of WGA (Triticum Vulgaris Lectin) (Sigma, UK) was assessed 
using a standard MTT assay (See cytotoxicity experiments).  A dose of 
0.4µg/ml was found to be minimally cytotoxic to cells in its own right.  Cells 
were cultured in 40mm Petri dishes until 50% confluent.  Cells were then 
incubated with FITC-WGA (Sigma) 0.4µg/ml in culture medium at 37
oC for 
exposures of 1 hour or 24 hours continuous exposure.  Following 1 hour 
exposures the culture medium was changed to fresh medium and cells were 
then incubated for various times in order to establish the optimum time of 
WGA localisation to the nuclear membrane.  The time intervals assessed in 
this experiment were 30 minutes, 1, 2, 4, 8, 16, 24, 48 hours.  After incubation   147
culture medium was discarded and replaced by PBS and the cellular 
localisation of FITC-WGA was visualised using con-focal microscopy.   
FITC-WGA nuclear localisation studies: 
Nuclear pore binding was assessed using nuclear preparations produced by a 
proven method (Appendix 1).  Nuclear preparations were then incubated with 
FITC-WGA (Sigma) 0.4µg/ml in culture medium at 37
oC for 10 minutes.   
Nuclei were then centrifuged at 800g (2000rpm) for five minutes and the 
FITC-WGA containing medium was removed.  Nuclei were then covered with 
0.5ml PBSI and resuspended.  The nuclear suspension was then dropped 
onto a slide and coverslipped.  Nuclei were viewed on the confocal 
microscope to visualise FITC-WGA localisation.     
Nuclear pore sizing using FITC-dextrans and the effects of WGA nuclear 
pore blockade:   
MGH-U1 and MGH-U1R cells were cultured in 25cm
2 flasks until 90% 
confluent.  One flask of each cell type had been pre-incubated with WGA 
0.4µg/ml in culture medium at 37
oC for 24 hours.  Scrape-loading of cells with 
various sized FITC-dextrans was then performed according to an established 
protocol [391] (Appendix 2).  The sizes of FITC-dextrans used were 4.4, 19.5, 
42 and 77 kilodaltons (KDa) (Sigma, UK).  The pre-exposed WGA cells were 
scrape-loaded with 19.5KDa FITC-dextran.  Once scape-loaded cells were 
centrifuged at 438g (1500rpm) for 3 minutes and the medium was pipetted off.  
Cells were re-suspended in fresh medium and plated out in 40mm Petri 
dishes.  Cellular localisation of the various sized FITC-dextrans was 
visualised using confocal microscopy.  Cells were viewed at several different 
time points to allow cells to become adherent, as well as to assess any 
changes in cellular localisation over time.  The time points at which cells were 
visualised were 6, 18, 24, 48 and 72 hours. 
The effects of WGA pre-incubation on nuclear uptake of epirubicin 
Whole cells 
MGH-U1 and MGH-U1-R cells were cultured in 40mm Petri dishes and 
allowed to settle for 24 hours.  Cells were then incubated with 0.2µg/ml WGA 
for 1 hour at 37
oC.  Cells were then incubated for a further 23 hours to allow 
WGA to redistribute to the nuclear membrane and then incubated with   148
epirubicin 10µg/ml for 1 hour at 37
oC.  Cells were covered with PBS and 
viewed by confocal microscopy.   
Nuclei 
MGH-U1 and MGH-U1-R cells were cultured in 25cm
2 flasks until 75-80% 
confluent.  Cells were then cultured in 0.4µg/ml WGA for 24 hours at 37
oC.  
Cells were then either exposed to epirubicin 10µg/ml for 2 hours at 37
oC   
followed by nuclear fractionation or nuclear fractionation was performed and 
cells were then exposed to epirubicin 10µg/ml for 10 minutes at 37
oC.   
Nuclear preparations were then suspended in PBSI, dropped onto slides, 
coverslipped and viewed by confocal microscopy using a x20 lens, to assess 
nuclear uptake of epirubicin post-WGA exposure.   
Cell fusion experiments using polyethylene glycol (PEG): 
Fusion of cells in suspension using polyethylene glycol (PEG) has previously 
been described, enabling production of larger multinucleate cells [392].  We 
modified and optimised this technique to allow fusion of adherent cells 
(Appendix 3).  
For cell fusion experiments, MGH-U1 and MGH-U1-R cells were harvested 
and cell density was adjusted to 5 x 10
4 cells/ml.  Cells were
 then seeded into 
40mm Petri dishes (Nunc, UK), either as single cell cultures, 1.5mls per Petri 
dish, or as mixed cultures, 0.75ml of each cell type per Petri dish.  In an 
attempt to determine whether any mixed fusions had taken place, in some 
experiments either the MGH-U1 or MGH-U1-R cells were grown as a single 
cell culture (0.75ml with 0.75ml culture medium added) and after 24hrs were 
exposed to FITC-Wheat Germ Agglutinin (FITC-WGA) (Sigma, UK) 0.4µg/ml 
in culture medium for 24 hours in normal culture conditions.  The FITC-WGA 
was then removed, cells were washed with PBS and 1.5mls of 5 x 10
4 cells/ml 
of the opposite cell type were added and incubated for a further 24 hours.  
Wheat germ agglutinin (WGA) is a lectin from triticum vulgaris, that binds 
selectively to nuclear membrane pores.  It allows us to identify one type of 
nucleus and hence recognise any mixed cell fusions with phenotypically 
different FITC-WGA staining nuclei, more easily. 
Cells were grown to confluence (approximately 48-72 hours in total) and then 
cell fusion using polyethylene glycol 50% w/v (Sigma, UK) was performed.   149
Protocol for cell fusion using polyethylene glycol (PEG) 
The optimal method for cell fusion was as follows.  Culture medium was 
pipetted off the cells and they were covered with 0.5mls of polyethylene glycol 
(PEG) 50%w/v (Sigma).  The cells were exposed to PEG for 5 minutes, with 
gentle agitation of the Petri dishes.  PEG was then serially diluted off using 
fresh culture medium over 1 minute.  This medium was then discarded and 
the cells were re-covered with 1.5mls of fresh medium.  Cell fusions were then 
incubated for 2 hours in normal culture conditions to allow the fusions to 
complete and recover.   
Cells were then exposed to epirubicin 10µg/ml in culture medium at 37
oC for 
60 minutes.  Epirubicin was pipetted off and cells were covered with PBS.  
FDA was added to a concentration of 500ng/ml after initial visualisation, in 
order to assess cell fusion viability.   
Metaphase arrest experiments  
Cells were
 plated out in 40mm Petri dishes, 1.5mls of 1 x 10
5 cells/ml cell 
suspension per dish.  Cells were cultured for 24 hours, allowing them to get 
established and commence log-phase cell growth.  They were then subjected 
to the following metaphase arrest protocol. 
Protocol for metaphase arrest 
Culture medium was changed to include demecolcine 0.05µg/ml and cells 
were incubated overnight to allow metaphase arrest to occur (Approximately 
16-24 hours).    
Once this time had passed we exposed our metaphase arrested cells to either 
epirubicin or idarubicin at a concentration of 10 – 20 µg/ml in culture medium 
for 60 minutes at 37
oC.   In later experiments higher concentrations of 
epirubicin were used (20 – 80µg/ml) to see if this would have any effect on 
chromosome staining. 
The drug was then pipetted off and cells were covered with 4mls of phosphate 
buffered saline (PBS).   Cell metaphases were then identified by direct 
fluorescence microscopy followed by confocal microscopy.  In our initial 
experiments fluorescein diacetate (FDA) was added to a final concentration of 
500ng/ml, to assess cell viability.  In later experiments cells were visualised 
and then acridine orange was added to a final concentration of 3µg/ml, in   150
order to visualise chromosomes in metaphase cells not stained by epirubicin 
or idarubicin. 
Confocal Time Series Experiments 
Confocal time series experiments were performed using drug-sensitive MGH-
U1 and RT112 cell lines and multidrug resistant (MDR) variants MGH-U1R 
and MGHU-MMC.  For confocal time series experiments, cells were harvested 
using trypsin-EDTA (Sigma, UK) and cell density was adjusted to  
1 x 10
5 cells/ml.  Cells were
 sub-cultured in 40mm Petri dishes (Nunc, UK).  
Cells were grown to 90-95% confluence (approximately 48 hours) and then 
used for time series incubation experiments.   
For time series the culture medium was changed to DMEM HEPES 
modification (containing 25mM HEPES buffering solution, Cat No. D6171, 
Sigma, UK).  This HEPES containing medium buffers the cells whilst 
incubated on the heated stage and also controls the pH of the medium as this 
has been shown to affect epirubicin uptake [199].  
Cells were placed on the Zeiss LSM 510 confocal microscope and incubated 
on the heated stage at 37
oC throughout each time series.  Samples were 
allowed 15 minutes to acclimatise before time series were started.  Cells were 
then visualised through a x40 water immersion lens.  Using the differential 
interference contrast (DIC) image in scanning mode, a Z-stack was set up to 
take 6 image slices through each cell sample.  As there is no cellular 
fluorescence initially, taking slices at 6 levels through our cells gave the best 
chance of capturing cell fluorescence during our time series, the level of 
maximum fluorescence capture was then used for subsequent analysis. The 
time series was set to take images every 2 minutes for 120 minutes.  
Cell samples were exposed to various drug regimes as set out below.  Drug 
concentrations represent their final concentrations in the HEPES medium. 
1. Epirubicin  10µg/ml   
2. Epirubicin  10µg/ml  combined with verapamil 100µg/ml 
The time series was commenced and the drugs were then added, meaning 
that baseline fluorescence for each cell was recorded, so they acted as their 
own controls.   Experiments were repeated twice for each cell type. 
Epirubicin fluorescence was excited by the 543nm HeNe laser and emission 
of wavelengths of 560nm and greater (red) were detected.  The laser power   151
was fixed at 50.5% and gain setting was fixed at 1250 throughout all time 
series.  Standardisation of all fluorescence excitation characteristics meant 
that we could directly compare the fluorescence – time curves of the different 
cell lines for samples with and without verapamil.  
Fluorescein diacetate (FDA) was added at the end of the time series to 
confirm viability in our cell samples.   
Confocal Time Series Data Analysis 
Analysis of epirubicin uptake during our confocal time series was performed 
using the region of interest (ROI) mode.  Regions of interest were drawn 
within the nuclei and cytoplasm of 20 cells from each sample and 
fluorescence uptake measurements were generated.  During time series 
some cells were quite mobile, so care was taken to place the ROIs over areas 
of the cells that were static for the duration of the time series.  The data from 
the ROIs were exported and analysed using Microsoft Excel, producing 
graphs of mean fluorescence over time with 95% confidence intervals, for 
each cell type.   The differences in epirubicin uptake between cell lines 
incubated with and without verapamil were then analysed.    
Cellular staining of P-gp using a FITC conjugated Anti-P-gp antibody 
(17F9, BD Biosciences): 
MGH-U1, RT112, MGH-U1R and MGHU-MMC cells were grown in 40mm 
Petri dishes until confluent.  Cells were then exposed to either Hanks 
Balanced Salt Solution (HBSS) with 1% Bovine Serum Albumin (BSA) or 
HBSS with 1% BSA and 20µl/ml of FITC labeled anti-P-gp antibody, 17F9 (BD 
Biosciences, UK) for 20 minutes at room temperature in a dark room. 
The medium was then pipetted off and cells were recovered with PBS and 
placed on ice.  Cells were then viewed on the confocal microscope using 
FITC laser and filter settings.   
Nuclear P-gp staining with a FITC conjugated Anti-P-gp antibody (17F9, 
BD Biosciences): 
MGH-U1 and MGH-U1R cells were grown in 25cm
2 flasks until confluent.  
Nuclear fractionation was then performed as per standardised protocol 
(Appendix 1).  Nuclei were then exposed to HBSS with 1% BSA and 20µl/ml 
of FITC labeled anti-P-gp antibody, 17F9 (BD, Biosciences) for 20 minutes at 
room temperature in a dark room.  Nuclei were then dropped onto a slide and   152
coverslipped.  They were then viewed by confocal microscopy using FITC 
laser and filter settings.   
Membrane Leakiness Studies using FITC-dextrans: 
MGH-U1 and MGH-U1R cells cultured in 40mm Petri dishes until confluent.  
Cells then killed by microwaving them in a 650W oven for 10 seconds on 
100% power.  Cells then exposed to 77KDa FITC-dextrans in PBS for 30 
minutes at 37
oC.  Cells then viewed by confocal microscopy to establish the 
cellular localisation of FITC-dextrans in dead cells.   
Green Fluorescent Protein cell line experiments: 
Two Green fluorescent protein (GFP) cell lines had previously been 
established in our research unit.  We assessed the purity of frozen cultures 
(Appendix 7) and the MDR characteristics of these cells after being frozen at -
180
oC.  We also assessed the potential of using GFP as a viability marker.   
GFP cells – epirubicin uptake characteristics: 
MGH-U1-GFP and MGH-U1R-GFP cells were cultured in 40mm Petri dishes 
until 75 – 100% confluent.  Cells were then exposed to epirubicin at a 
concentration of 10µg/ml in HEPES buffered medium (1:100 HEPES) for  
2 hours at 37
oC.  Culture medium was then pipetted off and replaced with 
PBS.  Cells were then viewed on the con-focal microscope to assess the drug 
uptake and accumulation characteristics of viable cells. 
Assessment of GFP as viability marker using time-lapse confocal 
microscopy: 
MGH-U1-GFP and MGH-U1R-GFP cells were cultured in 40mm Petri dishes 
until 75 – 100% confluent.   
Cell media was changed to DMEM HEPES buffered culture medium 
(containing 25mM HEPES buffer solution (Sigma, UK)).  Cells were then 
placed on the heated stage of the confocal microscope at 37
oC.  Cells 
exhibiting GFP fluorescence were visualised and confocal images were taken.   
Propidium iodide (PI) 50µg/ml was added to the medium to confirm cell 
viability (excluded from nuclei of viable cells).  A time series was then 
commenced at 1 minute intervals looking at both green (GFP) and Red (PI) 
fluorescence.  Several drops of glutaraldehyde were then added to kill the 
cells.  Time series were continued until cell death was confirmed by nuclear PI   153
uptake.   It was necessary to perform a z-stack time series as the level of 
maximum GFP fluorescence was different to the level of nuclear PI 
fluorescence.   
A control time series experiment was performed looking at viable MGH-U1-
GFP cells to confirm that any reduction in GFP fluorescence over time was 
not caused by fluorescence bleaching.   
2.72:  Flow cytometry experiments 
Epirubicin Dose Response: 
MGH-U1 and MGH-U1R cells were grown in 25cm
2 flasks until confluent.  
Cells were then exposed to various concentrations of epirubicin in culture 
medium supplemented with 1:100 HEPES medium at 37
oC for 120 minutes.  
The concentrations used were 1, 2.5, 5, 10, 20, 40 and 80µg/ml.  A control 
sample was also performed for each cell type.  Following incubation drug was 
immediately tipped off and cells were washed 3 times with ice-cold PBS.  
Cells were then harvested using trypsin-EDTA and transferred into centrifuge 
tubes.  They were then centrifuged at 438g (1500rpm) for 3 minutes and the 
supernatant was discarded.  The cell pellet was resuspended in 1ml of ice-
cold HEPES buffered medium and the cells were placed on ice.  Cells were 
then transferred into flow tubes and analysed on a FACScaliber flow 
cytometer (Becton Dickinson).  Epirubicin fluorescence was excited using the 
Argon 488nm laser and emissions were detected with the FL-2 detector 
(585nm +/- 15).  Experiments were repeated twice to confirm results. 
Idarubicin Dose Response: 
MGH-U1 and MGH-U1R cells were grown in 25cm
2 flasks until confluent.  
Cells were then exposed to various concentrations of idarubicin in culture 
medium supplemented with 1:100 HEPES medium at 37
oC for 120 minutes.  
The concentrations used were 1, 2.5, 5, 10, 20, 40 and 80µg/ml.  A control 
sample was also performed for each cell type.  Following incubation drug was 
immediately tipped off and cells were washed 3 times with ice-cold PBS.  
Cells were then harvested using trypsin-EDTA and transferred into centrifuge 
tubes.  They were then centrifuged at 438g (1500rpm) for 3 minutes and the 
supernatant was discarded.  The cell pellet was resuspended in 1ml of ice-
cold HEPES buffered medium and the cells were placed on ice.  Cells were 
then transferred into flow tubes and analysed on a FACScaliber flow   154
cytometer (Becton Dickinson).  Idarubicin fluorescence was excited using the 
Argon 488nm laser and emissions were detected with the FL-2 detector 
(585nm +/- 15).   Experiments were repeated twice to confirm results. 
Effects of WGA pre-incubation on Cellular Epirubicin Dose Response: 
MGH-U1 and MGH-U1R cells were grown in 25cm
2 flasks until 75-80% 
confluent.  Cells for WGA pre-incubation were then exposed to WGA 0.2µg/ml 
for 24 hours at 37
oC.  Control cells (no WGA pre-incubation) were left in 
standard CM.  Cells were then exposed to various concentrations of epirubicin 
in culture medium supplemented with 1:100 HEPES medium at 37
oC for 120 
minutes.  The concentrations used were 1, 2.5, 5, 10, 20, 40 and 80µg/ml.  A 
control sample was also performed for each cell type.  Following incubation 
drug was immediately tipped off and cells were washed 3 times with ice-cold 
PBS.  Cells were then harvested using trypsin-EDTA and transferred into 
centrifuge tubes.  They were then centrifuged at 438g (1500rpm) for 3 
minutes and the supernatant was discarded.  The cell pellet was resuspended 
in 1ml of ice-cold HEPES buffered medium and the cells were placed on ice.  
Cells were then transferred into flow tubes and analysed on a FACScaliber 
flow cytometer (Becton Dickinson).  Epirubicin fluorescence was excited using 
the Argon 488nm laser and emissions were detected with the FL-2 detector 
(585nm +/- 15).   
Effects of WGA pre-incubation on Nuclear Epirubicin Dose Response: 
MGH-U1 and MGH-U1R cells were grown in 60mm Petri dishes until 75-80% 
confluent.  Cells for WGA pre-incubation were then exposed to WGA 0.2µg/ml 
for 24 hours at 37
oC.  Control cells (no WGA pre-incubation) were left in 
standard CM.  Cells were then exposed to various concentrations of epirubicin 
in culture medium supplemented with 1:100 HEPES medium at 37
oC for 120 
minutes.  The concentrations used were 1, 2.5, 5, 10, 20, 40 and 80µg/ml.  A 
control sample was also performed for each cell type.  Following incubation 
drug was immediately tipped off and cells were washed 3 times with ice-cold 
PBSI.  Nuclear fractionation was then performed as per protocol (Appendix 1).  
The nuclear pellet was resuspended in 0.5ml of ice-cold PBSI and placed on 
ice.  Nuclei were then transferred into flow tubes and analysed on a 
FACScaliber flow cytometer (Becton Dickinson).    155
Mitomycin C dose response: 
MGH-U1 and MGH-U1R cells were grown in 25cm
2 flasks until confluent.  
Cells were then exposed to various concentrations of mitomycin C in culture 
medium supplemented with 1:100 HEPES medium at 37
oC for 120 minutes.  
The concentrations used were 125, 250, 500 and 1000µg/ml.  A control 
sample was also performed for each cell type.  Following incubation drug was 
immediately tipped off and cells were washed 3 times with ice-cold PBS.  
Cells were then harvested using trypsin-EDTA and transferred into centrifuge 
tubes.  They were then centrifuged at 438g (1500rpm) for 3 minutes and the 
supernatant was discarded.  The cell pellet was resuspended in 1ml of ice-
colds HEPES buffered medium and the cells were placed on ice.  Cells were 
then transferred into flow tubes and analysed on a FACScaliber flow 
cytometer (Becton Dickinson).  The 488nm Argon laser was used for 
excitation and detection was performed using all three fluorescence detectors, 
FL-1 (530nm +/-15), Fl-2 (585nm +/- 15) and Fl-3 detectors (>650nm). 
Assessing mitomycin C dose response by reduction acridine orange 
fluorescence: 
Previous studies have assessed mitomycin C uptake by a reduction in 
acridine orange fluorescence presumably due to similarities in binding sites of 
these two molecules [393].  MGH-U1 and MGH-U1R cells were grown in 
25cm
2 flasks until confluent.  Cells were then exposed to various 
concentrations of mitomycin C in culture medium supplemented with 1:100 
HEPES medium at 37
oC for 120 minutes.  The concentrations used were 125, 
250, 500 and 1000µg/ml.  Two control samples were also performed for each 
cell type one with and one without acridine orange exposure.  Following 
incubation drug was immediately tipped off and cells were washed 3 times 
with ice-cold PBS.  Cells were then harvested using trypsin-EDTA and 
transferred into centrifuge tubes.  They were then centrifuged at 438g 
(1500rpm) for 3 minutes and the supernatant was discarded.  The cell pellet 
was resuspended in 0.5ml of acridine orange 4µM/L for 10 minutes at 37
oC.  
Cells were then centrifuged at 438g (1500rpm) for 3 minutes and acridine 
orange was discarded and cells were resuspended in 0.5ml of ice-cold PBS 
and placed on ice.  Cells were then transferred into flow tubes and analysed 
on a FACScaliber flow cytometer (Becton Dickinson).  The 488nm Argon laser   156
was used for excitation and detection was performed using FL-1 (530nm +/- 
15) and FL-2 (585nm +/- 15) detectors.   
Effects of verapamil on epirubicin dose response: 
Cells for flow cytometric studies were grown to near confluence in 25cm
2 
flasks.  Cells were exposed to epirubicin and/or verapamil diluted in culture 
medium supplemented with 1:100 HEPES buffering medium as follows.  
1.  Control – No epirubicin and no verapamil 
2.  Verapamil only for 120 minutes 
3.  Epirubicin 10µg/ml for 60 minutes  
4.  Epirubicin 10µg/ml and Verapamil 100µg/ml for 60 minutes  
5.  Verapamil 100µg/ml for 60 minutes then Epirubicin 10µg/ml for 60 
minutes 
6.  Verapamil 100µg/ml for 60 minutes then Epirubicin 10µg/ml and 
Verapamil 100µg/ml for 60 minutes 
7.  Epirubicin10µg/ml for 120 minutes 
8.  Epirubicin 10µg/ml and Verapamil 100µg/ml for 120 minutes 
9.  Verapamil 100µg/ml for 60 minutes then Epirubicin 10µg/ml for 120 
minutes 
10. Verapamil 100µg/ml for 60 minutes then Epirubicin 10µg/ml and 
Verapamil 100µg/ml for 120 minutes 
During drug exposure cells were maintained in a humidified incubator with 5% 
CO2 at 37
oC.  After exposure, cells were trypsinised into suspension and 
10mls of culture medium was added to neutralize the trypsin-EDTA.  Cells 
were then centrifuged at 438g (1500rpm) for 3 minutes.  The supernatant was 
discarded and cells were resuspended in 1ml of ice-cold culture medium and 
placed on ice.  Samples were then run on the flow cytometer.   
Analysis of cellular drug uptake was performed using a Becton Dickinson 
FACScaliber flow cytometer.  Cellular drug fluorescence was excited using 
the 488nm Argon laser and epirubicin fluorescence (red) was detected using 
the FL-2 detector (585nm +/- 15).     157
Flow cytometric time series data analysis: 
We collected fluorescence data for 5,000 – 10,000 gated cells in each 
sample.  All experiments were repeated to confirm results.  Results were 
plotted as histograms with number of fluorescent events on the x-axis against 
fluorescence intensity units on a logarithmic scale on the y-axis. Histogram 
statistics were generated for each cell sample.  Comparisons were made 
between different cell types and the various exposure regimens using 
geomean fluorescence values.  Given the number of cells sampled, any 
differences between cell samples were significant.  Experiments were 
repeated to confirm results. 
Effect of verapamil pre-exposure on epirubicin uptake in isolated nuclei: 
MGH-U1 and MGH-U1R cells were cultured in 25cm
2 flasks until confluent.  
Cells were then either exposed to 100µg/ml verapamil in culture medium for 
120 minutes at 37
oC or kept in normal culture medium.  Nuclei were then 
extracted by a standardised protocol (Appendix 1) followed by exposure to 
epirubicin 10µg/ml for 10 minutes at 37
oC.  Nuclei were centrifuged at 800g 
(2000rpm) for 5 minutes and the epirubicin containing supernatant was 
discarded.  The nuclei were then re-suspended in 0.5ml of PBSI and placed 
on ice.  The samples were then transferred into flow tubes and run on the flow 
cytometer.   
Cellular P-gp staining with a FITC conjugated Anti-P-gp antibody (17F9, 
BD Biosciences): 
MGH-U1, RT112, MGH-U1R and MGHU-MMC cells were grown in 25 cm
2 
flasks until confluent.  Cells were then trypsinised into suspension.  Cells were 
counted using a haemocytometer and 5 x 10
5 cells were placed into each 
centrifuge tube.  They were then centrifuged at 438g (1500rpm) for 3 minutes 
and the supernatant was discarded.  Cells were then re-suspended in 0.5mls of 
their allocated fluid.  Controls were re-suspended in HBBS (Sigma, UK) 
containing 1% Bovine Serum Albumin (BSA) (Sigma, UK).   FITC-controls were 
re-suspended in HBSS containing 1% BSA and 20µl/ml of FITC labelled IgG 
(Sigma, UK).  FITC-anti-P-gp cells were re-suspended in HBSS containing 
1% BSA and 20µl/ml of FITC-anti-P-gp (17F9, BD Biosciences, UK).  Cells 
were then incubated at room temperature for 20 minutes.  Cells were then 
transferred to flow tubes, placed on ice and analysed on the flow cytometer.     158
Nuclear P-gp staining with a FITC conjugated Anti-P-gp antibody (17F9, 
BD Biosciences): 
MGH-U1, RT112, MGH-U1R and MGHU-MMC cells were grown in 25cm
2 
flasks until confluent.  Nuclei were then isolated as per standardised protocol 
(Appendix 1).  Nuclei were counted using a haemocytometer and 5 x 10
5 nuclei 
were placed into each centrifuge tube.  They were then centrifuged at 800g 
(2000rpm) for 5 minutes and the supernatant was discarded.  Nuclei were then 
re-suspended in 0.5mls of their allocated fluid.  Controls were re-suspended in 
HBSS (Sigma, UK) containing 1% Bovine Serum Albumin (BSA) (Sigma, UK).   
FITC-controls were re-suspended in HBSS containing 1% BSA and 20µl/ml of 
FITC labeled IgG (Sigma, UK).  FITC-anti-P-gp nuclei were re-suspended in 
HBSS containing 1% BSA and 20µl/ml of FITC-anti-P-gp (17F9, BD 
Biosciences, UK).  The samples were then incubated at room temperature for 
20 minutes.  They were then transferred to flow tubes, placed on ice and 
analysed on the flow cytometer.   
2.73:  Microinjection experiments:  
Microinjection of cytotoxic drugs into MDR cells provides a novel means of 
studying MDR status and mechanisms of MDR.  Microinjection of epirubicin 
into the cytoplasm of MDR cells, bypasses the plasma membrane P-gp efflux 
pump.  If MDR cells microinjected with epirubicin still exhibit their 
characteristic nuclear sparing, this would provide direct evidence of the 
nuclear membrane’s role and establish another mechanism of MDR in bladder 
cancer.   Microinjection also allows molecules that would not normally cross 
the plasma membrane to be injected into cells, e.g. FITC-dextrans.  
Cytoplasmic microinjection with epirubicin at 37
oC: 
MGH-U1, RT112, MGH-U1R and MGHU-MMC cells were cultured in low-
sided 40mm Petri dishes (Orange Scientific, UK) until 50 – 75% confluent. 
Cell culture medium was changed to HEPES buffered medium (1:100 
HEPES). Epirubicin (0.5mg/ml) was co-injected with a 77KDa FITC-dextran 
(0.5mg/ml) into the cytoplasm of adherent cells.  The FITC-dextran allowed us 
to clearly identify our injected cell population.  FITC-dextrans of 77KDa are 
ordinarily excluded from cells and cell nuclei, as they are too large to 
passively diffuse across these membranes.  The injection buffer used was 
48mM K2HPO4, 4.5mM KH2PO4, 14mM NaH2PO4, pH 7.2 (Eppendorf -   159
personal communication).  Once microinjected, cells were incubated for 60 
minutes in normal culture conditions to allow cell recovery and time for 
epirubicin to distribute itself within the cells. 
Microinjected cells were then viewed by confocal microscopy.  Injected cells 
were easily identified by their green FITC-dextran fluorescence, on direct 
fluorescence microscopy.  Confocal microscopy allowed direct visualisation of 
the distribution of the various fluophores within the microinjected cells.  
Epirubicin fluorescence was excited by a 543nm HeNe laser and emission of 
wavelengths of 560nm and greater (red) were detected.  FITC-dextran 
fluorescence was excited by a 488nm Argon laser and emission wavelengths 
between 505 and 530nm (green) were detected.  The multitrack scanning 
mode on the confocal microscope was used to reduce cross interference in 
the fluorescent signals of these two fluophores.   
Acridine orange (3µg/ml) stains the nuclei of viable cells green and was added 
after initial image capture in order to confirm cell viability.  Acridine orange has 
similar fluorescence properties to FITC and was detected with the same filter 
settings.  
Cytoplasmic microinjection with epirubicin on ice: 
By placing cells on ice, energy dependant cellular processes are abolished. 
MGH-U1 and MGH-U1R cells were cultured in low-sided 40mm Petri dishes 
(Orange Scientific, UK) until 50 – 75% confluent.  Cell culture medium was 
changed to ice-cold HEPES buffered medium (1:100 HEPES) and the cells 
were placed on ice to cool for 20 – 30 minutes.  The injection fluids and the 
microscope stage were also placed on ice.  The injection fluid was then 
centrifuged at 16000g (13000rpm) for 3 minutes at 4
oC in a Heraeus Biofuge 
Fresco centrifuge.  Epirubicin (0.5mg/ml) was co-injected with a 77KDa FITC-
dextran (0.5mg/ml) into the cytoplasm of adherent cells.  The injection buffer 
used was 48mM K2HPO4, 4.5mM KH2PO4, 14mM NaH2PO4, pH 7.2 
(Eppendorf - personal communication).  Once microinjected, cells were 
visualised by confocal microscopy as soon as possible.  Our injected cell 
population was identified by its FITC-dextran fluorescence.  Confocal 
microscopy allowed direct visualisation of the distribution of the various 
fluophores within the microinjected cells.  The same confocal settings were 
used as in the previous experiment protocol.     160
Acridine orange (3µg/ml) was again used to assess cell viability.   
Nuclear pore sizing by cytoplasmic microinjection of various sized FITC-
dextrans: 
Microinjection of various FITC-dextrans into the cytoplasm of cells allows us 
to size nuclear membrane pores depending on which FITC-dextrans are able 
to cross the nuclear membrane.  Microinjection had significant advantages 
over our previous attempts at nuclear pore sizing using a scrape-loading 
technique.  The scrape-loading technique wasted large quantities of dextrans 
and was frequently unsuccessful, with a low yield of cells that took up 
dextrans.   
MGH-U1 and MGH-U1R cells were cultured in low-sided 40mm Petri dishes 
(Orange Scientific, UK) until 50 – 75% confluent. Cell culture medium was 
changed to HEPES buffered medium (1:100 HEPES). 
Cells were then microinjected with 1mg/ml FITC-dextrans of various sizes in 
injection buffer.  FITC-dextran sizes used were 4.4KDa, 19.5KDa, 42KDa and 
77KDa (Sigma).  Once microinjected, cells were incubated for 60 minutes at 
37°C to allow cell recovery and distribution of the FITC-dextran to occur.  
Cells were the visualised using confocal microscopy.     
2.74:  Cytotoxicity experiments: 
Cytotoxicity experiments were performed using the MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; thiazolyl blue) assay. 
Plating Method 
Cells lines were trypsinised into suspension in culture medium as described 
previously.  Cell density was adjusted to 2 x 10
4 cells/ml.  One hundred 
microlitres of cell suspension was seeded into each well of 96-well culture-
grade microtitre plates (Nunc, UK), giving an initial plating cell concentration 
of 2 x 10
3 well
-1 (Figure 25).  Cells were allowed to settle for 24 hours in 
normal culture conditions.    
Cells were exposed to the following agents and incubated at 37°C for one 
hour.  Drug-containing medium was then removed, and the cells were 
cultured in drug free culture medium until control wells achieved 90% 
confluence.   
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Figure 25:   Diagram of a 96-well microtitre plate with 8 rows (A-H)  
      and 12 columns (1 – 12) 
 
Specific drug cytotoxicity experiments 
Cytotoxic drugs 
Dilutions of epirubicin, idarubicin and mitomycin C were made up from stock 
solutions, diluted in culture medium supplemented with 1:100 HEPES buffer 
solution (Sigma, UK).   
Epirubicin: 
Epirubicin was diluted to a concentration of 640µg/ml and serially diluted 
across two 96-well plates giving final assay concentrations of 320, 160, 80, 
40, 20, 10, 5, 2.5, 1.25, 0.63, 0.31, 0.16, 0.08, 0.04, 0.02, 0.01, 0.005, 0.0025 
µg/ml.   
Idarubicin: 
Idarubicin was diluted to a concentration of 20µg/ml and serially diluted across 
each 96-well plate giving final assay concentrations of 10, 5, 2.5, 1.25, 0.63, 
0.31, 0.16, 0.08, 0.04µg/ml.   
Mitomycin C  
Mitomycin C was diluted to a concentration of 1mg/ml and serially diluted 
across each 96-well plate giving final assay concentrations of 500, 250, 125, 
62.5, 31.25, 15.63, 7.81, 3.91, 1.95, 0.98µg/ml.   
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Wheat Germ Agglutinin (WGA) (Triticum vulgaris Lectin) 
WGA was diluted to a concentration of 25.6µg/ml and serially diluted across 
each 96-well plate giving final assay concentrations of  12.8, 6.4, 3.2, 1.6, 0.8, 
0.4, 0.2, 0.1, 0.05, 0.025 µg/ml.   
Drug Combinations 
Epirubicin and WGA: 
Cells were pre-incubated with 0.2µg/ml WGA for 60 minutes at 37
oC.  After 
exposure cells WGA tipped off and cells were recovered with fresh culture 
medium and re-incubated for a further 23 hours.  Cells were then exposed to 
epirubicin for 1 hour which was serially diluted across each 96-well plate 
giving final assay concentrations of 160, 80, 40, 20, 10, 5, 2.5, 1.25, 0.63 and 
0.31µg/ml. 
Epirubicin and Demecolcine 
Cells were pre-incubated with demecolcine at various concentrations for 24 
hours across the rows A – H of the well plates.  The final concentrations of 
demecolcine were 0.5, 0.25, 0.125, 0.06, 0.03, 0.016µg/ml.  After 24 hours the 
cells were then exposed to epirubicin for 1 hours which was serially diluted 
across the columns of the well plates, giving final assay concentrations of 40, 
20, 10, 5, 2.5, 1.25, 0.063, 0.031, 0.016, 0.008µg/ml.    
MTT Method 
Subsequently 50µl of 1mg/ml MTT diluted in culture medium was added to 
each well and the plates were incubated for a further 3 – 4 hours.  Medium 
containing MTT was then removed and the resultant formazan crystals were 
solubilised by the addition of 150µl of dimethyl sulphoxide (DMSO, 100%) per 
well.  The optical density (representing residual viable cell biomass) was 
determined on a Wallac microplate reader set to detect at 570nm.  Data was 
transferred from the well-plate reader to a spreadsheet.  Spreadsheet analysis 
allowed the mean residual viable biomass to be calculated for each drug 
dilution as a percentage of the control well mean residual viable biomass.  
The external cells were excluded for analysis purposes as they are subject to 
drying and inaccurate results.  Cytotoxicity graphs were then plotted to include 
95% confidence intervals.  The IC50 value (concentration of the drug required 
to inhibit cell growth by 50%) was calculated for each drug or drug 
combination.    163
Chapter 3:  Results:  Specific techniques and experiments 
3.1:  Confocal experiments 
Anthracycline incubation studies: Establishing cell phenotypes 
Epirubicin uptake at 37
oC 
At 37
oC, the sensitive bladder cancer cell lines, MGH-U1 and RT112 both 
exhibited the “sensitive phenotype” with a clear nuclear uptake pattern of 
epirubicin.  Comparatively, levels of epirubicin fluorescence in the cytoplasm 
were much lower (Figures 26a and b).  Fluorescein diacetate confirmed cell  
viability, with strong green fluorescence being demonstrated by all cells.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In contrast, the MDR cell lines, MGH-U1R and MGHU-MMC, both 
demonstrated the “resistant phenotype”, with nuclear sparing of epirubicin 
uptake when incubated with drug at 37
oC.  The drug within MDR cells is 
mainly cytoplasmic and appears to be packaged in cytoplasmic vesicles.  
Some cells also exhibit a rim of drug around their periphery, which may 
represent drug being effluxed or ejected from these vesicles by exocytosis 
(Figures 26c and d).  Fluorescein diacetate again confirmed cell viability with 
cells fluorescing bright green.    
 
 
 
Figure 26a:  MGH-U1 cells (x40 Lens; Digital Zoom 
x1; Epirubicin Gain 700). Top Left: Fluorescein 
Diacetate (FDA) fluorescence (Green); Top Right:  
Epirubicin Fluorescence (Red); Bottom Left:  
Differential Interference Contrast Image (DIC); Bottom 
Right: Overlay image 
Figure 26b:  RT112 cells (x40 Lens; Digital Zoom x2; 
Epirubicin Gain 700). Top Left: Fluorescein Diacetate 
(FDA) fluorescence (Green); Top Right:  Epirubicin 
Fluorescence (Red); Bottom Left:  Differential 
Interference Contrast Image (DIC); Bottom Right: 
Overlay image   164
 
 
 
 
 
 
 
 
 
 
 
 
 
Idarubicin uptake at 37
oC 
In contrast to epirubicin, all cell lines demonstrated nuclear sparing of 
idarubicin at 37
oC (Figures 27a – d).  This is the only anthracycline that has 
been shown to be excluded from the nuclei of both sensitive and resistant 
cells and remains something of an enigma.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27a:  MGH-U1 cells (x40 Lens; Digital Zoom 
x1; Gain 750) Top Left: Fluorescein Diacetate 
(FDA) fluorescence (Green); Top Right: Differential 
Interference Contrast Image (DIC); Bottom Left: 
Idarubicin Fluorescence (Red); Bottom Right: 
Overlay image 
Figure 27b:  RT112 cells (x40 Lens; Digital Zoom 
x1; Gain 725) Top Left: Fluorescein Diacetate 
(FDA) fluorescence (Green); Top Right: Differential 
Interference Contrast Image (DIC); Bottom Left: 
Idarubicin Fluorescence (Red); Bottom Right: 
Overlay image 
Figure 26c:  MGH-U1R cells (x40 Lens; Digital Zoom x1; 
Epirubicin Gain 1025). Top Left: Fluorescein Diacetate 
(FDA) fluorescence (Green); Top Right: Differential 
Interference Contrast Image (DIC); Bottom Left: 
Epirubicin Fluorescence (Red); Bottom Right: Overlay 
Figure 26d:  MGHU-MMC cells (x40 Lens; Digital Zoom x2; 
Epirubicin Gain 900). Top Left: Fluorescein Diacetate 
(FDA) fluorescence (Green); Top Right: Differential 
Interference Contrast Image (DIC); Bottom Left: Epirubicin 
Fluorescence (Red); Bottom Right: Overlay image   165
 
 
 
 
 
 
 
 
 
 
In sensitive cells the idarubicin appears to be concentrated in an area just 
outside the nucleus, which with further magnification appears to be the golgi 
apparatus (Figs 28a and b).  In resistant cells idarubicin is present to a lesser 
extent in the golgi, but also appears to be packaged in cytoplasmic vesicles 
(Figs 28c and d).  It is conceivable that drug is taken up by the golgi and 
packaged into vesicles ready for export from the cell by exocytosis.  It is also 
possible that this process occurs more rapidly in MDR cells as evidenced by 
the presence of more cytoplasmic vesicles. 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 28a:  MGH-U1 cells (x40 Lens; Digital Zoom 
x2; Gain 680) Top Left: Fluorescein Diacetate 
(FDA) fluorescence (Green); Top Right: Differential 
Interference Contrast Image (DIC); Bottom Left: 
Idarubicin Fluorescence (Red); Bottom Right: 
Overlay image  
Figure 28b:  RT112 cells (x40 Lens; Digital Zoom 
x2; Gain 725) Top Left: Fluorescein Diacetate 
(FDA) fluorescence (Green); Top Right: 
Differential Interference Contrast Image (DIC); 
Bottom Left: Idarubicin Fluorescence (Red); 
Bottom Right: Overlay image  
Figure 27c:  MGH-U1R cells (x40 Lens; Digital 
Zoom x1; Gain 750) Top Left: Fluorescein 
Diacetate (FDA) fluorescence (Green); Top Right: 
Differential Interference Contrast Image (DIC); 
Bottom Left: Idarubicin Fluorescence (Red); Bottom 
Right: Overlay image 
Figure 27d:  MGHU-MMC cells (x40 Lens; Digital 
Zoom x1; Gain 800) Top Left: Fluorescein 
Diacetate (FDA) fluorescence (Green); Top Right: 
Differential Interference Contrast Image (DIC); 
Bottom Left: Idarubicin Fluorescence (Red); Bottom 
Right: Overlay image   166
 
 
 
 
 
 
 
 
 
 
 
 
 
Epirubicin uptake at 0 – 4
oC 
The sensitive cell lines, MGH-U1 and RT112, demonstrate very low levels of 
epirubicin uptake when incubated on ice.  They also reverse their normal 
uptake pattern to a pattern of nuclear drug exclusion (Figures 29a and b). 
                    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 28c:  MGH-U1R cells (x40 Lens; Digital 
Zoom x2; Gain 865) Top Left: Fluorescein 
Diacetate (FDA) fluorescence (Green); Top Right: 
Differential Interference Contrast Image (DIC); 
Bottom Left: Idarubicin Fluorescence (Red); Bottom 
Right: Overlay image  
Figure 28d:  MGHU-MMC cells (x40 Lens; Digital 
Zoom x2; Gain 785) Top Left: Fluorescein 
Diacetate (FDA) fluorescence (Green); Top Right: 
Differential Interference Contrast Image (DIC); 
Bottom Left: Idarubicin Fluorescence (Red); Bottom 
Right: Overlay image  
Figure 29b:  RT112 cells (x40 Lens; Digital Zoom x2; 
Gain 1000); Top Left: Fluorescein Diacetate (FDA) 
fluorescence (Green); Top Right:  Epirubicin 
Fluorescence (Red); Bottom Left:  Differential 
Interference Contrast Image (DIC); Bottom Right: 
Overlay image 
Figure 29a:  MGHU-1 cells (x40 Lens; Digital Zoom x2; 
Gain 1000); Top Left: Fluorescein Diacetate (FDA) 
fluorescence (Green); Top Right:  Epirubicin 
Fluorescence (Red); Bottom Left:  Differential 
Interference Contrast Image (DIC); Bottom Right: 
Overlay image   167
The resistant cell lines, MGH-U1R and MGHU-MMC, also exhibit very low 
levels of drug uptake at 0 – 4
oC, which were comparable to sensitive cell drug 
levels at the same temperature.  The MDR cells maintained their normal 
nuclear sparing pattern of drug uptake and had similar levels of drug uptake to 
MDR cells incubated at 37
oC (Figures 29c and d).   
 
         
 
 
 
 
 
 
 
 
 
 
 
 
All cell lines were viable after incubation with epirubicin on ice, as 
demonstrated by green fluorescence on FDA staining.  
  
Idarubicin uptake at 0 – 4
oC 
All cell lines showed a similar nuclear sparing pattern of idarubicin uptake 
when incubated on ice (Figures 30a – d).  They also demonstrated clear 
viability with FDA staining.   
 
 
 
 
 
 
 
 
Figure 29c:  MGH-U1R cells (x40 Lens; Digital Zoom x2; 
Gain 950); Top Left: Fluorescein Diacetate (FDA) 
fluorescence (Green); Top Right:  Epirubicin 
Fluorescence (Red); Bottom Left:  Differential 
Interference Contrast Image (DIC); Bottom Right: 
Overlay image 
Figure 29d:  MGHU-MMC cells (x40 Lens; Digital Zoom x2; 
Gain 950); Top Left: Fluorescein Diacetate (FDA) 
fluorescence (Green); Top Right:  Epirubicin Fluorescence 
(Red); Bottom Left:  Differential Interference Contrast Image 
(DIC); Bottom Right: Overlay image   168
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Epirubicin uptake in dead cells at 37
oC 
Following cell killing, all cell types showed strong nuclear staining with 
epirubicin when incubated at 37
oC (Figure 31a – d).   Absence of FDA 
staining confirmed death in all cells after microwaving them in a 650W oven 
for 10 seconds on 100% power.  Sensitive cells showed no change in their 
pattern of drug uptake with cell death, whereas dead MDR cells altered their 
epirubicin uptake pattern to a strong nuclear staining pattern.  This result 
clearly demonstrates the need to confirm cell viability when MDR cells are 
Figure 30a:  MGH-U1 cells (x40 lens; Digital Zoom x1; 
Gain setting 756)  Idarubicin fluorescence (Red) 
overlayed on DIC image 
Figure 30c:  MGH-U1R cells (x40 lens; Digital Zoom 
x1; Gain setting 812)  Idarubicin fluorescence (Red) 
overlayed on DIC image 
Figure 30d:  MGHU-MMC cells (x40 lens; Digital Zoom 
x2; Gain setting 950) Top Left: Fluorescein Diacetate 
(FDA) fluorescence (Green); Top Right: Differential 
Interference Contrast Image (DIC); Bottom Left: 
Idarubicin Fluorescence (Red); Bottom Right: Overlay 
image 
Figure 30b:  RT112 cells (x40 lens; Digital Zoom x2; 
Gain setting 950) Top Left: Fluorescein Diacetate (FDA) 
fluorescence (Green); Top Right: Differential 
Interference Contrast Image (DIC); Bottom Left: 
Idarubicin Fluorescence (Red); Bottom Right: Overlay 
image   169
changed to a sensitive nuclear epirubicin uptake pattern by whatever 
pharmacological means, to ensure that MDR reversal is not simply due to cell 
death.   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Idarubicin uptake in dead cells at 37
oC 
After cell killing, all cell types showed no changes in their uptake pattern of 
idarubicin, all demonstrating a nuclear sparing pattern similar to that of viable 
cells (Figures 32a – d).  Again, much of the drug appears to be sequestered in 
Figure 31d:  Dead MGHU-MMC cells (x40 lens; Digital 
Zoom x2; Gain setting 800) Top Left: Fluorescein 
Diacetate (FDA) fluorescence (Green); Top Right: 
Differential Interference Contrast Image (DIC); Bottom 
Left: Epirubicin Fluorescence (Red); Bottom Right: 
Overlay image 
Figure 31c: Dead MGH-U1R cells (x40 lens; Digital  
Zoom x2; Gain setting 800) Top Left: Fluorescein 
Diacetate (FDA) fluorescence (Green); Top Right: 
Differential Interference Contrast Image (DIC); Bottom 
Left: Epirubicin Fluorescence (Red); Bottom Right: 
Overlay image 
Figure 31a: Dead MGH-U1 cells (x40 lens; Digital 
Zoom x2; Gain setting 825) Top Left: Fluorescein 
Diacetate (FDA) fluorescence (Green); Top Right: 
Differential Interference Contrast Image (DIC); Bottom 
Left: Epirubicin Fluorescence (Red); Bottom Right: 
Overlay image 
Figure 31b:  Dead RT112 cells (x40 lens; Digital Zoom 
x2; Gain setting 825) Top Left: Fluorescein Diacetate 
(FDA) fluorescence (Green); Top Right: Differential 
Interference Contrast Image (DIC); Bottom Left: 
Epirubicin Fluorescence (Red); Bottom Right: Overlay 
image   170
the Golgi apparatus as with viable cells.  Cell death was confirmed by the 
absence of green fluorescence when stained with FDA.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anthracycline incubation studies: Uptake in isolated nuclei 
Epirubicin uptake at 37
oC 
Epirubicin uptake in nuclear extracts from cells that were pre-exposed to 
epirubicin showed dramatic differences in nuclear uptake between MGH-U1 
(sensitive) and MGH-U1R (MDR) nuclei.   Figures 33a and b show the 
Figure 32a: Dead MGH-U1 cells (x40 lens; Digital 
Zoom x2; Gain setting 900) Top Left: Fluorescein 
Diacetate (FDA) fluorescence (Green); Top Right: 
Differential Interference Contrast Image (DIC); Bottom 
Left: Idarubicin Fluorescence (Red); Bottom Right: 
Overlay image 
Figure 32b:  Dead RT112 cells (x40 lens; Digital Zoom 
x2; Gain setting 900) Top Left: Fluorescein Diacetate 
(FDA) fluorescence (Green); Top Right: Differential 
Interference Contrast Image (DIC); Bottom Left: 
Idarubicin Fluorescence (Red); Bottom Right: Overlay 
image 
Figure 32c: Dead MGH-U1R cells (x40 lens; Digital 
Zoom x2; Gain setting 900) Top Left: Fluorescein 
Diacetate (FDA) fluorescence (Green); Top Right: 
Differential Interference Contrast Image (DIC); Bottom 
Left: Idarubicin Fluorescence (Red); Bottom Right: 
Overlay image 
Figure 32d:  Dead MGHU-MMC cells (x40 lens; Digital 
Zoom x2; Gain setting 900) Top Left: Fluorescein 
Diacetate (FDA) fluorescence (Green); Top Right: 
Differential Interference Contrast Image (DIC); Bottom 
Left: Idarubicin Fluorescence (Red); Bottom Right: 
Overlay image   171
epirubicin staining characteristics of MGH-U1 and MGH-U1R nuclei with the 
confocal gain setting for epirubicin fluorescence set at 825.  Figure 33d shows 
MGH-U1R nuclei (fluorescence only image) at a gain setting of 1000, now 
demonstrating weak epirubicin fluorescence.  There is significantly less 
nuclear fluorescence when compared to MGH-U1 cells (fluorescence only 
image) at a much lower gain setting of 825 (Figure 33c).  Nuclei tend to clump 
together when extracted from cells, making analysis of individual nuclear 
fluorescence counts using the confocal analysis software unfeasible.      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33d:  MGH-U1R nuclei extracted after 
exposure of cells to epirubicin 10µg/ml for 2 hours 
(x40 Lens; Gain 1000; Zoom x11)   
Epirubicin fluorescence only 
Figure 33c:  MGH-U1 nuclei extracted after 
exposure of cells to epirubicin 10µg/ml for 2 hours 
(x40 Lens; Gain 825; Zoom x6)   
Epirubicin fluorescence only 
Figure 33a:  MGH-U1 nuclei extracted after 
exposure of cells to epirubicin 10µg/ml for 2 hours 
(x40 Lens; Gain 825; Zoom x14)   
Epirubicin fluorescence overlaid on DIC image 
Figure 33b:  MGH-U1R nuclei extracted after 
exposure of cells to epirubicin 10µg/ml for 2 hours 
(x40 Lens; Gain 825; Zoom x11)   
Epirubicin fluorescence overlaid on DIC image   172
Direct exposure of nuclei to epirubicin after nuclear fractionation showed that 
levels of drug uptake in MGH-U1 and MGH-U1R nuclei were very similar.  
Figures 34a and c show the epirubicin staining characteristics of MGH-U1 and 
MGH-U1R nuclei with the same confocal gain setting of 825.  Figures 34b and 
d show the same nuclei at a lower gain setting of 735 allowing a clearer 
visualisation of epirubicin uptake in the isolated nuclei. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
Comparing nuclei that have been pre-exposed to epirubicin rather than 
exposed post nuclear fractionation shows that pre-exposed nuclei of both cell 
types take up much less epirubicin.  This difference is most noticeable in the 
Figure 34a:  MGH-U1 nuclei exposed to epirubicin 
10µg/ml for 10 minutes after nuclear fractionation 
(x40 Lens; Gain 825; Zoom x6)   
Epirubicin fluorescence only 
Figure 34b:  MGH-U1 nuclei exposed to epirubicin 
10µg/ml for 10 minutes after nuclear fractionation  
(x40 Lens; Gain 735; Zoom x6)   
Epirubicin fluorescence only 
Figure 34c:  MGH-U1R nuclei exposed to epirubicin 
10µg/ml for 10 minutes after nuclear fractionation 
(x40 Lens; Gain 825; Zoom x6)   
Epirubicin fluorescence only 
Figure 34d:  MGH-U1R nuclei exposed to epirubicin 
10µg/ml for 10 minutes after nuclear fractionation (x40 
Lens; Gain 735; Zoom x6)   
Epirubicin fluorescence only   173
MGH-U1R nuclei, but also exists in the MGH-U1 nuclei when images at 
similar gain settings of 825 are compared (Figure 33c and 34c).    
Idarubicin uptake at 37
oC  
The nuclear uptake of idarubicin is very similar in MGH-U1 and MGH-U1R 
nuclei extracted from cells pre-exposed to idarubicin.    This is shown in 
figures 35a and b where the nuclear idarubicin staining of MGH-U1 and MGH-
U1R nuclei can be compared, with the confocal gain set at 850.   
MGH-U1 and MGH-U1R nuclei exposed to idarubicin after nuclear 
fractionation showed very similar levels of drug uptake, at a confocal gain 
setting of 850, as demonstrated in figures 36a and b.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35a:  MGH-U1 nuclei extracted after 
exposure of cells to idarubicin 20µg/ml for 2 hours 
(x40 Lens; Gain 850; Zoom x6)   
Idarubicin fluorescence only  
Figure 35b:  MGH-U1R nuclei extracted after 
exposure of cells to idarubicin 20µg/ml for 2 hours 
(x40 Lens; Gain 850; Zoom x14)   
Idarubicin fluorescence only  
Figure 36a:  MGH-U1 nuclei exposed to idarubicin 
20µg/ml for 10 minutes after nuclear fractionation 
(x40 Lens; Gain 850; Zoom x9)   
Idarubicin fluorescence only 
Figure 36b:  MGH-U1R nuclei exposed to idarubicin 
20µg/ml for 10 minutes after nuclear fractionation 
(x40 Lens; Gain 850; Zoom x9)   
Idarubicin fluorescence only   174
There doesn’t appear to be much difference in idarubicin uptake between pre 
and post- nuclear fractionation exposure.  This suggests nuclear drug uptake 
is not affected by being in the cells and suggest that there is something 
preventing nuclear uptake in both sensitive and resistant nuclei that is a 
nuclear uptake problem rather that a cellular uptake problem.   
This highlights a common problem with confocal imaging, in that the 
fluorescence gain for your image is set based on the area with the highest 
levels of drug uptake.  If the fluophore is most concentrated in an area other 
than the nucleus, then it may appear that there is no nuclear uptake when in 
fact there could be low level nuclear uptake.    
In comparison to nuclei exposed to epirubicin, there are lower levels of 
nuclear fluorescence in nuclei exposed to idarubicin post-fractionation, 
despite using a higher concentration of drug (20µg/ml).  This again suggests 
that some nuclear factor contributes to idarubicin exclusion.  Perhaps 
idarubicin does not bind to DNA as avidly as epirubicin or when it does its 
fluorescence is quenched in some way.   
 
Mitomycin C fluorescence 
Direct fluorescence experiments: 
Dose response: 
Fluorescence was only detected with FITC detection settings using a 488nm 
laser to excite emissions and a long pass 505nm filter to detect fluorescence 
(Figures 37a – f).   
Whilst some cells demonstrated nice fluorescence, others did not.  The 
reasons for this are unclear.  Mitomycin C is quite an unstable drug, so it is 
possible that in some experiments the mitomycin C was degraded to a non-
fluorescent molecule.   
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Figure 37a : MGH-U1 cells – control (No mitomycin C)  
 (x40 lens; Gain setting 900) Baseline FITC fluorescence 
only  
Figure 37b : MGH-U1R cells – control (No mitomycin C) 
(x40 lens; Gain setting 900) Baseline FITC fluorescence 
only  
Figure 37c : MGH-U1 cells –  250µg/ml mitomycin C  
 (x40 lens; Gain setting 900) FITC fluorescence only  
Figure 37d : MGH-U1R cells –  250µg/ml mitomycin C  
 (x40 lens; Gain setting 900) FITC fluorescence only  
Figure 37e : MGH-U1 cells –  1000µg/ml mitomycin C  
 (x40 lens; Gain setting 900) FITC fluorescence only  
Figure 37f : MGH-U1R cells –  1000µg/ml mitomycin C 
(x40 lens; Gain setting 900) FITC fluorescence only    176
Time series:  
Time series experiments were performed looking at FITC fluorescence, 
comparing baseline cell fluorescence to fluorescence levels over 50 minutes 
once mitomycin C 250µg/ml was added to the culture medium.  The FITC 
detector gain was set at 900.   Cellular fluorescence levels over time were 
assessed using a region of interest (ROI) function, allowing us to plot graphs 
of fluorescence over time for MGH-U1 and MGH-U1R cells as shown below 
(Figure 38).  For MGH-U1, 18 cells were analysed, whereas for MGH-U1R 
only 5 cells were evaluable.  Confidence intervals (95%) for MGH-U1 cells 
were all ≤0.044 and for MGH-U1R cells were all ≤0.39. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38:    Graph of mitomycin C uptake over time in MGH-U1 and   
      MGH-U1R cells incubated with 250µg/ml of mitomycin C  
      for 50 minutes.  
 
Overall these experiments did not convincingly prove that we could detect 
mitomycin C fluorescence.  The MGH-U1 cells showed a small increase in 
fluorescence levels over time, suggesting that we may be able to detect low 
level mitomycin C fluorescence.  The MGH-U1R cells demonstrated peak 
fluorescence levels after 20 minutes.  From there fluorescence levels 
declined, again suggesting the presence of some low level mitomycin C 
fluorescence.  These falling levels of fluorescence may indicate that 
Time series of mitomycin C uptake in MGH-U1 and MGH-U1R cells 
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mitomycin C is being removed from the cells by an MDR mechanism such as 
P-gp related drug efflux or could possibly represent degradation of mitomycin 
C to non-fluorescent derivatives. 
Indirect fluorescence experiments: 
A comparison of control cells (incubated with acridine orange (AO) only) with 
cells incubated with either 250 or 1000µg/ml of mitomycin C followed by 
incubation with AO, are shown below for MGH-U1 and MGH-U1R cells  
(Table 16).  
 
Cell Type / 
MMC Dose 
 
Number of 
Nuclei 
 
Area 
µm
2 
 
Mean 
Fluorescen
ce 
 
Standard 
Deviation 
 
Maximum 
Frequency Intensity 
(Min – Max) 
 
MGH-U1: 
 Control 
 250 MMC 
 1000 MMC 
 
 
 
40 
48 
33 
 
 
6274.5 
7600.6 
4883.4 
 
 
102 
78 
68 
 
 
32 
31 
29 
 
 
107 (4 – 239) 
65 (5 – 214) 
61 (4 – 200) 
 
MGH-U1R: 
 Control 
 250 MMC 
 1000 MMC 
 
 
 
51 
58 
24 
 
 
5948.2 
7477.5 
2064.8 
 
 
103 
94 
76 
 
 
39 
42 
47 
 
 
86 (7 – 254) 
87 (5 – 251) 
39 (7 – 212) 
  
Table 16:    Acridine orange fluorescence after exposure of MGH-U1  
      and MGH-U1R cells to mitomycin C  
 
These results show that in sensitive cells nuclear AO fluorescence is reduced 
by incubation with mitomycin C with evidence of a dose response.  In the 
resistant cells, acridine orange fluorescence is also reduced by mitomycin C 
exposure, but to a lesser degree as one would expect.  The results for the 
MDR cells incubated with 1000µg/ml of mitomycin C may be slightly spurious 
as only 24 nuclei were evaluable.   
 
Wheat  Germ Agglutinin (WGA) nuclear pore binding studies 
FITC-WGA cellular localisation studies 
This experiment looked at the optimum time for localisation of FITC-WGA to 
the nuclear membrane.  Confocal images are shown below for MGH-U1 and 
MGH-U1R cells after incubation times of 30 minutes, 1, 2, 4, 8, 16, 24 and 48 
hours following exposure to 0.4µg/ml of FITC-WGA for 1 hour at 37
oC 
(Figures 39a – r).      178
MGH-U1 cells: 
 
 
 
 
 
 
  
 
Figure 39a: MGH-U1 cells: 30 minutes post FITC-
WGA exposure; FITC fluorescence only  
Figure 39b: MGH-U1 cells: 1 hour post FITC-WGA 
exposure; FITC fluorescence only  
Figure 39d: MGH-U1 cells: 4 hours post FITC-WGA 
exposure; FITC fluorescence only  
Figure 39c: MGH-U1 cells: 2 hours post FITC-WGA 
exposure; FITC fluorescence only  
Figure 39e: MGH-U1 cells: 8 hours post FITC-WGA 
exposure; FITC fluorescence only  
Figure 39f: MGH-U1 cells: 16 hours post FITC-WGA 
exposure; FITC fluorescence only    179
 
 
 
 
 
 
 
 
 
 
 
 
MGH-U-1R cells: 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39g: MGH-U1 cells: 24 hours post FITC-WGA 
exposure; FITC fluorescence only  
Figure 39b: MGH-U1 cells: 48 hours post FITC-WGA 
exposure; FITC fluorescence only  
Figure 39i: MGH-U1R cells: 30 minutes post FITC-
WGA exposure; FITC fluorescence only  
Figure 39j: MGH-U1R cells: 1 hour post FITC-WGA 
exposure; FITC fluorescence only  
Figure 39k: MGH-U1R cells: 2 hours post FITC-WGA 
exposure; FITC fluorescence only  
Figure 39l: MGH-U1R cells: 4 hours post FITC-WGA 
exposure; FITC fluorescence only    180
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
We also exposed cells to FITC-WGA 0.4µg/ml for 24 hours continuously. 
 
 
 
 
 
 
 
 
 
Figure 39n: MGH-U1R cells: 16 hours post FITC-
WGA exposure; FITC fluorescence only  
Figure 39m: MGH-U1R cells: 8 hours post FITC-WGA 
exposure; FITC fluorescence only  
Figure 12o: MGH-U1R cells: 24 hours post FITC-
WGA exposure; FITC fluorescence only  
Figure 39p: MGH-U1R cells: 48 hours post FITC-
WGA exposure; FITC fluorescence only  
Figure 39o: MGH-U1R cells: 24 hours post FITC-
WGA exposure; FITC fluorescence only  
Figure 39q: MGH-U1 cells: Continuous exposure to 
FITC-WGA for 24 hours; FITC fluorescence only  
Figure 39r: MGH-U1R cells: Continuous exposure to 
FITC-WGA for 24 hours; FITC fluorescence only    181
This experiment showed that FITC-WGA accumulates around the nuclear 
membrane almost immediately with 30 minute samples showing some peri-
nuclear staining.  Peri-nuclear staining increases with time reaching a plateau 
at about 4 hours which persists up to 24 hours.  Continuous exposure gives a 
similar pattern of peri-nuclear staining at 24 hours.  Levels of peri-nuclear 
staining at 48 hours are much lower, presumably due to dilution as a result of 
cell division.  
FITC-WGA nuclear localisation studies 
Nuclear preparations exposed to FITC-WGA again showed strong perinuclear 
staining suggesting active binding to nuclear pore complexes (Figures 40a–d).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 40c: Cluster of MGH-U1 nuclei: exposed to 
FITC-WGA 0.4µg/ml for 10 minutes after nuclear 
fractionation (x20 Lens; Gain 852; Zoom x16)   
FITC fluorescence only 
Figure 40d:  Cluster of MGH-U1R nuclei: exposed 
to FITC-WGA 0.4µg/ml for 10 minutes after nuclear 
fractionation (x20 Lens; Gain 831; Zoom x7)   
FITC fluorescence only 
Figure 40a:  Single MGH-U1 nucleus: exposed to 
FITC-WGA 0.4µg/ml for 10 minutes after nuclear 
fractionation (x20 Lens; Gain 1047; Zoom x20)   
FITC fluorescence overlaid on DIC image 
Figure 40b:  Two MGH-U1R nuclei: exposed to 
FITC-WGA 0.4µg/ml for 10 minutes after nuclear 
fractionation (x20 Lens; Gain 827; Zoom x9)   
FITC fluorescence only   182
Nuclear pore sizing using FITC-dextrans and the effects of WGA nuclear 
pore blockade   
Scrape-loading of cells with various sized FITC-dextrans was a slightly hit or 
miss procedure with cells being heterogeneous as to the amount of dextrans 
taken up.  This heterogeneity relates to the fact that FITC-dextran uptake is 
dependent on the small breaches made in the plasma membrane of cells 
during the scrape loading process, so was not unexpected.      
Cells were viewed at several different time points to assess any changes in 
cellular localisation over time.  The time points at which cells were visualised 
were 6, 18, 24, 48 and 72 hours. 
  
    
              
 
 
 
 
 
 
 
 
       
       
        
 
 
 
 
 
 
 
       
 
MGS 19.5 6 hrs 
6 hrs 
MGS 4.4 18 hrs 
MGS 4.4 72 hrs
4.4KDa  19.5KDa 42KDa 77KDa
24 hrs 
 6 hrs 
 
 
 
48 hrs 
 
 
   
 
 
 
6 hrs 6 hrs 6 hrs
18 hrs  18 hrs 18 hrs  18 hrs
24 hrs  24 hrs  24 hrs 
48 hrs 48 hrs 48 hrs  183
 
 
 
 
 
Figure 41:   MGH-U1 cells scrape-loaded with FITC-dextrans  
 
       
 
 
 
 
 
 
 
 
 
 
 
       
 
       
 
 
 
 
 
 
 
 
 
 
 
Figure 42:   MGH-U1R cells scrape-loaded with FITC-dextrans  
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These experiments showed that FITC-dextrans larger that 42KDa were 
excluded from the nuclei of MGH-U1 (sensitive) and MGH-U1R (MDR) cells.  
FITC-dextrans smaller than 19.5KDa gained entry to the nuclei of MGH-U1 
(sensitive) and MGH-U1R (MDR) cells. There were no changes in the 
distribution of the FITC-dextrans over time, suggesting that the FITC-dextrans  
enter the nucleus by passive diffusion through nuclear membrane pores and 
not by active transport, otherwise we would have expected increases in 
nuclear uptake with time (Figures 41 and 42).     
We assessed the ability of wheat germ agglutinin (WGA) to reduce the 
functional diameter of nuclear pores by first pre-incubating cells with WGA for 
24 hrs followed by scrape loading with the 19.5KDa FITC-dextran.  We 
reviewed the cells 24 hours later (Figures 43a and b). 
 
       
       
       
 
 
 
 
 
 
 
 
 
This study showed that WGA did not preclude entry of a 19.5KDa FITC-
dextran into the nuclei of MGH-U1 (sensitive) or MGH-U1R (MDR) cells.   
This does not mean that the functional diameter of the nuclear pores is not 
reduced by WGA, just that our experiment was too insensitive to detect a 
change in the functional diameter.  This experiment suggests that if epirubicin 
is permitted entry to the nucleus by passive diffusion, WGA should not affect  
this process, as epirubicin is only 0.58KDa in size. 
 
Figure 43a: MGH-U1 cells incubated with WGA  
and then scrape-loaded with 19.5KDa FITC-
dextran; FITC fluorescence only   
Figure 43b: MGH-U1R cells incubated with WGA  
and then scrape-loaded with 19.5KDa FITC-
dextran; FITC fluorescence only     185
The effects of WGA pre-incubation on nuclear uptake of epirubicin 
Whole cells:  
The results of incubating MGH-U1 and MGH-U1R cells with epirubicin with or 
without pre-incubation with WGA, on the phenotypic uptake of epirubicin are  
shown below (Figure 44a – d).    
  
 
  
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No change in the cellular distribution of epirubicin after exposure to WGA was 
demonstrated.  Sensitive cells maintained their sensitive nuclear uptake 
pattern and resistant cells exhibited their characteristic nuclear sparing of 
epirubicin uptake.  These results were confirmed on multiple occasions.  
Figure 44a: MGH-U1 cells incubated with epirubicin 
alone.  Epirubicin fluorescence overlaid on DIC 
image (Gain 800)  
Figure 44b: MGH-U1 cells pre-incubated with WGA 
and then incubated with epirubicin.  Epirubicin 
fluorescence overlaid on DIC image (Gain 800).  
Figure 44c: MGH-U1R cells incubated with 
epirubicin alone.  Epirubicin fluorescence overlaid 
on DIC image (Gain 1050)  
Figure 44d: MGH-U1R cells pre-incubated with 
WGA and then incubated with epirubicin.  
Epirubicin fluorescence overlaid on DIC image 
(Gain 1050)   186
Analysis was undertaken using a region of interest (ROI) function on the 
confocal microscope.  Gain settings for all analysis images were set at 1050.  
As we were primarily interested in the nuclear uptake of epirubicin, nuclear 
fluorescence was analysed in 20 cells from each sample.  To avoid any bias 
between samples, all nuclei were drawn around using the DIC image with no 
fluorescence. The fluorescence image was then reinstated and analysis 
undertaken.  Data from this experiment are displayed below (Table 17).  
Confocal microscopy is only a semi-quantitative means of measuring 
fluorescence and given the small differences between samples, these are not 
significant.  Flow cytometric experiments were performed to accurately 
analyse differences in cellular drug uptake attributable to WGA. 
 
Experiment 
 
n = 20 
Total Area
µm
2 
Mean 
Fluorescence 
(SD) 
Maximum 
Frequency / 
Intensity 
Range of 
Fluorescence 
MGH-U1 + 
Epirubicin 
alone 
4778.6  249 (25)  20733 at 
255 (Max) 
9 – 255 
MGH-U1 + 
WGA + 
Epirubicin  
4658.6  248 (27)  20214 at 
255 (Max) 
8 – 255 
MGH-U1R + 
Epirubicin 
alone 
4003.2  41 (32)  790 at 126  43 - 255 
MGH-U1R + 
WGA +  
Epirubicin 
4016.6  46 (35)  628 at 140  22 – 255 
 
Table 17:    Confocal microscopy ROI data for nuclear epirubicin uptake 
      cells pre-incubated with WGA 
 
 
Nuclei 
Results for MGH-U1 and MGH-U1R nuclear preparations pre-exposed to 
WGA are shown below. Nuclei that were exposed to epirubicin for 2 hours 
prior to nuclear fraction preparation are shown first (Figures 45a – d).   
The figures following these show the results of epirubicin uptake post-nuclear 
fractionation in control cells and cells that were pre-exposed to WGA (Figures 
46a – d).  
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Figure 45a:  MGH-U1 nuclei exposed to epirubicin 
for 2 hours before nuclear preparation. 
Fluorescence only image. Zoom x6. Gain 825. 
Figure 45c:  MGH-U1R nuclei exposed to epirubicin 
for 2 hours before nuclear preparation. 
Fluorescence only image. Zoom x6. Gain 1000. 
Figure 45d:  MGH-U1R nuclei exposed to WGA 
and then epirubicin for 2 hours before nuclear 
preparation. Fluorescence only image. Zoom x6. 
Gain 1000. 
Figure 45b:  MGH-U1 nuclei exposed to WGA and 
then epirubicin for 2 hours before nuclear 
preparation. Fluorescence only image. Zoom x9. 
Gain 825. 
Figure 46a:  MGH-U1 nuclei exposed to epirubicin 
for 10 minutes after nuclear preparation. 
Fluorescence only image. Zoom x6. Gain 735. 
Figure 46b:  MGH-U1 nuclei exposed to WGA and 
then to epirubicin for 10 minutes after nuclear 
preparation. Fluorescence only image. Zoom x6. 
Gain 735.   188
 
 
 
   
        
 
 
 
 
 
 
 
Analysis of nuclear fluorescence by confocal microscopy was impossible due 
to the clustering and random orientation of nuclei.  Generally though, WGA 
did not seem to exert any effect on the nuclear accumulation of epirubicin in 
sensitive or MDR cells.   
Flow cytometric analysis was later used to assess the impact of WGA on 
nuclear epirubicin fluorescence more accurately.    
 
Cell fusion experiments using polyethylene glycol (PEG): 
Fusion of cells offered a simple way to try and establish that the nuclear 
membrane plays a role in the MDR nuclear sparing phenotype.   
Demonstration of a mixed cell fusion with a phenotypically sensitive nucleus 
and a phenotypically resistant nucleus in the same cell environment, would 
have provided clear evidence that the nuclear membrane is involved in this 
phenomenon.    
The results of our non-mixed cell culture fusions showed that when sensitive 
cells fused together their normal pattern of epirubicin uptake was preserved 
with characteristic nuclear staining of both nuclei (Figure 47a).  Resistant cell 
fusions also showed preservation of their characteristic pattern of epirubicin 
uptake with nuclear sparing in both nuclei (Figure 47b).  Both cell fusion types 
were viable demonstrating strong green FDA fluorescence (Figures 47a – b).    
 
Figure 46c:  MGH-U1R nuclei exposed to epirubicin 
for 10 minutes after nuclear preparation. 
Fluorescence only image. Zoom x6. Gain 825. 
Figure 46d:  MGH-U1R nuclei exposed to WGA 
and then to epirubicin for 10 minutes after nuclear 
preparation. Fluorescence only image. Zoom x7. 
Gain 825.   189
 
 
 
 
 
 
 
 
 
 
Not infrequently, multinucleate cell fusion products are seen, all of which 
maintain their characteristic nuclear phenotype (Figures 47c – f). 
In mixed cell cultures we did not demonstrate any mixed cell fusions.  Again 
we saw multiple cell fusions with phenotypically similar nuclei from bi-nucleate 
to multi-nucleate cells (Figures 47g – j).  Again all fusion products appeared 
viable on staining with FDA.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 47d: Unmixed cell culture fusions: Resistant 
tri-nucleate cell fusion: Top Left: FDA fluorescence 
(Green); Top Right: DIC Image; Bottom Left: 
Epirubicin fluorescence (Red); Bottom Right: 
Overlay image 
Figure 47c: Unmixed cell culture fusions: Sensitive 
tri-nucleate cell fusion: Top Left: FDA fluorescence 
(Green); Top Right: DIC Image; Bottom Left: 
Epirubicin fluorescence (Red); Bottom Right: 
Overlay image 
Figure 47a: Unmixed cell culture fusions: Sensitive-
Sensitive cell fusion: Top Left: FDA fluorescence 
(Green); Top Right: Epirubicin fluorescence (Red); 
Bottom Left: DIC Image; Bottom Right: Overlay image 
Figure 47b: Unmixed cell culture fusions: Resistant-
Resistant cell fusion: Top Left: FDA fluorescence 
(Green); Top Right: DIC Image; Bottom Left: Epirubicin 
fluorescence (Red); Bottom Right: Overlay image   190
 
 
 
 
 
 
 
 
 
 
Despite numerous attempts we were unable to demonstrate a mixed cell 
fusion.  There are several potential explanations for this, it could be that we 
have failed to fuse a sensitive and resistant cell, or it is possible that by fusing 
the different cell types together one of the nuclei changes to the opposite 
phenotype, either the resistant nucleus becoming sensitive or vice versa.  
This would indicate that either there is some cytoplasmic-nuclear membrane 
interaction at play or that by fusing cells together the resultant alteration of the 
level of P-glycoprotein on the plasma membrane, results in a change of 
nuclear phenotype.   
It is the author’s impression that resistant-resistant fusions were much less 
common than sensitive-sensitive fusions.  A simple counting technique may 
have formed a stronger basis for this statement.  If true, this would suggest 
that the resistant nucleus changes to a sensitive phenotype.  This would 
suggest dilution in plasma membrane P-glycoprotein resulting in higher 
intracellular levels of epirubicin with increased nuclear uptake or that some 
cytoplasmic factor from the sensitive cell allows epirubicin to gain nuclear 
entry.  
As we could not exclude the presence of mixed cell fusion based on nuclear 
uptake characteristics with certainty, we looked for another method of 
demonstrating mixed cell fusions.  
Figure 47e: Unmixed cell culture fusions: Sensitive 
multi-nucleate cell fusion: Top Left: FDA 
fluorescence (Green); Top Right: DIC Image; 
Bottom Left: Epirubicin fluorescence (Red); Bottom 
Right: Overlay image 
Figure 47f: Unmixed cell culture fusions: Resistant 
multi-nucleate cell fusion: Top Left: FDA 
fluorescence (Green); Top Right: DIC Image; 
Bottom Left: Epirubicin fluorescence (Red); Bottom 
Right: Overlay image   191
This method involved pre-incubating either MGH-U1 or MGH-U1R cells with 
FITC-WGA prior to cell fusion to stain the nuclei with FITC fluorescence, 
making the sensitive and resistant nuclei distinguishable from one another.   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Only a couple of possible mixed fusions resulted from these experiments. 
Figures 47k – m show a possible mixed cell fusion with FITC staining of the 
sensitive nucleus and a non-FITC staining resistant nucleus.  The epirubicin 
uptake characteristics of both nuclei are of sensitive phenotype, suggesting 
that the resistant nucleus has changed to a sensitive phenotype as a result of 
cell fusion.  We performed several 3D reconstructions of this cell fusion to be 
Figure 47g: Mixed cell culture fusions: Sensitive-
Sensitive cell fusion: Top Left: FDA fluorescence 
(Green); Top Right: DIC Image; Bottom Left: 
Epirubicin fluorescence (Red); Bottom Right: 
Overlay image 
Figure 47h: Mixed cell culture fusions: Resistant-
Resistant cell fusion: Top Left: FDA fluorescence 
(Green); Top Right: DIC Image; Bottom Left: 
Epirubicin fluorescence (Red); Bottom Right: 
Overlay image 
Figure 47i: Mixed cell culture fusions: Sensitive tri-
nucleate cell fusion: Epirubicin fluorescence (Red) 
overlaid on DIC image. 
Figure 47j: Mixed cell culture fusions: Resistant tri-
nucleate cell fusion: Epirubicin fluorescence (Red) 
overlaid on DIC image.   192
certain that the cells had fused.  However, viability staining with FDA showed 
that this cell fusion was non-viable meaning that the nuclear epirubicin uptake 
could just be as a result of cell death and not cell fusion as originally thought 
(Figure 47n).  
The second of our possible mixed cell fusions is shown in figure 47o.  In this 
experiment the resistant nuclei were stained with FITC-WGA.  There is a 
resistant-resistant cell fusion on the right side of this picture, with both nuclei 
demonstrating FITC-WGA staining and very low levels of epirubicin 
fluorescence.  The fusion on the left side shows FITC-WGA staining of one or 
both nuclei and yet both nuclei are of sensitive phenotype.  Of note there is 
also another cell demonstrating FITC-WGA staining with a sensitive epirubicin 
uptake phenotype.  This may suggest that this cell fusion and cell are in fact 
non-viable and that is why their nuclear uptake characteristics have changed.  
We did not perform FDA analysis of cell viability on this sample so cannot be 
sure.   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 47k: Mixed cell culture fusions: MGH-
U1cells pre-incubated with FITC-WGA.  Appears to 
show a FITC-WGA stained sensitive nucleus and a 
non-FITC stained resistant nucleus 
Figure 47l: 3D reconstruction of mixed cell fusion 
shown in figure Xc.  Fluorescence only image.    193
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Metaphase arrest experiments  
During metaphase the nuclear membrane is absent and the cell’s 
chromosomes are free within the cytoplasm.  We incubated metaphase 
arrested cells with epirubicin, based on the rationale that if the chromosomes 
stained with epirubicin in both sensitive and resistant cells this would implicate 
the nuclear membrane in the nuclear sparing of epirubicin uptake in MDR 
cells.  Idarubicin experiments were performed in order to characterise the 
effects of metaphase on chromosomal staining with idarubicin, to see it the 
lack of a nuclear membrane had any effect on DNA staining.   
Epirubicin 
Sensitive cells showed strong chromosomal staining with epirubicin during 
metaphase.  FDA staining proved that these cells were viable (Figure 48a).   
There appeared to be very few resistant metaphase cells showing 
chromosomal epirubicin staining.  Furthermore on FDA staining, these  
Figure 47m: Lateral view of 3D reconstruction of 
mixed cell fusion shown in figure 19l.  
Fluorescence only image.  
Figure 47n: Mixed cell fusion from figure 19 k – m  
showing no FDA fluorescence suggesting the cell 
fusion is not viable.  Some FITC- WGA 
fluorescence is seen.    
Figure 47o: Mixed culture cell fusion: Right side of 
picture: resistant- resistant cell fusion with FITC- 
fluorescence and minimal nuclear epirubicin 
fluorescence; Left side of picture cell fusion of 
uncertain origin.     194
resistant cells showing chromosome staining were clearly non-viable (Figure 
48b).   
 
 
 
 
 
 
 
 
 
 
Because there was such a large discrepancy between the numbers of 
sensitive and resistant metaphase cells seen with epirubicin chromosome 
staining, we tried staining chromosomes with acridine orange.  This showed 
that there were in fact a large number of resistant cells in metaphase, but that 
their chromosomes had not stained with epirubicin. 
 
On imaging at higher digital magnification, there appeared to be filling defects 
in the cellular uptake of epirubicin at lower doses (Figures 48c and e).  These 
were shown to correspond to chromosomes that had not stained with 
epirubicin, by the subsequent addition of acridine orange, which clearly 
stained the chromosomes green (Figures 48d and f).  Cells in metaphase 
were generally rounded up and detached from the Petri dish making them 
quite mobile, so there was some cell movement following addition of the 
acridine orange. 
 
Figure 48a: MGH-U1 Metaphase cell: Top Left: 
FDA fluorescence (Green); Top Right: Epirubicin 
fluorescence (Red); Bottom Left: DIC Image; 
Bottom Right: Overlay image 
Figure 48b: MGH-U1R Metaphase cell: Top Left: 
FDA fluorescence (Green); Top Right: DIC Image; 
Bottom Left: Epirubicin fluorescence (Red); Bottom 
Right: Overlay image   195
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        
Incubation with epirubicin at higher doses causes some low level 
chromosomal staining in viable MGH-U1R cells (Figure 48g).  These central 
structures were again confirmed to be chromosomes by the addition of 
acridine orange (Figure 48h).  These results suggest that perhaps a 
combination of lower levels of intracellular epirubicin and the nuclear 
membrane both play some role in the exclusion of epirubicin from MDR 
nuclei.  
        
Figure 48c:  MGH-U1R cells showing filling defects 
in cytoplasmic epirubicin fluorescence.  Epirubicin 
fluorescence combined with DIC image. 
Figure 48d:  MGH-U1R cell from figure 48c with 
acridine orange staining of chromosomes 
corresponding to filling defects in cytoplasmic 
epirubicin fluorescence.  Acridine orange 
fluorescence combined with DIC image.  
Figure 48e:  MGH-U1R cells from figure 48c and d 
showing filling defects in cytoplasmic epirubicin 
fluorescence.  Epirubicin fluorescence only. 
Figure 48f:  MGH-U1R cell from figures 48c – e   
with acridine orange staining of chromosomes 
corresponding to filling defects in cytoplasmic 
epirubicin fluorescence.  Acridine orange 
fluorescence only.    196
 
 
 
 
 
 
 
 
 
 
 
 
Idarubicin 
Idarubicin failed to stain the chromosomes of any metaphase cells, sensitive 
or resistant, despite gaining reasonable levels of cellular fluorescence.  
Instead numerous rounded up cells with no distinct nuclei, had odd centrally 
situated filling defects.  When stained with propidium iodide after cell killing 
these filling defects were shown to be chromosomes (Figures 49a – f).   
These experiments showed that despite the absence of a nuclear membrane 
in metaphase cells there was no chromosomal staining with idarubicin.  We 
used higher doses of idarubicin in some of these experiments, but the 
samples were relatively acellular with no cells in metaphase.  This presumably 
related to cell killing at higher idarubicin levels with cells becoming non-
adherent and being lost during sample preparation.  We are unable to 
comment on whether chromosomes would have stained at higher drug levels, 
although this seems unlikely given the high cytoplasmic drug levels in the 
lower dose samples.  
 
 
 
 
 
 
Figure 48g: MGH-U1R Metaphase cell: Top Left: 
FDA fluorescence (Green); Top Right: DIC Image; 
Bottom Left: Epirubicin fluorescence (Red); Bottom 
Right: Overlay image. 
Figure 48h: MGH-U1R Metaphase cell (same cell 
as 48g): Top Left: Acridine orange fluorescence 
(Green); Top Right: DIC Image; Bottom Left: 
Acridine Orange fluorescence (Red); Bottom Right:   197
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
Figure 49a: MGH-U1 metaphase arrested cells 
incubated with idarubicin.  Fluorescence only images 
showing negative chromosome staining.
Figure 49c: Same metaphase cell as in 49b, killed 
with glutaraldehyde and stained with propidium 
iodide showing chromosomal staining in place of 
negative idarubicin staining (cell shrank with cell 
killing). 
Figure 49b: MGH-U1 metaphase arrested cell 
incubated with idarubicin.  Fluorescence only images 
showing negative chromosome staining. 
Figure 49d: MGH-U1R metaphase arrested cell 
stained with Idarubicin. Fluorescence only image 
showing negative chromosome staining 
Figure 49e: MGH-U1R metaphase arrested cell 
stained with Idarubicin. Fluorescence only image 
showing negative chromosome staining 
Figure 49f: MGH-U1R metaphase arrested cell 
stained initially with idarubicin – then killed and 
chromosomes stained with propidium iodide.  
Fluorescence only image showing cells staining 
negatively with idarubicin are in metaphase.     198
Confocal time series experiments 
Confocal time series experiments were performed using drug-sensitive MGH-
U1 and RT112 cell lines and multidrug resistant (MDR) variants, MGH-U1R 
and MGHU-MMC.  The time series results for each of the cell lines are shown 
in Figures 50a – d.   
These graphs show nuclear and cytoplasmic epirubicin uptake over time i.e. 
the rate of epirubicin uptake in these cellular compartments, with and without 
verapamil.   
We used the same confocal gain and laser settings for all experiments and 
the same fluorescence scale for all experiment graphs, allowing us to directly 
compare the differences in rates and levels of drug uptake between the cell 
lines.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 50a:    MGH-U1 confocal time series showing nuclear and  
      cytoplasmic epirubicin uptake with and without verapamil  
      (with 95% confidence intervals) 
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Figure 50b:    RT112 confocal time series showing nuclear and cytoplasmic 
      epirubicin uptake with and without verapamil (with 95%  
     confidence  intervals) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 50c:    MGH-U1R confocal time series showing nuclear and  
      cytoplasmic epirubicin uptake with and without verapamil  
      (with 95% confidence intervals) 
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Figure 50d:    MGHU-MMC confocal time series showing nuclear and  
      cytoplasmic epirubicin uptake with and without verapamil  
      (with 95% confidence intervals) 
 
Confocal time series analysis showed that in MGH-U1R and MGHU-MMC 
cells incubated with epirubicin alone, nuclear uptake only reached 48% and 
42.6% respectively, of sensitive MGH-U1 levels at 2 hours.  Verapamil 
increased the rate and 2-hour accumulation levels of epirubicin to 104.8% in 
MGH-U1R nuclei and 96.4% in MGHU-MMC nuclei when compared to  
MGH-U1 incubated with epirubicin alone.   
Comparison of nuclear epirubicin uptake curves for the MDR cell lines 
incubated with epirubicin and verapamil to the sensitive cell lines incubated 
with epirubicin alone are shown in figure 50e.  This clearly demonstrates that 
verapamil changes the uptake characteristics back to a sensitive phenotype 
with very similar final nuclear drug levels, although the sensitive cells had a 
faster initial drug uptake.  The RT112 cell line appeared much more sensitive 
in terms of drug uptake than the parental MGH-U1 cell line.  
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Figure 50e:  Comparison of nuclear epirubicin uptake in sensitive cells  
      incubated with epirubicin alone and MDR cells incubated  
      with epirubicin and verapamil (95% confidence intervals  
     for  clarity).   
 
However, comparison of cytoplasmic uptake curves shows that there is very 
little difference in epirubicin uptake between the MGH-U1, MGH-U1R and 
MGHU-MMC cell lines incubated with epirubicin alone.  The cytoplasmic 
uptake of RT112 cells is much greater in comparison and fits with their higher 
overall drug uptake levels (Figure 50f).  
The addition of verapamil appears to slow initial drug uptake levels in all cell 
lines.  In the RT112 it appears to reduce the nuclear and cytoplasmic uptake 
significantly.  The MGH-U1 cells ultimately have higher cytoplasmic levels 
than when incubated with epirubicin alone.  MDR cell lines have slower initial 
cytoplasmic drug uptake, but their final concentration is very similar when 
comparing epirubicin alone to epirubicin and verapamil (Figure 50g).      
The nuclear uptake of epirubicin in combination with verapamil continues to 
rise throughout the incubation period in all cell lines.  This suggests that 
epirubicin uptake levels may increase with exposure times longer than 2 
hours.  It takes about 80 minutes for nuclear drug levels in the MDR cell lines 
to reach that of MGH-U1 cells incubated with epirubicin alone.   
Nuclear fluorescence in sensitive cell lines incubated 
with epirubicin alone with MDR cell lines incubated 
with epirubicin and verapamil 
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Figure 50f:    Comparison of cytoplasmic epirubicin uptake in sensitive and 
      MDR cells incubated with epirubicin alone (95% confidence 
      intervals removed for clarity)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  Figure 50g:    Comparison of cytoplasmic epirubicin uptake in sensitive and 
      MDR cells incubated with epirubicin and verapamil (95%  
      confidence intervals removed for clarity).  
 
Combination therapy with verapamil appears to achieve increased nuclear 
drug uptake from about 40 minutes in both the MGH-U1R and MGHU-MMC 
Cytoplasmic epirubicin uptake when incubated with 
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cells.  In the MGH-U1R cells at 60 minutes, there is a 63% increase in nuclear 
uptake whilst at 2 hours this rises to 119% compared to epirubicin alone.  For 
the MGHU-MMC cell line at 60 minutes, there is a 46% increase in nuclear 
uptake whilst at 2 hours this rises to 126% compared to epirubicin alone.   
This suggests that whilst a 1 hour combination intravesical instillation should 
have benefit over epirubicin alone, combination instillations for longer periods 
up to 2 hours may bring improved benefits in terms of nuclear drug uptake 
and cytotoxicity.  
Cytoplasmic epirubicin uptake in the MGH-U1R and MGHU-MMC cell lines 
reaches a maximum level at 46 minutes and then the curves decline to 2hrs.  
With verapamil, the cytoplasmic uptake in these cells increases to maximum 
at 114 and 110 minutes respectively. These results may be demonstrating p-
glycoprotein mediated drug efflux, which is abolished by the addition of 
verapamil. 
In the absence of verapamil, cytoplasmic drug fluorescence in MDR cells is 
equal to nuclear drug fluorescence.  This suggests that either there is free 
diffusion across the nuclear membrane which equilibrates or that the amount 
of drug entering the nucleus reaches a steady state with an equal amount 
being effluxed from the nucleus.  It is interesting that verapamil only causes a 
minimal increase in cytoplasmic drug levels, but causes a dramatic increase 
in nuclear fluorescence levels, suggesting that it may also have some action 
at the nuclear membrane.   
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Regimen / Cell line  Maximum level of drug 
fluorescence 
(Time reached) 
Level of drug 
fluorescence at 
120 minutes 
Epirubicin alone – Nuclear 
uptake 
 
RT112 
MGH-U1 
MGH-U1R 
MGHU-MMC 
 
 
 
245.6 (120 minutes) 
158.1 (110 minutes) 
75.8  (116 minutes) 
73.8  (50 minutes) 
 
 
 
245.6 
158 
75.8 
67.3 
Epirubicin + Verapamil – 
Nuclear uptake 
 
RT112 
MGH-U1 
MGH-U1R 
MGHU-MMC 
 
 
 
223.7 (116 minutes) 
186.4 (106 minutes) 
165.6 (120 minutes) 
164.7 (110 minutes) 
 
 
 
222.8 
182.9 
165.6 
152.3 
Epirubicin alone – 
Cytoplasmic uptake 
 
RT112 
MGH-U1 
MGH-U1R 
MGHU-MMC 
 
 
 
186.7 (120 minutes) 
78.6  (40 minutes) 
69.4  (46 minutes) 
76.5  (46 minutes) 
 
 
 
186.7 
71.8 
57 
66.7 
Epirubicin + Verapamil – 
Cytoplasmic uptake 
 
RT112 
MGH-U1 
MGH-U1R 
MGHU-MMC 
 
 
 
99.3 (120 minutes) 
99.8 (90 minutes) 
76.2 (114 minutes) 
73.1 (110 minutes) 
 
 
 
99.3 
92.6 
75.1 
65.8 
 
  Table 18:    Comparison of maximum drug fluorescence levels and levels 
      of drug fluorescence at 2 hours in the nuclear and   
      cytoplasmic compartments for each cell line  205
 
 RT112 
EPI ALONE 
MGH-U1 
EPI ALONE 
RT112 
EPI + VER 
MGH-U1 
EPI + VER 
EPI ALONE 
NUCLEAR (%) 
 
MGH-U1R 
  Max 
  2-hour 
 
MGHU-MMC 
  Max 
  2-hour 
 
 
 
 
30.9 
30.9 
 
 
30 
27.4 
 
 
 
 
47.9 
48 
 
 
46.6 
42.6 
 
 
 
 
33.8 
34 
 
 
32.9 
30.2 
 
 
 
 
40.6 
41.4 
 
 
39.5 
32.9 
EPI + VER 
NUCLEAR (%) 
 
MGH-U1R 
  Max 
  2-hour 
 
MGHU-MMC 
  Max 
  2-hour 
 
 
 
 
67.4 
67.4 
 
 
67.1 
62 
 
 
 
 
104.7 
104.8 
 
 
104.2 
96.4 
 
 
 
 
74 
74.3 
 
 
73.6 
68.4 
 
 
 
 
88.8 
90.5 
 
 
88.4 
83.3 
EPI ALONE 
CYTOPLASM 
(%) 
 
MGH-U1R 
  Max 
  2-hour 
 
MGHU-MMC 
  Max 
  2-hour 
 
 
 
 
 
37.2 
30.5 
 
 
41 
35.7 
 
 
 
 
 
88.3 
79.4 
 
 
97.3 
92.9 
 
 
 
 
 
69.9 
57.4 
 
 
77 
67.2 
 
 
 
 
 
69.5 
61.6 
 
 
76.8 
72 
EPI + VER 
CYTOPLASM 
(%) 
 
MGH-U1R 
  Max 
  2-hour 
 
MGHU-MMC 
  Max 
  2-hour 
 
 
 
 
 
40.8 
40.2 
 
 
39.2 
35.2 
 
 
 
 
 
96.9 
104.6 
 
 
93 
91.6 
 
 
 
 
 
76.7 
75.6 
 
 
73.6 
66.2 
 
 
 
 
 
76.3 
81.1 
 
 
73.2 
71.1 
 
Table 19:    Comparison of drug fluorescence levels in MGH-U1R and  
      MGHU–MMC cells expressed as a percentage of RT112 /  
      MGH-U1 drug uptake levels    206
Cellular staining of P-gp using a FITC conjugated Anti-P-gp antibody 
(17F9, BD Biosciences) 
Cellular fluorescence related to FITC labelled anti-P-gp antibody, 17F9 (BD, 
Biosciences) was not readily detectable by confocal means (Figures 51a – g).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 51a:  MGH-U1 cells without FITC Anti-Pgp 
(Control).  FITC fluorescence detection combined 
with DIC image. Zoom x1; Gain 1000.  
Figure 51b:  MGH-U1 cells with FITC Anti-Pgp.   
FITC fluorescence detection combined with DIC 
image. Zoom x1; Gain 1000. 
Figure 51c:  RT112 cells without FITC Anti-Pgp 
(Control).  FITC fluorescence detection combined 
with DIC image. Zoom x1; Gain 1000. 
Figure 51d:  RT112 cells with FITC Anti-Pgp.   
FITC fluorescence detection combined with DIC 
image. Zoom x1; Gain 1000.   207
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nuclear P-gp staining with a FITC conjugated Anti-P-gp antibody (17F9, 
BD Biosciences) 
Nuclear isolates from MGH-U1 and MGH-U1R cells demonstrated very low 
levels of fluorescence at maximum gain setting, after exposure to a FITC-
labelled anti-P-gp antibody (Figures 52a and b).  Control nuclei (not shown) 
demonstrated similar low levels of green fluorescence at high gain settings.  
Given that we were unable to identify P-gp on the plasma membrane of MGH-
U1R cells by confocal microscopy, it seemed unlikely that this represented 
any true nuclear fluorescence related to the anti-P-gp antibody.      
 
Figure 51e:  MGH-U1R cells without FITC Anti-Pgp 
(Control).  FITC fluorescence detection combined 
with DIC image. Zoom x1; Gain 1000. 
Figure 51f:  MGH-U1R cells with FITC Anti-Pgp.   
FITC fluorescence detection combined with DIC 
image. Zoom x1; Gain 1000. 
Figure 51g:  MGHU-MMC cells without FITC Anti-
Pgp (Control).  FITC fluorescence detection 
combined with DIC image. Zoom x1; Gain 1000. 
Figure 51h:  MGHU-MMC cells with FITC Anti-Pgp.   
FITC fluorescence detection combined with DIC 
image. Zoom x1; Gain 1000.   208
 
 
 
 
 
 
 
 
 
Membrane Leakiness Studies using FITC-dextrans 
This experiment was performed to establish whether nuclear uptake of 
epirubicin in dead cells may be due to leaky membranes.  Dead MGH-U1 and 
MGH-U1R cells showed cytoplasmic and nuclear fluorescence when 
incubated with a 77KDa FITC-dextran, which would not normally gain entry to 
cells through the plasma membrane or to the nucleus through the nuclear 
membrane (Figures 53a and b).   This is highly suggestive that biological 
membranes become leaky after death and may account for the changes in 
epirubicin uptake and localisation observed in dead cells.   
 
 
   
 
 
 
 
 
 
 
 
 
 
Figure 53a: Dead MGH-U1 cells incubated with 
77KDa FITC-dextran.  Fluorescence only image 
showing cytoplasmic and nuclear uptake.  
Figure 53b: Dead MGH-U1R cells incubated with 
77KDa FITC-dextran.  Fluorescence only image 
showing cytoplasmic and nuclear uptake.  
Figure 52a:  MGH-U1 nuclei with FITC Anti-Pgp.   
FITC fluorescence detection only. Zoom x8; Gain 
1250. 
Figure 52b:  MGH-U1R nucleus with FITC Anti-
Pgp.  FITC fluorescence detection only. Zoom x18; 
Gain 1250.   209
Green Fluorescent Protein cell line experiments 
Two Green fluorescent protein (GFP) cell lines had previously been derived 
from MGH-U1 and MGH-U1R cell lines in our research unit.  We assessed the 
purity of frozen cultures and the MDR characteristics of these cells after being 
frozen at -180
oC, using confocal microscopy and later flow cytometry.  We 
also assessed the potential of using GFP as a viability marker.   
GFP cells – epirubicin uptake characteristics 
MGH-U1-GFP and MGH-U1R-GFP cells maintained their usual epirubicin 
uptake characteristics following being frozen, as shown below.  There was 
variability in the number of cells demonstrating GFP fluorescence between 
samples suggesting some frozen batches were purer that others (Figures 54a 
and b).  
    
 
 
 
 
 
 
 
 
 
 
Assessment of GFP as viability marker using time-lapse confocal 
microscopy 
Green-fluorescent protein transfected cells fluoresce green when excited by 
laser light.  It had been previously noted that dead GFP cells lose their 
fluorescence.  We therefore decided to assess whether GFP could be used as 
a marker of cell viability.   
MGH-U1-GFP and MGH-U1R-GFP were imaged after exposure to propidium 
iodide, this confirmed cell viability by the absence of PI from the nuclei of GFP 
Figure 54a:  MGH-U1-GFP cells (x40 Lens; Digital 
Zoom x1). Top Left: Green Fluorescent Protein 
(GFP) fluorescence (Green); Top Right:  Epirubicin 
Fluorescence (Red); Bottom Left:  Differential 
Interference Contrast Image (DIC); Bottom Right: 
Overlay image.
Figure 54b:  MGH-U1R-GFP cells (x40 Lens; 
Digital Zoom x1). Top Left: Green Fluorescent 
Protein (GFP) fluorescence (Green); Top Right:  
Epirubicin Fluorescence (Red); Bottom Left:  
Differential Interference Contrast Image (DIC); 
Bottom Right: Overlay image.   210
expressing cells (Figure 55a, b, d and e).  GFP fluorescence almost 
disappeared by 1 minute after the addition of glutaraldehyde.  Nuclear PI 
fluorescence gradually increased over a few minutes staining most nuclei 
quite strongly by 6 minutes, indicating that cell death had occurred.  
Interestingly in the MGH-U1R-GFP cells, one of the GFP cells and a couple of 
non-GFP expressing cells fail to take up propidium iodide.  This GFP cell does 
lose its GFP fluorescence suggesting that loss of GFP expression may 
precede cell death.  There is also some minor cross-over from the 
fluorescence signal of propidium iodide into the FITC detection range 
meaning that low level FITC fluorescence persists even after the cells are 
dead.   
 
 
 
    
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 55a:  Viable MGH-U1-GFP cells exposed to 
propidium iodide (x40 Lens; Digital Zoom x1). Top 
Left: Green Fluorescent Protein (GFP) fluorescence 
(Green); Top Right:  Propidium Iodide 
Fluorescence (Red); Bottom Left:  Differential 
Interference Contrast Image (DIC); Bottom Right: 
Overlay image.
Figure 55b:  MGH-U1-GFP cells exposed to 
propidium iodide and glutaraldehyde for 6 minutes 
(x40 Lens; Digital Zoom x1). Top Left: Green 
Fluorescent Protein (GFP) fluorescence (Green); 
Top Right:  Propidium Iodide Fluorescence (Red); 
Bottom Left:  Differential Interference Contrast 
Image (DIC); Bottom Right: Overlay image. 
Figure 55c:  MGH-U1-GFP cells exposed to 
propidium iodide and glutaraldehyde for 30 minutes 
(x40 Lens; Digital Zoom x1). Top Left: Green 
Fluorescent Protein (GFP) fluorescence (Green); 
Top Right:  Propidium Iodide Fluorescence (Red); 
Bottom Left:  Differential Interference Contrast 
Image (DIC); Bottom Right: Overlay image.   211
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control time series of GFP fluorescence showed very minimal reduction in 
GFP fluorescence over a 30 minutes period, suggesting that any large 
reduction in GFP fluorescence over time is caused by cell death rather than 
bleaching of this fluophore (Figures 55g and h).   
We conclude that GFP cell fluorescence is dramatically and immediately 
reduced as a result of cell death and could therefore be used as a marker of 
cell viability in vitro.   
   
 
Figure 55d:  Viable MGH-U1R-GFP cells exposed 
to propidium iodide (x40 Lens; Digital Zoom x1). 
Top Left: Green Fluorescent Protein (GFP) 
fluorescence (Green); Top Right:  Propidium Iodide 
Fluorescence (Red); Bottom Left:  Differential 
Interference Contrast Image (DIC); Bottom Right: 
Overlay image.
Figure 55e:  MGH-U1R-GFP cells exposed to 
propidium iodide and glutaraldehyde for 6 minutes 
(x40 Lens; Digital Zoom x1). Top Left: Green 
Fluorescent Protein (GFP) fluorescence (Green); 
Top Right:  Propidium Iodide Fluorescence (Red); 
Bottom Left:  Differential Interference Contrast 
Image (DIC); Bottom Right: Overlay image. 
Figure 55f:  MGH-U1R-GFP cells exposed to 
propidium iodide and glutaraldehyde for 30 minutes 
(x40 Lens; Digital Zoom x1). Top Left: Green 
Fluorescent Protein (GFP) fluorescence (Green); 
Top Right:  Propidium Iodide Fluorescence (Red); 
Bottom Left:  Differential Interference Contrast 
Image (DIC); Bottom Right: Overlay image.   212
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 56:    Time series of MGH-U1-GFP cell fluorescence for live and 
      killed cells over 30 minutes (with 95% confidence intervals) 
 
Figure 55g:  MGH-U1-GFP cells at 0 minutes 
(x40 Lens; Digital Zoom x1). Green Fluorescent 
Protein (GFP) fluorescence only. 
Figure 55h:  MGH-U1-GFP cells at 30 minutes  
 (x40 Lens; Digital Zoom x1). Green Fluorescent 
Protein (GFP) fluorescence only.  
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3.2:  Flow cytometry experiments 
Flow cytometric experiments were performed using a BD FACScaliber flow 
cytometer.  Early experiments were analysed using WinMDI version 2.8, 
which generated values for geomean and median fluorescence and 
coefficients of variation (CV) for each sample.  Later experiments were 
analysed using the BD FACScaliber software package generating values for 
geomean and median fluorescence and standard deviations, from which we 
were able to calculate 95% confidence intervals.   
Cellular epirubicin dose response 
Flow cytometric dose responses for epirubicin in MGH-U1 and MGH-U1R 
cells are shown in Figures 57 and 58.  Statistics generated for each sample 
are shown in table 20 and 21.   
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 57:    MHG-U1: Flow cytometric epirubicin dose response 
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Epirubicin 
Concentration 
Geomean 
Fluorescence  
Median 
Fluorescence 
CV 
Control 2.43  2.15  76.35 
1.25 26.21 29.69  34.07 
2.5 49.88  53.76  28.02 
5 82.38  87.38  23.9 
10 155.68  184.34  22.11 
20 293.64  365.17  21.69 
40 399.41  562.34  20.79 
80 554.48  763.51  19.13 
 
  Table 20:   MGH-U1 cells: Flow cytometric epirubicin dose response  
      statistics:  Geomean and median fluorescence and coefficient 
      of variation (CV) 
 
 
 
Figure 58:    MHG-U1R cells: Flow cytometric epirubicin dose response 
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Epirubicin 
Concentration 
Geomean 
Fluorescence 
Median 
Fluorescence 
CV 
Control 2.54  2.25  70.11 
1.25 5.74    4.61  54.99 
2.5 7.41  6.92 42.25 
5 7.90  7.04  36.08 
10 17.77  17.00  27.54 
20 21.39  20.17  29.27 
40 21.33  19.11  22.59 
80 36.33  33.68  20.81 
 
Table 21:   MGH-U1R cells: Flow cytometric epirubicin dose response 
      statistics:  Geomean and median fluorescence and coefficient 
      of variation (CV) 
 
Both cell lines demonstrated a clear dose response in epirubicin uptake, but 
this was much less pronounced in the MGH-U1R cells.  At the highest dose of 
epirubicin exposure, cellular uptake in MGH-U1 cells was over 15 times 
greater than in the MGH-U1R cells.   
 
Cellular idarubicin dose response 
Flow cytometric idarubicin dose responses for MGH-U1 and MGH-U1R cells 
are shown in figures 59 and 60.  Statistics generated for these samples are 
shown in tables 22 and 23.   
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Figure 59:   MGH-U1: Flow cytometric idarubicin dose response  
 
Idarubicin 
Concentration 
Geomean 
Fluorescence 
Median 
Fluorescence 
CV 
Control 2.22  2.0  76.28 
1.25 150.19  218.7 24.86 
2.5 166  310.59  27.82 
5 299.34  547.37  29.69 
10 694.56  1321.58  23.41 
20 695.70  1000  18.47 
40 92.96 94.75  27.56 
80 54.21 37.36  69.78 
  
Table 22:   MGH-U1: Flow cytometric idarubicin dose response statistics:  
      Geomean and median fluorescence and coefficient of  
     variation  (CV) 
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Figure 60:   MGH-U1R cells: Flow cytometric idarubicin dose response 
 
Idarubicin 
Concentration 
Geomean 
Fluorescence 
Median 
Fluorescence 
CV 
Control 2.21  2.15  61.13 
1.25 32.69  38.54 23.43 
2.5 57.94  65.52  21.47 
5 89.2 104.6  23.66 
10 198.37  257.13  21.6 
20 298.51  381.97  20.1 
40 72.66 78.44  25.86 
80 90.56 99.1 19.32 
 
Table 23:   MGH-U1R cells: Flow cytometric idarubicin dose response 
      statistics:  Geomean and median fluorescence and coefficient 
      of variation (CV) 
 
Fluorescence Intensity (Logarithmic scale) 
80 
40 
20 
10 
5 
2.5 
1.25 
Control
Idarubicin Concentration 
µg/ml 
10
4
10
3 10
2
10
1 
N
u
m
b
e
r
 
o
f
 
E
v
e
n
t
s
   218
Both cell lines demonstrated a clear dose response in idarubicin uptake up to 
20µg/ml.  At higher doses of idarubicin the samples were relatively acellular 
and demonstrated reduced levels of drug fluorescence.  This is probably as a 
result of cell death in the higher concentration samples, meaning that cells 
taking up the most drug in these samples died and were lost during sample 
preparation.  Hence the cells left behind were those with lower levels of drug 
uptake and fluorescence.  At the lowest concentration of idarubicin 
(1.25µg/ml), sensitive cells demonstrated over 5 times more intracellular drug 
fluorescence than the resistant cells.  At 20µg/ml, this gap in fluorescence is 
reduced, but the MGH-U1 cells still exhibit 2.33 times more fluorescence than 
the MGH-U1R cells.   
Effects of WGA pre-incubation on cellular epirubicin dose response 
The effects of WGA on cellular epirubicin uptake in MGH-U1 and MGH-U1R 
cells were examined using flow cytometry.  The dose response histograms 
are shown in Figures 61 – 64 and the statistics generated for these samples 
are shown in tables 24 and 25.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 61:   MGH-U1 cells: Flow cytometric epirubicin alone dose  
     response 
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  Figure 62:   MGH-U1 cells: Flow cytometric epirubicin + WGA dose  
     response 
 
  MGH-U1 cells – No WGA 
 
MGH-U1 cells – with WGA 
Epirubicin 
Concentration 
Geomean Median CV  Geomean Median CV 
Control 1.73 
 
1.61 89.34  1.65 
 
1.53 91.64 
1.25 17.63 
 
17.78 14.17  16.33  16.4  13.54 
2.5 33.87 
 
34.6 13.05  33.61 
 
34.91 10.98 
5 66.91 
 
66.71 10.17  66.41 
 
66.71 8.96 
10 128.34 
 
128.64 9.09  117.59 
 
117.57 8.34 
20 200.67 
 
210.97 9.10  214.94 
 
220.67 7.23 
40 297.43 
 
310.59 8.74  311.14 
 
319.08 7.18 
80 363.52 
 
365.17 7.12  358.66 
 
349.8 6.53 
 
Table 24:   MGH-U1 cells: Flow cytometric epirubicin dose response  
      statistics with and without WGA:  Geomean and median  
      fluorescence and coefficient of variation (CV) 
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Figure 63: MGH-U1R cells: Flow cytometric epirubicin alone dose response 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 64: MGH-U1R cells: Flow cytometric epirubicin + WGA dose response 
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  MGH-U1R cells – No WGA 
 
MGH-U1R cells – with WGA 
 
Epirubicin 
Concentration 
Geomean Median CV Geomean Median  CV 
Control 1.64 
 
1.53 86.45  1.49 
 
1.33 105.86 
1.25 2.54 
 
2.5 54.29  2.04 
 
1.98 66.69 
2.5 4.4 
 
4.29 43.29  2.57 
 
2.5 54.39 
5 3.97  3.89  43.14  3.02 
 
2.97 48.59 
10 5.06 
 
4.96 37.73  3.9 
 
3.72 43.01 
20 6.65 
 
6.55 32.13  4.91 
 
4.83 35.05 
40 11.26 
 
10.75 31.45  7.26 
 
7.3 28.25 
80 13.87 
 
13.34 27.08  11.22 
 
10.94 25.56 
 
Table 25:   MGH-U1R cells: Flow cytometric epirubicin dose response 
      statistics with and without WGA:  Geomean and median  
      fluorescence   and coefficient of variation (CV) 
 
A clear dose response in epirubicin uptake was seen in both MGH-U1 and 
MGH-U1R cells with and without prior WGA exposure.  The MGH-U1R cells 
showed much lower levels of epirubicin uptake across all concentrations, with 
the MGH-U1 cells demonstrating over 26 times more epirubicin fluorescence 
at the highest dose of 80µg/ml.   
In addition WGA did not increase the cellular uptake of epirubicin in either 
MGH-U1 or MGH-U1R cells, with epirubicin uptake levels at the highest 
concentrations being slightly lower if anything.     
Effects of WGA pre-incubation on nuclear epirubicin dose response  
The effects of WGA on epirubicin uptake in nuclear isolates from MGH-U1 
and MGH-U1R cells exposed to epirubicin before nuclear fractionation were 
also examined using flow cytometry.  The dose response histograms are 
shown in Figures 65 – 68 and the statistics generated for these samples are 
shown in tables 26 and 27.    
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Figure 65: MGH-U1 nuclei: Flow cytometric epirubicin alone dose response 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 66: MGH-U1 nuclei: Flow cytometric epirubicin + WGA dose response 
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MGH-U1 nuclei – No WGA  MGH-U1 nuclei – with WGA 
Epirubicin 
Concentration 
Geomean
 
Median CV Geomean  Median  CV 
Control 1.26  1.0  262.34  3.28 
 
2.97 48.72 
1.25 
 
11.08 11.04  19.57  5.52  5.62  33.2 
2.5 13.59 
 
12.52 21.69 8.63 
 
7.77 22.63 
5 18.2 
 
17.0 16.83  21.16 
 
20.35 19.41 
10 30.78 
 
28.39 15.2  30.68 
 
27.88 15.12 
20 60.93 
 
60.43 11.45 57.61  55.73 10.37 
40 115.78 
 
117.57 12.11  112.8 
 
108.43 12.65 
80 
 
167.84 159.63  13.27  139.91 142.02  13.81 
 
Table 26:   MGH-U1 nuclei:  Flow cytometric epirubicin dose response 
      statistics with and without WGA: Geomean and median  
      fluorescence and coefficient of variation (CV) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 67: MGH-U1R nuclei: Flow cytometric epirubicin alone dose response 
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Figure 68: MGH-U1 nuclei: Flow cytometric epirubicin + WGA dose response  
 
  MGH-U1R nuclei – No 
WGA 
 
MGH-U1R nuclei – with 
WGA 
 
Epirubicin 
Concentration 
Geomean Median CV Geomean  Median  CV 
Control 1.29  1.0  195.31 1.36 
 
1.06 151.52 
1.25 2.63 
 
2.46 60.86  2.72 
 
2.57 56.98 
2.5 4.36  4.29  39.76  3.57 
 
3.49 44.12 
5 4.65  4.66  36.86  4.85 
 
4.87 36.29 
10 4.3 
 
3.92 38.28  4.11  3.65 46.93 
20 9.07  8.91  23.71  8.48 
 
8.51 23.08 
40 
 
15.4  13.95 20.5  13.91  13.10 20.87 
80 
 
31.37 28.9  14.13  28.31 27.63  14.02 
 
Table 27:   MGH-U1R nuclei:  Flow cytometric epirubicin dose response 
      statistics with and without WGA:  Geomean and median  
      fluorescence   and coefficient of variation (CV) 
Fluorescence Intensity (Logarithmic scale) 
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Again the nuclear isolates demonstrated a clear dose response in epirubicin 
uptake, which was more pronounced in the MGH-U1 cells.  Without WGA 
MGH-U1 nuclei demonstrated more than 5 times more epirubicin fluorescence 
that the MGH-U1R cells.  WGA did not affect nuclear epirubicin uptake levels 
across the range of epirubicin concentrations.   
Mitomycin C dose response 
We looked for evidence of mitomycin C fluorescence across a range of 
excitation and emission wavelengths.  We excited the cells with 488 and 
633nm laser excitation and tried to detect fluorescence with all detectors (FL-
1, FL-2 and FL-3).  The results are shown below in tables 28 and 29.   
 
Mitomycin C 
Concentration 
µg/ml  
FL-1 
Geomean 
 
FL-2  
Geomean 
 
FL-3 
Geomean 
Control 1.57  3.68 
 
2.57 
 
125 1.43 
 
3.26 
 
2.28 
 
250 1.38 
 
3.15 
 
2.17 
 
500 1.50 
 
3.72 
 
2.6 
 
1000 1.97 
 
5.34 
 
3.64 
 
 
Table 28:  MGH-U1 cells:  Mitomycin C fluorescence dose response 
 
Mitomycin C 
Concentration 
µg/ml  
FL-1 
Geomean 
FL-2  
Geomean 
 
FL-3 
Geomean 
Control 1.74 
 
4.34 2.99 
125 1.63 
 
4.03 
 
2.74 
 
250 1.56 
 
3.81 
 
2.61 
 
500 1.57 
 
3.79 2.5 
 
1000 2.76 
 
7.99 
 
5.67 
 
 
Table 29:  MGH-U1R cells:  Mitomycin C fluorescence dose response   226
We were unable to detect any mitomycin C fluorescence between 
wavelengths of 505nm to over 650nm, in either the MGH-U1 or MGH-U1R 
cells. 
Assessing Mitomycin C dose response by reduction acridine orange 
fluorescence 
We tried an indirect method to assess the cellular uptake of mitomycin C, by 
looking for a reduction in cellular acridine orange (AO) uptake.  To detect 
acridine orange fluorescence we used an excitation wavelength of 488nm and 
detected fluorescence using the FL-1 detector (515 – 545nm) (Table 30).  
Mitomycin C (MMC) 
concentration 
µg/ml 
MGH-U1 
FL-1 Geomean AO 
Fluorescence 
MGH-U1R 
FL-1 Geomean AO 
Fluorescence 
Control – No MMC and no 
AO 
2.02 
 
1.44 
 
Control – AO only  1192.39 
 
498.63 
 
125 MMC + AO  480.29 
 
828.60 
 
250 MMC + AO  797.17 
 
1483.78 
 
500 MMC + AO  1651.85 
 
1293.19 
 
 
Table 30:    Acridine orange fluorescence dose response to mitomycin C 
      in MGH-U1 and MGH-U1R cells 
 
The cell samples exposed to 1000µg/ml of mitomycin C were not evaluable 
due to low cell numbers, presumably because of cell killing.  There appeared 
to be no inverse dose response in acridine orange fluorescence as a result of 
prior exposure to mitomycin C in either cell type.  It is possible that looking at 
the reduction of AO uptake in isolated nuclei would have been a more 
accurate surrogate marker of mitomycin C uptake, as it is the competition 
between these two agents to bind to DNA that is the basis of this assay.  It 
seems likely that cellular AO contamination may have skewed our results.    
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Effects of verapamil on epirubicin dose response 
MGH-U1 
 
Figure 69:   MGH-U1 cells: Geomean fluorescence values for various  
      combinations of epirubicin with and without verapamil 
 
MGH-U1 Samples 
n = 10,000 
Geomean 
Fluorescence 
Median 
Fluorescence 
95% 
Confidence 
Interval 
Control – No epirubicin and no 
verapamil  2.3 2.29 0.02 
Control – Verapamil only 
  2.38 2.41  0.02 
Epirubicin 1hr 
  53.11 52.8  0.65 
Epirubicin + Verapamil 1hr 
  57 55.73 0.63 
Verapamil 1hr then Epirubicin 
1hr  72.43 66.12  1.10 
Verapamil 1hr then Epirubicin 
and Verapamil 1hr  60.98 58.29  0.75 
Epirubicin 2hrs 
  120.15 61.82  2.02 
Epirubicin and Verapamil 2hrs  103.01  93.9  1.66 
Verapamil 1hr then Epirubicin 
2hrs  108.79 85.82  2.25 
Verapamil 1hr then Epirubicin 
+ Verapamil 2hrs  102.18 96.47  1.34 
Table 31:   MGH-U1 cells: Flow cytometric assessment of epirubicin  
      uptake in combinations with and without verapamil  
MGH-U1 (Sensitive)
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RT112: 
Figure 70:   RT112 cells: Geomean fluorescence values for various  
      combinations of epirubicin with and without verapamil 
 
RT112 Samples 
n = 10,000 
Geomean 
Fluorescence 
Median 
Fluorescence 
95% 
Confidence 
Interval 
Control – No epirubicin and 
no verapamil  2.36 2.25  0.22 
Control – Verapamil only 
  1.98 1.91  0.03 
Epirubicin 1hr 
  61.03 62.08  0.38 
Epirubicin + Verapamil 1hr 
  83.69 87.38  0.63 
Verapamil 1hr then 
Epirubicin 1hr  79.55 86.6  0.64 
Verapamil 1hr then 
Epirubicin and Verapamil 1hr  93.1 97.34  0.68 
Epirubicin 2hrs 
  103.37 104.6  0.75 
Epirubicin and Verapamil 
2hrs 
 
120.92 128.64  0.99 
Verapamil 1hr then 
Epirubicin 2hrs  139.25 159.63  1.36 
Verapamil 1hr then 
Epirubicin + Verapamil 2hrs  155.06 149.89  0.95 
Table 32:   RT112 cells: Flow cytometric assessment of epirubicin  
      uptake in combinations with and without verapamil  
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MGH-U1R 
 
 
 
 
 
 
 
 
 
 
 
Figure 71:   MGH-U1R cells: Geomean fluorescence values for various 
      combinations of epirubicin with and without verapamil 
 
MGH-U1R Samples 
n = 10,000 
Geomean 
Fluorescence 
Median 
Fluorescence 
95% 
Confidence 
Interval 
Control – No epirubicin and 
no verapamil  2.05 2.02  0.03 
Control – Verapamil only 
  1.57 1.49  0.02 
Epirubicin 1hr 
  6.17 5.99  0.12 
Epirubicin + Verapamil 1hr 
  52.35 52.8  0.31 
Verapamil 1hr then 
Epirubicin 1hr  48.47 48.7  0.55 
Verapamil 1hr then 
Epirubicin and Verapamil 1hr  51.28 51.86  0.38 
Epirubicin 2hrs 
  8.12 8.9  0.14 
Epirubicin and Verapamil 
2hrs  86.66 86.6  0.69 
Verapamil 1hr then 
Epirubicin 2hrs  66.06 6.71  0.57 
Verapamil 1hr then 
Epirubicin + Verapamil 2hrs  86.33 86.6  0.66 
Table 33:   MGH-U1R cells: Flow cytometric assessment of epirubicin 
      uptake in combinations with and without verapamil  
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MGHU-MMC 
Figure 72:   MGHU-MMC cells: Geomean fluorescence values for various 
      combinations of epirubicin with and without verapamil 
 
MGHU-MMC Samples 
n = 10,000 
Geomean 
Fluorescence 
Median 
Fluorescence 
95% 
Confidence 
Interval 
Control – No epirubicin and 
no verapamil  2.64 2.5  0.04 
Control – Verapamil only 
  2.65 2.5  0.04 
Epirubicin 1hr 
  8.14 7.7  0.19 
Epirubicin + Verapamil 1hr 
  77.14 77.74  0.51 
Verapamil 1hr then 
Epirubicin 1hr  43.38 45.73  0.41 
Verapamil 1hr then 
Epirubicin and Verapamil 1hr  48.12 49.58  0.36 
Epirubicin 2hrs 
  10.54 9.82  0.21 
Epirubicin and Verapamil 
2hrs  129.09 132.16  0.96 
Verapamil 1hr then 
Epirubicin 2hrs  78.51 77.74  0.59 
Verapamil 1hr then 
Epirubicin + Verapamil 2hrs  69.69 69.78  0.55 
Table 34:   MGHU-MMC cells: Flow cytometric assessment of epirubicin 
      uptake in combinations with and without verapamil  
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Flow studies of MGH-U1 cells showed that drug fluorescence levels at 1 hour 
were similar for cells incubated with epirubicin alone and epirubicin and 
verapamil, these results were consistent with confocal time series results.  
However, for 2 hour exposures fluorescence levels were higher for epirubicin 
alone compared to epirubicin and verapamil, which did not fit with our 
confocal time series results (Figure 50a).     
RT112 cells showed that 1 hour drug fluorescence was higher when 
epirubicin and verapamil were used in combination, which conflicted with the 
results of our confocal studies.  At 2 hours this difference persisted with 
maximum drug uptake being shown in cells pre-incubated with verapamil 
followed by co-incubation with epirubicin and verapamil for 2 hours, again 
contrary to our confocal results (Figure 50b). 
Flow cytometry showed that MGH-U1R cells had a 10.7-fold increase in 
cellular epirubicin fluorescence at 2 hours when co-incubated with epirubicin 
and verapamil compared with epirubicin alone.  Pre-incubation with verapamil 
did not contribute any further increase in drug uptake (Figure 71).    
Epirubicin uptake in MGHU-MMC cells was maximised by co-incubation with 
verapamil for 2 hours, showing a 12-fold increase over epirubicin alone at 2 
hours (Figure 72).   
Verapamil appeared to pre-sensitize MDR cells to epirubicin uptake for both 1 
and 2 hour exposures to epirubicin, but overall for MDR cells co-incubation for 
2 hours appeared to be the most advantageous regimen. 
Interestingly the RT112 cells also showed beneficial effects from combination 
regimens with 1 and 2 hour exposure to epirubicin, whereas in MGH-U1 cells 
there was only a benefit for 1 hour co-incubation regimens but not for 2 hour 
exposures.                                                                                                                              
Overall, our results suggest that optimal reversal of MDR by verapamil, would 
be achieved by a combination of epirubicin and verapamil for a 2 hour 
exposure.       232
Effect of verapamil pre-exposure on epirubicin uptake in isolated nuclei 
Figure 73: Effect of pre-exposure to verapamil on nuclear epirubicin uptake  
Sample   
(n = 10,000) 
Geomean 
Fluorescence 
Median 
Fluorescence 
CV 
MGH-U1 + 
Epirubicin 
 
103.98 99.1  11.63 
MGH-U1 + 
Verapamil + 
Epirubicin 
92.92 87.38 13.29 
MGH-U1R + 
Epirubicin 
 
93.61 89.77  9.98 
MGH-U1R + 
Verapamil + 
Epirubicin 
89.01 81.31 11.16 
 
Table 35: Effect of pre-exposure to verapamil on nuclear epirubicin uptake  
 
Pre-exposure to verapamil did not appear to have any effect on epirubicin 
uptake in isolated nuclei, if anything causing a slight reduction in nuclear 
epirubicin fluorescence.   
Effect of verapamil pre-exposure on epirubicin uptake in 
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Cellular P-gp staining with a FITC conjugated anti-P-gp antibody (17F9, 
BD Biosciences) 
Histograms of green fluorescence (FL-1 detector) are shown for BSA control, 
FITC control and the FITC anti-P-gp antibody samples for each cell type 
(Figures 74 – 77).  The geomean and median fluorescence values for each 
sample are shown in table 36.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Figure 74: MGH-U1 cells FITC fluorescence detection 
for a: BSA control; b: FITC IgG control; c: FITC Anti-
Pgp  
a
b
c
a
b
c
Figure 75: RT112 cells FITC fluorescence detection 
for a: BSA control; b: FITC IgG control; c: FITC Anti-
Pgp    234
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
These results show that MGH-U1R and MGHU-MMC cells demonstrate a 
significant increase in FITC fluorescence when incubated with the FITC Anti-Pgp 
antibody when compared to both the BSA control and the FITC IgG control, 
suggesting that both of these cell lines are positive for P-gp expression.  The 
MGH-U1 and RT112 cell lines both demonstrated reduced levels of FITC  
Anti-P-gp fluorescence when compared to a FITC-IgG control, suggesting that 
they are negative for P-gp expression.   
 
Figure 76: MGH-U1R cells:  FITC fluorescence 
detection for a: BSA control; b: FITC IgG control;  
c: FITC Anti-Pgp  
Figure 77: MGHU-MMC cells: FITC fluorescence 
detection for a: BSA control; b: FITC IgG control;  
c: FITC Anti-Pgp  
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Cell Sample 
(n = 10,000) 
Geomean 
Fluorescence 
Median 
Fluorescence 
CV 
MGH-U1 
BSA Control 
FITC Control 
FITC Anti-Pgp 
 
1.84 
10.66 
2.85 
 
1.75 
10.37 
2.76 
 
74.91 
15.92 
45.66 
RT112 
BSA Control 
FITC Control 
FITC Anti-Pgp 
 
5.74 
16.16 
7.68 
 
6.38 
15.96 
7.91 
 
34.2 
12.03 
21.94 
MGH-U1R 
BSA Control 
FITC Control 
FITC Anti-Pgp 
 
2.32 
9.87 
22.34 
 
2.29 
9.73 
22.47 
 
59.73 
17.51 
19.19 
MGHU-MMC 
BSA Control 
FITC Control 
FITC Anti-Pgp 
 
1.74 
11.68 
19.01 
 
1.68 
11.24 
20.72 
 
75.71 
17.32 
31.17 
  
Table 36:   Cellular FITC fluorescence levels for BSA control, FITC IgG  
      control and FITC Anti-Pgp for each cell type 
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Nuclear P-gp staining with a FITC conjugated Anti-P-gp antibody (17F9, 
BD Biosciences) 
Histograms of green fluorescence (FL-1 detector) are shown for BSA control, 
FITC IgG control and the FITC anti-P-gp antibody samples for each nuclear 
preparation sample (Figures 78 – 81).   
The geomean and median fluorescence values for each sample are shown in 
table 37.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 78: MGH-U1 nuclei:  FITC fluorescence 
detection for a: BSA control; b: FITC IgG control;  
c: FITC Anti-Pgp  
Figure 79: RT112 nuclei:  FITC fluorescence detection 
for a: BSA control; b: FITC IgG control;  
c: FITC Anti-Pgp  
  a
b
a
b
a
b
a 
b 
 
a
b
c
a
b
c  237
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nuclear FITC fluorescence with FITC Anti-Pgp antibody is reduced in all nuclei 
compared to FITC IgG controls, suggesting that P-gp is not expressed on the 
nuclear membrane of any of these cells.   
 
 
 
 
 
Figure 80: MGH-U1R nuclei:  FITC fluorescence 
detection for a: BSA control; b: FITC IgG control;  
c: FITC Anti-Pgp  
Figure 81: MGHU-MMC nuclei:  FITC fluorescence 
detection for a: BSA control; b: FITC IgG control;  
c: FITC Anti-Pgp  
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Nuclei 
Samples 
N =  Geomean 
Fluorescence 
Median 
Fluorescence 
CV 
MGH-U1 
Control 
FITC Control 
FITC Anti-Pgp 
 
5761 
5814 
5794 
 
3.38 
29.96 
8.88 
 
3.34 
32.78 
9.39 
 
46.31 
21.68 
31.84 
RT112 
Control 
FITC Control 
FITC Anti-Pgp 
 
14085 
13868 
11032 
 
 
1.44 
19.32 
5.17 
 
1.25 
19.46 
5.05 
 
110.89 
25.56 
40.7 
MGH-U1R 
Control 
FITC Control 
FITC Anti-Pgp 
 
10420 
14456 
4682 
 
2.66 
24.58 
6.96 
 
2.64 
27.14 
7.5 
 
52.14 
24.03 
34.94 
MGHU-MMC 
Control 
FITC Control 
FITC Anti-Pgp 
 
8130 
7911 
10243 
 
1.8 
16.36 
5.26 
 
1.68 
18.27 
6.32 
 
88.62 
27.86 
48.52 
 
Table 37:   Nuclear FITC fluorescence levels for BSA control, FITC IgG 
      control and FITC Anti-Pgp for each nuclear type 
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3.3:  Microinjection experiments  
Cytoplasmic microinjection with epirubicin at 37
oC  
Following microinjection with epirubicin, the sensitive cell lines, MGH-U1 and 
RT112, demonstrated a clear nuclear uptake pattern of epirubicin  
(Figures 82a and b) consistent with their incubated uptake characteristics.   
The MDR bladder cancer cell lines, MGH-U1R and MGH-U1-MMC, 
demonstrated characteristic nuclear sparing of epirubicin following 
microinjection, again consistent with their usual incubated uptake 
characteristics (Figures 82c and d). 
The 77KDa FITC-dextran allowed clear identification of injected cells, 
especially resistant ones, which otherwise had low levels of fluorescence.  
This size of FITC-dextran was excluded from the nuclei of all injected cells, 
allowing clear visualisation of nuclear epirubicin uptake, if present.   
Characteristically the epirubicin fluorescence associated with resistant cells 
was punctuate and on the surface or even outside the cells.  The dextran 
fluorescence was evenly distributed through the cytoplasm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 82a: MGH-U1 cells co-injected with epirubicin 
(0.5mg/ml) and 77KDa FITC-dextran (0.5mg/ml) (x40 
lens; Zoom x2; Gain 1050). Bottom left: Epirubicin 
fluorescence (Red) showing nuclear uptake pattern. 
Top left:  FITC-dextran fluorescence (Green) 
excluded from nucleus.  Top right: DIC image.  
Bottom right: Integrated image. 
Figure 82b: RT112 cells co-injected with epirubicin 
(0.5mg/ml) and 77KDa FITC-dextran (0.5mg/ml) (x40 
lens; Zoom x3; Gain 1050).  Bottom left: Epirubicin 
fluorescence (Red) showing nuclear uptake pattern.  
Top left:  FITC-dextran fluorescence (Green) 
excluded from nucleus.  Top right: DIC image.  
Bottom right: Integrated image.   240
 
 
 
 
 
 
 
 
 
 
 
Subsequent addition of acridine orange (3µg/ml) demonstrated strong nuclear 
staining, confirming the viability of all injected cells (Figures 83a – d). 
   
 
 
 
 
 
 
   
 
 
 
 
 
 
 
Figure 82c: MGH-U1R cells co-injected with 
epirubicin (0.5mg/ml) and 77KDa 
FITC-dextran (0.5mg/ml) (x40 lens; Zoom x3;  
Gain 1150).  Bottom left:  Epirubicin fluorescence 
(Red) showing nuclear sparing pattern with 
cytoplasmic vesicular staining.  Top left: FITC-dextran 
fluorescence (Green) excluded from nucleus.  Top 
right: DIC image.  Bottom right: Integrated image.  
Figure 82d: MGHU-MMC cell co-injected with 
epirubicin (0.5mg/ml) and 77KDa FITC-dextran 
(0.5mg/ml) (x40 lens; Zoom x4; Gain 1150). Bottom 
left: Epirubicin fluorescence (Red) showing nuclear 
sparing pattern with cytoplasmic vesicular staining. 
Top left: FITC-dextran fluorescence (Green) 
excluded from nucleus. Top right: DIC image. 
Bottom right: Integrated image.  
Figure 83a: MGH-U1 cells (same cells as Figure 82a) 
Fluorescence only image with acridine orange 
staining (Green) confirming cell viability.   
Figure 83b: RT112 cells (same cells as Figure 82b) 
Fluorescence only image with acridine orange 
staining (Green) confirming cell viability.     241
 
 
 
 
 
 
 
 
 
 
Cytoplasmic Microinjection with Epirubicin on Ice 
By placing cells on ice any energy dependant processes in the cells are 
abolished.  MGH-U1 cells microinjected with epirubicin at 0 – 4 degrees 
maintained their usual nuclear uptake characteristics, but nuclear epirubicin 
fluorescence levels were much lower than usual and there were higher levels 
of cytoplasmic fluorescence that normally seen in sensitive cells (Figures  
84a – c).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 83c: MGH-U1R cells (same cells as Figure 
82c) (x40 lens; Zoom x3) Fluorescence only image 
with acridine orange staining (Green) confirming 
cell viability.   
Figure 83d: MGHU-MMC cell (same cell as 
Figure 82d) (x40 lens; Zoom x4). Fluorescence 
only image with acridine orange staining (Green) 
confirming cell viability.   
Figures 84a:  MGH-U1 cells co-injected with epirubicin 
(0.5mg/ml) and 77KDa FITC dextran (0.5mg/ml) on 
ice (x40 Lens; Zoom x4; Gain 1150). Bottom left: 
Epirubicin fluorescence (Red) showing nuclear uptake 
pattern. Top left: FITC-dextran fluorescence (Green) 
excluded from nucleus.  Top right: DIC image.  Bottom 
right: Integrated image. 
Figures 84b:  MGH-U1 cells co-injected with epirubicin 
(0.5mg/ml) and 77KDa FITC dextran (0.5mg/ml) on 
ice (x40 Lens; Zoom x4; Gain 1150). Bottom left: 
Epirubicin fluorescence (Red) showing nuclear uptake 
pattern. Top left: FITC-dextran fluorescence (Green) 
excluded from nucleus.  Top right: DIC image.  Bottom 
right: Integrated image.   242
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MGH-U1R cells reversed to a nuclear uptake pattern with microinjection of 
epirubicin on ice (Figures 86a-c).  This is suggestive that some energy 
dependant process prevents nuclear epirubicin uptake.  This could either be 
through reduced excretion via energy dependant vesicular uptake and 
exocytosis or some energy dependant efflux mechanism on the nuclear 
membrane.  There appears to be a lot of epirubicin in vesicles within the 
cytoplasm of these cells which may suggest that cellular export by this 
mechanism is reduced.   
 
 
Figures 84c:  MGH-U1 cells co-injected with epirubicin 
(0.5mg/ml) and 77KDa FITC dextran (0.5mg/ml) on 
ice (x40 Lens; Zoom x6; Gain 1150). Bottom left: 
Epirubicin fluorescence (Red) showing nuclear uptake 
pattern. Top left: FITC-dextran fluorescence (Green) 
excluded from nucleus.  Top right: DIC image.  Bottom 
right: Integrated image. 
Figure 85a: MGH-U1 cell (same cell as Figure 84a) 
Acridine orange fluorescence (Green) confirming 
cell viability.  Fluorescence image combine with 
DIC image 
Figure 85b: MGH-U1 cell (same cell as Figure 84c) 
Acridine orange fluorescence (Green) confirming 
cell viability.  Fluorescence image combine with 
DIC image   243
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acridine orange (3µg/ml) again demonstrated that both sensitive and MDR 
cells were viable (Figures 85a – b and 87a – c).    
 
 
 
Figures 86c:  MGH-U1R cells co-injected with 
epirubicin (0.5mg/ml) and 77KDa FITC dextran 
(0.5mg/ml) on ice (x40 Lens; Zoom x3; Gain 1100). 
Bottom left: Epirubicin fluorescence (Red) showing 
nuclear uptake pattern. Top left: FITC-dextran 
fluorescence (Green) excluded from nucleus.  Top 
right: DIC image.  Bottom right: Integrated image. 
Figures 86b:  MGH-U1R cells co-injected with 
epirubicin (0.5mg/ml) and 77KDa FITC dextran 
(0.5mg/ml) on ice (x40 Lens; Zoom x5; Gain 1100). 
Bottom left: Epirubicin fluorescence (Red) showing 
nuclear uptake pattern. Top left: FITC-dextran 
fluorescence (Green) excluded from nucleus.  Top 
right: DIC image.  Bottom right: Integrated image. 
Figures 86a:  MGH-U1R cells co-injected with 
epirubicin (0.5mg/ml) and 77KDa FITC dextran 
(0.5mg/ml) on ice (x40 Lens; Zoom x5; Gain 1100). 
Bottom left: Epirubicin fluorescence (Red) showing 
nuclear uptake pattern. Top left: FITC-dextran 
fluorescence (Green) excluded from nucleus.  Top 
right: DIC image.  Bottom right: Integrated image. 
Figure 87a: MGH-U1 cell (same cell as Figure 86a) 
Acridine orange fluorescence (Green) confirming 
cell viability.  Fluorescence image combine with 
DIC image   244
 
 
 
 
 
 
 
 
 
 
Nuclear pore sizing by cytoplasmic microinjection of various sized FITC-
dextrans 
Microinjection was a more successful means of delivering FITC-dextrans into 
the cytoplasm of cells.  It can be seen clearly that FITC-dextrans of 4.4KDa 
and 19.5KDa are able to passively diffuse through the nuclear pores of both 
MGH-U1 and MGH-U1R cells, although the 19.5KDa dextran may not pass as 
readily across the MGH-U1R nuclear membrane, as evidenced by a mild 
degree of nuclear sparing (Figures 88a – d and 89a – d).  The 43KDa and 
77KDa FITC-dextrans are excluded from the nuclei of both cell types 
suggesting they are too large to passively diffuse through nuclear membrane 
pores (Figures 88e – h and 89e – h).   
 
 
 
 
 
 
 
Figure 87b: MGH-U1 cell (same cell as Figure 86b) 
Acridine orange fluorescence (Green) confirming 
cell viability.  Fluorescence image combine with 
DIC image 
Figure 87c: MGH-U1 cell (same cell as Figure 86c) 
Acridine orange fluorescence (Green) confirming 
cell viability.  Fluorescence image combine with 
DIC image   245
 
                           
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 88a: MGH-U-1 cells microinjected with 
4.4KDa FITC-Dextran (x40 Lens; Zoom x1).   
FITC-fluoresence only (Green), showing nuclear 
uptake of the dextran. 
Figure 88b: MGH-U-1 cells microinjected with 
4.4KDa FITC-Dextran (x40 Lens; Zoom x4).   
FITC-fluoresence only (Green), showing nuclear 
uptake of the dextran. 
Figure 88c: MGH-U-1S cells microinjected with 
19.5KDa FITC-Dextran (x40 Lens; Zoom x2).  
FITC-fluoresence only (Green), showing nuclear 
uptake of the dextran. 
Figure 88d: MGH-U1 cell microinjected with 
19.5KDa FITC-Dextran (x40 Lens; Zoom x3).  
FITC-fluoresence only (Green), showing nuclear 
uptake of the dextran. 
Figure 88e: MGH-U-1 cells microinjected with 
42KDa FITC-Dextran (x40 Lens; Zoom x1).  FITC-
fluoresence only (Green), showing nuclear 
exclusion of the dextran. 
Figure 88f: MGH-U-1 cell microinjected with 42KDa 
FITC-Dextran (x40 Lens; Zoom x4).  FITC-
fluoresence only (Green), showing nuclear 
exclusion of the dextran.   246
 
 
 
 
 
 
 
 
 
 
 
Figure 88g: MGH-U-1 cells microinjected with 
77KDa FITC-Dextran (x40 Lens; Zoom x1).  FITC-
fluoresence only (Green), showing nuclear exclusion 
of the dextran. 
Figure 88h: MGH-U-1S cell microinjected with 
77KDa FITC-Dextran (x40 Lens; Zoom x1).  FITC-
fluoresence only (Green), showing nuclear exclusion 
of the dextran. 
Figure 89a: MGH-U1R cells microinjected with 
4.3KDa FITC-Dextran (x40 Lens; Zoom x2).  FITC-
fluoresence only (Green), showing nuclear uptake of 
the dextran. 
Figure 89b: MGH-U1R cell microinjected with 
4.3KDa FITC-Dextran (x40 Lens; Zoom x4).  FITC-
fluoresence only (Green), showing nuclear uptake of 
the dextran.
Figure 89c: MGH-U1R cells microinjected with 
19.5KDa FITC-Dextran (x40 Lens; Zoom x2).  FITC-
fluoresence only (Green), showing nuclear uptake of 
the dextran. 
Figure 89d: MGH-U1R cell microinjected with 
19.5KDa FITC-Dextran (x40 Lens; Zoom x4).  FITC-
fluoresence only (Green), showing nuclear uptake of 
the dextran.   247
 
 
 
 
 
Figure 89g: MGH-U1R cells microinjected with 
77KDa FITC-Dextran (x40 Lens; Zoom x1).  FITC-
fluoresence only (Green), showing nuclear 
exclusion of the dextran. 
Figure 89h: MGH-U1R cell microinjected with 
77KDa FITC-Dextran (x40 Lens; Zoom x3).  FITC-
fluoresence only (Green), showing nuclear 
exclusion of the dextran. 
Figure 89e: MGH-U1R cells microinjected with 
42KDa FITC-Dextran (x40 Lens; Zoom x 2).  FITC-
fluoresence only (Green), showing nuclear 
exclusion of the dextran. 
Figure 89f: MGH-U1R cell microinjected with 
42KDa FITC-Dextran (x40 Lens; Zoom x 4).  FITC-
fluoresence only (Green), showing nuclear 
exclusion of the dextran.   248
3.4:  Cytotoxicity experiments: 
Epirubicin Cytotoxicity Curves  
Individual epirubicin cytotoxicity curves are plotted below for all cell lines 
(Figures 90a – d). The IC50 values (concentration of the drug required to 
inhibit cell growth by 50%) were calculated from the cytotoxicity curves.  The 
IC50 for the sensitive cell lines, MGH-U1 and RT112, were similar at 0.2 and 
0.6µg/ml respectively.  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 90a:    MGH-U1 epirubicin cytotoxicity curve 
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Figure 90b:    RT112 epirubicin cytotoxicity curve  
 
The IC50 values for the MDR cell lines, MGH-U1R and MGHU-MMC, were 
also similar at 120 and 160 µg/ml respectively. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 90c:    MGH-U1R epirubicin cytotoxicity curve 
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Figure 90d:    MGHU-MMC epirubicin cytotoxicity curve 
 
Idarubicin cytotoxicity curves 
Idarubicin cytotoxicity curves were plotted for MGH-U1 and MGH-U1R cells 
Figures 91a and b).  Their IC50 values were <0.08 and 2µg/ml respectively.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 91a:  MGH-U1 idarubicin cytotoxicity curve 
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  Figure 91b:  MGH-U1R idarubicin cytotoxicity curve 
 
Mitomycin C cytotoxicity curves 
Mitomycin C cytotoxicity curves were plotted for MGH-U1 and MGH-U1R cells 
(Figures 92a and b).   Their IC50 values were 7 and 75µg/ml respectively.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 92a:    MGH-U1 mitomycin C cytotoxicity curve 
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Figure 92b:    MGH-U1R mitomycin C cytotoxicity curve 
 
 
Wheat germ agglutinin (WGA) cytotoxicity curves 
WGA cytotoxicity curves were plotted for MGH-U1 and MGH-U1R cells 
(Figures 93a – d).  For 1-hour exposures IC50 values were not reached for 
either cell type.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 93a:   MGH-U1 WGA cytoxicity curve – 1 hour exposure 
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Figure 93b:  MGH-U1R WGA cytotoxicity curve – 1 hour exposure  
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 93c:  MGH-U1 WGA cytotoxicity curve – 24 hour continuous  
     exposure   
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Figure 93d:  MGH-U1R WGA cytotoxicity curve – 24 hour continuous  
     exposure   
 
Continuous exposure to WGA for 24 hours demonstrated some cytotoxicity in 
both MGH-U1 and MGH-U1R cells with IC50 values of around 2µg/ml.     
Drug Combinations 
Epirubicin and WGA  
The combination of WGA with epirubicin did not alter epirubicin cytotoxicity in 
MGH-U1 cells, although the IC50 was not determined accurately because we 
did not look at concentrations of epirubicin below 0.31µg/ml (Figure 94a).   
The MGH-U1R cells did demonstrate increased cytotoxicity of epirubicin in 
combination with WGA with a reduction in IC50 values from 80 to 3.75µg/ml.  
Some of this increased cytotoxicity is a direct result of WGA cytotoxicity but in 
the centre of this graph the curves diverge suggesting there may be some 
additive effect (Figure 94b).   
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Figure 94a:   MGH-U1 Cytotoxicity of epirubicin in combination with WGA 
 
Figure 94b:   MGH-U1R Cytotoxicity of epirubicin in combination with WGA 
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Epirubicin and Demecolcine 
Demecolcine appears to be cytotoxic in its own right, with sensitive cells being 
killed at very low doses and epirubicin having very little additional effect 
(Figure 95a).  Combination of demecolcine and epirubicin appears to have a 
concentration dependent additive effect in MGH-U1R cells (Figure 95b).  At 
the highest concentration of demecolcine the IC-50 value for epirubicin is 
reduced to around 2µg/ml.  This suggests that cells arrested in metaphase 
with their chromosomal material exposed are more susceptible to epirubicin.  
It may also imply that the nuclear membrane plays a role in excluding 
epirubicin from its nuclear site of action.   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  Figure 95a:   MGH-U1 cytotoxicity with a combination of epirubicin and  
     demecolcine 
 
 
 
 
 
 
Epirubicin Cytotoxicity Curve: MGH-U1 Cells 
Combination with Demecolcine
0
20
40
60
80
100
120
0 0.08 0.16 0.31 0.63 1.25 2.5 5 10 20 40
Epirubicin Concentration mcg/ml
%
 
R
e
s
i
d
u
a
l
 
B
i
o
m
a
s
s
No Demecolcine
0.008 mcg/ml Demecolcine
0.016 mcg/ml Demecolcine
0.031 mcg/ml Demecolcine
0.063 mcg.ml Demecolcine
0.125 mcg/ml Demecoline
0.25 mcg/ml Demecolcine  257
 
 
 
 
 
 
 
 
 
 
  Figure 95b:   MGH-U1R cytotoxicity with a combination of epirubicin and 
     demecolcine 
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3.5:  Summary of results: 
Hypothesis 1: 
“The nuclear membrane is responsible for nuclear sparing of epirubicin uptake 
in MDR bladder cancer cells.” 
1. The nuclear epirubicin staining characteristics of sensitive and MDR 
bladder cancer cell lines were determined.  Sensitive cells showed strong 
nuclear uptake of epirubicin whereas MDR cells demonstrated a clear nuclear 
sparing pattern of epirubicin uptake.  
2. Cell fusion experiments failed to demonstrate any cell fusion products 
containing nuclei of different phenotypes.  This suggests that when sensitive 
and MDR cells fuse, one of the nuclei changes its characteristic uptake 
pattern.  There could be several explanations for this, all of which are 
examined in the following discussion section.  
3. Metaphase arrest experiments: We were only able to demonstrate 
chromosomal epirubicin staining in viable MDR cells at higher epirubicin 
concentrations.  This suggests that a combination of resistance factors 
including the nuclear membrane contribute to nuclear sparing.    
4. Microinjection studies:  Sensitive cells microinjected with epirubicin 
demonstrated their normal pattern of nuclear epirubicin staining.  MDR cells 
microinjected with epirubicin continued to demonstrate nuclear sparing of 
epirubicin uptake suggesting that the nuclear membrane is responsible for the 
nuclear sparing phenomenon. 
Hypothesis 2: 
“An active efflux mechanism is responsible for nuclear sparing of epirubicin in 
MDR bladder cancer cells.” 
1.  Cell death reversed the nuclear sparing pattern of MDR cells to a sensitive 
phenotype.  When incubated with epirbicin on ice both sensitive and MDR 
cells demonstrated nuclear sparing of epirubicin uptake, which may have 
been due to slower diffusion times or due to abolition of an active transport 
process for nuclear epirubicin uptake in sensitive cells. 
2. Epirubicin  uptake  in  MDR nuclear isolates exposed to epirubicin pre- and 
post-nuclear fractionation demonstrated much lower levels of fluorescence in 
pre-exposed nuclei.  This suggests that active cell processes are responsible   259
for reduced nuclear uptake of epirubicin as opposed to the nuclear membrane 
per se.  
3.  Nuclear pore sizing using various sized FITC-dextrans showed that 
molecules of 19.5KDa and less gained easy entry the nuclei of sensitive and 
MDR cells by passive diffusion.  Molecules larger than 42KDa were excluded 
from the nuclei of both sensitive and MDR nuclei.  This means that by size 
criteria alone epirubicin (0.58KDa) should gain easy access through the 
nuclear membrane of sensitive and MDR cells  
4.  Blockade of nuclear pores using WGA did not appear to influence the 
uptake of epirubicin by either sensitive or MDR cells when assessed using 
confocal microscopy and flow cytometric assays.  Neither did it preclude entry 
of the 19.5KDa FITC-dextran to the nuclei of sensitive or MDR cells, 
suggesting that any reduction in nuclear pore diameter is irrelevant in terms of 
diffusion of small molecules.   
5.  Direct microinjection of cells that were cooled on ice demonstrated that 
whilst sensitive cells maintained their nuclear uptake pattern of epirubicin, 
MDR cells showed reversal of their nuclear sparing pattern to a nuclear 
uptake pattern.  This strongly suggests that there may be an active efflux 
pump on the nuclear membrane of MDR cells that is responsible for the 
nuclear sparing phenomenon.   
6.  The MDR cell lines used in this study were known to express  
P-glycoprotein.  Using a flow cytometric assay with a FITC-labelled anti-Pgp 
antibody we demonstrated that MDR cells expressed P-gp at a cellular level 
but that the nuclei of MDR cells did not express P-gp.  This means that 
another active efflux pump on the nuclear membrane must be responsible for 
the nuclear sparing phenomenon. 
7.  Verapamil reverses the nuclear sparing pattern of MDR cells.  Time series 
confocal microscopy demonstrated that increases in cellular uptake of 
epirubicin in MDR cells co-incubated with verapamil appeared to due to 
increased nuclear uptake rather than increased cytoplasmic levels.  This 
suggests than verapamil may also have an effect at the nuclear membrane 
level as well as on P-gp at the cell membrane level.     260
Other results:  
Hypothesis 3: 
“The nuclear membrane is not responsible for nuclear exclusion of idarubicin 
in sensitive and MDR bladder cancer cells.” 
1.  Both sensitive and MDR cells demonstrate nuclear sparing of idarubicin 
uptake. 
2.  Nuclear isolates from sensitive and MDR cells showed similar levels of 
idarubicin fluorescence and in addition the levels of fluorescence did not 
appear to be affected by whether the nuclei were exposed to idarubicin before 
or after nuclear fractionation.  
3.  During metaphase arrest there appeared to be a lack of chromosomal 
idarubicin staining as demonstrated by central areas without fluorescence.  
When examined with other DNA stains these areas were clearly seen to be 
chromosomes.   
Hypothesis 4: 
“Mitomycin C fluorescence can be detected using direct or indirect 
fluorescence methods, allowing us to study its cellular uptake and 
localisation.” 
1.  We were unable to demonstrate any convincing evidence of Mitomycin C 
fluorescence in sensitive or MDR cells using confocal microscopy (including 
time series uptake studies) and flow cytometric analysis. 
2.  An indirect assay of Mitomycin C uptake in sensitive and MDR cells 
utilising displacement of acridine orange DNA staining, again did not 
demonstrate a dose response using confocal microscopy or flow cytometric 
analysis.  
Hypothesis 5: 
“GFP fluorescence can be used as a viability stain in cell lines.”  
1.  GFP fluorescence appears to be lost immediately as a result of cell death 
and could therefore be used as a marker of cell death in vitro.  
Hypothesis 6: 
“Changes in the localisation of epirubicin in MDR bladder cancer cells 
following cell death are due to leakiness of the cell and nuclear membranes.”  
1.  Following cell death MDR cells reverse their nuclear sparing pattern to a   261
nuclear uptake pattern.  This may be due to abolition of energy dependent 
processes or increased leakiness of the cell and nuclear membrane.  
2.  After cell death, a 77KDa FITC-labelled dextran was shown to gain access 
to the cell and nucleus of sensitive and MDR cells suggesting that cell 
membranes become leaky following cell death and may account for changes 
in nuclear epirubicin uptake.     262
Discussion  
Much has been published about the nuclear sparing phenomenon exhibited 
by MDR cells when incubated with various anthracyclines and anthraquinones 
[244,340,347,348,350].  It is likely that nuclear sparing of other cytotoxic drugs 
also occurs in MDR cells leading to reduced efficacy, but studies to support 
this assertion are currently lacking. 
In addition, few investigations have been performed to look at the role of the 
nuclear membrane in this nuclear sparing phenomenon [352].  This study is 
the most comprehensive assessment of the role of the nuclear membrane in 
this phenomenon in viable, adherent bladder cancer cells in situ to date. 
Epirubicin uptake characteristics of sensitive and MDR bladder cell 
lines:  Temperature and viability studies 
In drug-sensitive, viable bladder cancer cell lines a clear nuclear uptake 
pattern of epirubicin is seen at 37
oC, with comparatively little cytoplasmic drug 
uptake.  In contrast when incubated on ice (0 – 4
oC), despite demonstrating 
good levels of cytoplasmic epirubicin uptake, sensitive cells exhibit nuclear 
sparing of drug uptake.  These results were consistent with previously 
reported results for the same cell lines [199,199,347,348,386].  In sensitive 
cells, epirubicin most likely gains access to the nucleus via one or both of two 
mechanisms, passive diffusion and/or active transport.  As diffusion 
processes tend to be slower at low temperatures, nuclear fluorescence may 
be reduced as a result of slower passive diffusion through the cell.  In 
addition, if epirubicin is actively transported into the nucleus then this energy-
requiring process will be abolished at low temperatures, which could also 
explain the lack of nuclear epirubicin uptake seen at low temperatures.  If 
epirubicin is actively transported into the nucleus of sensitive cells, this would 
imply that the epirubicin has become bound to a protein or molecule larger 
than 40KDa, meaning that passive diffusion into the nucleus is no longer 
possible.   
In contrast, viable MDR cell lines showed nuclear sparing of epirubicin at 
37
oC, with drug being sequestered in cytoplasmic vesicles.  In addition a rim 
of drug was seen around the periphery of some cells, suggesting that drug 
was being effluxed or ejected from the cells by exocytosis.  The nuclear 
sparing demonstrated by these cells could result from one or more of the   263
following mechanisms; reduced intracellular drug levels as a result of P-gp 
mediated drug efflux, vesicular sequestration of drug, nuclear drug efflux or 
reduced nuclear import.  When incubated on ice (0 – 4
oC) there was no 
apparent change in the intracellular distribution or levels of drug uptake in 
MDR cells.  This finding is somewhat surprising, as it suggests that the 
abolition of energy dependent efflux mechanisms at low temperatures does 
not affect drug uptake.  However, this result concurs with previously reported 
results, where epirubicin uptake was examined using flow cytometry, showing 
no difference in cellular uptake between MDR cells incubated with epirubicin 
at 0
oC and 37
oC [346].  
Non-viable sensitive and MDR bladder cancer cell lines both demonstrated a 
nuclear uptake pattern of epirubicin.  Increased “leakiness” of both cellular 
and nuclear membranes can be demonstrated following cell death, with a 
77KDa FITC-dextran, not usually taken up into the intracellular compartment 
of viable intact cells, gaining entry to both the cytoplasm and nucleus of non-
viable cells.  This membrane “leakiness” is the most likely reason for the 
nuclear uptake of epirubicin in dead MDR cells, although energy dependent 
mechanisms of drug efflux or expulsion are also abolished by cell death.         
This observation clearly emphasizes the importance of determining cell 
viability in any experiments where it is claimed that the MDR status of cells 
has changed from a resistant to a sensitive nuclear uptake pattern, to ensure 
that nuclear staining is not the result of cell death.   
Cell viability was confirmed in all experiments examining the MDR 
characteristics of cells, using either fluorescein diacetate or acridine orange 
fluorescence.  Experiments looking at GFP expressing cell lines suggested 
that GFP could also be used as a marker of cell viability.   
Flow cytometric studies of epirubicin uptake in sensitive and MDR cells 
demonstrated a clear dose response, which was much less pronounced in the 
MDR cell line.  At the highest dose of epirubicin, the sensitive cells 
demonstrated over 15 times more drug fluorescence than the MDR cells.        264
Investigation of nuclear MDR factors: 
Nuclear pore sizing studies: 
Nuclear pore sizing experiments using scrape-loading and microinjection 
techniques showed that FITC-dextrans of 19.5KDa and less passed easily 
into the nuclei of sensitive and MDR cells by passive diffusion.  In contrast 
FITC-dextrans larger than 42KDa did not gain entry to the nuclei of sensitive 
or resistant nuclei.  Epirubicin is a tiny molecule approximately 0.58KDa in 
size, so that by size criteria it should easily diffuse through the nuclear pores 
of sensitive and MDR cells.   
This result suggests that other mechanisms must be involved the cellular 
localisation of epirubicin in MDR cells, as it is spared from the nuclei of 
resistant cells even when microinjected directly into the cell cytoplasm.  
This implies that either epirubicin is getting into the nucleus and then being 
effluxed or that it is denied entry into the nucleus in some way.   
Nuclear isolate studies: 
In nuclei exposed to epirubicin after nuclear isolation, there appeared to be 
equivalent high levels of epirubicin uptake in sensitive and resistant nuclei.  
One assumes that the study of nuclear isolates allow us to examine any 
inherent nuclear mechanisms of MDR.  Some studies have utilised nuclei 
suspended in cytosolic substitutes and have shown results that appear to 
demonstrate metabolic activity in isolated nuclei [234,352].  However, our 
nuclei were not suspended in cytosol substitute and are therefore unlikely to 
behave as “viable” nuclei.  We know that non-viable cells demonstrate high 
levels of epirubicin nuclear uptake.  Whether extracted nuclei can be 
classified as “viable” remains unknown.  It is therefore possible that 
“leakiness” of the nuclear membrane could account for the high levels of 
nuclear fluorescence observed in nuclear isolates.  In addition, by removing 
the cellular apparatus, we have abolished any cellular mechanisms of nuclear 
exclusion, as well as any energy dependent mechanisms of nuclear uptake or 
exclusion.  If one assumes that the nuclear membrane remains intact in 
nuclear isolates, then the only mechanism of nuclear drug entry can be 
passive diffusion across the nuclear membrane.  We can therefore conclude 
that diffusion of epirubicin across the nuclear membrane is equal in sensitive 
and resistant cells in the absence of other processes.     265
Flow cytometric studies looking at concentration dependent nuclear epirubicin 
uptake in sensitive and resistant nuclear isolates would be a more accurate 
way of studying drug uptake in nuclear isolates.  If equivalent concentration 
dependant uptake was demonstrated in the different nuclei, this would confirm 
that diffusion is the main mechanism of nuclear transport being studied when 
exposing nuclear isolates to drug.  
In addition, nuclear isolates exposed to epirubicin after nuclear fractionation 
demonstrated much higher levels of epirubicin uptake than nuclear isolates 
from cells exposed to epirubicin prior to nuclear fractionation, for both 
sensitive and MDR nuclei.  This difference was more pronounced in MDR 
nuclei, but also present for sensitive nuclei, suggesting that the cellular 
apparatus reduces nuclear uptake of epirubicin in both cell types.   
In nuclei exposed to epirubicin before nuclear fractionation, sensitive nuclei 
demonstrated higher levels of nuclear fluorescence than resistant nuclei, as 
expected.   Flow cytometric studies showed that over a range of epirubicin 
concentrations from 1.25 – 80µg/ml, sensitive nuclei took up between 3.1 – 
7.5 times more epirubicin. This result confirms that the cellular apparatus of 
MDR cells is more effective at excluding epirubicin from the nucleus than that 
of sensitive cells.       
Nuclear pore blockade studies: 
WGA binds to nuclear pores and has been shown to block some active 
transport processes across the nuclear membrane, including active nuclear 
transport of adriamycin (doxorubicin) in a drug sensitive lymphoblastic tumour 
cell line [352].  FITC-WGA was seen to clearly localise to the nuclear 
membrane within a few hours, reaching a plateau at 4 hours which persisted 
for up to 24 hours.  Nuclear isolates also demonstrated clear ring 
enhancement following exposure to FITC-WGA suggesting nuclear pore 
binding of WGA.  Nuclear pore blockade with WGA did not change the 
nuclear uptake of a 19.5KDa FITC-dextran, suggesting that by size criteria 
WGA should have no effect on nuclear epirubicin uptake occurring by passive 
diffusion.  This meant that any alteration of epirubicin uptake mediated by 
WGA would have to be through blockade of active transport.       266
Confocal studies of epirubicin uptake in sensitive and MDR cells following 
WGA exposure showed no changes in the levels of cellular uptake or 
localisation of epirubicin.  Confocal examination of nuclear isolates from cells 
exposed to WGA followed by epirubicin exposure either pre- or post-nuclear 
fractionation did not demonstrate any differences in nuclear epirubicin uptake 
attributable to WGA.   
In sensitive and resistant cells with or without pre-exposure to WGA, flow 
cytometric studies of whole cells and nuclear isolates demonstrated no 
significant differences in epirubicin uptake attributable to WGA.    
These results contradict previously published results that demonstrated 
reduced epirubicin uptake in isolated drug sensitive nuclei exposed to WGA 
followed by doxorubicin [352] and increased epirubicin uptake in the nuclei of 
MDR cells exposed to WGA [394].   
Cell fusion studies: 
Demonstration of a mixed cell fusion with phenotypically sensitive and 
resistant nuclei within the same cell environment would have provided clear 
evidence that the nuclear membrane also acts a barrier to nuclear drug 
uptake in resistant cells.  However, no mixed cell fusion products were 
demonstrated despite numerous attempts.  Instead numerous cell fusion 
products containing phenotypically similar nuclei were seen.   
The lack of mixed cell fusion products suggests that fusion of sensitive and 
resistant cells results in a change in the nuclear epirubicin uptake 
characteristics of one of the nuclei, either the resistant nuclei taking on a 
sensitive phenotype or vice versa.   
Sensitive type fusion products appeared to be more common than resistant 
cell fusions.  A simple counting technique would have provided stronger 
evidence for this statement.  If true, this would suggest that the resistant 
nucleus changes to a sensitive phenotype.   
There are several possible explanations for failing to demonstrate a mixed cell 
fusion, the first and most obvious being that we had failed to fuse a sensitive 
with a resistant cell, but this seems unlikely given our numerous attempts.   
There are several possible explanations for the change from resistant to 
sensitive phenotype.  One explanation could be a dilution in the cellular levels 
of P-gp resulting in higher intracellular concentrations of epirubicin which in   267
turn leads to increased nuclear uptake, changing the resistant nucleus to a 
sensitive pattern.  Another possibility would be a dilution of intracellular MDR 
mechanisms, for example P-gp, LRP or cytoplasmic vault mediated vesicular 
drug sequestration, increasing cytoplasmic drug concentrations and nuclear 
uptake.  A reduction in a nuclear efflux mechanism mediated by vault 
complexes may also explain the change in nuclear phenotype.   
MGH-U1R cells have been shown to express LRP (Personal communication, 
Matthew Hayes), so a dilution of LRP or vault structures may result in reduced 
intracytoplasmic vesicular sequestration of drug [285] or reduced efflux of 
epirubicin from the nuclear compartment, as has been suggest by other 
workers [286-288].   
Another possible mechanism may involve the numerous nuclear pore 
complexes that allow “molecular trafficking” between the nucleus and the 
cytoplasm.  Nuclear pore complexes are large 120 Megadalton 
supramolecular assemblies that straddle the double-membraned nuclear 
envelope [358] and share the presence of the LRP with cytoplasmic vaults 
[270].  These nuclear pores allow passive diffusion of molecules up to 40KDa 
molecular weight.  They also allow the transport of larger molecules, up to 
several megadaltons, by energy dependant transport mechanisms, provided 
they carry a nuclear localisation sequence that facilitates nuclear pore binding 
and transport [358].  It has been suggested that cytoplasmic vaults may also 
constitute the central plugs of the NPC, and might mediate the transport of a 
variety of molecules between nucleus and cytoplasm [280].  It is possible 
vaults might be acting in some such regulatory capacity, mediating 
cytoplasmic/nucleocytoplasmic drug transport.   
Epirubicin is known to have a high affinity for protein binding in serum, so one 
possible explanation may be that epirubucin binds to proteins within the 
cytoplasm and is excluded from the nucleus if these proteins do not carry the 
nuclear localisation sequence necessary for transport into the nucleus of MDR 
cells.  This theory is partially supported by previous work looking at the role of 
the nuclear membrane in adriamycin (doxorubicin) uptake in isolated sensitive 
and MDR nuclei, from a lymphoblastic tumour cell line [352].  This work 
showed that in isolated nuclei, nuclear transport of adriamycin is reduced in 
MDR cells when compared to sensitive cells.  Furthermore blockade of active   268
nuclear transport by Wheat Germ Agglutinin (WGA; Triticum vulgaris lectin) 
reduced sensitive nuclear uptake of adriamycin to approximately the level of 
MDR nuclear uptake, but had no effect on adriamycin accumulation in MDR 
nuclei.  This suggests that sensitive cells have two mechanisms by which 
nuclear adriamycin uptake is achieved: passive diffusion and active transport.  
Adriamycin is thus transported into the nucleus of sensitive cells bound to 
proteins, whereas MDR cells allow adriamycin into their nuclei by passive 
diffusion only, with an absence of active transport.  This absence of active  
transport in MDR nuclei has several possible explanations, the two most 
probable being either that adriamycin binds to different proteins that don’t 
carry the necessary sequence for nuclear transport or that the nuclear 
localisation sequence receptor on the nuclear pore complex is different in 
MDR cells.   
In a mixed cell fusion it is possible that epirubicin undergoes nuclear transport 
bound to proteins.  This would involve some cytoplasmic-nuclear membrane 
interaction, suggesting that a certain cytoplasmic factor from the sensitive cell 
allows epirubicin to gain entry to the MDR nucleus.  This could be either a 
factor that promotes for nuclear transport of epirubicin or a sensitive cytosolic 
protein that binds epirubicin and is recognised and transported by the nuclear 
pore complex of the MDR nucleus, converting it to a sensitive pattern.  
Further evidence to support the theory that sensitive cells transport 
anthracyclines into their nuclei bound to proteins, comes from a study that 
demonstrated in sensitive leukaemic cells that adriamycin was transported 
into nuclei bound to proteasomes [395].  Proteasomes are intracellular 
proteinase complexes involved in nonlysosomal protein degradation.  They 
can be localised in both the cytoplasm and the nucleus and hence carry the 
nuclear localisation sequence necessary for active transport from the 
cytoplasm into the nucleus.    
The protein binding of anthracyclines in cells needs to be investigated further 
to assess if there are differences between sensitive and resistant cancer cells 
that may account for their differences in nuclear uptake.       269
Metaphase arrest studies: 
Metaphase experiments were performed to see if the chromosomes of MDR 
cells could be stained during metaphase.  Evidence of this would provide 
strong indirect evidence of the nuclear membrane’s role in nuclear sparing, as 
the nuclear membrane is absent during metaphase.   
Viable, sensitive cells showed clear chromosomal staining with epirubicin, 
whereas viable MDR cells did not demonstrate any chromosomal staining with 
epirubicin at lower doses.  This finding was confirmed by the subsequent 
addition of acridine orange which showed numerous cells in metaphase that 
had not stained with epirubicin.  However, at higher concentrations of 
epirubicin low level chromosomal staining could be seen, being confirmed by 
the addition of acridine orange.  These results suggest that low intracellular 
levels of epirubicin in MDR cells along with some nuclear membrane 
mechanism both play a part in the nuclear sparing of epirubicin in MDR cells.   
An important question is what happens to the nuclear membrane during 
metaphase? It seems inconceivable that a cell would leave its chromosomal 
material completely unprotected during cell division, although one recognises 
that most cytotoxic agents exert their effects during this phase of the cell 
cycle.  It is possible that when the nuclear membrane disperses that the 
nuclear membrane pores or another efflux mechanism could be distributed in 
a peri-nuclear location and actually efflux epirubicin away from chromosomes.  
It is also possible that cytoplasmic vaults could redistribute to a peri-
chromosal location, denying epirubicin access to chromosomes during 
metaphase.   
Another explanation for the absence of chromosomal epirubicin staining at 
low drug concentrations might be that there is some electrostatic repulsion of 
drug from chromosomes.  DNA is said to be negatively charged by virtue of its 
histones.  It is possible that epirubicin entering MDR cells becomes similarly 
charged and is therefore repelled from the chromosomes.  It is also possible  
that epirubicin becomes bound to negatively charged cytoplasmic proteins in 
MDR cells that are repelled from the chromosomes.  Differences in protein 
binding between sensitive and resistant cells could explain the discrepancy 
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given the presence of low level chromosomal staining seen at higher 
epirubicin concentrations.      
The increased cytotoxicity of epirubicin when combined with demecolcine 
could also suggest enhanced DNA binding of epirubicin in metaphase cells.   
Microinjection studies: 
Microinjection provided a novel means of investigating the nuclear sparing 
phenomenon associated with MDR.  Previous investigators have questioned 
whether the nuclear sparing phenomenon is merely a reflection of low levels 
of drug accumulation in MDR cells, due to drug efflux by P-glycoprotein, or 
whether the nuclear membrane is also playing a role 
[244,340,346,348,352,394]. Microinjection of epirubicin bypasses the P-gp 
efflux pump on the plasma membrane, delivering a bolus of drug directly into 
the cell cytoplasm.  The persistence of nuclear sparing following 
microinjection would be highly suggestive that the nuclear membrane plays a 
role in MDR.   
Microinjection of sensitive cells at 37
oC demonstrated their usual nuclear 
uptake pattern of epirubicin.  Microinjection of resistant cells at 37
oC 
demonstrated clear nuclear sparing of epirubicin uptake, suggesting that P-gp 
mediated cellular efflux does not account for this phenomenon.    
Efflux of the drug still takes place to some degree, as evidenced by the 
differences in overall drug fluorescence between sensitive and resistant cells 
at 37
oC. This observation suggests that the plasma membrane P-gp pump 
effluxes drug from the cell cytoplasm, as well as excluding drug while it 
crosses the plasma membrane as has been suggested by previous studies 
[396,397].  There was some delay in visualising injected cells, owing to the 
location of microinjection and confocal facilities at our institution, thus allowing 
time for some efflux to occur in our MDR cell samples.  This delay also 
allowed time for drug to be packaged in vesicles within the cytoplasm of MDR 
cells, as has been noted in previous confocal studies using standard 
anthracycline exposure methods [347].   
These results showed that cells microinjected with epirubicin show the same 
basic pattern of nuclear drug uptake or exclusion to cells incubated with 
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membrane acts as a barrier to nuclear epirubicin uptake in MDR cells and 
must therefore play a role in multidrug resistance.   
We attempted to clarify the mechanism(s) by which the nuclear membrane 
excludes epirubicin from the nuclei of MDR cells by microinjecting cells whilst 
on ice, to inhibit energy dependant processes.   
When microinjected with epirubicin at 0 – 4
oC sensitive cells demonstrated 
slightly reduced levels of nuclear fluorescence when compared to sensitive 
cells at 37
oC, but still showed a predominant nuclear uptake pattern.    
Resistant cells injected with epirubicin at 0 – 4
oC showed reversal of their 
usual epirubicin uptake pattern to a “sensitive” nuclear uptake pattern.  They 
also demonstrated higher cytoplasmic levels of epirubicin.    
These results suggest that some intracellular process is responsible for 
nuclear sparing of drug uptake in MDR cells.  The fact that when energy 
dependent processes are abolished, epirubicin gains entry to the nucleus 
suggests the mechanism must involve some energy dependent process.  The 
most likely explanation would be an energy dependent efflux pump associated 
with the nuclear membrane.  One possible mechanism for this could be vaults 
associated with the nuclear pore complexes [280].  Other studies have 
demonstrated vault induced efflux of anthracyclines at nuclear membrane 
level [286,287] and MGH-U1R cells are known to express LRP, the human 
major vault protein (personal communication, Matthew Hayes).  Another 
recent study of nuclear drug efflux in human leukaemic cell lines suggests that 
efflux occurs by an ATP independent, passive diffusion mechanism that 
follows extracellular drug clearance [398].  Other possibilities include other 
energy dependent mechanisms reducing intracytoplasmic drug concentrations 
by vesicular drug sequestration, such mechanisms could include vesicle 
bound P-gp, LRP or vault transporters.   
Time series studies: 
Confocal microscopy time series experiments provided an interesting insight 
to intracellular uptake and localisation of epirubicin in sensitive and resistant 
cells. 
Cytoplasmic epirubicin levels were remarkably constant between sensitive 
and MDR cells lines of the same lineage, suggesting that P-gp does not alter 
cellular uptake of epirubicin greatly.  Despite this, nuclear epirubicin uptake   272
levels were much higher in sensitive cells, with MDR nuclei showing much 
lower levels that were remarkably similar to cytoplasmic drug levels.  If entry 
to the nucleus occurs by passive diffusion one might expect cytoplasmic and 
nuclear levels to equilibrate across the nuclear membrane.  This appears to 
happen in MDR cells perhaps suggesting that diffusion accounts for the 
limited nuclear uptake in MDR cells and is thus ultimately controlled by P-gp.  
However, given the affinity of epirubicin for DNA binding one would expect 
epirubicin to bind to the DNA in MDR nuclei, hence reducing the 
nucleoplasmic epirubicin concentration creating a diffusion gradient across 
the nuclear membrane.  This situation would result in increasing nuclear 
binding of epirubicin with increasing fluorescence levels, which does not 
occur.  This again suggests that there is another transporter probably 
associated with nuclear membrane that is responsible for maintaining 
equilibrium across the nuclear membrane with passive diffusion being 
matched by drug efflux.        
In sensitive cells, cytoplasmic epirubicin levels are fairly constant in one cell 
line (MGH-U1) and are certainly below nuclear levels in the other cell line 
(RT112).  The fact that nuclear uptake exceeds cytoplasmic drug 
concentrations suggests that the mechanism of transport across the nuclear 
membrane is not solely due to passive diffusion, otherwise cytoplasmic and 
nuclear levels would equilibrate.  This discrepancy in the rates of cytoplasmic 
and nuclear accumulation of drug, suggests that either there is some active 
transport mechanism is involved in nuclear epirubicin import in sensitive cells 
or that once epirubicin is bound to DNA in the nucleus that it no longer 
contributes to nucleoplasmic epirubicin concentration, so that passive 
diffusion occurs across the nuclear membrane at a rate determined by DNA 
binding.   
Verapamil appears to exert a minimal effect on cytoplasmic uptake of 
epirubicin and yet increases nuclear uptake of epirubicin dramatically in MDR 
cells.  The presumed mechanism of action of verapamil has always been 
through competitive inhibition of P-gp mediated drug efflux, but without clear 
evidence of increased cytoplasmic epirubicin levels these experiments do not 
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membrane to increase nuclear epirubicin uptake by inhibition of a nuclear 
membrane export pump such as LRP or cytoplasmic vault structures.     
It must be recognised that these time series experiments looked at a single 
levels through each cell which whilst representative of drug uptake in each 
cellular compartment may not reveal the full picture.  Confocal microscopy is 
also only a semiquantitative method of fluorescence measurement making it 
less accurate than flow cytometry in terms of absolute fluorescence 
measurements.  
Flow cytometric time series experiments demonstrated significant increases in 
epirubicin uptake in MDR cells when combined with verapamil exposure.  Co-
incubation of MDR cells with epirubicin and verapamil for 2 hours resulted in a 
10.7 – 12 fold increase in intracellular fluorescence levels over epirubicin 
alone for 2 hours.  Our confocal experiments suggest that most of this results 
from increased nuclear epirubicin uptake.  Performing similar time series 
experiments followed by nuclear fractionation would have shown us if 
increases in nuclear uptake account for these large differences in overall 
uptake.  These experiments suggest that combinations of epirubicin and 
verapamil instilled for longer periods may enhance MDR reversal and 
increase intracellular levels of epirubicin, resulting in improved cytotoxicity.   
Previous researchers have demonstrated increased cytotoxicity associated 
with epirubicin and verapamil co-incubation in cell lines [199].   
P-gp studies  
One possibility that might have accounted for a nuclear efflux mechanism is 
the expression of P-gp on the nuclear membrane. One previous study in the 
literature identified P-gp on the nuclear membrane of the MDR breast cancer 
cell line, MCF-7 DX [234].  This study used anti-P-gp monoclonal antibodies, 
MM4.17, MC57 and JSB-1 to immunolabel P-gp on the nuclear membrane 
using two methods.   Firstly, they immunolabelled P-gp on isolated nuclei, 
followed by FITC-conjugated secondary antibody and either confocal or flow 
cytometric analysis.  Secondly, they used immunoelectron microscopic 
imaging of fixed cells embedded in epoxy resin that had been exposed to the 
same primary antibodies, followed by gold-conjugated secondary reagents.  
Using flow cytometry, this study also demonstrated P-gp mediated 
doxorubicin efflux from isolated nuclei that had been exposed to doxorubicin   274
and then incubated in drug free medium containing 1mM ATP.  However, 
another study showed P-gp was absent from the nuclear membrane of a 
lymphoblastic tumour cell line that exhibits the MDR phenotype [399].   
We looked for cellular and nuclear expression of P-gp using a flow cytometric 
assay utilising a FITC labelled monoclonal antibody directed against P-gp 
(17F9) to determine whether P-gp was responsible for the nuclear efflux of 
epirubicin in our MDR cells.  This showed that whilst both MDR cell lines used 
in this study expressed P-gp at a cellular level, there was no evidence of P-gp 
expression on the nuclear membrane to account for a drug efflux at this level.  
Our results were consistent with previous studies of P-gp distribution in the 
MGH-U1R cell line, using straightforward immunostaining of P-gp with cold 
acetone/ethanol fixation and JSB-1, another monoclonal antibody against P-
gp (Claire Davies – personal communication).    
Mitomycin C 
We were unable to demonstrate any direct fluorescence from mitomycin C to 
determine whether similar reductions in cellular and nuclear accumulation of 
mitomycin C occur in MDR cells.   
Confocal studies looking at an indirect method of examining nuclear uptake of 
mitomycin C using reduction in acridine orange DNA staining suggested that 
nuclear uptake was reduced in MDR cells compared to sensitive cells.  
Confocal microscopy is only a semiquantitative method of measuring 
fluorescence and measurements are only taken through a single level of the 
cells which may introduce some intersample variation.    
A similar indirect flow cytometric assay looking at cellular uptake of mitomycin 
C using acridine orange showed no correlation between reduction in AO 
fluorescence and mitomycin C dose response.  However, a flow cytometric 
study looking at reduction in nuclear acridine orange uptake secondary to 
mitomycin C exposure would have been a better assay, as the reduction in 
acridine orange DNA binding as a result of mitomycin C DNA binding is what 
we are really interested in.   
The nuclear sparing of cytotoxic drugs has also been demonstrated in 
previous studies looking at nuclear uptake of anthraquinones in MDR cells by 
fluorescence methods [244,350,351].  This suggests that other drugs that are   275
susceptible to MDR mechanisms, such as mitomycin C, may also be subject 
to nuclear sparing.    
Idarubicin 
The fact that idarubicin appears to be excluded from the nuclei of viable, 
sensitive and MDR cells at both 37
oC and 0 – 4
oC and is also excluded from 
the nuclei of dead cells remains somewhat of an enigma. 
Flow cytometric studies showed a clear dose response to idarubicin in both 
sensitive and MDR cells, with sensitive cells showing 2.3 – 5 times greater 
levels of drug fluorescence.  
Isolated nuclei from sensitive and MDR cells incubated with idarubicin did 
demonstrate nuclear fluorescence, with similar levels being seen in sensitive 
and MDR cells.  Nuclei exposed to idarubicin after nuclear extraction also 
have similar levels of idarubicin uptake to those exposed before nuclear 
fractionation.  The fluorescence levels exhibited by nuclei exposed to 
idarubicin are lower than respective epirubicin fluorescence levels in isolated 
nuclei exposed before or after nuclear fractionation.  This might suggest that 
idarubicin DNA binding may have a certain threshold above which no further 
binding can occur.   
Confocal microscopic images are generally adjusted to look at the area of the 
cell with the highest levels of fluorescence.  The very high levels of 
cytoplasmic idarubicin uptake could mean that when the cells are visualised 
and the gain settings adjusted to show cytoplasmic idarubicin levels, it gives 
the impression of a total absence of nuclear fluorescence when in fact there is 
just relative sparing of drug from the nucleus. 
Metaphase experiments were also of interest, as they clearly demonstrated 
that chromosomes of both sensitive and resistant cells did not stain with 
idarubicin during metaphase despite high levels of cytoplasmic fluorescence.   
This suggests that the nuclear membrane is not responsible for the reduction 
in DNA staining.   
It seems likely therefore that the reduced idarubicin DNA binding may be due 
to either a low idarubicin binding threshold over which no further drug can 
bind, or some electrostatic repulsion of idarubicin or repulsion once bound to 
a particular protein which may be similar in both sensitive and MDR cells.     276
An experiment that would help to determine if there is a saturation threshold 
for idarubicin binding would be to perform a dose response in nuclear isolates 
exposed to various concentrations of idarubicin pre- and post- nuclear 
fractionation.  If this demonstrated saturation of nuclear fluorescence this 
would suggest nuclear idarubicin binding reaches a certain threshold and then 
can bind no more.  It may also suggest quenching of drug fluorescence once 
bound to DNA, suggesting that nuclear fluorescence bears no relation to 
nuclear drug uptake for idarubicin.   
As idarubicin’s predominant cytotoxic actions are within the nucleus, 
quenching of idarubicin fluorescence may also be suggested by the fact that 
the IC50 value for idarubicin cytotoxicity in MDR cells is significantly lower 
than for epirubicin.  
 
The lack of any formal statistical analysis may be viewed by some as a 
weakness of this thesis.  Formal statistical analysis was not performed for 
confocal microscopy experiments as this is a semi-quantitative technique.  
There are a number of variables that can interfere with meaningful analysis of 
confocal images.  We attempted to exclude variables between samples by 
standardising laser and detector gain settings.  Despite this, there will always 
be some variation in the cross-section plane of the sample cells.  This cannot 
be adequately controlled between samples making formal statistical analysis 
less meaningful.  Many of our experiments were designed to detect large 
discrepancies in cellular uptake and localisation between cell types, or to 
determine the intracellular localisation of a substance, both of which can be 
viewed and commented on by direct observation alone.  
In terms of flow cytometric data analysis, because of the large number of cells 
examined in each sample, even the smallest differences between samples 
are likely to be highly statistically significant.  Whether these differences 
equate to meaningful biological effects is a matter for debate.  The larger 
differences that were observed between samples are highly likely to represent 
biologically significant effects.      
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Future directions: 
In addition to the potential lines of work highlighted throughout the discussion, 
the following areas of research follow-on from our studies and would be of 
additional interest.   
As stated there is some evidence that anthracyclines may be transported into 
the nuclei of sensitive cells bound to proteins that are actively transported via 
nuclear pores [352,395].  We performed some very basic protein analysis on 
our sensitive and resistant cell lines to see if there were differences in protein 
expression (Appendix 4).  It would be interesting to refine this protein analysis 
to see if it is possible to demonstrate whether the anthracyclines, epirubicin 
and idarubicin, bind to intracellular proteins.  It would also be interesting to 
establish whether there are any differences in the binding of these drugs 
between sensitive and MDR cells, which might explain their differences in 
cellular localisation.  
We also performed some preliminary experiments extracting cytoplasmic 
fractions from sensitive cells and co-injecting this cytoplasmic fraction with 
epirubicin into MDR cells.  In these studies we were able to demonstrate 
reversal to a nuclear uptake pattern in viable MDR cells, suggesting that 
sensitive cell cytoplasm may contain some factor necessary for nuclear 
transport of epirubicin or indeed may contain a protein which binds epirubicin 
and undergoes nuclear transportation.  Obviously these were uncontrolled 
experiments, so the results are highly speculative and have therefore not 
been included in the main body of work.  However, these results certainly 
warrant further investigation and refinement.  Perhaps with time it would be 
possible to define a specific cytoplasmic fraction or indeed a specific protein 
that would act as a nuclear transport carrier of epirubicin allowing entry to 
MDR nuclei (Appendix 5). 
Following on from our microinjection experiments, it would be of interest to 
inject epirubicin into the cytoplasm or nuclei of sensitive and MDR cells and 
watch the movement of drug using real-time fluorescence video capture.  This 
would provide a direct insight into drug handling at the cytoplasmic and 
nuclear level.  Injection of cells or nuclei at 0 – 4
oC followed by cell warming 
with real-time imaging would also be of interest.  This would allow us to 
determine whether nuclear epirubicin uptake is reversible or whether   278
demonstration of nuclear uptake indicates that irreversible DNA binding has 
occurred.    
Some newer modified anthracyclines, annamycin and doxorubicin-peptide, do 
not act as substrates for ABC transporters including P-gp [400-402].  
Visualisation of the cellular localisation of these drugs using confocal 
microscopy, would give a clear answer as to whether P-gp function bears any 
relation to the nuclear sparing of anthracyclines.       
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Appendix 1:  Nuclear Preparation Protocol [390]: 
Cells were cultured in 25cm
2 flasks until 90 – 95% confluent.  Cells were then 
washed three times in PBS containing protease- and phosphatase-inhibitors 
(PBSI), comprising: 
     9.2mM  Na2HPO4 
     10mM  NaH2PO4 
     0.15M NaCl 
     1mM  Na3VO4 
      1mM PMSF (phenylmethylsulphonyl fluoride) 
     5µgml
-1 Leupeptin 
     1 µgml
-1 Aprotinin 
Immediate release of nuclei from cells was then initiated in 2 mls lysis buffer 
(10mM HEPES, 1.5mM MgCl2 pH5.5) by the addition of 10 drops of Zaponin 
(Coulter Electronics, UK).  The supernatant was pipetted off immediately and 
layered over a 20% solution of sucrose in PBSI in polythene centrifuge test 
tubes.  These samples were spun at 800g for five minutes, and the top phase 
was discarded.  A further single PBSI wash was performed, and the 
suspension was re-spun through 20% sucrose/PBSI at 800g for five minutes, 
and again the top phase was discarded.  The presence of fractionated nuclei 
was confirmed by phase contrast light microscopy.  
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Appendix 2:  Scrape-loading protocol [391]: 
McNeil described this method of incorporating large macromolecules into 
cells.  We used this method in our initial attempts to determine the size of 
nuclear pores using FITC-labelled dextran molecules of various sizes.  
Dextrans do not usually gain access to the cell cytoplasm as they are large 
inert molecules.  Temporary disruption of the plasma membrane allows these 
molecules to enter the cell cytoplasm, with subsequent closure of the plasma 
membrane preventing their escape.  Once they have gained entry into the 
cells, the dextrans distribute throughout the cell and are slowly excreted by 
exocytosis.    
Cells were cultured in 25ml flasks until 90% confluent. The medium was then 
tipped off and replaced with 2ml of 10mg/ml FITC-dextran solution, diluted in 
PBS.  Flasks were laid on ice to cool the cells.  
The cells were then gently scraped with a sterile rubber policeman until all the 
cells were in suspension, “scrape-loading” them with FITC-dextran.  The cells 
were then covered with 8mls of ice-cold culture medium.  Once all flasks were 
scrape-loaded the cells were centrifuged at 438g (1500rpm) for 3 minutes and 
resuspended in fresh culture medium.  Cells were then plated out into 40mm 
Petri dishes and re-incubated.  Cells were then viewed by confocal 
microscopy at various time points to assess the cellular distribution of the 
FITC-dextrans.   
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Appendix 3: 
Optimisation of Cell fusion using Polyethylene Glycol (PEG): 
Effect of time of PEG exposure: 
MGH-U1 and MGH-U1R cells were cultured in 40mm Petri dishes as a mixed 
culture, 1ml of 10
5 cell/ml of each cell type at 37
oC until confluent. 
Cell culture media was pipetted off and cells were then covered with 0.5mls of 
polyethylene glycol (PEG) 50% w/v and gently agitated for various exposure 
times of 2, 3, 5, 10, 20, 40 and 60 minutes.  The PEG was then serially diluted 
by the addition of ice-cold culture medium.  This was then pipetted off and 
replaced with fresh culture medium.  The samples were then incubated for a 
further hour at 37
oC to allow cell fusion to complete and recover.   
The culture medium was then tipped off and cells were fixed by covering them 
with buffered formalin saline for 60 minutes.  The cells were then stained with 
methylene blue and fusions were counted in 9 random fields at x20 
magnification. 
Results: 
Time of PEG exposure 
(minutes) 
Number of cell fusions counted 
2 99 
3 62 
5 125 
10  144 – some cells damaged 
20  Some fusions – cells damaged ++ 
40  Cells damaged +++ 
60  Cells damaged +++ 
 
At higher exposure times some cells demonstrated damage with 
disappearance of their plasma membranes. 
Overall the optimal number of fusions with the fewest damaged cells was 
achieved with an exposure time of 5 minutes and this was used for all 
subsequent PEG fusion experiments.  
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Effect of incubation time following exposure to PEG: 
MGH-U1 and MGH-U1R cells were cultured in 40mm Petri dishes as a mixed 
culture, 1ml of 10
5 cell/ml of each cell type at 37
oC until confluent. 
Cell culture media was pipetted off and cells were then covered with 0.5mls of 
polyethylene glycol (PEG) 50% w/v and gently agitated for 5 minutes.  The 
PEG was then serially diluted by the addition of ice-cold culture medium.  This 
was then pipetted off and replaced with fresh culture medium.  The samples 
were then incubated at 37
oC for various times to allow cell fusion to complete 
and recover.  The times used were 30 minutes, 1, 2, 4, 8 and 24 hours.  The 
culture medium was then tipped off and cells were fixed by covering them with 
buffered formalin saline for 60 minutes.  The cells were then stained with 
methylene blue and fusions were counted in 9 random fields through at x20 
magnification. 
Results: 
Time of incubation after PEG 
exposure 
Number of cell fusions counted 
30 minutes  92 
1 hour  141 
2 hours  189 
4 hours  151 
8 hours  142 
24 hours  100 
 
The optimum time of incubation post-PEG exposure was shown to be 2 hours 
and this was used for all future PEG fusion experiments.   283
Appendix 4:  Basic protein analysis of sensitive and MDR cells 
We performed some basic protein analysis using gel electrophoresis, to 
determine if there were any alterations in protein expression between the 
sensitive and resistant cell lines.    
SDS Gel plates were prepared according to the following standardised 
protocol.   
Preparation of SDS gel electrophoresis plates 
Reagents 
Solution A = Protogel (Ultra Pure):  30% w/v Acrylamide: 0.8% Bis-
Acrylamide stock solution (37.5:1); National Diagnostics, UK 
Solution B = Protogel Buffer:  1.5M Tris, 0.384% SDS, pH 8.8; National 
Diagnostics, UK 
Solution C = Protogel Stacking Buffer:  0.5M Tris
.HCl, 0.4% SDS, pH 6.8;  
National Diagnostics, UK 
De-ionised, distilled H2O (16.5 Ohm)  
APS = Ammonium Persulphate;  Fisher Bioreagents, Fischer Scientific UK): 
Dilute 0.1g in 1ml de-ionised H2O 
TEMED = N, N, N’, N’- Tetramethylethylethylenediamine (C6H12N2):  
Electrophoresis Reagent; (Sigma, UK) 
 
Resolving Gel (10% SDS Gel) Mixture 
Compound 1  Plate  2 Plates  4 Plates 
Solution A  1.35mls 2.7mls  5.4mls 
Solution B  1.0mls 2.0mls 4.0mls 
De-I, dist H2O   1.625mls 3.25mls  6.5mls 
APS  38µl 75µl 150µl 
TEMED  5µl 10µl  20µl 
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Stacking Gel (10% SDS Gel) Mixture 
Compound 1  Plate  2 Plates  4 Plates 
Solution A  188µl 375µl 750µl 
Solution C  313µl 625µl 1.25ml 
De-I, dist H2O  0.75ml 1.5ml  3.0ml 
APS  10µl 20µl 40µl 
TEMED  2.5µl 5µl  10µl 
Method for producing gel plates 
1.  Put together glass plates making sure bottom of plates are aligned and 
Biorad sign is at top of plate. 
2.  Place plates into green clamp and clamp in place making sure bottom of 
plates are aligned 
3.  Place plates in to plate holding clamp making sure the bottom of the plates 
are pushed firmly against the grey seal. 
4.  Using a pipette fill the gap between the plates with resolving gel mixture up 
to the lower level of green plastic clamp. 
5.  Using a pipette fill the remaining gap to level with top of plate with de-
ionised, distilled H2O. 
6.  Once resolving gel is set, 10-15 minutes. Tip off water. 
7.  Using a pipette fill the gap to the top of the plate with stacking gel mixture 
and insert Biorad 10 well comb.  Allow to set, 10-15 minutes. 
The gel plate is then ready for electrophoresis. 
 
Protein Sample Preparation: 
Cells were cultured in 25cm
2 flasks until confluent.  Cells were then harvested 
into suspension using trypsin-EDTA.  The suspension was then centrifuged at 
1800rpm for 3 minutes and the Trypsin containing medium was pipetted off.  
The cells were washed with PBS and re-centrifuged twice.  The cells were 
then re-suspended in 5mls of PBS and counted using a haemocytometer 
slide.  Cell numbers were adjusted to 75,000 cells per sample.  The samples 
were then placed into centrifuge tubes and centrifuged at 1800rpm for 3   285
minutes.  The PBS was removed and cells were resuspended in 1ml of PBS 
and transferred into eppendorf tubes.  Cells were then pelleted again by 
ultracentrifugation at 6000rpm for 3 minutes.  The supernatant was pipetted 
off and cells were re-suspended in 25µl PBS.  Cell suspension was then 
mixed thoroughly with 25µl SDS double strength loading buffer.  Protein 
samples were then heated in a Grant Heater Block at 90
oC for 5 minutes to 
dissolve the cell membranes and denature the cell proteins.  Protein samples 
were then ultrasonicated using a harmonic ultrasonicator.  Samples were then 
re-centrifuged at 6000rpm for 2 minutes to separate out any precipitates.  
Samples were then loaded into gel plate wells.   
Gel Electrophoresis  
Two gel plates were clamped into the gel electrophoresis cradle and placed 
into the electrophoresis chamber.   
Electrophoresis buffer was made up fresh as a 1:10 dilution of 10X 
TRIS/Glycine/SDS in distilled, deionised H2O.  The area between the plates 
was filled up to the top of the plates and the outer electrophoresis container 
was filled until approximately 2/5ths full.  The Biorad comb was then removed 
and a sample injector guide was placed between the plates.  The gel plate 
wells were filled by slowly pipetting 15µl of each sample into individual wells 
within the stacking gel.  One well was reserved for protein marker sample in 
order to roughly size the electrophoresed proteins.  The protein marker well 
was filled with 5µl of SigmaMarker
TM Wide Molecular Weight Range (Product 
No. 4038, Sigma, UK). The order of protein extracts added to each gel plate 
was noted.  The lid was placed on the electrophoresis chamber and the 
electrical leads were connected to the Biorad Machine (Red – Red and Black 
– Black).  The gel plate was run at a voltage of 150volts for 50 minutes.   
The plates were then removed and the plates were unclamped and gently 
prised apart.  The gels were then removed from the plate and placed in a wet 
plastic container ready for staining. 
Gel Plate Staining  
Gel plates were stained using Silver staining (Silver stain plus, Bio-rad, 
Catalog Number 161-0449) as per the following protocol.  
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SDS Gel Electrophoresis Staining protocol: Silver stain 
The following preparations are adequate for staining two mini gels (8 x 10cm), 
0.75 – 1mm thick.   
1.  Fixative step – 20 minutes 
  Fixative Enhancer Solution Preparation  
  Reagent Grade Methanol    200ml      50% v/v 
  Reagent Grade Acetic Acid 40ml     10%  v/v 
  Fixative Enhancer Concentrate  40ml      10% v/v 
  Deionised  Distilled  Water   120ml    30%  v/v 
  Total      400ml    100%  v/v 
After gel electrophoresis, place gels in the Fixative Enhancer Solution.  With 
gentle agitation fix the gels for 20 minutes. 
2. Rinse Step – 20 minutes 
Decant the Fixative Enhancer Solution from the staining vessel.  Rinse the 
gels in 400ml of deionised distilled water for 10 minutes with gentle agitation.  
After 10 minutes, decant water and replace with fresh rinse water.  Rinse for 
an additional 10 minutes.  Decant rinse water. 
3. Staining and Developing Step – 20 minutes 
Staining Solution Preparation and Procedure   
The staining solution was prepared within 5 minutes of use.  
Place 35ml deionised water into a large beaker and stir with a Teflon coated 
stirring bar.  Add the following to the beaker in this order: 
5.0 ml Silver complex solution 
5.0 ml Reduction moderator solution 
5.0 ml Image developer reagent 
Immediately before use quickly add 50ml of the room temperature 
development accelerator solution to the beaker.  Swirl well.  Add the contents 
of the beaker to the staining vessel.  Stain with gentle agitation.  Stain the gels 
for approximately 20 minutes or until desired staining intensity is reached 
(Watch).  It may take at least 15 minutes before the first bands become 
visible.  After the desired staining is reached place the gels in 5% acetic acid 
to stop the reaction. 
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4. Stop Step – 15 minutes 
Prepare a 5% acetic acid solution to stop the staining reaction.  Place gels in 
stop solution for a minimum of 15 minutes.  After stopping the reaction rinse 
the gels in high purity water for 5 minutes.  The gels are then ready for 
imaging and storing. 
This silver staining protocol is taken from Bio-Rad Silver Stain Plus technical 
data sheet (Bio-Rad, Catalog Number 161-0449). 
Gel Plate Imaging and Analysis 
Gels were then scanned using GeneSnap (Syngene) image acquisition 
software to produce a digital image.  Gel plates were stored wet in plastic 
heat-sealed bags.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 96:    Analysis of differences in protein expression of MGH-U1 and 
      MGH-UR cells (SDS Gel electrophoresis plate) 
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Very basic visual analysis reveals several differences of protein expression 
between sensitive and MDR cells from the same lineage.  There are also 
many similarities in protein expression between samples.  There appears to 
be a band of protein expression in the MGH-U1R cells between the 205 and 
116KDa region which is likely to represent P-gp expression (170KDa).  More 
detailed analysis using software packages such as GeneTools (Syngene) 
would have allowed more detailed analysis of the differences in the proteins 
expressed by each cell line.  This software would allow identification of the 
molecular weight of the additional proteins expressed by the MDR cell line 
and quantify any differences in similar proteins expressed by each cell line.    289
Appendix 5:  Co-injection of MDR cells with epirubicin and a sensitive 
cell cytosol extract  
We postulated that our inability to demonstrate a mixed cell fusion may 
indicate some cytoplasmic-nuclear membrane interaction between sensitive 
cell cytoplasm and MDR nuclei, resulting in nuclear transport of epirubicin into 
MDR nuclei.  We decided to co-inject epirubicin combined with a sensitive cell 
cytosol extract into MGH-U1R cells at 37
oC, to see if this reversed the nuclear 
sparing pattern of epirubicin uptake in MDR cells.   
Method for cell cytosol preparation: 
1.  MGH-U1 (sensitive) cells were grown to confluence in a 75cm flask 
2.  Cells were then washed four times with PBS 
3.  Cells were harvested using a rubber policeman 
4.  Cells were pelleted by centrifuging at 1000rpm for 10 minutes and the 
supernatant was discarded 
5.  Cells were covered with 1ml of cold 0.02M TRIS buffer containing a 
protease inhibitor cocktail and agitated for 10 seconds every 5 minutes for 
15 minutes 
6.  The sample was then centrifuged at 2000g for 20 minutes and the 
supernatant was transferred to an ultracentrifuge tube 
7.  The sample was then ultracentrifuged at 376,000g at 4C for 30 minutes. 
The protease inhibitor cocktail used contained the following inhibitors: 
 AEBSF  104  millimolar 
  Aprotinin  0.08 millimolar (80 micromolar) 
 Leupeptin  2  millimolar 
 Bestatin  4  millimolar 
  Pepstatin A  1.5 millimolar 
 E-64    1.4  millimolar      (Product No. 8340, Sigma, UK) 
 
Method for injection: 
MGH-U1R cells were cultured in low-sided 40mm Petri dishes (Orange 
Scientific, UK) until 50 – 75% confluent. Cell culture medium was changed to 
HEPES buffered medium (1:100 HEPES).  The injection mixtured contained 
0.05mls of epirubicin (2mg/ml), 0.1ml of a 77KDa FITC-dextran (1mg/ml) and 
0.05mls of cytosol extract.  This gave final concentrations of 0.5mg/ml for   290
epirubicin and FITC-dextran.  These were then co-injected into the cytoplasm 
of MGH-U1R cells.  The FITC-dextran allowed us to clearly identify our 
injected cell population.  FITC-dextrans of 77KDa are ordinarily excluded from 
cells and cell nuclei, as they are too large to passively diffuse across these 
membranes.  The injection buffer used was 48mM K2HPO4, 4.5mM KH2PO4, 
14mM NaH2PO4, pH 7.2 (Eppendorf - personal communication).  Once 
microinjected, cells were incubated for 60 minutes in normal culture conditions 
to allow cell recovery and time for epirubicin to distribute itself within the cells. 
Microinjected cells were then viewed by confocal microscopy.  Injected cells 
were easily identified by their green FITC-dextran fluorescence, on direct 
fluorescence microscopy.  Confocal microscopy allowed direct visualisation of 
the distribution of the various fluophores within the microinjected cells.  
Acridine orange (3µg/ml) stains the nuclei of viable cells green and was added 
after initial image capture in order to confirm cell viability.   
Results: 
The results of this experiment are shown below, with MGH-U1R cells showing 
a clear nuclear uptake pattern of epirubicin when microinjected with epirubicin 
in combination with sensitive cytosol extract.  Cell viability was confirmed in all 
cells by strong nuclear acridine orange fluorescence. 
These results suggest that some factor in sensitive cell cytosol allows 
epirubicin to gain entry into the nuclei of MDR cells.  This may be a cytosolic 
nuclear transport factor which facilitated active transport of epirubicin or a 
protein that binds epirubicin and is recognised and transported by the NPCs 
of the MDR nucleus.  
These experiments were uncontrolled, so clearly further work needs to be 
done to clarify the significance of these results.  Future experiments would 
involve coinjecting epirubicin and similarly extracted resistant cell cytosol into 
MDR cells, to ensure that nuclear sparing of epirubicin uptake is preserved 
using the same technique.    291
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 97:  MGH-U1R cells co-injected with epirubicin and a  
   sensitive  cell  cytosol  extract showing string nuclear 
   staining  with  epirubicin (Left hand side images).   
   Viability  of  cells  confirmed by strong nuclear acridine 
   orange  staining  (Right hand side images).   292
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